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Abstract 
Naeem Asad 
Department of Chemistry, July 2014 
The University of Kansas 
 The focus of this dissertation is to utilize vinyl sulfonamides in a series of 
reaction protocols towards the synthesis of sultam molecules by exploiting several 
salient features inherent to sulfonamides, including (i) electrophilicity of the β-carbon 
for Michael addition, (ii) low pKa suitable for alkylation, (iii) exploitation of the 
double bond for Heck, Diels-Alder and metathesis reactions.  Overall, vinyl 
sulfonamides undergo several selective transformations to allow access to diverse 
sultams, which can be further utilized in library synthesis.  Chapter one outlines the 
biological activity of sulfonamides and sultams and ends with a mini-review on the 
use of vinyl sulfonamides for sultam synthesis.  Chapter two begins with a brief 
review of the bioactivity of acyl sulfonamides and acyl sultams, and then details a 
one-pot, sequential protocol employing complementary ambiphile (an entity having a 
nucleophilic and an electrophilic center) pairing (CAP) of vinyl sulfonamides with a 
variety of unprotected amino acids via aza-Michael addition followed by 
intramolecular EDC coupling (amidation).  Utilizing this methodology diverse, sp3-
rich mono- and bicyclic acyl sultams were synthesized in a highly scalable manner.  
In addition, stereochemically-rich building blocks were constructed and a method was 
developed to provide quick access to all possible isomers.  This method was also 
further extended to include one-pot, sequential 3-, 4-, and 5-multicomponent 
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protocols.  Chapter 3 describes a stereo-controlled diversification of (8R,9aS)-8-
hydroxy-2-(prop-2-yn-1-yl)hexahydro-pyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 
3,3-dioxide 3.1.1, utilizing a one-pot, click–OACC esterification protocol and a one-
pot, sequential Mitsunobu alkylation pathway.   
The core (8R,9aS)-8-hydroxy-2-(prop-2-yn-1-yl)hexahydropyrrolo[2,1-d][1,2,5]thia-
diazepin-1(2H)-one 3,3-dioxide, was synthesized rapidly on a multi-gram scale by a 
one-pot, sequential sulfonylation, Michael and EDC/amide coupling protocol.  
A compound library comprised of 135/158-members was generated utilizing these 
protocols.  Chapter 3 also describes an efficient one-pot, sequential or 4-component 
protocol to access a library of stereochemically-rich acyl sultams containing varied 
elements of skeletal and peripheral diversity.  The 3-component protocol consisted of 
sulfonylation of amines with 2-chloroethane sulfonyl chloride, aza-Michael with 
amino acids and amide coupling, and was extended to a similar 4-component 
procedure involving the aforementioned reactions followed by the fourth reaction, 
including: (i) a [3+2] Huisgen cycloaddition when propargyl amine was utilized in the 
sulfonylation step and (ii) carbamoylation when L-trans-hydroxyproline was 
employed in the aza-Michael reaction.   
The construction of two libraries of triazole-containing isothiazolidine 1,1-
dioxides utilizing click/OACC esterification protocol is also reported in chapter 3.  A 
core dihydroisothiazole 1,1-dioxide scaffold was prepared rapidly on multi-gram 
scale via ring-closing metathesis (RCM), followed by propargylation.  In this method, 
an aza-Michael reaction employing three amino alcohols was used to generate three 
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daughter scaffolds.  This was followed by a one-pot, click/esterification protocol 
utilizing an oligomeric coupling reagent (OACC) to generate a 41-member library of 
triazole-containing isothiazole 1,1-dioxides. 
Chapter 4 describes the utilization of facilitated, chromatography-free 
intermolecular Monomer-on-Monomer Mitsunobu protocols on hydroxy-pyrrolo 
thiadiazepin-dioxide scaffolds.  The MoM Mitsunobu reaction was employed by 
norbornenyl-tagged benzyl ethyl azodicarboxylate (Nb-BEAD) and Nb-tagged 
triphenylphosphine (Nb-TPP) whereby purification/sequestration of excess and spent 
reagents was rapidly achieved using ring-opening metathesis (ROM) polymerization. 
Facile purification was carried-out utilizing surface-initiated polymerization by three 
sequestration methods: (i) from free metathesis catalyst (G-II) (ii) Nb-tagged silica 
(Nb-Si) (iii) Nb-tagged Cobalt-graphite (Nb-Co/C) magnetic nanoparticles. Another 
purification protocol is reported which utilizes a ROMP derived process for the 
diversification of tricyclic sultams (epoxybenzo[d]isothiazole 1,1-dioxides). This 
chromatography-free method permits easy isolation of reductive-Heck products and 
retrieval of excess starting material utilizing a sequestration protocol involving 
metathesis catalysts and a catalyst-armed Si-surface.  
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Chapter 1 
 
Introduction 
Vinyl Sulfonamides:  
Versatile Linchpins for the  
Synthesis of Diverse Sultams 
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Preface 
This dissertation is focused on the development of new methods for the facile 
construction of cyclic sulfonamide-based (sultam) scaffolds, with an emphasis on the use of 
vinyl sulfonamides as the central building block for the assembly of sultam-based libraries 
for biological screening (Figure 1).  Chapter one begins with a brief introduction of the 
biological profiles of sulfonamides and their cyclic analogs, and is followed by a mini-review 
of the utilization of vinyl sulfonamides in the field for the synthesis of sultam-based scaffolds.  
Chapter two starts with a survey of the biological properties of acyl sulfonamides and acyl 
sultams, before providing a detailed account of a new strategy to synthesize amino acid-
derived 7- and 8-membered acyl sultams, in particular pyrrolo[2,1-d][1,2,5]thiadiazepin-
1(2H)-one 3,3-dioxides.  Chapter three encompasses utilization of ring opening metathesis 
(ROM) polymerization technologies for facilitated synthesis, as well as one-pot sequential 
protocols, towards the diversification of hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-
one 3,3-dioxide libraries.  Finally, chapter four reports on the development of sequestration 
protocols aimed at integrating synthesis/diversification and purification, of 
hydroxyhexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide sultam scaffolds.   
 
Figure 1.1 One-pot sequential, protocols towards sultam libraries. 
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1.1 Introduction 
1.2 Sulfonamides: An Important Class of Medicinal Agents  
New advances in genomics and proteomics have paved the pathway for the discovery 
of an estimated 20,000–25,000 genes, which are believed to encode up to one million 
proteins. 1   Despite this vast wealth of information, small-molecule therapeutic agents 
currently target only a small fraction of these proteins (approximately 500).2  In order to 
address this void in chemical space, there has been enormous growth in high throughput 
screening (HTS), emphasizing the demand for diverse small molecule libraries to discover 
biologically active compounds.  It has been estimated that there are approximately 1060 small 
molecule structures of molecular weight (MW) less than 500; however, only 108 chemical 
entities meeting this requirement have either been synthesized or isolated from natural 
sources.3  Since it is impractical to survey this vast chemical space,4 the chosen space to 
explore must be ideally biologically relevant, as well as sparsely populated in order to be 
most productive in assisting efforts in both drug design and basic biology.  Interest in this 
regard, has led efforts at exploring sulfonamides and their corresponding cyclic analogs 
(sultams), as this subset of chemical space has gained increasing acclamation due to their 
inherent chemical and biological properties, making them promising candidates in library 
development and drug discovery.2 
Sulfonamides have vast potential as pharmaceutical and agricultural agents owing to 
their distinct and extensive biological profiles.  A survey of chemical properties involving 
pKa measurements reveals that pKa's of sulfonamides span a rough range from that of a 
carboxylate (pKa ~5) to the higher, less acidic, carboxamides (pKa ~ 15).  This property has 
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prompted their use as amide surrogates and carboxylic acid replacement groups.5  Hofmann 
performed a systematic study of the conformation of the sulfonamide bond at different levels 
of ab initio MO theory.6 Their studies revealed distinct differences between the sulfonamide 
and the amide/peptide bond. Some important differences include (i) different values of the 
torsion angle ω (<CαSNCα) that are about 100 and 60º in the two basic conformers of the 
sulfonamide bond, but about 180 and 0º for the amide peptide bond. The rotation barriers 
around the S-N bond were distinctly lower than the amide peptide bond making the 
sulfonamide bond more flexible. Also the nature of the sulfonamide nitrogen was pyramidal 
compared to the amide nitrogen, which had a planar geometry.  
As sulfonamides possess both hydrogen bond donor and acceptor sites, they are 
armed to potentially coordinate to amino acid residues located within enzymes. 7  
Sulfonamides bearing acidic N–H moieties are usually more bioavailable and have increased 
water solubility relative to other polar groups such as amides.7  In addition, these non-
hydrolyzable amide surrogates possess other unique physical properties, such as crystallinity, 
tunable pKa’s (R1SO2NHR2), and hydrolytic stability.  Taken collectively, these interesting 
properties have promoted the incorporation of the sulfonamide group into a growing number 
of compounds, many of which have demonstrated interesting biological activity, vide infra.   
The biological properties of sulfonamides encompass a wide array of activities.  In 
this regard, sulfonamides have been utilized in the development of novel peptidomimetics8 
matrix metalloproteinase inhibitors,9 thrombin inhibitors,10 fibrinogen receptor antagonists,11 
endothelin-A receptor antagonists, 12  and glycoprotein IIB/IIIA inhibitors, 13  as well as 
squalene epoxidase inhibitors14 and sultam herbicides.15   
 5 
 The aforementioned non-hydrolyzability of the sulfonamide moiety imparts an 
increase in metabolic stability towards protease-catalyzed degradation of 
peptidosulfonamides.16  Thus, they have found widespread use as transition state analogues 
for amide bond hydrolysis and have found applications as novel non-peptidal HIV protease 
inhibitors.17  In addition, studies on histamine H3 receptor antagonists have demonstrated 
superior in vitro profiles of sulfonamides when compared to their corresponding amide 
analogs.18   
Sulfonamides have also been found to be promising carbonic anhydrase and matrix 
metalloproteinase inhibitors, two members of a family of zinc-containing enzymes whose 
function is related to arthritis and cancer.19  Further studies have revealed that inhibition 
towards these enzymes is attributed to their ability to mimic the tetrahedral transition state 
when binding to catalytic zinc ions located at the active site of the enzymes.20  
 Sulfonamides also display other wide-ranging activities, including antibacterial, 
diuretic, hypoglycemic, anti-thyroid, and most recently, anti-tumor activity. 21   Some 
biologically active sulfonamides on the market include the antibacterial agent sulfathiazole,2a 
the carbonic anhydrase inhibitor acetazolamide2 which has been clinically used for more than 
45 years, the anticancer agent E7070 (Figure 1.2), which is currently in advanced clinical 
trials,22 the HIV protease inhibitor amprenavir,23 and most recently Viagra (Sildenafil),24 one 
of the most marketable drugs used for male erectile dysfunction.   
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Figure 1.2 Representative bioactive sulfonamides.  
 
 While naturally occurring sulfonamides are relatively scarce, there are a few 
examples, namely altemicidin25 and psammaplin C. 26  Altemicidin was isolated from the 
actinomycete strain Streptomyces sioyaensis, which has shown tumor cell growth inhibition, 
and Psammaplin C, was isolated from the marine sponge Psammaplysilla purpurea (Figure 
1.3).  Due to their scarcity as well as their attractive biological features, sulfonamides are 
lucrative targets for organic synthesis and biological testing.   
 
Figure 1.3 Naturally occurring sulfonamides. 
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1.3 Sultams: Cyclic Sulfonamides 
1.3.1 Biological Properties  of Sultams 
Sultams, the cyclic analogs of sulfonamides, are cyclic amide surrogates that 
represent an important medicinal chemo-type due to their wide chemical and biological 
profiles.27  Although not found in nature,28 they possess potent biological activity, including 
several with medicinal value, and have thus found extensive use in drug development.  Their 
innate properties have enabled their widespread use as reagents,29 chiral auxiliaries in 
asymmetric synthesis,30,31,32 artificial sweeteners (saccharin) in food industry,33 and ionic 
liquids serving as novel reaction media.34  In addition, they have also found use in a number 
of medicinal and agricultural agents.35  As non-hydrolyzable cyclic amide surrogates, sultams 
are also an ideal functional group in the synthesis of cyclic peptidomimetics.36 
Sultams have also been shown to exhibit broad inhibitory properties against a variety 
of enzymes including: HIV integrase,37 lipoxygenase,38 TNF a-converting enzyme,39 Calpain 
I40 and MMP-241 (Figure 1.4). Sultams also possess an array of biological activity, such as 
anticancer,42 antimicrobial,43 antimalarial,44 antileukemic,45 and AMPA receptor modulatory 
properties with potential for treating disorders of the brain.46  In addition, this impressive 
biological profile is supplemented by a number of chemical properties including facile 
coupling pathways for their formation, stability to hydrolysis, polarity and their crystalline 
nature.  Taken collectively, these attributes have allowed sultams to emerge as privileged 
structures in drug discovery. 
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Figure 1.4 Representative bioactive cyclic sulfonamides (sultams).   
 
Sultams have also gained prominence as attractive drug targets due to their extensive 
chemical and biological profiles.2a Sultams have been utilized as drugs (Figure 1.5), such as 
the anti-epileptic agent sulthiame,47 the anti-inflammatory agents ampiroxicam48 S-247449 
and acetazolamide 50  (carbonic anhydrase) used to treat glaucoma and seizures. 
Brinzolamide51  [trade name: Azopt®] is also as a carbonic anhydrase inhibitor, as well as a 
treatment for glaucoma.  Chlorothiazide52 [trade name: Diuril] as a thiazide diuretic, and 
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Benzthiazide 53  [trade name: Exna] is used for the treatment of blood pressure. 
Bendroflumethiazide54 [trade name: Naturetin] is used to treat hypertension, as well as heart 
failure. Naturetin also treats hypertension and heart failure, while Methyclothiazide55 [trade 
name: Aquatensen, Enduron] is used to treat high blood pressure and fluid retention. 
Hydrochlorothiazide56 [trade name: HydroDiuril, Esidrix] is utilized for the treatment of 
hypertension.  Trichlormethiazide [trade name: Achetin] has similar properties to 
hydrochlorothiazide, Polythiazide57 [trade name: Aquatensen, Renese] treats hypertension, 
congestive heart failure, edema, diabetes insipidus, renal tubular acidosis and prevents kidney 
stones to name a few uses. Cyclothiazide58 [trade name: Anhydron] is a positive allosteric 
modulator of the AMPA receptor, as well as a GABAA receptor negative allosteric 
modulator. Cyclothiazide59 is used as an adjunctive therapy in edema and is also used for the 
treatment of hypertension. Hydroflumethiazide60 [trade name: Saluron, Diucardin] is a drug 
for acute or chronic vascular hypertension. Diazoxide 61  [trade name: Proglycem] is 
potassium channel activator and inhibits the secretion of insulin from the pancreas.  
A second family of sultam drugs is a class of medications called non-steroidal anti-
inflammatory drugs (NSAIDs), including piroxicam62  [trade name: Feldene], meloxicam63 
[trade name: Mobic], Iornoxicam [trade name: Xefo] and Tenoxicam [trade name: Mobiflex]. 
These drugs impart both analgesic and antipyretic properties by a non-selective inhibition of 
cyclooxygenase (COX). Meloxicam, introduced by Boehringer-Ingelheim, selectively 
inhibits COX-2 over COX-1 and is usually used for pain relief. Lornoxicam and tenoxicam 
are utilized for the treatment of various types of pain resulting from inflammation of joints  
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Figure 1.5 Sultam drugs 
such as osteoarthritis, surgery, sciatica and other inflammations.  
 
1.4  Reactivity of Sulfonamides 
The biological activity of sultams has warranted them as attractive targets in drug 
discovery and inspired chemical methods for their synthesis.  In 2011, Majumdar and co-
workers,64 reported an extensive review of recent methods developed to access condensed 
(fused) sultams, including ring-closing metathesis (RCM), Diels-Alder, 65  and [3+2]-
cycloaddition reactions.  Our group has recently reported a number of methodologies for 
generation of various sultams.66  The aim of this introductory chapter will be to discuss 
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recent methods utilizing the versatile vinyl sulfonamide moiety.  
Methodologies employed for the synthesis of lactams can also be applied to sultams. 
However, sulfonamides differ in their physical and chemical attributes, when compared to 
their amide counterparts.  The presence of two electronegative oxygen atoms within the SO2 
moiety imparts greater inductive effect within sulfonamide than amide, and thus typically 
imparts a lower pKa, which enables alkylation under mild conditions (Figure 1.6).   
 
Figure 1.6 Sulfonamides vs amides. 
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engenders vinyl sulfonamides as potentially better Michael acceptors compared to the amide 
counterparts.66a,b,g-i  
This fact is substantiated by in silico calculations, which demonstrate a more electron 
deficient sulfur atom within the SO2 moiety than the carbonyl carbon atom of the lactam 
functional group (Figure 1.6).67  This property was exploited in a number of intramolecular 
oxa/aza-Michael reactions on vinyl sulfonamides furnishing 7- and 8-membered sultams, the 
latter in a unique “contra Baldwin Rules”, 8-endo-trig pathway.68  This cyclization is also 
aided by additional differences of atomic radius between sulfur and carbon (sulfur 100 pm, 
carbon 70 pm).  The properties outlined above for vinyl sulfonamides were also utilized in 
SNAr reactions of α-fluoro-benzenesulfonamides as compared to their amide analogs (Figure 
1.6).69  Benzene sulfonamides also undergo alkylation under mild conditions while the 
corresponding amides require much harsher conditions (usually a strong base).   
Taken collectively, the properties of sulfonamides such as low pKa and the ability to 
have highly electrophilic carbon centers (α- and β-) next to the sulfonamide functionality can 
be exploited in a number of reactions.  The next section will discuss methods developed 
utilizing the highly electrophilic double bond of vinyl sulfonamides in Michael additions, 
Heck reactions, Diels-Alder reactions and metathesis reactions towards the synthesis of 
complex sultams. 
 
1.5 Use of Vinyl Sulfonamide Synthons in the Construction of Sultams 
Ethylenesulfonic acids were first synthesized in 1887, however, it was more than a 
decade later for higher derivatives such as sulfonamides to be prepared by Autenreith and 
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Rudolph in 1901.70  While 2-aminoalkanesulfonic acids, ethylenesulfonic acid esters and 
propenesulfonic acids were synthesized in 1949.71  The reactivity of β-chloroethanesulphonyl 
chloride was explored by Leymann72 as early as 1885 who suggested the reaction of this 
compound with 3 equivalents of aniline in dry ether resulted in the synthesis of β-
phenylaminoethanesulphonanilide and a small amount of phenylanhydrotaurine.  In 1901, 
Autenreith and Rudolph 73  identified Leymann’s phenylanhydrotaurine as ethylene 
sulphonanilide and stated that it is due to the interaction of β-chloroethanesulphonyl chloride 
with aniline in cold benzene. Leymann had presumed the presence of  
β-chloroethanesulphonanilide in the oily residue isolated from their reaction.  Goldberg74 
attempted to isolate the β-chloroethanesulphonanilide by the reaction of β-
chloroethanesulphonyl chloride (1 equiv.) with aniline (2 equiv.) in acetone without the 
presence alkali yielding only ethylenesulphonilide together with a small amount of 
phenylaminoethanesulphonanilide.  Goldberg postulated three reactions were involved in this 
process which included (i) formation of the sulfonamide (ii) dehydrohalogenation and (iii) 
addition of amine to the double bond of the ethylenesulfonamide produced in the reaction. 
They also found out that alkyl amines reacted faster than aryl amines.  This was further 
substantiated by the fact that it was possible to isolate the ethylenesulfonarylamide in 
substantial yield when employing aryl amines, while the faster reacting alkyl amines only 
provided alkylaminoethanesulfonalkylamides.  Their route was more direct for the synthesis 
of ethylenesulfonarylamides by reaction of arylamines with β-chloroethanesulphonyl 
chloride compared with the routes described by others, including Kohler (1897,) 75  
Autenreith and Rudolph (1901), Autenreith and Koburger (1903), 76  and Cohen and 
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Clutterbuck (1922)77 that involves the utilization of ethane-α,β-disulfonyl chloride (Figure 
1.7).   
 
Figure 1.7 Various sulfonyl chlorides.  
Goldberg and co-workers also suggested that the low reactivity of  
α-chloroethanesulphonyl chloride,78 compared to β-chloroethanesulphonyl chloride, was due 
to the lability of the β-halogen in β-chloroethanesulphonyl chloride.  In 1951 Snyder79 and 
co-workers, as well as Rondestvedt and Wygant80 (1952) further tried to carry out the first 
examples of Diels-Alder reactions with vinyl sulfonamides.  However, thermal conditions 
failed to produce products in contrast to the successful Diels-Alder reactions of vinyl 
sulfonyl chlorides, vinyl sulfonic acids and vinyl methyl sulfone.   
In 1955, when Rondestvedt and Chang81 were able to carry out Michael additions of 
diazomethane and phenyl azide into various derivatives of ethylenesulfonic acid, including 
N,N-diethylethylenesulfonamide (Scheme 1.1).  The addition of diazomethane generated 
pyrazoles, which underwent isomerization by reaction with bromine forming the sulfonamide 
1.1.3, and also yielding compound 1.1.4 as an HBr salt.  
Scheme 1.1 Addition of diazomethane and phenyl azide to derivatives of 
ethylenesulfonamide. 
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1.5.1 Diels-Alder and metathesis strategies  
In 1996, Metz and co-workers used Lewis acid-catalyzed Diels-Alder conditions to 
carry out the first synthesis of sultams using vinyl sulfonamides, whereby they reported a 
highly diastereoselective intramolecular Diels-Alder of vinyl sulfonamides bearing furans or 
1,3-diene moieties to access δ− and γ-sultams (Scheme 1.2).65  They also synthesized 
enantiomerically pure δ- and γ-sultams utilizing Lewis acid-catalyzed intramolecular [4+2] 
cycloaddition of N-1-phenylethyl and furan-substituted vinyl sulfonamides by thermal 
activation and under high pressure.  The method was further optimized for reductive 
debenzylation of the sultams.   
Scheme 1.2 Accessing δ−  and γ−sultams via intramolecular Diels-Alder. 
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Scheme 1.3 Ring closing metathesis (RCM) reactions on allyl- and vinyl sulfonamides. 
 
In 2001, Chiacchio and co-workers84 synthesized a number of homo-chiral dipoles 
bearing a sulfonamide group from L-aminoacids (Scheme 1.4).  These dipoles were further 
utilized for the synthesis of enantiomerically pure, annulated sultams with different 
functional handles.  
 
Scheme 1.4 Homochiral annulated sultams via intramolecular [3+2] cycloaddition. 
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iosthiazole-1,1-dioxides was accomplished using different dipolarophiles as shown in 
Scheme 1.4. 
In 2001, Tozer and coworkers 85  synthesized substituted 2,3,3a-
hexahydrobenzo[d]isothiazole 1,1-dioxides and 3,4,4a,5,6,8a-hexahydro-2H-
benzo[e][1,2]thiazine 1,1-dioxides by a thermal Diels-Alder reaction of triene derivatives of 
buta-1,3-diene-1-sulfonic acid amides (Scheme 1.5).  A histamine H3 receptor antagonist 2-
(4-chlorobenzyl)-5-(1H—imidazol-4-yl)-2,3,3a,4,5,7a-hexahydrobenzo[d]isothiazole 
1,1dioxide 1.5.6 was synthesized utilizing the aforementioned methodology. 
Scheme 1.5 Hexahydrobenzo[d]isothiazoles and Hexahydro-2H-benzo[e]thiazine 1,1-
dioxides via Diels-Alder reaction.. 
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metathesis polymerization (ROMP or ROM polymerization) afforded the oligomeric 
sulfonamides of various length that were shown to be soluble in CH2Cl2. 
Scheme 1.6 RCM towards α,β-unsaturated γ-sultams. 
 
In 2009, Hanson and coworkers 87  reported a ring opening metathesis/ring-closing 
metathesis/cross metathesis (ROM–RCM–CM) cascade strategy furnishing a diverse 
collection of bi- and tricyclic sultams (Scheme 1.7).  This strategy allowed for the synthesis  
Scheme 1.7 Ring opening metathesis–ring closing metathesis–cross metathesis (ROM–
RCM–CM) protocol towards tricyclic sultams. 
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of functionalized sultam scaffolds via intramolecular Diels-Alder (IMDA) reactions in good 
yields and selectivity, which underwent metathesis cascades producing a variety of tricyclic 
sultams.  The ROM–RCM–CM protocol furnished sultams in good to excellent yields.  The 
skeletal and appendage-based diversity was controlled by elements incorporated into the 
sultam precursors or via the CM partner.  
In 2011, Hanson and coworkers reported a purification protocol involving the 
sequestration of excess IMDA-derived scaffold by employing ROM polymerization (ROMP) 
furnishing the oxa-norbornene scaffolds 1.8.1 (6-epoxybenzo[d]isothiazole-2-carboxylate 
1,1-dioxides) (Scheme 1.8).88  The method utilized excess scaffold and the diversification 
protocol included a reductive Heck reaction.  Upon completion of the reaction the separation 
of the starting material (excess scaffold) and the product was very tedious using standard 
column chromatography.  However, sequestration of the excess material was possible via a  
Scheme 1.8 Oxa-norbornene sequestrations by ROM polymerization (ROMP). 
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significant advances in this aspect, library planning is still the limiting factor in these 
strategies.89 In this regard, diversity-oriented synthesis (DOS)89,90 has surfaced as a means to 
address this issue by devising strategies for the facile synthesis of multiple scaffolds89-91 
possessing skeletal diversity.90-92  Forward-synthetic analysis89,90 and functional group (FG) 
pairing93 are important tools utilized in DOS. Forward-synthetic analysis defines strategies, 
which generate multiple scaffolds in the fewest possible steps, while FG pairing involves 
selective pairing of functional groups on a central functionalized linchpin, affording a variety 
of scaffolds with minimum steps.  These concepts form the basis of “Build/Couple/Pair 
(BCP)” paradigm established by Schreiber and co-workers.93b  This approach involves a 
“build phase” to construct chiral building blocks.  These building blocks possess orthogonal 
sets of functionalities which can be exploited for subsequent “Coupling and FG pairing” 
providing access to different scaffolds.   
 In 2008–2009, Hanson and co-workers devised a functional group (FG) pairing 
cyclization approach termed, "Click, Click Cyclize" that is essentially a sub-set of the BCP 
paradigm.  The approach is premised on FG pairing between a central FG and an array of 
functional groups affording skeletally diverse sultams.  This method was designed to gain 
access to skeletally diverse five-, six-, seven-, eight-, and nine-membered diverse sultams.  
Central to this protocol was the design and construction of building blocks termed as 
sulfonamide-linchpins that can be assembled via use of two consecutive “Click” reactions 
inherent to sulfonamide formation.94  In the formation of the sulfonamide linchpins, the first 
“Click” reaction is a sulfonylation of an amine with a sulfonyl chloride under mild conditions 
to generate a 2º sulfonamide, having a free SO2NH group of suitable pKa to allow a second 
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“Click” alkylation reaction to occur furnishing a 3º sulfonamide (Figure 1.8).  Once 
assembled, the 3º sulfonamide linchpin can undergo FG pairing95 with the respective 
functional handles leading to subsequent cyclization and facile assembly of skeletally and 
peripherally diverse sultam heterocycles. 
 
Figure 1.8 Sulfonamide linchpins 
Within the realm of Click, Click Cyclize we are continually exploring a number of 
reaction pathways involving FG-pairing between a central A sulfonamide-FG and different 
incorporated FG's within the sulfonamide linchpin (i.e B, C and D) (Figure 1.9).  Among the 
most commonly employed linchpins studied in our laboratory include those possessing a 
vinyl sulfonamide moiety (the focus of this chapter) as well as α-halo benzene sulfonamides.  
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More recent efforts have now been expanded to aziridinyl α-fluorobenzene sulfonamides, α-
Br-vinyl sulfonamides, and methyl aminoester/anthranilic ester sulfonamides (ongoing work 
in the group).  A rationally designed sulfonamide linchpin can produce a reaction manifold 
yielding at least four different scaffolds displaying skeletal diversity and peripheral ligand 
disparity (ie. pairing between A and B, A–C, A–D and A–E).  Overall, a number of strategies 
have been developed in our group utilizing Click, Click Cyclize and exploiting the FG-
pairing strategies.  A brief overview utilizing vinyl and α-halobenzene sulfonamides is 
highlighted in Figure 1.10.66  
 
Figure 1.10 Representative methods developed utilizing click–click–cyclize. 
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the oxa-Michael and Baylis−Hillman reactions on vinyl sulfonamides (prepared by suitably 
protected amino alcohols) a divergent synthetic approach was devised for the synthesis of 
new sultams (Scheme 1.9).  In this method, which was later termed Click, Click, Cyclize, 
both 7- and 8-membered ring sultam scaffolds were synthesized using oxa-Michael 
pathways, whereas the Baylis-Hillman pathway provided five- and six-membered ring 
sultams.  Good to excellent diastereoselectivity was obtained in Baylis-Hillman protocol.  A 
notable feature was that the oxa-Michael reaction to synthesize the 8-membered ring sultams 
provides empirical evidence validating 8-endo-trig cyclization pathways.    
Scheme 1.9 Oxa-Michael and Baylis-Hillman routes. 
 
In 2013, Zhou and coworkers continued this work further in their synthesis five- and 
seven-membered sultam derivatives through intra-Michael additions and they improved the 
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Scheme 1.10a Oxa-Michael and Baylis-Hillman. 
 
two different pathways in which they opened up an epoxide with an amine, followed by 
TBS-protection and subsequent sulfonylation with 2-chloroethane sulfonylchloride to furnish 
the Michael accepting linchpin 1.10.1 (Scheme 1.10a).  The reaction of linchpin 1.10.1 with 
TBAF afforded scaffold 1.10.2 via an oxa-Michael reaction (Scheme 1.10b). 
Scheme 1.10b Different Michael addition protocols. 
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furnished ketone 1.10.3.  Reaction of 1.10.3 with NaOtBu provided the five-membered 
scaffolds 1.10.5 through an intra-Michael reaction with the carbon next to the carbonyl group 
bearing an acidic hydrogen undergoing 5-endo-trig intramolecular cyclizations, which are 
traditionally disfavored according to Baldwin’s rules.  The same ketone 1.10.3 also 
underwent Baylis-Hillman reaction with DABCO and dioxane/H2O, which proved to be a 
good solvent for an otherwise sluggish ketone-type Baylis–Hillman reaction.  After the 
synthesis of the scaffold 1.10.4, four intermolecular Michael reactions with carbon-, 
nitrogen-, oxygen-, and sulfur-based nucleophiles were carried out. 
1.5.4 Click, Click, Cyclize and Functional Group Pairing 
In 2009, Hanson and co-workers reported a diversity-oriented synthesis (DOS) strategy 
termed “Click, Click, Cyclize” (Scheme 1.11).97  The central tertiary vinyl sulfonamide 
linchpins were exposed to a number of FG pairing pathways, which encompassed 
intramolecular Heck, aza-Michael, ring-closing enyne metathesis, Pauson-Khand, and 
chemoselective oxidation/Baylis-Hillman reactions.  A sulfonylation/allylation sequence 
yielded tertiary vinyl sulfonamide 1.11.2. However, when the allylation was done with 2,3-
dibromoprop-1-ene it furnished 1.11.2b, followed by a regioselective 6-endo-trig 
intramolecular Heck cyclization to afford the δ-sultam 1.11.4.  Allylation of sulfonamide 
linchpin 1.11.1 with allyl bromide provided 1.11.2a, which upon RCM yielded the five-
membered Michael accepting sultam scaffold 1.11.7.  Alternatively, ozonolysis of the 
allylated linchpin 1.11.2a followed by the Baylis-Hillman reaction, afforded scaffold 1.11.8.  
Michael reaction with allyl amine on the allylated linchpin followed by reaction with 
PhCOCl and then RCM produced the 10-membered scaffold 1.11.5.  In addition, hydrolysis 
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with LiOH, and DCC coupling, after the Michael reaction with allyl amine generated the 
amide-containing scaffold 1.11.6.  
 
Scheme 1.11 Click–click–cyclize and functional group pairing. 
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propargylated linchpin 1.11.3 afforded scaffold 1.11.9.  Collectively, the ease of substrate 
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Click, Click, Cyclize paradigm. 
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Different Hetero-Michael Strategies (Oxa-, Aza- and Thia-Michael) 
1.5.5. Oxa-Michael 
 In 2010, a formal [4+3] epoxide cascade protocol utilizing vinyl sulfonamides and a 
variety of epoxides was developed for the generation of oxathiazepine-1,1′-dioxides98 
(Scheme 1.12).  This protocol combines an epoxide ring opening with an SNAr on  
α-fluorobenzene sulfaamides as well as oxa-Michael cyclization pathway on 
vinylsulfonamides.  Using this method, oxathiazepine-1,1′-dioxides were synthesized in good 
yields as shown in Scheme 12. 
Scheme 1.12 Formal [4+3] epoxide cascade protocol. 
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sultam core scaffolds were synthesized based upon the protocol described above.  The 
peripheral diversity was performed in the form of a sequential, two-step [3+2] Huisgen and 
cycloaddition/Pd-catalyzed Suzuki-Miyaura coupling sequence to afford the aforementioned 
library.   
Scheme 1.13 Automated synthesis of of thiadiazepan-1,1-dioxide-4-ones. 
 
In 2011, Hanson and co-workers100 also reported the construction of two libraries of 
triazol-isothiazolidine 1,1-dioxides employing a one-pot Click/aza-Michael as well as a 
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Scheme 1.14 Synthesis of triazol-isothiazolidine 1,1-dioxides employing a one-pot click/aza-
Michael as well as a click/OACC esterification protocol. 
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furnish a 180-member triazol-isothiazolidine 1,1-dioxide library.  In order to exploit the 
click-esterification protocol, three different scaffolds were synthesized by an aza-Michael of 
three different amino alcohols.  The aforementioned scaffolds were diversified by a one-pot,  
multi-component click/esterification protocol employing a ROMP-derived coupling reagent 
(OACC) affording a 41-member library of triazol-isothiazole 1,1-dioxides. This methodology 
will be further elaborated in Chapter 3. 
 
1.5.7 Double-aza-Michael (DaM strategy) 
 In 2011, the electrophilic nature of the vinyl sulfonamides in aza-Michael reactions 
was further exploited to generate 1,2,5-thiadiazepane 1,1-dioxides using a strategy, termed 
double aza-Michael (DaM) (Scheme 1.15).101  In this approach, linchpin 1.15.1 was prepared 
by sulfonylation of 2-chloroethane sulfonyl chloride with TBS-protected serine methyl ester.  
Scheme 1.15 Double-aza-Michael (DaM strategy). 
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reaction took place with primary amines to generate functionalized 1,2,5-thiadiazepane 1,1-
dioxides.  The reaction was further optimized to include the elimination and the double aza-
Michael in a one-pot sequence.   
 In 2012, this method was optimized further on a continuous flow chemistry platform 
in collaboration with the Organ group at York University, resulting in scale out of the inter-
/intramolecular double aza-Michael addition using microwave-assisted, continuous flow 
organic synthesis platform (MACOS).102  The protocol was optimized for utilization in scale-
out on a MACOS platform.  This protocol was utilized for the synthesis of a 50-member 
library of functionalized 1,2,5 thiadiazepane 1,1-dioxides on a 100–300 mg scale with overall 
yields between 50–80% and over 90% purity utilizing a multicapillary flow reactor. 
 In 2012, a facile one-pot, sequential strategy utilizing in situ Huisgen cycloaddition 
following the double-aza-Michael was also developed, making this method amenable to 
library synthesis (Scheme 1.16).  Thus, a 96-member library of triazolated 1,2,5-
thiadiazepane 1,1-dioxides was completed on a Chemspeed Accelerator (SLT-100) 
automated parallel synthesis platform, resulting in the successful preparation of 94 out of 96  
Scheme 1.16 One-pot sequential double-aza-Michael (DaM strategy) and Huisgen 
cycloaddition. 
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possible products.103  The key step was a one-pot, sequential elimination, double-aza-Michael 
reaction, and [3+2] Huisgen cycloaddition pathway that were automated and utilized in the 
production of two sets of triazolated sultam products. 
 
1.5.8 Heck-Aza-Michael  
In 2012, Hanson and co-workers developed the synthesis of unique isoindoline- and 
tetrahydroisoquinoline (THIQ)-containing tricyclic sultams, utilizing a Heck-aza-Michael 
(HaM) strategy (Scheme 1.17a).104  The isoindoline and the THIQ rings were installed 
through a Heck reaction on a vinylsulfonamide, followed by one-pot deprotection and 
intramolecular aza-Michael reaction.  Subsequent cyclizations were carried out with either 
paraformaldehyde condensation or 1,1′-carbonyldiimidazole coupling yielding a number of 
tricyclic sultams.  This strategy was utilized for the synthesis of 160-member library, along 
with their isoindolines/THIQ and secondary sulfonamides precursors. 
Scheme 1.17a Heck-aza-Michael (HaM). 
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member library of isoindoline-annulated sultams in a few hours with excellent overall yields 
(54–87%) from simple starting materials. 
Scheme 1.17b Utilization of MACOS in the Heck-aza-Michael (HaM) pathway. 
 
1.5.9 Oxa-Michael and Aza-Michael 
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Scheme 1.18 Selective synthesis of seven- and eight-membered ring sultams via two tandem 
reaction protocols. 
 
 
1.5.10 Thia-Michael 
In 2012, Hanson and co-workers continued to further explore the Michael reaction 
with other nucleophiles and reported a thia-Michael protocol on the vinyl sulfonamide in a 
one-pot sulfonylation/intramolecular thia-Michael reactions for the synthesis of 1,5,2-
dithiazepine 1,1-dioxide (Scheme 1.19a).107  Sulfonylation was carried out by utilizing 
cysteine ethyl ester/cysteamine and 2-chloroethanesulfonyl chloride, and subsequent in situ 
intramolecular thia-Michael addition yielded the 1,5,2-dithiazepine-1,1-dioxide scaffolds.   
Scheme 1.19a One-pot sulfonylation and intramolecular thia-Michael. 
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Notably, the only report of synthesis of 1,5,2-dithiazepane 1,1-dioxide (1.19.3a) 
utilized 2,2'-dithiobis(ethylamine) dihydrochloride 108  in a two-step sequence involving 
sulfonylation and utilization of sodium borohydride to cleave the S–S bond resulting in the 
thia-Michael to afford desired product (Scheme 1.19b). During optimization studies a survey 
of base, additive, solvent and temperature showed that 3.5 equivalent of Et3N, 0.1 equivalent 
of DMAP, 40 ºC in CH2Cl2 provided the best results.  The reaction was carried out under 
mild conditions and the products were easily recrystallized and isolated as colorless needles 
albeit in moderate yields.  The moderate yields were attributed to polymerization via 
intermolecular pathways, 109 decomposition of cysteine ethyl ester was also noticed due to the 
detection of hydrogen sulfide smell.  The reaction was carried out up to 40-gram scale 
Scheme 1.19b Thia-Michael and further diversifications 
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various diversification pathways were explored as outlined in Scheme 18.  Benzylation of 
1.19.3b using substituted benzyl bromides gave products 1.19.4 in good yield.  Reaction with 
acyl chloride, in the presence of Et3N and DMAP resulted in acyl-products 1.19.5.  
Reduction of the ester group with NaBH4 followed by reaction with isocyanates furnished 
carbamates 1.19.6.  Amides 1.19.7 were synthesized via a two-step sequence of benzylation 
and amidation of the ester.  
 The aforementioned method was extended to include a library of bicyclic sultams 
incorporating 1,5,2-dithiazepine 1,1-dioxides.110  As already mentioned, the desired product 
1.19.3 was obtained in a single reaction step on 20-gram scale after recrystallization (CHCl3).  
With the large quantity of scaffold in hand, the free sulfonamide N-H and the nearby ester 
group were utilized for functional group manipulations and additional cyclization as shown is 
Scheme 1.20. 
Scheme 1.20 Thia-Michael and secondary cyclizations. 
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Amidation utilizing Boc-protected amino acids and subsequent treatment with TFA 
followed by quenching with water affected the in situ cyclization affording the secondary 
cyclization to form fused sultams 1.20.1 (Scheme 1.20).  A number of N-substituted (R)-
dihydro-2H-imidazo[1,5-b][1,5,2]dithiazepine-6,8(3H,7H)-dione 1,1-dioxides 1.20.2 were 
synthesized by treatment of 1.19.3b with isocyanates utilizing basic condition (K2CO3) in 
THF.  Reduction of 1.20.3b followed by mesylation and then treatment with primary and 
secondary amines furnished the diamines 1.20.3.  The primary amines provided additional 
cyclization oppurtunities. Reaction of 1.20.3b with 1,1'-carbonyldiimidazole (CDI), 1,2-
dibromoethane afforded the sultams 1.20.5, reaction with paraformaldehyde and 1,2-
dibromoethane furnished bicyclic products 1.20.4. 
In 2014, Hanson and coworkers 111  developed a one-pot, sequential protocol 
encompassing complementary ambiphile pairing (CAP) strategy involving the union of a 
vinyl sulfonamide with a variety of unprotected amino acids via aza-Michael addition and 
subsequent intramolecular amidation (Scheme 1.21).  Diverse, sp3-rich and stereochemically  
Scheme 1.21 Assembly of stereochemically rich acyl sultams. 
 
N
NS
OO
O
Ph
N
N
S
OO
O
Y
Ph
N
N
S
OO
O
Ph
N
N
S
OO
O
R1
Y
±
N
N
S
OO
O
R1
HO
S
Cl
O O
HN CO2H
HO
Cl
H2N R1
one-pot
sequential
multigram
protocol
N
N
S
OO
O
O
N
N
N
R4
R3
O
N
N
S
OO
O
HO
N
N
N
R4
3/4/5 
component
one-pot 
sequential 
protocols
Y = CH2, S Y = CH2, O ±
±
 37 
rich mono- and bicyclic acyl sultams were assembled in a highly scalable manner.  Modular 
pairing of stereochemically rich building blocks could be utilized to gain quick access to all 
possible isomers just by the change of the starting material stereochemistry.  This method 
was further extrapolated to one-pot, sequential 3-, 4-, and 5-multicomponent protocols.  The 
aforementioned method will be discussed thoroughly in Chapter 2. 
 
1.6 Conclusion 
In conclusion, the electrophilicity of the vinyl sulfonamide has been explored in a 
number of reactions including RCM, Diels-Alder, Baylis-Hillman Michael, as well as the 
Heck reaction, to develop methodologies for synthesis of a number of novel sultam scaffolds.  
Ring closing metathesis was employed to synthesize 5–, 6–, 7–membered sultams bearing the 
vinyl functionality in the ring, which was further employed in the Michael reaction.  Vinyl 
sulfonamides underwent Diels Alder reaction with side chains containing furans forming 
tricyclic 6-epoxybenzo[d]isothiazole 1,1-dioxide.  Vinyl sulfonamides were also utilized in 
the Baylis-Hillman reaction to construct five membered 4-hydroxy-5-
methyleneisothiazolidine 1,1-dioxides and six membered 5-hydroxy-6-methylene-1,2-
thiazinane 1,1-dioxides.  The vinyl sulfonamides were also exploited in a number of Michael 
reactions utilizing different nitrogen, oxygen as well as sulfur nucleophiles towards a number 
of sultams. Heck reaction was also exploited on vinyl sulfonamide giving rise to the Heck-
aza-Michael (HaM) strategy. These sultam moieties are void in the literature and have been 
synthesized for the exploration of chemical and biological space.  
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Chapter 2 
 
 
 
Rapid, Scalable Assembly of Stereochemically Rich, 
Mono- and Bicyclic Acyl Sultams 
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2.1 Introduction 
2.1.1 Complementary Ambiphilic Pairing Strategy (CAP-strategy) 
 The rapid synthesis of novel small molecule collections for high throughput 
screening (HTS), with a minimum number of steps and minimal use of protecting groups 
is an important goal in modern drug discovery.1  Ambiphilic reagents,2 also referred to as 
amphoteric molecules 3  and amphiphilic molecules, 4  have been utilized in organic 
synthesis in order to achieve step and atom economy,5 by taking advantage of the 
nucleophilicity and electrophilicity2,6,7,8,9 of orthogonal functional groups, thus increasing 
synthetic efficiency.  Recently, our group reported methods using ambiphilic vinyl 
sulfonamides or  
2-fluorobenzenesulfonamides with other ambiphilic reagents, namely epoxides10 and 
ortho-quinone methides11 for formal [4+3] and [4+4] complementary ambiphilic pairing 
(CAP) reactions in the synthesis of sultams (Scheme 2.1).   This chapter details our 
efforts toward the synthesis of non-benzofused sp3-rich12 mono- and bicyclic acyl sultams 
displaying skeletal and stereochemical diversity. 
Scheme 2.1. CAP strategies utilizing epoxides, ortho-quinone methides, and amino acids.  
 
 Amino acids are ideal starting materials due to their resident stereocenters, enriched 
functional group variance and extensive commercial availability.  In addition, they 
incorporate ambiphilic FGs that could undergo aza-Michael addition (amino group) and a 
S
N
H
O O
R
H2N
R1
OH
O
S
N
H
O O
R1
X
Formal [4+3] CAP
O
R2
S
N
H
O O
R2
F
O
o-Quinone
 Methide
R1
O CH2
Formal [4+4] CAP Herein reported 
CAP method
NucE+
Nuc E+
NucE+
Nuc E+
Ambiphile 2
Ambiphile 1
Merging
Ambiphilic
Synthons
 60 
coupling reaction (carboxylic acid).  To the best of our knowledge, the literature contains 
only a few reports since the early studies of the Michael addition of unprotected amino 
acids to acrylonitrile.13  Specifically, addition to acrylonitrile has been utilized to provide 
precursors for the synthesis of polyamines via reduction of cyano groups 14  and 
pyrrolidone15 or pyrazoles16 through Dieckmann condensations.  Other Michael acceptors 
for the addition of amino acids that have been reported include: esters,17 acrylaldehyde,18 
vinyl sulfones,19 and vinyl phosphoryl compounds.20  In spite of the versatile Michael 
reactions of unprotected amino acids, their addition to vinyl sulfonamides was absent 
from the literature before our work in this area.  
 
2.1.2 Bioactive acyl sultams/sulfonamides 
 Acyl sultams, which are a subset of sultams, that encompass unique physical and 
chemical properties rendering them attractive targets for probing biological systems.  
They exhibit a variety of biological activities, including antibacterial, anticancer, and 
anti-inflammatory properties, as well as unique biological profiles in different cell 
assays.21  A few important acyl sulfonamides and sultams with their relevant biological 
activity are discussed below.   
 In 2005, La Motta21a and coworkers synthesized acetic acid derivatives of naphtho 
[1,2-d ]isothiazole (NiT) which proved to be aldose reductase (ALR2) inhibitors (Scheme 
2.2).  Compound 2.2.1 exhibited modest inhibitory activity (IC50) 10 µM), but when the 
acetic acid functionality was replaced with a non-polar group, inactive or poorly active 
compounds were obtained.  This indicated that the 2-acetic acid group is most plausibly 
the pharmacophore, while the 4-carboxylic moiety has only an ancillary role.  
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Scheme 2.2. Some bioactive acyl sultams. 
  
 In 1998, Di Santo21b and co-workers synthesized novel inhibitors of human 
immunodeficiency virus type 1 (HIV-1) 1,2,5-benzothiadiazepine and pyrrolo[2,2-
d]benzothiadiazepine derivatives 2.2.2 possessing specific anti-human immunodeficiency 
virus type 1 (anti-HIV-1) activity (Scheme 2.2).  Bi- and tricyclic thiadiazine ring 
homologues of 7-chloro-2-ethyl-2H-1,2,4-benzothiadiazin-3-(4H)-one 1,1-dioxide were 
synthesized which possessed anti-HIV-1 activity.  
 In 1989, Abou-Gharbia and co-workers21c tested a variety of tetrahydro- and 
hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones 2.2.3 in a series of 
in vitro and in vivo tests to determine their pharmacological profile.  These compounds 
were orally active in blocking the conditioned avoidance response (CAR) but did not 
antagonize stereotypical apomorphine-induced behavior (Scheme 2.2).  Several 
compounds demonstrated moderate to high affinity for the 5-HT1A receptor-binding site.  
These compounds were also found to have potential anxiolytic activity. 
 In 1989, Chen and co-workers21e reported a variety of 4-amido-isothiazolidinone 
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oxide derivatives 2.2.4.  They designed these compounds as bacterial serine protease 
inhibitors. However, some of these compounds portrayed weak antibacterial activity as 
well. 
 In 1993, Groutas and co-workers21f synthesized a number of saccharin derivatives 
2.2.5 and evaluated their inhibitory activity towards human leukocyte elastase and 
cathepsin G.  A number of these compounds proved to be efficient and time-dependent 
inhibitors of elastase (Scheme 2.2).  
 In 2006, Güzel and co-workers21g demonstrated that reacting  
2-chloromethylsaccharin with substituted potassium dithiocarbamates and substituted 
potassium dithiocarbonates yielded (1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-
yl)methyl N,N-disubstituted dithiocarbamates and (1,1-dioxido-3-oxo-1,2-benzisothiazol-
2(3H)-yl)methyl O-alkyldithiocarbonates, respectively 2.2.6 (Scheme 2.2).  Evaluation of 
these compounds showed they possessed in vitro anti-mycobacterial activity against 
Mycobacterium tuberculosis H37Rv.  Some of these compounds showed cytotoxicity, 
especially against leukemia cell lines CCRF-CEM, HL-60(TB), RPMI-8226, SR and 
against the non-small cell lung cancer NCI-H522 cell line.  Cytotoxicity against the 
leukemia cell line HL-60(TB) and favorable cytotoxicity against the ovarian cancer cell 
line OVCAR-3 was also portrayed by some compounds. 
 In 2001, Pomarnacka and co-workers21i reported the syntheses of 3,4-dihydro-2H-
1,5,2-benzo[f]dithiazepin-3-one 1,1-dioxides 2.2.7 and their corresponding 1,1,5,5-
tetraoxides (Scheme 2.2).  They were evaluated at the US National Cancer Institute 
(Bethesda) revealing the in vitro antitumor activity of 7-chloro-3,4-dihydro-8-methyl-4-
phenyl-2H-1,5,2-benzo[f]dithiazepin-3-one 1,1-dioxide. 
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 In 2012, McGow and co-workers22 synthesized conformationally constrained 1,6- 
and 2,6-macrocyclic HCV NS5b 2.2.8 as polymerase inhibitors (Scheme 2.2).  The 
nitrogen or phenyl ring in the C2 position of the central indole core was tethered to an 
acylsulfamide acid bioisostere.  These macrocycles were designed and tested for their 
anti-HCV potency. This transformational route afforded non-zwitterionic finger loop-
directed inhibitors with improved cell potency and pharmacokinetic profile.  
 In 2013, Glunz and co-workers 23  successfully replaced the more basic P1 
benzamidine of an acylsulfonamide factor VIIa inhibitor with aminoisoquinoline and 
isoquinoline groups that improved the bioavailability in this chemotype (Scheme 2.3a).  
In 2014, Llinàs24 and co-workers discovered inhibitors of hepatitis C virus NS3-4A 
protease with an improved barrier to resistance and had a favorable liver distribution.  
They reported that the macrocyclic acylsulfonamide 2.3.2 was an HCV protease inhibitor 
that displayed potency against relevant clinically resistant variants (Scheme 2.3a).   
Scheme 2.3a. Some bioactive acyl sulfonamides. 
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 In 2012, Schroeder and co-workers25 synthesized 5-butyl-1,4-diphenyl pyrazole and 
2-amino-5-chloro pyrimidine acylsulfonamides 2.3.3a and 2.3.3b as potent dual 
antagonists of Bcl-2 and Bcl-xL (Scheme 2.3a).  In 2012, Rikimaru and co-workers26 
synthesized non-TZD, non-carboxylic acid peroxisome proliferator-activated receptor 
(PPARy) agonists by replacing the benzylpyrazole core of the previously reported 
agonists.  They introduced a pentylsulfonamide group into arylpropionic acids derived 
from previously synthesized PPARy ligands and identified 2-pyridyloxybenzene-
acylsulfonamide 2.3.4a as their lead compound.   
 In 2012, Chen27 began with an indole-based C3 pyridone lead HCV polymerase 
inhibitor 2.3.5a, and performed structure activity relationship (SAR) studies at various 
positions of the indole core.  Acylsulfonamides were incorporated as acid isosteres to 
improve pharmacokinetic (PK) properties at the C2 position (Scheme 2.3b).  Further 
optimization resulted in the identification of compound 2.3.5b as having excellent 
potency in both NS5B enzyme (IC50  = 8 nM) and cell-based replicon (EC50 = 0.02 µM) 
assays.  Zhu28 designed and synthesized a series of pyridine acyl sulfonamide derivatives 
as potential cyclooxygenase-2 (COX-2) inhibitors.  Compound 2.3.6 displayed the most 
potent COX-2 inhibitory activity with an IC50 of 0.8 µM.  Antitumor and anti-
inflammatory assays showed that compound 2.3.6 possessed high anti-proliferative 
activity against B16-F10, HepG2 and MCF-7 cancer cell lines as well as COX-2-derived 
prostaglandin E2 (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line 
with IC50 values of 2.8, 1.2, 1.8 and 0.15 µM, respectively.  Docking studies were 
performed to determine the probable binding model at the COX-2 active site.   
 In 2009, Singh and co-workers29 developed a series of potent and selective EP3 
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receptor antagonists.  Utilizing a pharmacophore model developed for the EP3 receptor, 
they synthesized a series of 3,4-disubstituted indoles 2.3.7, which proved to be high 
affinity ligands for the EP3 receptor (Scheme 2.3b).  In 2008, Burch and co-workers30 
discovered a new series of EP4 antagonists based on a quinoline acylsulfonamide scaffold 
2.3.8 for the treatment of chronic inflammation.  The binding potency of these 
compounds was at sub-nanomolar level, and they exhibited intrinsic binding potency 
towards the EP4 receptor.  These molecules also portrayed excellent selectivity towards 
other prostanoid receptors.   
 In 2007, Yan and co-workers 31  designed a novel series of thiazolone-
acylsulfonamides 2.3.9 as HCV NS5B polymerase allosteric inhibitors (Scheme 2.3b).  
The potential of these moieties to explore an additional pocket in the allosteric site was 
steered by structure based drug designs (SBDD) utilizing the docking results.  These 
molecules contain thiazolone and an acylsulfonamide linker that was connected with a 
substituted aromatic ring.  These compounds portrayed low µM activity.   
 In 2004, Lobb32 reported two closely related diaryl acylsulfonamides 2.3.10 as 
potent antitumor agents against a broad spectrum of human tumor xenografts (colon, 
lung, breast, ovary, and prostate) in nude mice (Scheme 2.3b).  Their activity against 
colorectal cancer xenografts was most interesting.  Although the molecular target of the 
compounds is still unclear, it was found that the vascular endothelial growth factor-
dependent human umbilical vein endothelial cells assay in combination with a soft agar 
disk diffusion assay, allowed for optimization of potency in the series.  The authors also 
reported pharmacokinetic properties and in vivo activity in an HCT116 xenograft model 
for the mentioned compounds.   
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 Burke 33  reported a family of new analogues that utilize acylsulfonamido 
functionality 2.3.11 to both mimic water of hydration and to provide an additional new 
site for elaboration not found in the parent carboxyl-containing analogue (Scheme 2.3b).  
This work was built on a previous report, which stated that 6-(phosphonodifluoromethyl)-
2-naphthoic acid binds to the protein-tyrosine phosphatase PTP1B with its 2-carboxyl 
group, interacting through a bridging water molecule.  Aryl acylsulfonamides studied in 
this paper are a structure-based extension of inhibitor design in the development of 
PTP1B inhibitors. 
Scheme 2.3b. Some bioactive acyl sulfonamides. 
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acyl sultams were absent from the literature before we started this work.  The next section 
of chapter two details our efforts in this regard. 
 
2.2 Results and Discussions 
 In light of the rich biological profile highlighted in the preceding section, we 
focused efforts toward the generation of an unexplored class of acylsultams, namely non-
benzofused sp3-rich 34  mono- and bicyclic acyl sultams displaying skeletal and 
stereochemical diversity.  In this approach, we utilized a strategy, termed complementary 
ambiphilic pairing (CAP), vide infra, whereby vinyl sulfonamides and unprotected amino 
acids were employed in a one-pot, sequential aza-Michael addition/intramolecular 
amidation reaction (formally a [4+3] heterocyclization) (Figure 2.1).  
 The development of multicomponent, one-pot reaction strategies that allow for 
facile assembly of heterocyclic scaffolds, with minimum purification is particularly 
desirable in modern organic synthesis.35  These one-pot strategies are amenable to 
diversity-oriented synthesis (DOS), which has emerged as a powerful strategy for 
systematically probing biological space aimed at uncovering novel leads.36  Among 
several approaches, the build-couple-pair,37 and functional group pairing37b strategies 
(Chapter 1) have featured prominently in advancing DOS.  We recently reported the 
concepts of complementary ambiphilic pairing (CAP)38 and reaction pairing39 as DOS 
strategies for the facile generation of diverse sultam scaffolds.  In this regard, the 
complementary union of ambiphilic40 synthons, in a formal [m+n] fashion ([4+3] and 
[4+4]), allows access to diverse cyclic heterocycles in a step-economical approach.41  It 
was envisioned that the combination of ambiphilic vinyl sulfonamides and amino acids 
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could be used in a CAP reaction to generate sp3-rich34 monocyclic and bicyclic 7-
membered acyl sultams in a library amenable approach (Figure 2.1).   
Figure 2.1. Complementary ambiphilic pairing (CAP): vinyl sulfonamides and 
unprotected amino acids 
 
 The CAP method employed utilizes the ambiphilic nature of both vinyl 
sulfonamides and amino acids, whereby sulfonamides due to their ambiphilic nature, can 
readily undergo hetero-Michael additions as well as facile amidation.  Moreover, amino 
acids are ideal starting materials as they allow for encoding stereochemical, skeletal and 
peripheral diversity.  Previous investigations have shown that vinyl sulfonamides are 
ambiphilic synthons that readily undergo N-alkylations, 42  and participate in [4+3] 
epoxide-opening/Michael protocols.38a  However, while amino acids have been shown to 
undergo aza-Michael to acrylonitrile,43 acrylate esters,44 acrylaldehydes,45 sulfones,46 and 
vinylphosphoryl compounds47, the aza-Michael addition of unprotected amino acids to 
vinyl sulfonamides was void in the literature before we started this body of work. 
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2.2.1 Optimization of conditions 
 Our investigation started with the Michael addition of trans-3-hydroxy-(L)-proline 
to N-propargylic vinyl sulfonamide in the presence of 0.2 equivalents of DBU.  Different 
solvents (MeOH and CH3CN) were probed for this reaction.  It was noticed that 
overnight stirring with these solvents at 60 ºC did not furnish the product (Table 2.1, 
entry 2).  However, changing the base to Et3N generated the product in moderate yield.  
Due to the partial solubility of amino acids in MeOH a 1:1 mixture of MeOH/H2O was 
employed as the solvent, along with Et3N as the base, cleanly furnishing the desired 
Michael adduct with complete consumption of the starting material.  The reaction 
mixture was further concentrated to dryness followed by the addition of DMF along with 
EDC, HOBt and Et3N with overnight stirring to afford the desired bicyclic acyl sultam 
2.4.2e in 64% yield.  
 
2.2.2 Scope and scale-up of reaction 
 Investigation of the substrate scope and the scalability disclosed that the reaction 
worked well with a variety of alkyl- and benzyl amine-derived vinyl sulfonamides 
affording the desired products in good to excellent yields on multi-gram scales (Scheme 
2.4).  This one-pot protocol was shown to be scalable to produce 28 grams of 2.4.2e (64% 
isolated yield).  Also significant, is the ability to utilize a hydroxy-functionalized amino 
acid without the need for any protection in the Michael addition step (Table 2.1). 
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Scheme 2.4. Scope and scale-up of bicyclic acyl sultam 2.4.2e.   
 
Table 2.1.  
entry R scale 2.4.2 yield %a 
1 Bn 0.2 g NR 0b 
2 propargyl 0.2 g NR 0b 
3 n-butyl 2 g 2.4.2a 67c 
4 4-OMe-Bn 1 g 2.4.2b 72c 
5 allyl 12 g 2.4.2c 86c 
6 Bn 12 g 2.4.2d 76c 
7 propargyl 28 g 2.4.2e 64c 
aFinal isolated yield after flash chromatography. bConditions: DBU (0.2 equiv) in MeOH 
or DBU (0.2 equiv) in MeCN. cAza-Michael: trans-L-Hydroxyproline (1.0 equiv), Et3N 
(3.0 equiv), MeOH/H2O (0.5 M, 1:1), 60 ºC, 12 h. Amidation: EDC (2.0 equiv), HOBt 
(0.2 equiv), Et3N (2.0 equiv), DMF (0.05 M), rt, 14 h.   
  
2.2.3 Stereochemical diversity 
 Investigations were next focused on a modular approach using chiral amino ester-
derived vinyl sulfonamides.  Utilizing the enantiomers of α-methylbenzylamine-derived 
vinyl sulfonamides, 2.5.2 and 2.5.3, together with both L-trans- and D-cis-
hydroxyproline in the aforementioned CAP method, gratifyingly furnished a collection of 
four diastereoisomers (2.5.4, 2.5.5, 2.5.6 and 2.5.7) in good yields without any signs of 
racemization (Scheme 2.5).  
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Scheme 2.5. Generation of stereochemical diversity. 
 
 Further extension to bicyclic acyl sultams was realized utilizing a variety of cyclic 
amino acids (Scheme 2.6).  In this method, the generation of stereochemically-rich 
libraries could be achieved by a simple change in the amino acid/amino ester pair. 
Scheme 2.6. One-pot, sequential [4+3] CAP strategy to generate bicyclic sultams with 
an array of cyclic amino acids.  
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Hence, (L)-alanine tert-butyl ester-derived vinyl sulfonamide was subjected to the 
established one-pot, CAP protocol employing D- and L-proline affording the acyl sultams 
2.6.8 and 2.6.9 without decomposition of the ester (Scheme 2.6).  Some interesting 
examples include azetidine 2-carboxylic acid, (R)-thiazolidine-4-carboxylic acid, 2-
(pyrrolidin-2-yl)acetic acid and morpholine 3-carboxylic acid to provide the 4,7-fused, 
5,7-fused, 5,8-fused, and 6,7-fused bicyclic systems, respectively.   
 The methodology was further extended to acyclic amino acids with a variety of  
N-substituted vinyl sulfonamides utilizing the same protocol (Table 2.2).  Amino acids 
bearing alkyl side chains (leucine, isoleucine, valine and alanine) gave good yields in a  
highly scalable manner.  The reaction conditions also tolerated amino acids with 
Scheme 2.7. Substrate scope – acyclic amino acids. 
 
Table 2.2.  Monocyclic scaffolds. 
entry R1 R2 2.7.1 yield %a 
1 Ph iBu 2.7.1a 63 
2 4-F-Ph sec-Bu 2.7.1b 65 
3 4-F-Ph iPr 2.7.1c 67 
4 4-Cl-Ph Me 2.7.1d 65 
5 (CH2)6CH3 CH2SH 2.7.1e 33 
6 Ph (4-OH)-Bn 2.7.1f 41 
a Final isolated yield after flash chromatography. 
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unprotected nucleophilic side chains (unprotected, trifunctional amino acids) such as 
tyrosine and cysteine, which reacted well, albeit in lower yields. 
 
2.2.4 One-pot, sequential [4+3] CAP 3/4/5-component reaction 
 Synthesis of functionally diverse small molecule collections for high throughput 
screening is an important aspect of modern drug discovery.  In this respect, the 
development of multicomponent, one-pot reaction strategies is particularly important for 
the facile assembly of heterocyclic scaffolds, with minimum purification is highly 
desirable.48  Moreover, methods that aspire to the step, atom, and redox economy, as well 
as the virtues of protecting-group-free synthesis are among the most efficient.5  Recently, 
Hayashi and coworkers49 have brought to light the significance of multi-reaction, one-pot 
protocols.  Building on these results the CAP method was next extended to a one-pot, 
sequential protocol by increasing the number of reactions that could be carried out before 
chromatographic intervention, and thus increasing synthetic efficiency.35a-d  In this 
regard, a one-pot, sequential 3-component protocol was devised and started with the 
sulfonylation of 2-chloroethane sulfonyl chloride with benzyl amine utilizing Et3N (2.0 
equiv).  Upon completion of reaction, the mixture was concentrated to dryness and the 
crude sulfonamide was subjected to the established one-pot, aza-Michael addition–
intramolecular amidation with a variety of cyclic amino acids, to furnish the desired 
products in 39–85% final isolated yields.  This one-pot, sequential 3-component protocol 
was also found to work with acyclic amino acids (DMF was the preferred solvent for 
cyclic amino acids, while CHCl3 at 50 ºC was used for acyclic amino acids) to furnish the 
corresponding acyl sultams in moderate to good overall yields. 
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 Building upon these results, a one-pot process that would also incorporate 
diversification was devised (Scheme 2.8).  In this regard, highly functionalized sultam 
scaffolds were constructed utilizing one-pot, sequential, 4 and 5-component reaction 
sequences.  Initially, the method was further extended to a one-pot, sequential, 4-
component reaction protocol using different pathways (Scheme 2.8).  Four reactions were 
set up employing the one-pot sulfonylation–aza-Michael−intramolecular amidation 
sequence with benzyl and propargyl amines and trans -3-hydroxy-(L)-proline.  Upon 
completion of the four parallel reactions, solvent was evaporated, followed by the 
addition of CH2Cl2.  To the first crude reaction a fourth component, cyclohexyl 
isocyanate, was added followed by DMAP and heating at 50ºC to furnish the desired 
carbamate 2.8.1 in 37% yield after chromatography (78% avg yield/rxn).  To the second 
reaction, CH2Cl2/t-BuOH/H2O were added in a 1:1:1 ratio, followed by the addition of 
copper sulfate, sodium L-ascorbate and 4-methylbenzyl azide, to generate the 
corresponding triazoylated thiadiazepin-1(2H )-one-3,3-dioxide 2.8.2 in 45% yield after 
chromatography (82% avg yield/rxn).  The third crude reaction was carried on to an 
esterification reaction with 4-methyl benzoic acid utilizing EDC, HOBt, Et3N to afford 
the corresponding esterified product 2.8.3 in 42% yield after chromatography (81% avg 
yield/rxn).  The fourth reaction mixture, esterification with 4-methyl benzoic acid (fourth 
component) was performed in the same manner as above, followed by the subsequent 
click reaction with 4-methylbenzyl azide (fifth component) furnishing the desired 
triazolyl esterified [1,2,5]thiadiazepin-1(2H)-one-3,3-dioxide 2.8.2 in 35% yield (81% 
avg yield/rxn). 
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Scheme 2.8. One-pot, sequential 4/5-component reaction to stereochemically-rich 
sultams. 
 
 
2.3 Conclusion 
 In conclusion, a highly scalable, one-pot CAP reaction employing vinyl 
sulfonamides and amino acids for the preparation of skeletally, stereochemically and 
peripherally diverse sp3-rich acyl sultam scaffolds has been developed.  The methodology 
was also extended to various one-pot, sequential 3-, 4- and 5-component reaction 
protocols.  The developed method is easily adaptable for the preparation of 
stereochemically rich acyl sultam libraries.  The synthesized libraries utilizing this 
method will be discussed in Chapter 3. 
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Chapter 3:  
One-pot, Sequential Methods and ROMP-Facilitated 
Protocols for use in the Synthesis of Sultams Libraries 
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The development of protocols for the rapid synthesis of novel/privileged heterocyclic 
small molecule collections for high throughput screening (HTS) with minimized steps and 
protecting group manipulations is an important aspect in modern drug discovery.1  The 
necessity for the synthesis of these small molecules, which can act as new pharmaceutical 
leads and small molecular probes, is an important objective of NIH (National Institute of 
Health).  In order to pursue this goal, the development and emergence of new methods, 
protocols and technologies to access diverse collections of small molecules in a rapid fashion 
is very important.2  
Section: 3.1  Stereo-controlled Diversification of sp3-Rich Bicyclic Acyl Sultams via 
One-pot Click-Esterification and One-pot Sequential Click-Mitsunobu Protocols 
Building on the importance of sultams as drug-like molecules, a library of 
thiadiazepan-1,1-dioxide-4-ones 3  was synthesized and sent to different biological 
collaborators for testing.  These compounds demonstrated promising activity in a number of 
assays.  The results prompted us to synthesize analogs of these compounds.  Initially, a 
simple change in the location of the carbonyl within the side chain was targeted, (derived 
from the corresponding amino acid) affording novel acyl sultams as shown in Figure 3.1.  
Acyl sultams, which are a subset of sultams, possess unique physical and chemical properties 
rendering them attractive targets for probing biological systems.  During the last decade a 
variety of bioactive acyl sulfonamides/sultams pharmacophores have been reported that 
embody an array of bioactivities, including antibacterial, anticancer and anti-inflammatory 
properties as highlighted in Figure 3.2.4  
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Figure 3.1. Thiadiazepin-1(2H)-one 3,3-dioxide vs thiadiazepan-1,1-dioxide-4-ones. 
 
 
Figure 3.2 Bioactive acyl sultams. 
Acyl sultam scaffold 3.1.1 was synthesized according to the procedure reported 
previously in our group and detailed in Chapter 2 (Scheme 3.1).5  The protocol for the 
synthesis of the scaffold comprised of sulfonylation with propargyl amine, Michael addition 
with L-trans-hydroxyproline and amide coupling to afford the scaffold (8,9aS)-8-hydroxy-2-
(prop-2-yn-1-yl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide 3.1.1 on 
a 28 gram scale with 64% yield over three steps in a one-pot sequence (average yield of 87% 
per step).  In addition, the core scaffold contains a propargyl handle, which can undergo 
Huisgen [3+2] cycloaddition and also bears an alcohol moiety, which can be esterified 
utilizing classical coupling conditions as well as the Mitsunobu6 alkylation reaction.  Overall, 
this approach imparts the element of stereochemical diversity, since both cis- and trans-
diastereoisomers can be generated in a facile manner.  
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Scheme 3.1 Synthesis of the core scaffold 3.1.1. 
 
 For diversification, a simple strategy employing esterification and Huisgen [3+2] 
cycloaddition on the propargyl moiety was utilized (Figure 3.3).  Alternatively, Mitsunobu 
alkylation of the carbinol, followed by Huisgen [3+2] cycloaddition, would provide the 
diastereoisomer (L-cis-hydroxyproline-derived compound).  The protocol was fine-tuned to 
carry out these processes in a one-pot (esterification-click) and one-pot sequential manner 
(Mitsunobu-click).  A 135/158-member compound library was generated utilizing these 
protocols. 
 
Figure 3.3 Stereochemical diversification via Mitsunobu and esterification. 
3.1.1 Results and Discussion 
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(OACC) 7 was employed as the coupling reagent and the click reaction was carried out in the 
N
N
S
OO
O
EDC, HOBt 
Et3N
DMF, rt, 
14 hrs
HO
S
N
H
O O
HN CO2H
HO
Et3N
MeOH, H2O
60 ºC, 12 h
N
COOH
N
H
S
OO
HO
3.1.1
Cl
S
Cl
OO
H2N
Et3N
CH2Cl2
N
N
S
OO
O
O
N
N
N
R2
R1
ON
N
S
OO
O
HO
R1-CO2H
R2 N3
N
N
S
OO
O
O
N
N
N
R2
R1
O
N C N Cy
Oligomeric alkyl 
carbodiimide
OACC 3.2 mmol/g
One-Pot, Click – OACC 
Esterification Protocol
One-Pot, Click – MoM 
Mitsunobu Protocol
Nb-taggd benzylethyl 
azodicarboxylate Nb-BEAD
Nb-tagged 
triphenyl phosphine Nb-TPP
ROMP-facilitated
One-Pot, sequential
3-component  Protocols
Monomer on Monomer (MoM)
Mitsunobu
 92 
same pot utilizing a protocol previously developed in the Hanson laboratory.8  Minimal 
optimization was required for the employment of this methodology.  The first condition 
investigated utilized 1 equivalent of scaffold, 1.1 equivalents of azide, 1.1 equivalents of 
carboxylic acid, 10 mol% equivalents of CuI as well as 10 mol% equivalents of DBU and 
DMAP along with 1.1 equivalents of OACC yielding 54% of the product. Increasing the 
mol% of CuI to 30 resulted in a slight decrease in the yield, and heating at 50ºC also resulted 
in a 45% yield. Increasing the mol % of CuI to 30 mol% and DBU as well as DMAP to 50 
mol% again resulted in a similar yield. However, a marked increase in yield was noticed with  
Scheme 3.2 One-pot, click esterification protocol. 
 
Table 3.1 Optimization of conditions for the one-pot, click esterification protocol. 
entrya azide (1) (equiv.) 
RCO2H 
{1} 
(equiv.) 
CuI  
(mol %) 
DBU 
(mol%) 
DMAP 
(mol%) 
OACC 
(equiv.) 
Temp. Isolated 
yield (%) 
1 1.1 1.1 10  10  10  1.1 rt 54% 
2 1.1 1.1 30  10  10  1.1 rt 45% 
3 1.1 1.1 30  10  10  1.1 50ºC 47% 
4 1.1 1.1 30  50  50  1.1 rt 46% 
5 1.1 1.1 30  10  10  1.5 50ºC 64% 
aReactions carried out utilizing 3.1.1 (50 mg,  0.2 mmol, 1 equiv.) in 0.5 M CH2Cl2 for 12 hrs 
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30 mol% CuI, 10 mol% DBU and DMAP, 1.1 equiv. azide and carboxylic acid and most 
notably, increasing the equivalents of OACC to 1.5 at 50ºC afforded the desired product in 
64% yield in a one-pot protocol over two steps (84% yield per reaction). This protocol was 
considered adequate for the synthesis of a library. 
Stereochemical diversification was further exploited by utilizing the Mitsunobu 
reaction to furnish the cis-diastereoisomer from the same starting material.  Steps were taken 
for the development of a one-pot, sequential click Mitsunobu protocol to access the 
derivatized cis-diastereomer as shown in Scheme 3.4.  This streamlined route would avoid 
utilizing expensive L-cis-hydroxyproline, as well as proceeding through the whole process of 
making a new starting material, emphasizing the importance of the Mitsunobu reaction, 
which affords the cis-diastereoisomer of the esterified product in a single step.  In addition, 
developing a one-pot, sequential protocol for both the Mitsunobu and click reactions was 
deemed challenging, as any remaining unspent triphenyl phosphine (utilized in the 
Mitsunobu) and azide (utilized in the click) would react with each other to form an 
iminophosphorane, which on hydrolysis would yield the corresponding amine (Staudinger 
reaction).9  The Mitsunobu reaction, being more sensitive, was performed first followed by 
addition of the excess azide, CuI and DMAP to effect the Huisgen [3+2].  Even though the 
Mitsunobu reaction is widely used for stereospecific inversion of an alcoholic stereocenter, 
the purification procedure is tedious due to the formation of a number of side products.  
Thus, utilizing monomeric norbornenyl (Nb) tagged-BEAD and monomeric Nb tagged-PPh3 
for the Mitsunobu10 reaction facilitated the purification of these reagents as well as of the by-
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products, the monomeric norbornenyl (Nb) tagged-reduced-BEAD and monomeric Nb-
tagged-PPh3=O by application of ROMP sequestration using Nb-tagged silica as the last step.   
In order to develop this protocol, a variety of conditions were investigated.  The 
initial conditions employed included adding 1 equivalent of the scaffold, 1.2 equivalents of 
carboxylic acid, 1.2 equivalents of NB-BEAD, 1.2 equivalents of Nb tagged-PPh3, in CH2Cl2 
at rt and stirring for 10 minutes, followed by the addition of 2 equivalents of azide and 
subsequent addition of 20 mol % of CuI as well as 20 mol % of DBU followed by subsequent 
sequestration with the Grubbs second generation catalyst (G-II catalyst)11 which afforded no 
product.  Changing the equivalents of the acid component from 1.2 to 2.0 still afforded no 
product.  Heating in THF at 45ºC afforded no product as well.  However, when the reaction 
was carried out in THF at room temperature the required product was isolated in 26% yield 
after column chromatography.  Increasing the equivalents of the azide to 3.0, and performing 
the reaction in THF at room temperature, as well as increasing the time for the Mitsunobu 
reaction from 10 minutes to 12 hours, provided a boost in the yield to 47%.  
 Further optimization revealed that addition of 1.0 equivalent of the scaffold, 1.2 
equivalents of carboxylic acid, 1.5 equivalents of NB-BEAD, 1.5 equivalents of PPh3, in 
THF at room temperature and running the reaction for 12 hours afforded the Mitsunobu 
intermediate with complete consumption of the starting material by TLC.  After the 
completion of the Mitsunobu reaction, 3.0 equivalents of azide were added, followed by the 
addition of 20 mol% CuI and 20 mol% DBU (Table 3.2, entry 6).  The reaction was run for 
another 12 h, and sequestered by the addition of the G-II catalyst11 followed by the addition 
of Nb-tagged silica to scavenge the by-products and excess starting material.  The 
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polymerization reaction was left to stir at 45ºC overnight, and was followed by cooling of the 
reaction to room temperature and subsequent addition of ethyl vinyl ether (EVE) to quench  
Scheme 3.3. One-pot, sequential click Mitsunobu protocol. 
 
Table 3.2 Optimization of one-pot, sequential click Mitsunobu protocol. 
entrya 
azide 
{1} 
(equiv.) 
RCO2H 
(1) 
(equiv.) 
CuI 
(mol 
%) 
DBU 
(mol%) 
Grubbs-
II 
(mol%) 
Nb-
BEAD 
(equiv.) 
Nb-
PPh3 
(equiv.) 
Solvent Temp. 
Isolated 
yield (%) 
1 2 1.2 20 20 20 1.2 1.2 CH2Cl2 rt No Pdt. 
2 2 2 20 20 20 1.2 1.2 CH2Cl2 rt No Pdt. 
3 2 1.2 20 20 20 2 2 THF 45ºC No Pdt. 
4 2 1.2 20 20 20 1.2 1.2 THF rt 26% 
5 3 1.2 20 20 20 1.2 1.2 THF rt 47% 
6 3 1.2 20 20 20 1.5 1.5 THF rt 63% 
aReactions carried out utilizing 3.1 (10 mg,  0.04 mmol, 1 equiv.) for 12 hrs 
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the reaction.  The reaction was run for an additional 30 minutes, followed by addition of 
EtOAc, and filtration through an SiO2 SPE.  After purification through a column, the final 
product was obtained in 63% yield.  These reaction conditions were considered satisfactory 
to carry on to a library platform.  After optimizing the conditions, a prototype library was 
synthesized utilizing the click-esterification protocol employing 4-fluorobenzoic acid and 
azides {1}, {2}, {3}, {9} and {10} as shown in Table 3.3.  
Table 3.3. Prototype library demonstrating utilization of carboxylic acid 1 with azides  
azides {1}, {2}, {3}, {9} and {10}  Scaffold (Carboxylic acid, {Azide}). 
entrya Compound 
Isolated 
yield (%) entry
a Compound  
Isolated yield 
(%) 
1 3.2.1(1) {1} 92 4 3.2.1 (1) {4} 68 
 2 3.2.1 (1) {2} 77 5 3.2.1 (1) {9} 64 
3 3.2.1 (1) {3} 74 6 3.2.1 (1) {10} 54 
All samples were submitted to purification by reverse-phase automated mass-directed 
LCMS.  The LCMS traces showed these compounds could be easily purified, and the yields 
were good to excellent. 
 
 
Figure 3.4a. Carboxylic acids (1–11) building blocks for the click esterification library. 
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Figure 3.4b. Azides {1–10} building blocks for the click esterification library 
 
After successful synthesis of the prototype library, a 110-member library utilizing the 
one pot click-esterification methodology was synthesized.  The carboxylic acids and the 
azides utilized for this library are shown in Figure 3.4.  A 48-member library utilizing click-
Mitsunobu was also synthesized utilizing carboxylic acids and azides as shown in Figure 3.5.  
 
Figure 3.5. Carboxylic acids (1), (3), (4), (5), (8), (10) and azides {1}, {2}, {4}, {5}, {6}, {10}, 
{11},{12}, {13} building blocks for the click Mitsunobu library. 
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Efficacious synthesis of 98/110 compounds from one-pot click-esterification protocol and 
37/48 compounds from the click Mitsunobu protocol was carried out possessing >90% purity 
by automated mass-directed LCMS.  A total of 135 acyl sultams were successfully generated 
(85% success rate) with purities >90%.  Building blocks for the click Mitsunobu library are 
shown in Figure 3.5. All samples were submitted to purification by reverse-phase automated 
mass-directed LCMS.  
Overall, the core scaffold was synthesized on a multigram scale by utilizing a one-pot 
sulfonylation, Michael and amidation protocol.  Two libraries of triazole-containing 
hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide were synthesized.  The 
libraries were synthesized by one-pot protocols utilizing either a one-pot click-esterification 
or a one-pot click-Mitsunobu protocol.  The success rate of these protocols was 85%.  The 
minimal optimization indicated the applicability and generalizability of these protocols to 
other complicated systems.  The employment of esterification and Mitsunobu showcased the 
importance of stereochemical diversity attainable in a single step from the same starting 
material.  These acyl sultams are a diverse set of molecules that have not been reported and 
which are currently being submitted for evaluation of their biological activity in high-
throughput screening efforts.   
  
 99 
Section: 3.2 Modular One-pot, Sequential Protocols Towards Diverse Acyl Sultam 
Libraries  
Part 2 of chapter 3 describes an efficient one-pot, sequential 4-component protocol to 
access a library of stereochemically-rich acyl sultams containing varied elements of skeletal 
and peripheral diversity.  A sequence involving a 4-component procedure that includes 
sulfonylation, Michael and EDC coupling, followed by a fourth reaction: (i) a [3+2] Huisgen 
cycloaddition when propargyl amine was utilized in the sulfonylation step and (ii) 
carbamoylation when L-hydroxyproline was employed in the aza-Michael reaction to form 
scaffolds with skeletal and peripheral diversity (Figure 3.6).  
 
Figure 3.6. One-pot, four component protocol. 
One-pot, sequential multicomponent protocols are versatile strategies to rapidly 
generate structurally distinct and complex moieties in an efficient manner.  These methods 
have important ramifications in economical, environmental and synthetic aspects and as a 
result, these procedures have gained prominence in modern organic synthesis.12  One-pot, 
sequential strategies can be utilized to effect multiple transformations in the same flask thus, 
avoiding several purification steps and minimizing hazardous chemical waste making this 
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process green and eco-friendly.  In contrast, these one-pot/one-pot sequential transformations 
have several obstacles that need to be circumvented. Some of these hurdles include 
compatibility of the multiple reactions; side products from earlier reactions may interfere 
with the one-pot protocols and minimal usage of solvents and reagents.  Nevertheless, these 
one-pot protocols are highly desirable for the utility of time, energy and purification as well 
as less accumulation of waste.  
Application of these one-pot, sequential protocols to diversity-oriented synthesis 
(DOS) has emerged as a facilitating platform for the synthesis of new heterocyclic small 
molecules for high throughput screening (HTS). 13  Within the realms of DOS, accessing 
diversity elements including skeletal, stereo-chemical, functional and appendage on small 
multiple scaffold libraries are highly desired for probing chemical space. Incorporating these 
essential elements into library synthesis generally affords considerable ‘molecular shape 
space’ coverage, which correlates to broad biological space.14   
Keeping these parameters in mind a second one-pot, sequential 4-component protocol 
was developed involving sulfonylation of amine with 2-chloroethane sulfonyl chloride, 
followed by the Michael reaction with an amino acid and subsequent amide cyclization to 
access desired acyl sultam scaffolds followed by either a carbamoylation or Huisgen [3 + 2] 
affording the desired diversified products.  Two pathways were envisioned – (i) sulfonylation 
with propargylamine afforded a propargylic handle for a click reaction as the fourth step 
providing the triazolated product and (ii) aza-Michael reaction with hydroxyproline afforded 
a hydroxyl functional handle for carbamoylation with isocyanates.   
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Scheme 3.4. One-pot, sequential 4-component pathways to diverse sultams. 
 
3.2.1 Results and Discussion 
Library Synthesis. The one-pot, sequential 4-component protocol commenced with 
the sulfonylation of an amine utilizing 2-chloroethane sulfonyl chloride in the presence of 
Et3N and CH2Cl2 followed by removal of the solvent in vacuo and then subsequent Michael 
addition with the corresponding amino acid using Et3N as the reaction promoter/proton 
scavenger and MeOH:H2O 1:1 as the solvent.  The reaction went to completion only after 
stirring for 12 h at 60 ºC and the resulting concentrated crude mixture proceeded to the 
amidation step with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), 1-
hydroxybenzotriazole (HOBt), Et3N and DMF as solvent.   
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Figure 3.7. One-pot, sequential 4-component utilizing isocyanates to carbamates. 
 
Figure 3.8. One-pot, sequential 4-component utilizing azides for the click reaction. 
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This was followed by distributing the DMF (containing the product) into small vials 
of equal volume followed by the evaporation of the solvent and then addition of CH2Cl2 as 
the new solvent, followed by the addition of a stock solution of DMAP and the isocyanate.  
The reaction was run at 50ºC for 12 hours followed by washing with water and extraction of 
the water layer with EtOAc.  The starting materials for this protocol are shown in Scheme 3.  
Similarly for the click reaction, DMF was distributed into small vials followed by 
evaporation as before followed by the addition of CH2Cl2/t-BuOH/H2O in a 1:1:1 ratio.  This 
was followed by the addition of the azide, CuSO4 and sodium-L-Ascorbate.  The reaction 
was then run for 12 hours washed with water and extracted with EtOAc.  The amines and 
isocyanates utilized for the carbamate library are shown in Scheme 3 while the amino acids 
and azides employed for the click library are shown in Scheme 4.  The diversity reagents 
were selected based on the physico-chemical property filters that were applied during the in 
silico analysis (see Supp Info).  
Over all, the automated production of a library of 66/85-member triazolated 1,2,5-
thiadiazepane 1,1-dioxides and 39/48-member carbamate library was successfully completed.  
The products have been submitted for evaluation of their biological activity in high-
throughput screening assays at the NIH MLPCN and the results will be reported in due 
course. 
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Section: 3.3  Triazole-containing Isothiazolidine 1,1-dioxide Library Synthesis: One-
Pot, Multi-Component Protocols for Small Molecular Probe Discovery  
Part 3 describes the synthesis of two libraries of triazole-containing isothiazolidine 
1,1-dioxides employing either a one-pot click-OACC esterification protocol.  The core 
dihydroisothiazole 1,1-dioxide scaffold was synthesized rapidly on multi-gram scale via 
RCM.  Next, three daughter scaffolds were generated by the aza-Michael of three amino 
alcohols.  The scaffolds were diversified by a one-pot, multi-component click-esterification 
protocol utilizing a ROMP-derived coupling reagent (OACC) to generate a 41-member 
library of triazole-containing isothiazole 1,1-dioxides (Figure 3.9).   
Figure 3.9. One-pot, click esterification. 
 
A new chemotype, the β-amino sultams and their corresponding sulfonate analogues 
have shown interesting biological properties.  Such reports include the inhibition of HIV-1 
replication and antibacterial activity (Figure 3.10).15  
 
Figure 3.10. Biologically active β-amino sultams and sulfonates. 
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Ring closing metathesis (RCM)16 can be utilized for the synthesis of 5-, 6- and 7- 
membered sultams from the corresponding vinyl and allyl sulfonamides.  When the RCM is 
carried out with vinyl sulfonamides, the corresponding sultam retains the α,β-unsaturated 
functionality incorporated within the ring, and can be further diversified utilizing hetero-
Michael reactions.  Hetero-Michael reactions have been broadly utilized to access a variety 
of heterocycles.17  The Michael reaction is also an efficient cyclization protocol to access a 
variety of sultam motifs leading to the proposed triazole-containing isothiazolidine 1,1-
dioxide library.18 
3.3 Results and Discussion 
 The corresponding core scaffold 2-(prop-2-yn-1-yl)-2,3-dihydroisothiazole 1,1-
dioxide 3.5.1 was rapidly generated on multi-gram scale via a 3-step sulfonylation, RCM, 
propargylation protocol (Scheme 3.5).  Notably, the addition of metathesis catalyst 
[(IMesH2)(PCy3)(Cl)2Ru=CHPh] (G-II),11 in 5 equal portions every 30 minutes was key to 
maintaining the observed high conversation of the RCM cyclization. 
Scheme 3.5. Gram-scale syntheses of core 2-(prop-2-yn-1-yl)-2,3-dihydroisothiazole 1,1-
dioxide 3.7 via RCM. 
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Diversification was achieved by utilizing two orthogonal reaction pathways, the 
Huisgen [3+2] and the esterification reaction. The esterification was carried out by the 
utilization of an immobilized, soluble ROMP-derived coupling reagent OACC.19  This high 
load reagent afforded efficient coupling of a variety of acids with 3.9, 3.10 or 3.11, followed 
by facile removal via a simple precipitation/filtration protocol. 
Three daughter isothiazole 1,1-dioxide scaffolds 3.5.3, 3.5.4 and 3.5.5 were 
synthesized by utilization of aza-Michael of the corresponding amino alcohols with 
dihydroisothiazole 1,1-dioxide 3.5.2 in an efficient multi-gram synthesis.  After the synthesis 
of these core isothiazole 1,1-dioxide (3.5.3, 3.5.4 and 3.5.5) scaffolds prepared, a 90-member 
library was designed (Figure 3.11).  
 
Figure 3.11.  Core Scaffolds 3.5.3, 3.5.4 and 3.5.5, azide building blocks A–F and acid 
building blocks {1–5}. 
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A one-pot click/OACC esterification protocol for the synthesis of the library was 
achieved utilizing 1.2 equivalents of acid {1–5}, azide (2 equiv.), OACC (1.5 equiv.), CuI 
(30 mol%), DBU (10 mol%) and anhydrous CH2Cl2 (Table 3.4).  Reactions were carried out 
at 50 ºC for 12 h, whereby upon completion the crude reactions were diluted, filtered and 
concentrated.  Utilizing these conditions, an initial validation set of isothiazolidine-1,1-
dioxides was investigated to evaluate the reaction conditions (Table 3.4). 
Table 3.4. One-Pot, click/OACC esterification. 
 
entry scaffold azide acid yield (%) 
1 3.5.3 D 1 48 
2 3.5.3 A 2 52 
3 3.5.3 A 3 47 
4 3.5.3 A 3 60 
5 3.5.4 A 2 40 
6 3.5.4 A 3 42 
7 3.5.4 A 3 43 
a Reaction conditions: Isothiazole 1,1-dioxide (40 mg, 1 equiv.), acid (1.2 equiv.), 
azide (2 equiv.), OACC (1.5 equiv.), CuI (30 mol%), DBU (10 mol%), dry CH2Cl2 
(0.2M), 50 ºC, 12 h.  b Isolated yields after standard column chromatography 
(EtOAc, Rf = 0.3–0.6).  
Upon completion, the validation set was diluted in EtOAc to precipitate the spent 
oligomer, followed by filtration through silica SPE and concentration.  All samples were 
purified by column chromatography, characterized and then submitted to purification by 
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reverse-phase automated mass-directed LCMS.  Despite their stability when isolated after 
standard chromatography, it was observed that esters generated with acids {1} and {3} 
underwent complete hydrolysis during automated mass-directed LCMS.  Analysis indicated 
that after successful purification, hydrolysis occurred during the final step of removal of the 
solvent utilized (CH3CN, H2O, DMSO and NH4OH).  Due to this observation, another library 
was redesigned removing acids {1} and {3} to propose a 54-member library. 
Under these conditions, 41 out of 54 compounds were successfully isolated >90% 
purity after purification by automated mass-directed LCMS.  Crude reaction analysis 
indicated that all 54 reactions worked, however it is proposed that the failed reactions and 
low yields observed were due to hydrolysis of the desired product in the final stages of 
purification.   
In conclusion, a library of triazole-containing isothiazolidine 1,1-dioxides was 
prepared utilizing a click-esterification protocol for utilization in HTS screening collections.  
A 41-member library of triazole-containing isothiazole 1,1-dioxide library was prepared via a 
one-pot, click/OACC esterification utilizing a soluble oligomeric coupling reagent OACC. 
This screening set of sultams represent a diverse motif not currently reported and have been 
submitted for evaluation of their biological activity in high-throughput screening.   
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Section 4.1 Facilitated Intermolecular Monomer-on-Monomer (MoM) Mitsunobu 
Reaction on Hydroxy-pyrrolo Thiadiazepin-dioxide Scaffolds 
 The Mitsunobu Reaction, discovered by Prof. Oyo Mitsunobu1 in 1967, is a 
stereospecific redox reaction of an alcohol and a carboxylic acid in the presence of 
triphenylphosphine and diethyl azodicarboxylate (DEAD) to furnish the corresponding 
ester with inversion of stereochemistry.  The Mitsunobu reaction has a number of 
variants2 that have a privileged role in organic synthesis and medicinal chemistry due to 
its ability to access small molecules for drug discovery. 3   It also provides 
stereospecificity, compatibility with a wide range of functional groups, wide substrate 
scope and mild reaction conditions.  Utilizing the Mitsunobu reaction, primary or 
secondary alcohols can be substituted by nucleophiles employing a redox combination of 
a trialkyl or triarylphosphine and a dialkyl azodicarboxylate (usually DEAD or DIAD) 
yielding the C-C, C-S, C-N, and C-O bond formation, as well as inverting the 
stereochemistry of the alcoholic moiety without the need for pre-activation of the alcohol.  
The Mitsunobu reaction is also promoted under relatively mild conditions by a 
combination of a tertiary phosphine and an azodicarboxylate, usually triphenylphosphine 
(PPh3) and diethyl or diisopropyl ester (DEAD or DIAD), respectively. 
Despite these attributes, one major drawback of this reaction is the tedious and 
time-consuming purification protocols usually required for the isolation of the pure 
product from the unreacted reagents (DEAD, PPh3) and by-products (reduced DEAD and 
O=PPh3).  Due to these implications the Mitsunobu is not ideal for parallel synthesis and 
high-throughput chemistry, and thus has inspired several variants aimed at circumventing 
purification issues.4   
We have reported separation-friendly strategies utilizing ring opening metathesis 
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polymerization (ROMP) reagents in order to facilitate the isolation of the products in the 
Mitsunobu reactions.  These protocols included ROMP-derived oligomeric 
triphenylphosphine and oligomeric azodicarboxylate on a polymer-on-polymer (PoP) 
Mitsunobu reaction 5  under purification-free processes and a monomer-on-monomer 
(MoM) 6  Mitsunobu reaction, employing monomeric norbornenyl-tagged 
triphenylphosphine and benzyl/ethyl azodicarboxylate reagents followed by subsequent 
sequestration.  The sequestration in the second case was carried out using ring-opening 
metathesis polymerization (ROMP) initiated by any one of these three methods utilizing 
Grubbs catalyst7  [(IMesH2)(PCy3)(Cl)2Ru=CHPh, G-II]: (i) free Grubbs catalyst in 
solution, (ii) silica-armed surface or (iii) surface-immobilized catalyst-armed with Co/C 
magnetic nanoparticles (Nps) (Scheme 4.1). 
Scheme 4.1: Surface-immobilized catalyst-armed silica and Co/C magnetic nanoparticle. 
 
 
4.2 Results and Discussion 
In 2011, Hanson and co-workers reported the first use of MoM Mitsunobu6a as 
well as its use for the synthesis of benzofused thiadiazepine-dioxides6b via an 
intramolecular 7-membered MoM Mitsunobu cyclization reaction. Facile purification 
was accomplished utilizing ROMP sequestration initiated by free metathesis catalyst or 
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catalyst-armed particle surfaces.  Building on these efforts, we have developed an 
intermolecular MoM Mitsunobu esterification and etherification on hydroxy-pyrrolo 
thiadiazepin-dioxide scaffolds to generate heterocyclic molecules.  
The hydroxy-pyrrolo thiadiazepin-dioxide scaffolds were rapidly synthesized via 
sulfonylation on the 2-chloroethane sulfonyl chloride followed by a Michael addition of 
L-trans-hydroxyproline to vinyl sulfonamide affording the desired Michael adduct 
(Scheme 4.2).8  The cyclization was effected by the addition of EDCI, HOBT and Et3N in 
DMF as a solvent to generate the hydroxypyrrolo-thiadiazepin 1,1-dioxide scaffolds in 
good yields. 
Scheme 4.2. Synthesis of hydroxy-pyrrolo thiadiazepin-dioxide scaffolds. 
 
After synthesizing the bicyclic acyl sultams (hydroxy-pyrrolo thiadiazepin-
dioxide) in a one-pot sequential protocol, we carried out MoM-Mitsunobu esterification 
with different aromatic acids utilizing Nb-TPP and Nb-BEAD in THF to afford the 
esterified and etherified products with an inversion of stereochemistry (Scheme 4.3).  The 
reaction mixture was purified by ROM polymerization utilizing addition of free 
metathesis catalyst [(IMesH2)(PCy3)(Cl)2Ru=CHPh, G-II].7 The protocol included the 
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of the spent reagents and by-products to generate the desired esterified/etherified 
N
N
S
OO
O
RN
H
S
OO
R
N CO2H
EDC, HOBt 
Et3N
DMF, rt 
14 h
HO HO
S
N
H
O O
R
HN CO2H
HO
Et3N
MeOH, H2O
60 ºC, 12 h
R = Ph, 4-MePh, 
4-OMePh, 4-FPh
H2N R
Cl
S
Cl
OO
Et3N
CH2Cl2
One-pot sequential protocol
4.2.1
 119 
thiadiazepin-dioxide scaffolds in good yields and excellent crude purity.  The typical 
multi-spot crude reaction mixture was purified, giving a single TLC spot for the product, 
utilizing the polymerization sequestration protocol.  Precipitation of the excess reagents 
and by-products was carried out by slow addition of diethyl ether (Et2O).  Even though 
removal of the polymerized and spent reagents from the crude reaction mixture was 
successful, the method was still not ideal for a high-throughput platform. Thus, 
alternative sequestration methods were investigated, utilizing a catalyst-armed surface 
generated either from Nb-tagged silica or an Nb-tagged Co/C magnetic particle to yield 
the esterified/etherified hydroxypyrrolo-thiadiazepin-dioxide scaffolds without the need 
for SiO2 purification. 
Scheme 4.3. Intermolecular MoM Mitsunobu esterification on hydroxypyrrolo-
thiadiazepin-dioxide scaffolds. 
 
In the Nb-tagged SiO2 method, sequestration of excess reagents and by-products 
was carried out after ROM polymerization, using Nb-tagged SiO2.  This method yielded 
products in >95% crude purity by simple filtration through Celite® SPE and collecting the 
solution, followed by evaporating the solvent.  Alternatively, Nb-tagged Co/C magnetic 
particles were applied for the sequestration of excess reagents/spent reagents on the 
surface of the magnetic Co/C beads.  Using this procedure, compounds could be obtained 
in good yields and >95% crude purity by collecting the nanobeads with an external 
magnet, decanting the solution and evaporating the solvent.  The important thing to note 
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about this protocol is the ease with which it is carried out by simple introduction of an 
external magnet on the wall of the tube, being an operational advantage to conventional 
filtration techniques (Figure 4.1). 
 
Figure 4.1: (a) Sequestration utilizing Co/C magnetic nanoparticles (a) Nb-tagged Co/C 
nanoparticles (c) Nb-tagged silica particles. 
 
Building upon these results, the diversification of the scaffolds utilizing the MoM 
Mitsunobu were expanded to the etherification reactions on hydroxypyrrolo-thiadiazepin-
dioxide scaffolds using the intermolecular MoM Mitsunobu reaction employing aromatic 
phenols to generate etherified and esterified sultams with inversion of stereochemistry 
4.4.4–4.4.13 (Scheme 4.4).   
4.3 Conclusion 
In conclusion, MoM intermolecular Mitsunobu protocol was utilized for the 
esterification/etherification of hydroxypyrrolo-thiadiazepin-dioxide scaffolds 
synthesizing new heterocyclic sulfonamide molecules. Facile purification of crude 
reaction mixtures was carried out by utilization of ROM polymerization, which resulted 
in sequestration of excess reagents/spent reagents. Three methods of sequestration were 
utilized for the purification protocols that included; free metathesis catalyst G-II,7 
catalyst-armed surfaces generated from Nb-tagged Si-particles and catalyst-armed 
surfaces generated from Nb-tagged Co/C magnetic nanoparticles. 
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Scheme 4.4. Intermolecular MoM Mitsunobu etherification on hydroxy-pyrrolo 
thiadiazepin-dioxide scaffolds.  
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Section 4.4. Synthesis of epoxybenzo[d]isothiazole 1,1-dioxides via a reductive-Heck, 
metathesis-sequestration protocol 
Development of new methodologies and technologies is required for the growing 
need of new pharmaceutical leads in high throughput screening.9  Accessing novel 
heterocyclic scaffolds with a minimum number of steps is one key strategy being 
developed in modern drug discovery. 
In order to facilitate protocols for the synthesis of compounds in an abridged 
manner, the integration of synthesis and purification has led to seminal advances in both 
combinatorial and parallel synthetic chemistry.10  This approach is possible utilizing 
resin-bound substrates bearing excess reagents or employing solution phase substrates 
with excess immobilized reagents.11  These protocols have been employed extensively in 
organic synthesis. Although less commonly encountered, there is a third scenario, which 
utilizes the excess precious starting material that can be recovered by ring opening 
metathesis polymerization. The promising approach would reclaim the starting material 
for further conversion to the desired product. 
The following represents a new chromatography-free method for the synthesis of 
complex sultams 12 , 13  which affords easy isolation of reductive-Heck products and 
reclamation of excess starting material via sequestration by metathesis catalysts and 
catalyst-armed surfaces. 
4.5 Results and Discussion 
The Hanson group reported synthesis of a number of sultams derived by  
intramolecular Diels-Alder (IMDA) reactions to afford the oxa-norbornene scaffold 4.5.1 
utilizing metathesis cascade protocols.14  The core scaffold was synthesized on a gram-
scale utilizing a method reported by Metz and coworkers.15  This scaffold could undergo 
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a ring-opening, ring-closing, cross-metathesis (ROM-RCM-CM) with a variety of CM 
partners in one-pot protocols.  The diversification pathways were further expanded by 
investigating reductive Heck reactions with the scaffold 4.5.1.  It was noted that 
employing Pd(OAc)2, Zn and excess scaffold 4.5.1 (1.5 equiv.) with the aryl coupling 
partner (1 equiv.) did push the reaction to completion.16  Even though an excess of the 
scaffold 4.5.1 was utilized, only 60% of the product was obtained albeit with excellent 
regio- and diastereoselectivity (>19:1).  The drawback was the difficulty of purification 
of the crude reaction mixture via standard chromatography because the Rf values of the 
desired product 4.5.2a and the starting material 4.5.1 (Scheme 4.5) were nearly identical.  
Scheme 4.5. Reductive Heck diversification of 4.5.1 utilizing excess reagent. 
 
As previously noted, yields could be improved if an excess of scaffold 4.5.1 (1.5 
equiv.) was employed.  However, the usual purification protocols limited the application 
of this method for high-throughput generation of sultam derivatives 4.5.2.17 It was 
envisioned that the remaining starting material 4.5.1, possessing an oxa-norbornene motif 
("armed scaffold"), could be removed via exposure to metathesis catalyst and phase 
trafficking through ROM polymerization (ROMP) to afford the oligomeric scaffold 
4.6.3.18,19  A simple precipitation of the oligomeric reagent would result in facile isolation 
of the desired product and the starting material oligomer could be recovered, an atom 
economical approach (Scheme 4.6).   
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Scheme 4.6. Reductive Heck diversification of 4.5.1 utilizing its excess. 
 
To test this protocol, we began with the reductive Heck reaction of the sultam 
4.5.1 (1.5 equiv.) with 4-MeO-PhI (1 equiv.) in the presence of Pd(OAc)2 and Zn in DMF 
at 60 ºC.  When the reaction was complete, the mixture was filtered through Celite to 
remove Zn, concentrated, and subjected to ROM polymerization using the  
G-II catalyst.7  Precipitation of the oligomeric starting material with ethyl acetate, 
followed by a filtration yield the reductive Heck sultam 4.5.2a in 82% yield and >95% 
pure (Table 1, entry 1).  Based on the success of the reductive-Heck, metathesis-
sequestration protocol, nine aryl iodides were converted to reductive Heck products with 
yields ranging from 65 to 89% (Table 1, entry 2–10). 
Although this protocol was successful, the required precipitation of each reaction 
was not suitable for application of this method as a high throughput platform.  This was 
addressed by the employing a catalyst-armed surface generated from Nb-tagged silica 
particles.20,21 This protocol was superior because purification only required  filtration 
rather than added solvent (EtOAc) to precipitate the spent oligomer.  Sultam 4.7.1 was 
subjected to standard reductive-Heck conditions and upon completion of the reaction 
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Table 4.1. Reductive Heck, followed by ROMP sequestration. 
 
Entry R1 Yield % Purity %[a] Pdt. 
1 p-CH3O-Ph 82 >95 4.5.2a 
2 p-F-Ph 77 >95 4.5.2b 
3 p-CO2CH3-Ph 86 >95 4.5.2c 
4 p-OH-Ph 89 >95 4.5.2d 
5 m-F-Ph 82 >95 4.5.2e 
6 3,5 di-CH3-Ph 76 >95 4.5.2f 
7 p-CH3-Ph 75b >95 4.5.2g 
8 2-thiophene-Ph 81b >95 4.5.2h 
9 p-CF3O-Ph 73 c >95 4.5.2i 
10 p-CN-Ph 65c >95 4.5.2j 
[a] Purity determined by 1H NMR, [b] dr = 3:1 determined by 1H 
NMR. [c] dr = 4:1 determined by 1H NMR. 
 
the crude mixture was cannulated into a reaction vessel containing “pre-armed” Nb-
tagged Si-particles.  This was monitered by heating for 30 minutes – 1 hr (TLC 
monitoring) and subsequent filtration of the crude reaction mixture through a Celite® SPE 
to furnish the desired product 4.7.5a-b in good to excellent crude yields and greater than 
95% purity (Scheme 4.7). 
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Scheme 4.7. Sequestration of excess SM 4.7.1 via catalyst-armed  
Si-particles. 
 
After the reductive-Heck-metathesis sequestration protocol, the reclaimed 
oligomerized scaffold 4.6.3 was exposed to reductive ozonolysis 22  furnishing diol 
intermediate 4.8.1, which on reaction with ROMP-derived oligomeric sulfonyl chloride 
(OSC)23 yielded polyether 4.8.2 without a need for further purification (Scheme 4.8). 
Scheme 4.8. Diversification-release of corresponding derived-sultams from reclaimed 
oligomer 4.6.3. 
 
The oligomer 4.6.3 was converted into 4.8.3 without further purification by 
deprotection and benzylation with benzyl iodide.  The diversification and subsequent 
release of the oligomer was accomplished by a Barrett's vanishing support24 protocol 
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using a 3-step Suzuki,25 reductive ozonolysis that furnished the corresponding diols 
4.8.4a–d in good overall yield and purities.  Filtration through SiO2 SPE afforded pure 
products, whereas, in some cases, a simple filtration through a SiO2 SPE provided X-ray 
quality crystals. 
This methodology has several advantages, which include:  
atom economy, oligomeric starting materials (i.e. reclaimed scaffolds) were diversified to 
afford new compounds, additional linker (in contrast to traditional SPOC) were not 
needed, and parallel processing could be carried out with minimal waste stream. 
4.6 Conclusion 
ROM polymerization has been employed for the development of an atom-
economical and purification friendly protocol for the diversification of sultam scaffolds 
via a reductive-Heck reaction. Isolation of reductive-Heck products and reclamation of 
excess oligomeric sultam scaffolds via precipitation were accomplished in a convenient 
manner utilizing chromatography-free methods. The recovered oligomeric scaffold was 
diversified into an array of new, skeletally diverse sultam scaffolds via a vanishing 
support protocol using solution phase processing. Furthermore this method can be 
exploited for different types of norbornene systems for high-throughput platforms. 
  
 128 
4.7 References 
	  
[1] (a) Mitsunobu, O.; Yamada, Y. "Preparation of Esters of Carboxylic and 
Phosphoric Acid via Quaternary Phosphonium Salts". Bull. Chem. Soc. Jpn., 
1967, 40, 2380–2382. (b) Mitsunobu, O. "The Use of Diethyl Azodicarboxylate 
and Triphenylphosphine in Synthesis and Transformation of Natural Products". 
Synthesis 1981, 1–28. 
[2] For leading reviews on the Mitsunobu reaction, see: (a) Mitsunobu, O. The Use of 
Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and 
Transformation of Natural Products. Synthesis, 1981, 1–28.  (b) Hughes, D. L. 
Progress in the Mitsunobu Reaction. A Review. Org. Prep. Proced. Int., 1996, 28, 
127–164.  (c) Nam, N.-H.; Sardari, S.; Parang, K. Reactions of Solid-Supported 
Reagents and Solid Supports with Alcohols and Phenols through Their Hydroxyl 
Functional Group. J. Comb. Chem., 2003, 5, 479–546.  (d) Dandapani, S.; Curran, 
D. P. Separation-Friendly Mitsunobu Reactions: A Microcosm of Recent 
Developments in Separation Strategies. Chem.–Eur. J., 2004, 10, 3130–3138. (e) 
Dembinski, R. Recent Advances in the Mitsunobu Reaction: Modified Reagents 
and the Quest for Chromatography-Free Separation. Eur. J. Org. Chem., 2004, 
2763–2772. (f) But, T. Y. S.; Toy, P. H.; The Mitsunobu Reaction: Origin, 
Mechanism, Improvements, and Applications. Chem.–Asian J., 2007, 2, 1340–
1355. (g) Reynolds, A. J.; Kassiou, M. Recent Advances in the Mitsunobu 
Reaction: Modifications and Applications to Biologically Active Molecules. Curr. 
Org. Chem., 2009, 13, 1610–1632. (h) Swamy, K. C. K.; N. N. B.; Kumar, 
Balaraman, E.; Kumar, K. V. P. P. Mitsunobu and Related Reactions: Advances 
and Applications. Chem. Rev., 2009, 109, 2551–2651 and references cited therein. 
[3] (a) Abero, M. A.; Lin, N.-H.; Garvey, D. S.; Gunn, D. E.; Hettinger, A.-M.; 
Wasicak, J. T.; Pavlik, P. A.; Martin, Y. C.; Donnelly-Roberts, D. L.; Sullivan, J. 
P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Novel 3-Pyridyl Ethers with 
Subnanomolar Affinity for Central Neuronal Nicotinic Acetylcholine Receptors. 
J. Med. Chem., 1996, 39, 817–825.  (b) Park, A.-Y.; Moon, H. R.; Kim, K. R.; 
Chun, M. W.; Jeong, L. S. Synthesis of novel L-N-MCd4T as a potent anti-HIV 
 129 
	  
agent. Org. Biomol. Chem., 2006, 22, 4065–4067. (c) Zapf, C. W.; Del Valle, J. 
R.; Goodman, M. Utilizing the intramolecular Fukuyama–Mitsunobu reaction for 
a flexible synthesis of novel heterocyclic scaffolds for peptidomimetic drug 
design. Bioorg. Med. Chem. Lett., 2005, 15, 4033–4036.  
[4] (a) Chu, Q.; Henry, C.; Curran, D. P. Second-Generation Tags for Fluorous 
Chemistry Exemplified with a New Fluorous Mitsunobu Reagent. Org. Lett., 
2008, 10, 2453–2456. (b) Lan, P.; Porco, Jr., J. A.; South, M. S.; Parlow, J. J. The 
Development of a Chromatography-Free Mitsunobu Reaction:   Synthesis and 
Applications of an Anthracene-Tagged Phosphine Reagent. J. Comb. Chem., 
2003, 5, 660–669.  (c) Starkey, G. W.; Parlow, J. J.; Flynn, D. L. Chemically-
tagged Mitsunobu reagents for use in solution-phase chemical library synthesis. 
Bioorg. Med. Chem. Lett., 1998, 8, 2385–2390.  (d) Danapani, S.; Newsome, J. J.; 
Curran, D. P. Separation tagging with cyclodextrin-binding groups: Mitsunobu 
reactions with bis-(2-(1-adamantyl)ethyl) azodicarboxylate (BadEAD) and bis-(1-
adamantylmethyl) azodicarboxylate (BadMAD). Tetrahedron Lett., 2004, 45, 
6653–6656.  (e) But, T. Y. S.; Toy, P. H. Organocatalytic Mitsunobu Reactions. J. 
Am. Chem. Soc., 2006, 128, 9636–9637.  (f) Taft, B. R.; Swift, E. C.; Lipshutz, B. 
H. A Convenient Preparation of Di-p-chlorobenzyl Azodicarboxylate (DCAD) for 
Mitsunobu Couplings. Synthesis, 2009, 2, 322–334.  (g) Yang, J.; Dai, L.; Wang 
X.; Chen, Y. Di-p-nitrobenzyl azodicarboxylate (DNAD): an alternative azo-
reagent for the Mitsunobu reaction. Tetrahedron, 2011, 67, 1456–1462.  (h) 
Figlus, M.; Tarruella, A. C.; Messer, A.; Sollis, S. L.; Hartley, R. C. Low 
molecular weight MPEG-assisted organic synthesis. Chem. Commun., 2010, 46, 
4405–4407.  (i) Figlus, M.; Wellaway, N.; Cooper, A. W. J.; Sollis, S. L.; Hartley, 
R. C. Synthesis of Arrays Using Low Molecular Weight MPEG-Assisted 
Mitsunobu Reaction. ACS Comb. Sci., 2011, 13, 280–285.  (j) Bergbreiter, D. E.; 
Yang, Y.-C.; Hobbs, C. E. Polyisobutylene-Supported Phosphines as Recyclable 
and Regenerable Catalysts and Reagents. J. Org. Chem., 2011, 76, 6912–6917.  
 130 
	  
[5] Harned, A. M.; Song He, H.; Toy, P. H.; Flynn, D. L.; Hanson, P. R. 
Multipolymer Solution-Phase Reactions: Application to the Mitsunobu Reaction. 
J. Am. Chem. Soc. 2005, 127, 52–53. 
[6] (a) Maity, P. K.; Rolfe, A.; Samarakoon, T. B.; Faisal, S.; Kurtz, R. D.; Long, T. 
R.; Schatz, A.; Flynn, D. L.; Grass, R. N.; Stark, W. J.; Reiser, O.; Hanson, P. R. 
Monomer-on-Monomer (MoM) Mitsunobu Reaction: Facile Purification Utilizing 
Surface-Initiated Sequestration. Org. Lett. 2011, 13, 8–10.  (b) Maity, P. K.; 
Kainz, Q. M.; Faisal, S.; Rolfe, A.; Samarakoon, T. B.; Basha, F. Z.; Reiser, O.; 
Hanson, P. R. Intramolecular Monomer-on-Monomer (MoM) Mitsunobu 
Cyclization for the Synthesis of Thiadiazepine-dioxides. Chem. Commun. 2011, 
47, 12524–12526. 
[7]	   First Generation Grubbs Catalyst G-I: (a) Schwab, P.; France, M. B.; Ziller, J. 
W.; Grubbs, R. H. Angew. Chem. Int. Ed. Engl. 1995, 34, 2039–2041;   (b) 
Schwab, P.; Grubbs, R. H.; Ziller, J. W. J. Am. Chem. Soc. 1996, 118, 100–110. 
(c) Second Generation Grubbs Catalyst G-II: Scholl, M; Ding, S.; Lee, C. W.; 
Grubbs, R. H. Org. Lett. 1999, 1, 953–956. (d) Hoveyda Grubbs-Second 
Generation Catalyst HG-II: Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; 
Hoveyda, A. H. J. Am. Chem. Soc. 2000, 122, 8168–8179. (A variety of 
metathesis catalyst include [(PCy3)2(Cl)2Ru=CHPh; G-I], 
[(IMesH2)(PCy3)(Cl)2Ru=CHPh; G-II], and the Hoveyda-Grubbs 1st-generation 
catalyst [(IMesH2)(Oi-Pr)(Cl)2Ru=CHC6H4; HG-I], the Hoveyda-Grubbs 2nd-
generation catalyst [(PCy3)(Oi-Pr)(Cl)2Ru=CHC6H4; HG-II]).	  
[8] Asad, N.; Samarakoon, T. B.; Zang, Q.; Loh, J. K.; Javed, S.; Hanson, P. 
R. Rapid, Scalable Assembly of Stereochemically Rich, Mono- and Bicyclic Acyl 
Sultams. Org. Lett. 2014, 16, 82–85. 
[9] (a) Nicolaou, K. C.; Chen, J. S. The art of total synthesis through cascade 
reactions. Chem. Soc. Rev. 2009, 38, 2993–3009. (b) Enders, D.; Grndal, C.; 
Hüttl, M. R. M. Asymmetric organocatalytic domino reactions. Angew. Chem. Int. 
Ed. 2007, 46, 1570–1581. (c) Tietze, L. F.; Beifuss, U. Sequential 
 131 
	  
Transformations in Organic Chemistry: A Synthetic Strategy with a Future. 
Angew. Chem. Int. Ed. Engl. 1993, 32, 131–163. 
[10] (a) Dolle, R. E.; Le Bourdonnec, B.; Goodman, A. J.; Morales, G. A.; Thomas, C. 
J.; Zhang, W. Comprehensive survey of chemical libraries for drug discovery and 
chemical biology: 2008. J. Comb. Chem. 2009, 11, 739−790. (b) Salimi, H.; 
Rahimi, A.; Pourjavadi A. Applications of polymeric reagents in organic 
synthesis. Monatshefte fur Chemie 2007, 138, 363−379. (c) Ley, S. V.; 
Baxendale, I. R.; Bream, R. N.; Jackson, P. S.; Leach, A. G.; Longbottom, D. A.; 
Nesi, M.; Scott, J. S.; Storer, R. I.; Taylor, S. J. Multi-step organic synthesis using 
solid-supported reagents and scavengers: a new paradigm in chemical library 
generation. J. Chem. Soc. Perk. Trans. 1. 2000, 23, 3815−4195. 
[11] (a) Dickerson, T. J.; Reed, N. N.; Janda, K. D. Soluble polymers as scaffolds for 
recoverable catalysts and reagents. Chem. Rev. 2002, 102, 3325–3344. (b) van 
Heerbeek, R.; Kamer, P. C. J.; van Leeuwen, P. W. N. M.; Reek, J. N. H. 
Dendrimers as support for recoverable catalysts and reagents. Chem. Rev. 2002, 
102, 3717–3756. (c) Flynn, D. L.; Crich, J. Z.; Devraj, R. V.; Hockerman, S. L.; 
Parlow, J. J.; South, M. S.; Woodard, S. Chemical Library Purification Strategies 
Based on Principles of Complementary Molecular Reactivity and Molecular 
Recognition. J. Am. Chem. Soc. 1997, 119, 4874–4881. (d) Acharya, A. N.; Nefzi, 
A.; Ostresh, J. M.; Houghten, R. A. Tethered libraries: solid-phase synthesis of 
substituted urea-linked bicyclic guanidines. J. Comb. Chem. 2001, 3, 189–195. 
[12] Sultams, the cyclic analogs of sulfonamides, although not found in nature, 
represent a subclass of relatively unexplored molecular space for the discovery of 
new therapeutic drugs.  Recent reports have demonstrated that sultams possess a 
broad spectrum of biological activity despite not being “preordained”, as with 
rationally designed or medicinally active natural products.   
[13] For an extensive list of biological sultams and methods for synthesis see: 
Jimenez-Hopkins, M.; Hanson, P. R. An RCM Strategy to Stereodiverse δ-Sultam 
Scaffolds. Org. Lett. 2008, 10, 2223–2226. 
 132 
	  
[14] Jeon, K. O.; Rayabarapu, D.; Rolfe, A.; Volp, K.; Omar, I.; Hanson, P. Metathesis 
Cascade Strategies (ROM-RCM-CM): A DOS Approach to Skeletally Diverse 
Sultams. Tetrahedron 2009, 65, 4992–5000.  For additional reference on complex 
sultam synthesis, see: (a) Rolfe, A.; Samarakoon, T. B.; Hanson, P. R. Formal 
[4+3] Epoxide Cascade Reaction via a Complementary Ambiphilic Pairing. Org. 
Lett. 2010, 12, 1216–1219. (b) Rolfe, A.; Lushington, G. H.; Hanson, P. R. 
Reagent Based DOS: A Click, Click, Cyclize Strategy to Probe Chemical Space. 
Org. Biomol. Chem. 2010, 9, 2198–2203. (c) Samarakoon, T, Hur, M. Y; Kurtz, 
R. D.; Hanson, P. R. A Formal [4+4] Complementary Ambiphile Pairing (CAP) 
Reaction: A New Cyclization Pathway for ortho-Quinone Methides. Org. Lett. 
2010, 12, 2182–2185. (d) Rayabarappu, D. R.; Zhou, A.; Jeon, K.; Samarakoon, 
T.; Rolfe, A.; Siddiqui, H. Tetrahedron 2009, 65, 3180–3188. (e) Jiménez-
Hopkins, M.; Hanson, P. R. An RCM Strategy to Stereodiverse δ-Sultam 
Scaffolds. Org. Lett. 2008, 10, 2223–2226. 
[15] Metz, P.; Seng, D.; Frohlich, R.; Wibbeling, B. Intramolecular Diels-Alder 
Reactions of Vinylsulfonamides. Synlett. 1996, 741–742.  
[16] (a) Chen, C. L.; Martin, S. F. Facile synthesis of 2-substituted 1,2-dihydro-1-
naphthols and 2-substituted 1-naphthols. Org. Lett. 2004, 6, 3581–3584. (b) Duan, 
J. P.; Cheng, C. H. Palladium-catalyzed stereoselective reductive coupling 
reactions of organic halides with 7-heteroatom norbornadienes. Tetrahedron Lett. 
1993, 34, 4019–4022. 
[17] Isolated yield after performing standard column chromatography. 
[18]  For reviews concerning use of ROMP technology, see: (a) Barrett, A. G. M.; 
Hopkins, B. T.; Köbberling, J. ROMPgel reagents in parallel synthesis. J. Chem. 
Rev. 2002, 102, 3301–3324. (b) Flynn, D. L.; Hanson, P. R.; Berk, S. C.; Makara, 
G. M. New developments in chemical library synthesis. Norbornenyl tags for use 
in phase-switching, sequestration, capture-release and soluble support 
applications. Curr. Opin. Drug Discovery Dev. 2002, 5, 571–579. (c) Harned, A. 
M.; Probst, D. A.; Hanson, P. R. The Use of Olefin Metathesis in Combinatorial 
 133 
	  
Chemistry: Supported and Chromatography-Free Syntheses. In Handbook of 
Metathesis; Grubbs, R. H., Ed.: Wiley-VCH: Weinheim, Germany, 2003; pp 361–
402. (d) Harned, A. M.; Zhang, M.; Vedantham, P.; Mukherjee, S.; Herpel, R. H.; 
Flynn, D. L.; Hanson, P. R. Long-term follow-up of Langerhans cell histiocytosis: 
39 years' experience at a single centre. Aldrichim. Acta 2005, 38, 3–16. 
[19] (a) Long, T.; Maity, P. K; Samarakoon T. B; Hanson, P. R. ROMP-Derived 
Oligomeric Phosphates for Application in Facile Benzylation. Org. Lett. 2010, 12, 
2904–2907. (b) Rolfe, A.; Probst, D.; Volp, K.; Omar, I.; Flynn, D.; Hanson, P. R. 
High-load, Oligomeric dichlorotriazine (ODCT): A Versatile ROMP-derived 
Reagent and Scavenger. J. Org. Chem. 2008, 73, 8785–8790. (c) Stoianova, D. S.; 
Yao, L.; Rolfe, A.; Samarakoon, T.; Hanson, P. R. High-load, Oligomeric 
Monoamine Hydrochloride: Facile Generation via ROM Polymerization and 
Application as an Electrophile Scavenger. Tetrahedron Lett. 2008, 49, 4553–
4555. (d) Barrett, A. G. M.; Hopkins, B. T.; Love, A. C.; Tedeschi, L. Parallel 
synthesis of terminal alkynes using a ROMPgel-supported ethyl 1-diazo-2-
oxopropylphosphonate. Org. Lett. 2004, 6, 835–837. (e) Arstad, E.; Barrett, A. G. 
M.; Tedeschi, L. ROMPgel-supported tris(triphenylphosphine)rhodium(I) 
chloride: a selective hydrogenation catalyst for parallel synthesis. Tetrahedron 
Lett. 2003, 44, 2703–2707. (f) Mukherjee, S.; Poon, K. W. C.; Flynn, D. L.; 
Hanson, P. R. Capture-ROMP-Release: Application to the Synthesis of Amines 
and Alkylhydrazines. Tetrahedron Lett. 2003, 44, 7187–7190.  
[20] (a) Buchmeiser, M. R. Polymer-supported well-defined metathesis catalysts. 
Chem. Rev. 2009, 109, 303–321. (b) Elias, X.; Pleixats, R.; Man, M. W. C. 
Hybrid silica materials derived from Hoveyda–Grubbs ruthenium carbenes. 
Electronic effects of the nitro group on the activity and recyclability as diene and 
enyne metathesis catalysts. Tetrahedron 2008, 64, 6770–6781. (c) Mayr, M.; 
Buchmeiser, M. R.; Wurst, K. Synthesis of a Silica-Based Heterogeneous Second 
Generation Grubbs Catalyst. Adv. Synth. Catal. 2002, 344, 712–719. (d) Krause, 
J. O.; Lubbad, S.; Muyken, O.; Buchmeiser, M. R. Monolith- and Silica-
 134 
	  
Supported Carboxylate-Based Grubbs–Herrmann-Type Metathesis Catalysts. Adv. 
Synth. Catal. 2003, 345, 996–1004.  
[21] (a) Rolfe, A.; Loh, J. K.; Maity, P. K.; Hanson, P. R. High-Load, Hybrid Si-
ROMP Reagents. Org. Lett. 2011, 1, 4–7. (b) Maity, P.; Rolfe, A.; Samarakoon, 
T. B.; Faisal, S.; Kurtz, R.; Long, T. R.; Schätz, A.; Flynn, D.; Grass, R. N.; Stark, 
W. J.; Reiser, O.; Hanson, P. R. Monomer-on-Monomer (MoM) Mitsunobu 
Reaction: Facile Purification Utilizing Surface-Initiated Sequestration. Org. Lett. 
2011, 1, 8–10. 
[22] Cheng, C.; Qi, K.; Khoshdel, E.; Wooley, K. L. Tandem synthesis of core-shell 
brush copolymers and their transformation to peripherally cross-linked and 
hollowed nanostructures. J. Am. Chem. Soc. 2006, 128, 6808–6809.  
[23] (a) Moore, J. D.; Herpel, R. H.; Lichtsinn, J. R.; Flynn, D. L.; Hanson, P. R. 
ROMP-Generated Oligomeric Sulfonyl Chlorides as Versatile Soluble 
Scavenging Agents. Org. Lett. 2003, 5, 105–107. (b) Zhang, M; Flynn, D. L.; 
Hanson, P. R. Oligomeric Benzylsulfonium Salts: Facile Benzylation via High-
Load ROMP Reagents. J. Org. Chem. 2007, 72, 3194–3198. 
[24] Vanishing Supports: Ball, C. P.; Barrett, A. G. M.; Poitout, L. F.; Smith, M. L.; 
Thorn, Z. E. Polymer Backbone Disassembly - Polymerizable Templates And 
Vanishing Supports In High Loading Parallel Synthesis. Chem. Comm. 1998, 22, 
2453–2454. 
[25] It is worth noting that the Suzuki reaction of the corresponding monomer 4.2.8 
afforded an inseparable mixture of products (Suzuki product as well as product 
resulting from the double Heck-addition across the double bond), thus further 
substantiating the use of the titled process. 
 SI–135 
 
 
 
 
 
Chapter 5:  
Supporting Information 
Experimental for Chapters 2-4 
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5.1: Experimental for Chapter 2 
All air and moisture sensitive reactions were carried out in flame- or oven-dried glassware under argon 
atmosphere using standard gas tight syringes, cannula, and septa. Stirring was achieved with oven-dried, 
magnetic stir bars. CH2Cl2 was purified by passage through the Solv-Tek purification system employing 
activated Al2O3 (Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518-1520). Et3N was 
purified by passage over basic alumina and stored over KOH. Flash column chromatography was performed 
with SiO2 from Mallinckrodt Chemicals (V120-25, Silica gel, 60 A, 40–63 μm). Thin layer chromatography 
was performed on silica gel 60F254 plates (EMD-5715-7, Merck). Deuterated solvents were purchased from 
Cambridge Isotope laboratories. 1H, 13C NMR spectra were recorded on a Bruker DRX-400 spectrometer 
operating at 400 MHz as well as a Bruker DRX-500 spectrometer operating at 500 MHz, 126 MHz respectively. 
The reference for CDCl3 was set up at 7.28 ppm and acetone at 2.05 ppm. High-resolution mass spectrometry 
(HRMS) and FAB spectra were obtained in one of two manners: (i) on a VG Instrument ZAB double-focusing 
mass spectrometer and (ii) on a LCT Premier Spectrometer (Micromass UK Limited) operating on ESI 
(MeOH). Gas chromatography (GC) was performed using an Agilent Technologies 6890N. GC/mass 
spectrometry was performed using a Quattro micro GC (Micromass UK Limited). 
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Rapid, Scalable Assembly of Stereochemically Rich, Mono- and Bicyclic Acyl Sultams 
General Procedure A: preparation of vinyl sulfonamide.  To a round bottom flask containing a solution of 
amine (1.0 equiv.) in dry CH2Cl2 (0.5 M), was added Et3N (2.0 equiv.).  The reaction mixture was cooled to 0 
ºC, stirred for 20 min, after which 2-chloroethane sulfonyl chloride (1.0 equiv.) was added to the reaction 
mixture in a drop-wise fashion. The reaction was warmed to rt and stirred overnight.  The reaction was 
quenched with 10% aq. HCl, the organic layer was separated, and the aqueous layer was extracted with CH2Cl2 
(2x).  The combined organic layers were washed with brine, dried (Na2SO4), and concentrated under reduced 
pressure to afford the desired vinyl sulfonamide. 
 
General Procedure B: one-pot, sequential (Michael and amide coupling).  To a round-bottomed flask 
attached with a condenser/pressure tube containing a solution of sulfonamide (172 mmol, 1.0 equiv.) in MeOH 
(0.5 M) and water (0.5 M), was added Et3N (516 mmol, 3.0 equiv.) followed by amino acid (172 mmol, 1.0 
equiv.).  The reaction mixture was stirred at 60 ºC for 12 h, after which the solvents were evaporated to dryness.  
To the crude mixture, DMF (0.05 M) was added, followed by EDC (344 mmol, 2.0 equiv.), HOBt (34.4 mmol, 
0.2 equiv.) and Et3N (344 mmol, 2.0 equiv.).  The reaction was stirred at rt for 12 h followed by evaporation of 
DMF upon completion of reaction.  Water was added to the crude mixture, which was extracted with EtOAc 
(2x).  The organic layer was separated and the combined organic layers were dried (Na2SO4) and concentrated 
under reduced pressure to afford the crude product, which was purified by flash chromatography (100% 
EtOAc). 
 
General Procedure C: one-pot, sequential 3-component (sulfonylation, Michael and amide coupling).  To 
a round bottom flask/pressure tube containing a solution of amine (3.8 mmol, 1.0 equiv.) in dry CH2Cl2 (0.5 M), 
was added Et3N (7.6 mmol, 2.0 equiv.).   The reaction mixture was cooled to 0 ºC, stirred for 20 min followed 
by the drop-wise addition of 2-chloroethane sulfonyl chloride (3.8 mmol, 1.0 equiv.).  The reaction was warmed 
to rt and left to stir overnight.  CH2Cl2 was removed in vacuo upon completion of the reaction.  MeOH (0.5 M), 
 SI–138 
 
water (0.5 M), Et3N (11.4 mmol, 3.0 equiv.) and amino acid (3.8 mmol, 1.0 equiv.) were added to the reaction 
mixture, which was stirred at 60 ºC for 12 h, after which the solvents were evaporated to dryness.  DMF (0.05 
M) (for cyclic amino acids), EDC (7.6 mmol, 2.0 equiv.), HOBt (0.76 mmol, 0.2 equiv.) and Et3N (7.6 mmol, 
2.0 equiv.) were added to the crude mixture.  The reaction was stirred at rt for 12 h, followed by evaporation of 
DMF.  Water was added to the crude mixture, which was extracted with EtOAc (2x).  The combined organic 
layers were dried (Na2SO4) and concentrated under reduced pressure to afford the crude product, which was 
purified by flash chromatography (100% EtOAc). For acyclic amino acids, CHCl3 was utilized as the solvent, 
followed by addition of EDC (7.6 mmol, 2.0 equiv.), HOBt (0.76 mmol, 0.2 equiv.) and Et3N (7.6 mmol, 2.0 
equiv.).   The reaction was stirred at 50 ºC for 12 h after which time; water (equal volume of CHCl3 used) was 
added to the crude mixture and extraction of aqueous layer with EtOAc (2x).  The combined organic layers 
were dried (Na2SO4) and concentrated under reduced pressure to afford the crude product, which was purified 
by flash chromatography (100% EtOAc). 
 
General Procedure D: one-pot, sequential 4-component (sulfonylation, Michael addition, amide coupling 
and carbamate formation.  To a pressure tube containing a solution of amine (0.38 mmol, 1.0 equiv.) in dry 
CH2Cl2 (0.5 M), was added Et3N (0.76 mmol, 2.0 equiv.).  The reaction mixture was cooled to 0 ºC, stirred for 
20 min, after which 2-chloroethane sulfonyl chloride (0.38 mmol, 1.0 equiv.) was added drop-wise.  The 
reaction mixture was warmed to rt and left to stir overnight. CH2Cl2 was removed in vacuo upon the completion 
of reaction, followed by addition of MeOH (0.5 M), water (0.5 M), Et3N (1.14 mmol, 3.0 equiv.) and amino 
acid (0.38 mmol, 1.0 equiv.).  The reaction was stirred at 60 ºC for 12 h.  Upon the removal of solvents, CHCl3  
(0.05 M) was added to the crude mixture followed by EDC (0.46 mmol, 1.2 equiv.), HOBt (0.076 mmol, 0.2 
equiv.) and Et3N (0.76 mmol, 2.0 equiv.) for the amide coupling reaction.  The reaction was stirred at 50 ºC for 
12 h, followed by evaporation of solvent.  Carbamoylation commenced with addition of CH2Cl2 (0.5 M), 
isocyanate (0.76 mmol, 2 equiv.), DMAP (0.19 mmol, 0.5 equiv.) and Et3N (0.76 mmol, 2 equiv.).  The reaction 
was stirred overnight at 50 ºC after which time, water was added to the crude mixture, followed by extraction 
with EtOAc.  The organic layer was separated and the aqueous layer was extracted with EtOAc (2x).  The 
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combined organic layers were dried (Na2SO4) and concentrated under reduced pressure to afford the crude 
product, which was purified by flash chromatography (1:1 EtOAc:Hexane). 
 
General Procedure E: one-pot, sequential 4-component (sulfonylation, Michael addition, amide coupling 
and click reaction).  To a pressure tube containing a solution of amine (0.38 mmol, 1.0 equiv.) in dry CH2Cl2 
(0.5 M), was added Et3N (0.79 mmol, 2.0 equiv.).  The reaction mixture was cooled to 0 ºC, stirred for 20 min, 
after which 2-chloroethane sulfonyl chloride (0.38 mmol, 1.0 equiv.) was added drop-wise.  The reaction was 
warmed to rt and left to stir overnight.  After completion of the reaction, CH2Cl2 was removed under reduced 
pressure.  MeOH (0.5 M), water (0.5 M), Et3N (1.14 mmol, 3.0 equiv.) and amino acid (0.38 mmol, 1.0 equiv.) 
were next added to the mixture for the Michael reaction.  The mixture was stirred at 60 ºC in a sealed tube for 
12 h, after which the solvents were again evaporated to dryness.  CHCl3 (0.05 M) was added to the crude 
mixture followed by EDC (0.46 mmol, 1.2 equiv.), HOBt (0.076 mmol, 0.2 equiv.) and Et3N (0.76 mmol, 2.0 
equiv.) for the amide formation reaction.  The reaction was stirred at 50 ºC for 12 h, followed by evaporation of 
solvent.  Next, step-wise addition of CH2Cl2, alkyl azide and t-butanol was performed, followed by sequential 
addition of aqueous solutions of CuSO4 (0.19 mmol, 0.5 equiv.) and L-Na-Ascorbate (0.23 mmol, 0.6 equiv.).  
The reaction was stirred overnight at rt, after which time, water was added to the crude mixture, followed by 
extraction with EtOAc.  The organic layer was separated, and the aqueous layer extracted with EtOAc (2x).  
The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure to afford the crude 
product, which was purified by flash chromatography (100% EtOAc). 
General Procedure F: one-pot, sequential 4-component (sulfonlation, Michael, amide coupling and 
esterification). A solution of amine (0.38 mmol, 1.0 equiv.) in dry CH2Cl2 (0.5 M), along with Et3N (0.76 
mmol, 2.0 equiv.) was added to a pressure tube.  The reaction mixture was cooled to 0 ºC, stirred for 20 min, 
after which 2-chloroethane sulfonyl chloride (0.38 mmol, 1.0 equiv.) was added to the reaction mixture in a 
drop-wise manner.  The reaction was warmed to rt and left to stir overnight.  CH2Cl2 was removed in vacuo 
upon the completion of reaction, followed by addition of MeOH (0.5 M), water (0.5 M), Et3N (1.14 mmol, 3.0 
equiv.) and amino acid (0.38 mmol, 1 equiv.) for the Michael reaction.  The reaction mixture was stirred at 60 
 SI–140 
 
ºC in a sealed tube for 12 h, after which solvents were evaporated to dryness.  CHCl3 (0.05 M) was added to the 
crude mixture followed by EDC (0.46 mmol, 1.2 equiv.), HOBt (0.076 mmol, 0.2 equiv.) and Et3N (0.76 mmol, 
2.0 equiv.) for the amide coupling reaction.  The reaction was stirred for 12 h at 50 ºC.  After completion of the 
reaction, additional EDC (0.46 mmol, 1.2 equiv.), HOBt (0.57 mmol, 1.5 equiv.), Et3N (0.76 mmol, 2.0 equiv.) 
and carboxylic acid were added to the mixture for the esterification step.  The reaction was again stirred 
overnight at 50 ºC.  Upon completion of the reaction, water was added to the crude mixture, which was 
extracted with EtOAc.  The organic layer was separated and the aqueous layer was extracted with EtOAc (2x).  
The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure to afford the crude 
product, which was purified by flash chromatography (1:1 EtOAc:Hexane). 
General Procedure G: one-pot, sequential 5-component (sulfonylation, Michael addition, amide coupling, 
esterification and click reaction).  To a pressure tube containing a solution of amine (0.38 mmol, 1.0 equiv.) 
in dry CH2Cl2 (0.5 M), was added Et3N (0.76 mmol, 2.0 equiv.).  The reaction mixture was cooled to 0 ºC, 
stirred for 20 min, after which 2-chloroethane sulfonyl chloride (0.38 mmol, 1.0 equiv.) was added in a drop-
wise manner.  The reaction was warmed to rt and left to stir overnight.  After completion of the reaction, 
CH2Cl2 was removed in vacuo, followed by addition of MeOH (0.5 M), water (0.5 M), Et3N (1.14 mmol, 3.0 
equiv.) and amino acid for the Michael reaction.  The reaction mixture was stirred at 60 ºC for 12 h in the sealed 
tube.  The solvents were evaporated to dryness.  Amide coupling reaction commenced with addition of CHCl3 
(0.05 M), followed by EDC (0.46 mmol, 1.2 equiv.), HOBt (0.076 mmol, 0.2 equiv.) and Et3N (0.76 mmol, 2.0 
equiv.).  The reaction was stirred at 50 ºC for 12 h.  Upon completion of the reaction, EDC (0.76 mmol, 1.2 
equiv.), HOBt (0.57 mmol, 1.5 equiv.) and Et3N (0.76 mmol, 2.0 equiv.) were added to the crude mixture, 
followed by the carboxylic acid for the esterification step.  The reaction was heated at 50 ºC for 12 h and 
solvent was removed under reduced pressure.  Next, step-wise addition of CH2Cl2, alkyl azide and t-BuOH was 
performed, followed by sequential addition of aqueous solutions of CuSO4 (0.19 mmol, 0.5 equiv.) and L-Na-
ascorbate (0.23 mmol, 0.6 equiv.).  The reaction was stirred overnight at rt, after which time, water was added 
to the crude mixture, followed by extraction with EtOAc.  The organic layer was separated, and the aqueous 
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layer extracted with EtOAc (2x).  The combined organic layers were dried (Na2SO4) and concentrated under 
reduced pressure to afford the crude product, which was purified by flash chromatography (2:1 EtOAc:Hexane). 
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 (8R,9aS)-8-hydroxy-2-butylhexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (2.4.2a) 
 
According to the reaction protocol described in general procedure B, compound 2.4.2a (67%, 2.04 g) was 
isolated after chromatography as a light orange solid. 
M. P. 112–113 ºC; 
Rf = 0.56 (100% EtOAc); 
FTIR (neat) 3637, 3102, 2991, 2901, 1712, 1453, 1349, 1193 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +23.2° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 4.44–4.36 [m, 2H, NCH2CH(OH)CH2CH(C=O)], 3.90–3.74 [m, 2H, 
(C=O)NCH2CH2CH2CH3], 3.50–3.35 [m, 4H, O2SCH2CHaHbNCHaHbCH(OH)], 3.27 (dt, J = 12.2, 3.2 Hz, 1H, 
O2SCH2CHaHbN), 2.75 [dddd, J = 12.8, 5.9, 5.9 1.0 Hz, 1H, NCH2CH(OH)CHaHbCH(C=O)], 2.67 [ddd, J = 
9.9, 5.2, 1.2 Hz, 1H, NCHaHbCH(OH)CH2CH(C=O)], 1.96 [dddd, J = 13.2, 8.9, 5.6, 1.2 Hz, 1H, 
NCH2CH(OH)CHaHbCH(C=O)], 1.68–1.56 (m, 3H, OH, n-butyl), 1.41–1.30 (m, 2H, n-butyl), 0.94 (td, J = 7.4, 
1.8 Hz, 3H, n-butyl); 
13C NMR (126 MHz, CDCl3) δ ppm 171.0, 62.9, 61.5, 58.7, 55.9, 50.4, 46.8, 32.4, 31.5, 19.6, 13.5; 
HRMS calculated for C11H20N2O4SH (M+H)+ 277.1222; found 277.1222 (TOF MS ES+). 
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(8R,9aS)-8-hydroxy-2-(4-methoxybenzyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-
dioxide (2.4.2b) 
 
According to the reaction protocol described in general procedure B, compound 2.4.2b (72%, 1.02 g) was 
isolated after chromatography as a dark orange solid. 
M. P. 125–127 ºC; 
Rf = 0.38 (100% EtOAc); 
FTIR (thin film) 3365, 3299, 3155, 2956, 1708, 1444, 1355, 1155, 1213, 835 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +26.6° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.37–7.33 (m, 2H), 6.87–6.83 (m, 2H), 5.09 (d, J = 15.0 Hz, 1H, 
NCHaHbPh), 4.85 (d, J = 14.9 Hz, 1H, NCHaHbPh), 4.42 [dd, J = 8.8, 5.8 Hz, 1H, 
NCH2CH(OH)CH2CH(C=O)], 4.39 [dddd, J = 5.4, 5.4, 5.3, 5.3 Hz, 1H, NCH2CH(OH)CH2CH(C=O)], 3.80 (s, 
3H, Ar-OCH3), 3.45–3.33 (m, 3H, O2SCH2CHaHbN), 3.23–3.10 [m, 2H, O2SCH2CHaHbNCHaHbCH(OH)], 2.75 
[dddd, J = 12.5, 5.8, 5.8, 1.0 Hz, 1H, NCH2CH(OH)CHaHbCH(C=O)], 2.64 [ddd, J = 9.8, 5.3, 1.1 Hz, 1H, 
O2SCH2CHaHbNCHaHbCH(OH)], 1.95 [dddd, J = 14.4, 8.7, 5.7, 1.1 Hz, 1H, NCH2CH(OH)CHaHbCH(C=O)], 
1.89 (s, 1H, OH); 
13C NMR (126 MHz, CDCl3) δ ppm 171.5, 159.1, 130.1 (2), 128.7, 113.8 (2), 77.3, 70.17, 64.1, 56.5, 55.3, 
52.4, 48.1, 36.6; 
HRMS calculated for C15H20N2O5SNa (M+Na)+ 363.0991; found 363.1004  (TOF MS ES+).  
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(8R,9aS)-2-allyl-8-hydroxyhexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (2.4.2c) 
 
According to the reaction protocol described in general procedure B, compound 2.4.2c (86%, 12.1 g) was 
isolated after chromatography as a light brown solid.   
According to the reaction protocol described in general procedure C, compound 2.4.2c (39%, 0.15 g) was 
isolated after chromatography as a white solid. 
M. P. 113–116 ºC; 
Rf = 0.42 (100% EtOAc); 
[𝜶]𝑫𝟐𝟎
 = +25.8° (c = 0.36, MeOH); 
FTIR (thin film) 3373, 3331, 2928, 1705, 1647, 1447, 1344, 1150, 1082, 989, 915 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 5.88 (dddd, J = 17.2, 10.3, 6.2, 5.3 Hz, 1H, CH2CH=CH2), 5.35 (dddd, J = 
17.1, 1.4, 1.4, 1.4 Hz, 1H, CH2CH=CHcisHtrans), 5.24 (dddd, J = 10.3, 1.2, 1.2, 1.2 Hz, 1H, CH2CH=CHcisHtrans), 
4.51–4.36 [m, 4H, NCH2CH(OH)CH2CH(C=O)NCH2], 3.52–3.33 [m, 4H, O2SCH2CHaHbNCHaHbCH(OH)], 
3.29 (dt, J = 12.7, 3.5 Hz, 1H, O2SCH2CHaHbN), 2.76 [dddd, J = 12.8, 5.8, 5.8, 1.0 Hz, 1H, 
NCH2CH(OH)CHaHbCH(C=O)], 2.68 [ddd, J = 9.9, 5.3, 1.2 Hz, 1H, NCHaHbCH(OH)CH2CH(C=O)], 1.96 
[dddd, J = 14.2, 8.8, 5.7, 1.2 Hz, 1H, NCH2CH(OH)CHaHbCH(C=O)], 1.57 (s, 1H, OH); 
13C NMR (126 MHz, CDCl3) δ ppm 171.3, 132.2, 118.5, 70.4, 64.3, 64.3, 56.7, 52.7, 47.8, 36.7; 
HRMS calculated for C10H16N2O4SH (M + H)+ 261.0909; found 261.0894 (TOF MS ES+). 
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(8R,9aS)-2-benzyl-8-hydroxyhexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (2.4.2d) 
 
According to the reaction protocol described in general procedure B, compound 2.4.2d (76%, 5.05 g) was 
isolated after chromatography as a light brown solid. 
According to the reaction protocol described in general procedure C, compound 2.4.2d (69%, 0.51 g) was 
isolated after chromatography as a light brown solid.  
M. P. 109–110 ºC;  
Rf = 0.52 (100% EtOAc); 
FTIR (neat) 3639, 3109, 2953, 2901, 1701, 1454, 1360, 1142, 1102, 712 cm-1; 
[𝜶]𝑫𝟐𝟎 = +25.2° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.42–7.37 (m, 2H), 7.36–7.32 (m, 2H), 7.31–7.28 (m, 1H), 5.13 (d, J = 
15.1 Hz, 1H, NCHaHbPh), 4.90 (d, J = 15.1 Hz, 1H, NCHaHbPh), 4.46 [dd, J = 10.6, 6.0 Hz, 1H, 
NCH2CH(OH)CH2CH(C=O)], 4.42 [dddd, J = 5.2, 5.2, 5.2, 5.2 Hz, 1H, NCH2CH(OH)CH2CH(C=O)], 3.49–
3.42 (m, 1H, O2SCHaHbCH2N), 3.41–3.35 (m, 2H, O2SCHaHbCHaHbN), 3.26–3.17 (m, 2H, 
O2SCH2CHaHbNCHaHb), 2.76 [dddd, J = 13.5, 5.9, 5.9, 1.0 Hz, 1H NCH2CH(OH)CHaHbCH(C=O)], 2.65 [ddd, 
J = 9.9, 5.2, 1.2 Hz, 1H, O2SCH2CH2NCHaHb)], 2.07 (bs, 1H, OH), 1.95 [dddd, J = 13.3, 8.5, 5.6, 1.0 Hz, 1H, 
NCH2CH(OH)CHaHbCH(C=O)]; 
13C NMR (126 MHz, CDCl3) δ ppm 170.6, 136.3, 128.6, 128.1(2), 127.7(2), 63.9, 61.6, 58.9, 55.4, 50.3, 49.0, 
32.3; 
HRMS calculated for C14H18N2O4SH (M+H)+ 311.1066; found 311.1061 (TOF MS ES+). 
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(8R,9aS)-8-hydroxy-2-(prop-2-yn-1-yl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide 
(2.4.2e) 
 
According to the reaction protocol described in general procedure B, compound 2.4.2e (64%, 28.1 g) was 
isolated after chromatography as a light brown solid. 
M. P. 94–95 ºC; 
Rf = 0.38 (100% EtOAc); 
FTIR (thin film) 3566, 3172, 2979, 2077, 1681, 1357, 1155, 1070 cm-1; 
[𝜶]𝑫𝟐𝟎 = +22.7° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 4.73 (dd, J = 17.5, 2.4 Hz, 1H, NCHaHbCCH), 4.51 (dd, J = 17.5, 2.4 Hz, 
1H, NCHaHbCCH), 4.47–4.40 [m, 2H, NCH2CH(OH)CH2CH(C=O)], 3.55–3.44 (m, 3H, O2SCH2CHaHbN), 
3.42 [ddd, J = 9.9, 4.7, 1.0 Hz, 1H, NCHaHbCH(OH)CH2], 3.30 (dd, J = 9.1, 3.4 Hz, 1H, O2SCH2CHaHbN), 
2.76 [dddd, J = 13.0, 6.0, 5.9, 1.0 Hz, 1H, NCH2CH(OH)CHaHb], 2.69 [ddd, J = 9.9, 5.2, 1.1 Hz, 1H, 
NCHaHbCH(OH)CH2], 2.30 (dd, J = 2.4, 2.3 Hz, 1H, NCH2CCH), 1.98 [dddd, J = 13.3, 8.6, 5.6, 1.1 Hz, 1H, 
NCH2CH(OH)CHaHb], 1.61 (s, 1H, OH); 
13C NMR (126 MHz, CDCl3) δ ppm 170.2, 77.8, 71.9, 70.2, 64.1, 63.7, 56.6, 52.3, 36.5, 34.4; 
HRMS calculated for C10H14N2O4SNa (M+Na)+ 281.0572; found 281.0580 (TOF MS ES+). 
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5-benzyl-4-thia-1,5-diazabicyclo[5.2.0]nonan-6-one 4,4-dioxide (2.6.1) 
 
According to the reaction protocol described in general procedure B, compound 2.6.1 (75%, 0.21 g) was 
isolated after chromatography as a yellow solid. 
According to the reaction protocol described in general procedure C, compound 2.6.1 (85%, 0.102 g) was 
isolated after chromatography as a white solid. 
M. P. 82–84 ºC; 
Rf = 0.53 (1:1 Hexane:EtOAc); 
FTIR (thin film) 2974, 2839, 1712, 1693, 1496, 1371, 1149, 1037, 727 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.44–7.39 (m, 2H), 7.38–7.33 (m, 2H), 7.32–7.27 (m, 1H), 5.17 (d, J = 
15.2 Hz, 1H, NCHaHbPh), 4.87 (d, J = 15.3 Hz, 1H, NCHaHbPh), 4.56 (dd, J = 8.2, 8.2 Hz, 1H, C=OCHCH2), 
3.38–3.29 (m, 2H, O2SCHaHbCH2NCHaHbCH2), 3.22–3.09 (m, 3H, O2SCHaHbCHaHbNCHaHbCH2), 3.05–3.00 
(m, 1H, O2SCH2CHaHbNCH2), 2.61 [dddd, J = 10.4, 10.4, 8.5, 8.5 Hz, 1H, NCH2CHaHbCH(C=O)], 2.13 [dddd, 
J = 10.4, 7.6, 7.6, 2.0 Hz, 1H, NCH2CHaHbCH(C=O)]; 
13C NMR (126 MHz, CDCl3) δ ppm 171.9, 136.5, 128.5 (2), 128.1 (2), 127.6, 65.8, 55.4, 51.4, 50.5, 48.0, 20.5; 
HRMS calculated for C13H16N2O3SH (M+H)+ 281.0960, found 281.0968 (TOF MS ES+). 
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(S)-2-benzylhexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (2.6.2) 
 
According to the reaction protocol described in general procedure B, compound 2.6.2 (82%, 0.097 g) was 
isolated after chromatography as a white solid. 
According to the reaction protocol described in general procedure C, compound 2.6.2 (85%, 0.098 g) was 
isolated after chromatography as a white solid. 
M. P. 89–91 ºC; 
Rf = 0.52 (1:1 Hexane:EtOAc); 
FTIR (thin film) 2927, 1701, 1454, 1365, 1218, 1151, 732 cm-1; 
[𝜶]𝑫𝟐𝟎 = +29.2° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.43–7.39 (m, 2H), 7.36–7.31 (m, 2H), 7.30–7.26 (m, 1H), 5.14 (d, J = 
15.2 Hz, 1H, NCHaHbPh), 4.93 (d, J = 15.1 Hz, 1H, NCHaHbPh), 4.16 (dd, J = 9.8, 2.5 Hz, 1H, C=OCHCH2), 
3.39–3.34 (m, 1H, O2SCHaHbCH2), 3.28–3.19 (m, 3H, O2SCHaHbCH2N), 3.17–3.12 [m, 1H, 
NCHaHbCH2CH2CH(C=O)], 2.70–2.63 [m, 1H, NCHaHbCH2CH2CH(C=O)], 2.63–2.54 [m, 1H, 
NCH2CH2CHaHbCH(C=O)], 1.95–1.85 [m, 1H, NCH2CH2CHaHbCH(C=O)], 1.82–1.74 [m, 2H 
NCH2CH2CH2CH(C=O)];  
13C NMR (126 MHz, CDCl3) δ ppm 171.9, 136.5, 128.5 (2), 128.3 (2), 127.6, 64.3, 57.8, 56.2, 50.7, 48.6, 27.2, 
24.7; 
HRMS calculated for C14H18N2O3SH (M+H)+ 295.1116, found 295.1116 (TOF MS ES+). 
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(R)-2-benzylhexahydro-1H-thiazolo[4,3-d][1,2,5]thiadiazepin-1-one 3,3-dioxide (2.6.3) 
 
According to the reaction protocol described in general procedure B, compound 2.6.3 (70%, 0.098 g) was 
isolated after chromatography as a brown solid.  
According to the reaction protocol described in general procedure C, compound 2.6.3 (76%, 0.21 g) was 
isolated after chromatography as a brown solid. 
M. P. 98–99 ºC; 
Rf = 0.51 (1:1 Hexane:EtOAc); 
FTIR (thin film) 2927, 1701, 1496, 1456, 1373, 1151, 1022, 730 cm-1; 
[𝜶]𝑫𝟐𝟎 = -21.7° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.43–7.39 (m, 2H), 7.37–7.32 (m, 2H), 7.32–7.27 (m, 1H), 5.17 (d, J = 
15.1 Hz, 1H, NCHaHbPh), 4.92 (d, J = 15.1 Hz, 1H, NCHaHbPh), 4.44 (dd, J = 7.3, 5.4 Hz, 1H, C=OCHCH2), 
4.21 (d, J = 9.1 Hz, 1H, NCHaHbS), 3.89 (d, J = 9.1 Hz, 1H, NCHaHbS), 3.69 (dd, J = 12.1, 5.4 Hz, 1H, 
NCH2SCHaHbCH), 3.61–3.54 (m, 1H, O2SCHaHbCH2N), 3.43–3.38 (m, 1H, O2SCH2CHaHbN), 3.34–3.23 (m, 
2H, O2SCHaHbCHaHbN), 3.16 (dd, J = 12.1, 7.3 Hz, 1H, NCH2SCHaHbCH); 
13C NMR (126 MHz, CDCl3) δ ppm 167.0, 136.4, 128.6 (2), 128.4 (2), 127.8, 67.3, 60.9, 55.8, 51.7, 48.7, 34.1; 
HRMS calculated for C13H16N2O3S2H (M+H)+ 313.0681, found 313.0685  (TOF MS ES+). 
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3-benzylhexahydro-1H-pyrrolo[2,1-e][1,2,6]thiadiazocin-2(3H)-one 4,4-dioxide (2.6.4) 
 
According to the reaction protocol described in general procedure B, compound 2.6.4 (65%, 0.096 g) was 
isolated after chromatography as a light yellow solid. 
M. P. 87–90 ºC; 
Rf = 0.70 (1:1 Hexane:EtOAc); 
FTIR (thin film) 3286, 2931, 1703, 1645, 1494, 1454, 1398, 1284, 1137, 730 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.48–7.43 (m, 2H), 7.34–7.25 (m, 3H), 5.51 (d, J = 14.9 Hz, 1H, 
NCHaHbPh), 4.75 (d, J = 14.8 Hz, 1H, NCHaHbPh), 4.08 (dd, J = 12.4, 8.6 Hz, 1H, O2SCHaHbCH2N), 3.30–
3.20 (m, 1H, O2SCHaHbCH2N), 3.07–2.93 (m, 4H, O2SCH2CH2NCH, NCHaHbCH2), 2.81–2.68 [m, 1H, 
NCHCHaHb(C=O)], 2.54 [d, J = 13.0 Hz, 1H, NCHCHaHb(C=O)], 2.47 (dd, J = 16.8, 8.2 Hz, 1H, 
NCHaHbCH2), 2.10–1.91 [m, 2H, NCH2CHaHbCHaHbCH(C=O)], 1.85–1.71 [m, 2H, 
NCH2CHaHbCHaHbCH(C=O)]; 
13C NMR (126 MHz, CDCl3) δ ppm 171.7, 136.4, 129.2 (2), 128.2 (2), 127.7, 64.2, 56.8, 56.2, 48.5, 47.7, 37.5, 
29.8, 22.6; 
HRMS calculated for C15H20N2O3SH (M+H)+ 309.1273, found 309.1282  (TOF MS ES+). 
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2-(4-chlorobenzyl)octahydro-1H-pyrido[2,1-d][1,2,5]thiadiazepin-1-one 3,3-dioxide (2.6.5) 
 
According to the reaction protocol described in general procedure B, compound 2.6.5 (75%, 0.105 g) was 
isolated after chromatography as a brown solid. 
According to the reaction protocol described in general procedure C, compound 2.6.5 (82%, 0.11 g) was 
isolated after chromatography as a brown solid. 
M. P. 88–91 ºC; 
Rf = 0.45 (1:1 Hexane:EtOAc); 
FTIR (thin film) 2975, 2923, 2833, 1704, 1444, 1355, 1153, 825 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.43–7.38 (m, 2H), 7.32–7.28 (m, 2H), 5.06 (d, J = 15.0 Hz, 1H, 
NCHaHbPh), 4.88 (d, J = 15.0 Hz, 1H, NCHaHbPh), 4.28 (dd, J = 3.8, 3.4 Hz, 1H, C=OCHCH2), 3.79 (m, 1H, 
O2SCHaHbCH2N), 3.40–3.32 (m, 1H, O2SCH2CHaHbN), 3.28–3.19 (m, 2H, O2SCHaHbCHaHbN), 2.52–2.42 (m, 
2H, NCH2CH2), 2.10–2.03 (m, 1H, NCH2CH2CH2CHaHbCH), 1.80–1.67 (m, 1H, NCH2CH2CHaHbCH2CH), 
1.63 (m, 1H, NCH2CHaHbCH2CH2CH), 1.60–1.49 (m, 3H, NCH2CHaHbCHaHbCHaHbCH);  
13C NMR (126 MHz, CDCl3) δ ppm 173.0, 135.7, 133.7, 130.2 (2), 128.7 (2), 60.7, 53.0, 52.1, 47.7, 47.6, 27.4, 
25.8, 19.9; 
HRMS calculated for C15H19ClN2O3SH (M+H)+ 343.0883, found 343.0883 (TOF MS ES+). 
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2-(4-methoxybenzyl)octahydro-1H-pyrido[2,1-d][1,2,5]thiadiazepin-1-one 3,3-dioxide (2.6.6) 
 
According to the reaction protocol described in general procedure B, compound 2.6.6 (71%, 0.105 g) was 
isolated after chromatography as a dark yellow solid. 
M. P. 91–93 ºC; 
Rf = 0.37 (1:1 Hexane:EtOAc); 
FTIR (thin film) 2979, 2927, 1704, 1444, 1357, 1155, 842 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.44–7.40 (m, 2H), 6.87–6.84 (m, 2H), 5.13 (d, J = 14.7 Hz, 1H, 
NCHaHbPh), 4.85 (d, J = 14.7 Hz, 1H, NCHaHbPh), 4.28 (dd, J = 4.7, 2.7 Hz, 1H, C=OCHCH2), 3.81 (s, 3H, 
Ar-OCH3), 3.79–3.71 (m, 1H, O2SCHaHbCH2N), 3.35–3.28 (m, 1H, O2SCH2CHaHbN), 3.25–3.17 (m, 2H, 
O2SCHaHbCHaHbN), 2.45–2.39 (m, 2H, NCH2CH2), 2.13–2.05 (m, 1H, NCH2CH2CH2CHaHbCH), 1.81–1.70 
(m, 1H, NCH2CH2CHaHbCH2CH), 1.62 (m, 1H, NCH2CHaHbCH2CH2CH), 1.65–1.47 (m, 3H, 
NCH2CHaHbCHaHbCHaHbCH); 
13C NMR (126 MHz, CDCl3) δ ppm 173.0, 159.2, 130.5 (2), 129.4, 113.6 (2), 60.6, 55.2, 53.0, 52.1, 47.6, 27.4, 
29.7, 25.8, 19.8; 
HRMS calculated for C16H22N2O4SH (M+H)+ 339.1379, found 339.1388  (TOF MS ES+). 
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2-(4-(trifluoromethoxy)benzyl)hexahydro-[1,4]oxazino[3,4-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide 
(2.6.7) 
 
 
According to the reaction protocol described in general procedure B, compound 2.6.7 (47%, 0.18 g) was 
isolated after chromatography as a yellow solid. 
M. P. 102–107 ºC; 
Rf = 0.53 (100% EtOAc); 
FTIR (thin film) 3121, 2962, 2916, 1682, 1508, 1435, 1346, 1219, 1151, 1043, 851 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.55 (d, J = 8.6 Hz, 2H), 7.19 (d, J = 7.8 Hz, 2H), 5.12 (d, J = 14.9 Hz, 1H, 
NCHaHbPh), 4.95 (d, J = 14.9 Hz, 1H, NCHaHbPh), 4.34 (d, J = 10.9 Hz, 1H, NCH2CH2OCHaHbCH), 4.11 [m, 
1H, OCH2CH(C=O)], 3.94–3.84 (m, 1H, O2SCHaHbCH2N), 3.76 (ddd, J = 10.9, 3.3, 1.6 Hz, 1H, 
NCH2CHaHbOCH2CH), 3.69–3.60 (m, 2H, NCH2CHaHbOCHaHbCH), 3.47–3.39 (m, 1H, O2SCH2CHaHbN), 
3.31 (dd, J = 14.3, 14.2 Hz, 2H, O2SCHaHbCHaHbN), 2.77 (dd, J = 11.2, 11.1 Hz, 1H, NCHaHbCH2O), 2.38 (d, 
J = 11.9 Hz, 1H, NCHaHbCH2O); 
13C NMR (126 MHz, CDCl3) δ ppm 171.2, 148.9, 135.6, 130.6 (2), 121.0 (2), 120.4 (d, JC–F = 257.4 Hz), 67.5, 
66.9, 61.3, 52.7, 51.7, 47.8, 47.2; 
HRMS calculated for C15H17F3N2O5SH (M + H)+ 395.0898; found 395.0913 (TOF MS ES+). 
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(S)-tert-butyl 2-((S)-3,3-dioxido-1-oxohexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-2(1H)-yl)propanoate 
(2.6.8) 
 
According to the reaction protocol described in general procedure B, compound 2.6.8 (77%, 0.49 g) was 
isolated after chromatography as a light brown solid. 
M. P. 84–86 ºC; 
Rf = 0.55 (1:1 Hexane:EtOAc); 
FTIR (thin film) 2943, 2829, 1731, 1703, 1697, 1444, 1357, 1182 cm-1; 
[𝜶]𝑫𝟐𝟎 = -29.2° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 4.90 [q, J = 6.9 Hz, 1H, NCH(CH3)CO2tBu], 4.14 (dd, J = 9.8, 2.5 Hz, 1H, 
C=OCHCH2), 3.70 (ddd, J = 14.0, 10.2, 6.0 Hz, 1H, O2SCHaHbCH2), 3.40 (dt, J = 14.0, 2.8 Hz, 1H, 
O2SCHaHbCH2), 3.35–3.22 (m, 2H, O2SCH2CH2N), 3.16–3.11 (m, 1H, NCHaHbCH2CH2CH), 2.66–2.56 (m, 
2H, NCHaHbCH2CHaHbCH), 1.93–1.83 (m, 1H, NCH2CH2CHaHbCH), 1.83–1.70 (m, 2H, NCH2CH2CH2CH), 
1.57 [d, J = 6.9 Hz, 3H, NCH(CH3)CO2tBu], 1.45 [s, 9H, CO2C(CH3)3]; 
13C NMR (126 MHz, CDCl3) δ ppm 170.6, 168.6, 82.0, 63.6, 57.7, 56.1, 55.4, 50.5, 27.8, 27.2, 24.8, 16.3 (3); 
HRMS calculated for C14H24N2O5SNa (M+Na)+ 355.1304, found 355.1309 (TOF MS ES+). 
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(S)-tert-butyl 2-((R)-3,3-dioxido-1-oxohexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-2(1H)-yl)propanoate 
(2.6.9) 
 
According to the reaction protocol described in general procedure B, compound 2.6.9 (80%, 0.51 g) was 
isolated after chromatography as a dark brown solid. 
M. P. 84–85 ºC; 
Rf = 0.51 (1:1 Hexane:EtOAc); 
FTIR (thin film) 2943, 2871, 1737, 1703, 1697, 1444, 1384, 1325, 1126 cm-1; 
[𝜶]𝑫𝟐𝟎 = +15.7° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 4.91 [q, J = 6.9 Hz, 1H, NCH(CH3)CO2tBu], 4.46–4.37 (m, 2H, 
C=OCHCH2, O2SCHaHbCH2N), 3.69 (ddd, J = 13.4, 12.1, 4.3 Hz, 1H, O2SCHaHbCH2N), 3.51–3.36 (m, 3H, 
O2SCH2CH2NHaHb), 3.33–3.26 (m, 1H, O2SCH2CH2NHaHb), 2.74 (ddd, J = 12.9, 5.8, 5.8 Hz, 1H, 
NCH2CH2CHaHbCH), 2.67 (dd, J = 9.6, 5.6 Hz, 1H, NCH2CH2CHaHbCH), 1.94 (ddd, J = 13.2, 8.5, 5.6 Hz, 1H, 
NCH2CHaHbCH2CH), 1.64–1.60 (m, 1H, NCH2CHaHbCH2CH), 1.58 [d, J = 7.0 Hz, 3H, NCH(CH3)CO2tBu], 
1.46 [s, 9H, CO2C(CH3)3]; 
13C NMR (126 MHz, CDCl3) δ ppm 171.3, 169.3, 82.1, 64.3, 57.8, 56.6, 55.0, 50.8, 27.9, 27.3, 24.5, 16.7 (3); 
HRMS calculated for C14H24N2O5SNa (M+Na)+ 355.1304, found 355.1304 (TOF MS ES+). 
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(8R,9aS)-8-hydroxy-2-((S)-1-phenylethyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-
dioxide (2.5.7) 
 
According to the reaction protocol described in general procedure B, compound 2.5.7 (85%, 0.50 g) was 
isolated after chromatography as a dark yellow solid. 
M. P. 104–106 ºC; 
Rf = 0.52 (100% EtOAc); 
FTIR (thin film) 3523, 3392, 2835, 1701, 1496, 1375, 1276, 1147, 734 cm-1; 
[𝜶]𝑫𝟐𝟎 = +23.7° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.44–7.39 (m, 2H), 7.37–7.32 (m, 2H), 7.28–7.24 (m, 1H), 5.89 (q, J = 7.1 
Hz, 1H, NCHCH3Ph), 4.41 (dd, J = 8.7, 6.0 Hz, 1H, C=OCHCH2), 4.29 [dddd, J = 5.4, 5.4, 5.3, 5.3 Hz, 1H, 
CH2CH(OH)CH2], 3.54–3.41 (m, 3H, O2SCH2CHaHbN), 3.35 [dd, J = 9.9, 4.6 Hz, 1H, 
NCHaHbCH(OH)CH2CH(C=O)], 3.31–3.25 (m, 1H, O2SCH2CHaHbN), 2.68–2.60 [m, 2H, 
NCHaHbCH(OH)CHaHbCH(C=O)], 1.97–1.92 [m, 1H, (OH)CHCHaHbCH(C=O)], 1.91 (d, J = 7.1 Hz, 3H, 
NCHCH3Ph), 1.61 (bs, 1H, OH); 
13C NMR (126 MHz, CDCl3) δ ppm 170.0, 138.8, 126.7 (2), 125.6, 125.1 (2), 68.6, 63.7, 62.6, 55.5, 55.0, 50.9, 
35.2, 16.5; 
HRMS calculated for C15H20N2O4SNa (M+Na)+ 347.1041, found 347.1042  (TOF MS ES+). 
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(8R,9aS)-8-hydroxy-2-((R)-1-phenylethyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-
dioxide (2.5.8) 
 
According to the reaction protocol described in general procedure B, compound 2.5.8 (73%, 0.48 g) was 
isolated after chromatography as a brown solid. 
M. P. 106–109 ºC; 
Rf = 0.47 (100% EtOAc); 
FTIR (thin film) 3651, 3276, 2979, 1713, 1435, 1383, 1221, 1151, 742 cm-1; 
[𝜶]𝑫𝟐𝟎 = +21.6° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.35–7.31 (m, 2H), 7.30–7.24 (m, 2H), 7.21–7.16 (m, 1H), 5.88 (q, J = 7.1 
Hz, 1H, NCHCH3Ph), 4.36–4.28 [m, 2H, CH2CH(OH)CH2CHCH2(C=O)], 3.35–3.27 (m, 2H, O2SCH2CH2N), 
3.19 (dt, J = 13.5, 3.4 Hz, 1H, O2SCH2CHaHbN), 3.13 (dt, J = 13.2, 3.4 Hz, 1H, O2SCH2CHaHbN), 3.03 [ddd, J 
= 13.8, 12.4, 4.0 Hz, 1H, NCHaHbCH(OH)CH2CH(C=O)], 2.62 [ddd, J = 12.9, 7.0, 6.0 Hz, 1H, 
NCHaHbCH(OH)CH2CH(C=O)], 2.57 [ddd, J = 9.8, 5.2, 0.8 Hz, 1H, NCH2CH(OH)CHaHbCH(C=O)], 1.84 
[dddd, J = 14.2, 8.6, 5.5, 1.1 Hz, 1H, NCH2CH(OH)CHaHbCH(C=O)], 1.77 (d, J = 7.1 Hz, 3H, NCHCH3Ph), 
1.60 (bs, 1H, OH); 
13C NMR (126 MHz, CDCl3) δ ppm 171.6, 139.8, 128.2 (2), 127.2, 127.1 (2), 70.2, 65.0, 64.2, 57.0, 56.0, 52.4, 
36.8, 17.4; 
HRMS calculated for C15H20N2O4SH (M+H)+ 325.1222, found 325.1221  (TOF MS ES+). 
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(8R,9aR)-8-hydroxy-2-((S)-1-phenylethyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-
dioxide (2.5.9) 
 
According to the reaction protocol described in general procedure B, compound 2.5.9 (75%, 0.51 g) was 
isolated after chromatography as a dark yellow solid. 
M. P. 106–107 ºC; 
Rf = 0.58 (100% EtOAc); 
FTIR (thin film) 3539, 3280, 2975, 1755, 1631 1452, 1321, 1276, 1151, 734 cm-1; 
[𝜶]𝑫𝟐𝟎 = -19.7° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.42–7.35 (m, 4H), 7.34–7.29 (m, 1H), 5.22–5.10 (m, 1H, NCHCH3Ph), 
4.82 (bs, 1H, OH), 4.63 [dddd, J = 6.9, 6.9, 6.8, 6.8 Hz, 1H, CH2CH(OH)CH2], 3.47–3.45 (m, 1H, 
C=OCHCH2), 3.07 [dd, J = 12.4, 1.4 Hz, 1H, NCHaHbCH(OH)CH2], 3.01–2.82 (m, 3H, O2SCH2CHaHbN), 2.70 
(ddd, J = 12.3, 7.3, 5.4 Hz, 1H, O2SCH2CHaHbN), 2.16 [d, J = 11.3 Hz, 1H, NCHaHbCH(OH)CH2], 2.05 [ddd, J 
= 12.4, 4.6, 1.6 Hz,   1H, NCH2CH(OH)CHaHb], 1.78 [dd, J = 10.7, 1.8 Hz, 1H, NCH2CH(OH)CHaHb], 1.55 (d, 
J = 7.3 Hz, 3H, NCHCH3Ph); 
13C NMR (126 MHz, CDCl3) δ ppm 171.4, 142.7, 129.0 (2), 128.0, 126.3 (2), 79.5, 62.5, 55.6, 53.9, 52.4, 48.7, 
39.1, 24.2; 
HRMS calculated for C15H20N2O4SNa (M+Na)+ 347.1041, found 347.1037  (TOF MS ES+). 
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(8R,9aR)-8-hydroxy-2-((R)-1-phenylethyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-
dioxide (2.5.7) 
 
According to the reaction protocol described in general procedure B, compound 2.5.7 (70%, 0.49 g) was 
isolated after chromatography as a dark yellow solid. 
M. P. 108–110 ºC; 
Rf = 0.53 (100% EtOAc); 
FTIR (thin film) 3523, 3110, 2941, 2835, 1701, 1448, 1375, 1209, 1151, 734 cm-1; 
[𝜶]𝑫𝟐𝟎 = -15.7° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.39–7.35 (m, 4H), 7.33–7.26 (m, 1H), 5.61 (d, J = 7.34, 1H, NCHCH3Ph), 
4.81 (bs, 1H, OH), 4.61 [dddd, J = 7.0, 7.0, 6.9, 6.9 Hz, 1H, CH2CH(OH)CH2], 3.46–3.43 (m, 1H, 
C=OCHCH2), 3.11 [dd, J = 10.7, 1.4 Hz, 1H, NCHaHbCH(OH)CH2], 3.01–2.91 (m, 2H, O2SCH2CH2N), 2.81–
2.74 (m, 1H, O2SCH2CHaHbN), 2.64–2.56 (m, 1H, O2SCH2CHaHbN), 2.02–1.97 [m, 1H, 
NCHaHbCH(OH)CH2], 1.89–1.85 [m, 1H, NCH2CH(OH)CHaHb], 1.76 [dd, J = 10.8, 1.8 Hz, 1H, 
NCH2CH(OH)CHaHb], 1.53 (d, J = 6.9 Hz, 3H, NCHCH3Ph); 
13C NMR (126 MHz, CDCl3) δ ppm 171.7, 143.0, 129.1 (2), 127.8, 126.4 (2), 79.5, 62.4, 55.3, 53.8, 52.1, 48.3, 
39.1, 24.1; 
HRMS calculated for C15H20N2O4SNa (M+Na)+ 347.1041, found 347.1044  (TOF MS ES+). 
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(S)-2-benzyl-4-isobutyl-1,2,5-thiadiazepan-3-one 1,1-dioxide (2.7.1a) 
 
According to the reaction protocol described in general procedure B, compound 2.7.1a (63%, 5.05 g) was 
isolated after chromatography as a light yellow solid. 
According to the reaction protocol described in general procedure C, compound 2.7.1a (61%, 0.49 g) was 
isolated after chromatography as a light yellow solid. 
M. P. 74–76 ºC; 
Rf = 0.56 (100% EtOAc); 
FTIR (thin film) 3357, 3087, 2952, 1697, 1585, 1467, 1365, 1209, 1147 cm-1; 
[𝜶]𝑫𝟐𝟎 = +25.0° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.43–7.39 (m, 2H), 7.36–7.31 (m, 2H), 7.31–7.25 (m, 1H), 5.18 (d, J = 
15.0 Hz, 1H, NCHaHbPh), 4.89 (d, J = 14.9 Hz, 1H, NCHaHbPh), 4.18 (dd, J = 8.6, 4.7 Hz, 1H, HNCHCH2), 
3.55–3.45 (m, 1H, O2SCHaHbCH2), 3.36 (ddd, J = 14.7, 4.1, 2.8 Hz, 1H, O2SCHaHbCH2), 3.28 (dt, J = 14.3, 2.7 
Hz, 1H, CH2CHaHbNH), 2.94 (ddd, J = 14.2, 12.1, 4.1 Hz, 1H, CH2CHaHbNH), 1.78–1.69 (m, 2H, CHCH2CH), 
1.41 (p, J = 9.2 Hz, 1H, CH3CHCH3), 0.95 (d, J = 6.1 Hz, 3H, CH3CHCH3,), 0.93 (d, J = 6.0 Hz, 3H, 
CH3CHCH3); 
13C NMR (126 MHz, CDCl3) δ ppm 173.2, 147.2, 136.5, 128.4 (2), 127.6 (2), 58.3, 56.8, 48.2, 45.3, 40.7, 24.5, 
23.0, 22.1; 
HRMS calculated for C15H22N2O3SNa (M+Na)+ 333.1429; found 333.1429 (TOF MS ES+). 
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(4S)-4-(sec-butyl)-2-(4-fluorobenzyl)-1,2,5-thiadiazepan-3-one 1,1-dioxide (2.7.1b) 
 
According to the reaction protocol described in general procedure B, compound 2.7.1b (65%, 0.21 g) was 
isolated after chromatography as a light yellow solid. 
According to the reaction protocol described in general procedure C, compound 7.1b (65%, 0.21 g) was isolated 
after chromatography as a light yellow solid. 
M. P. 79–81 ºC; 
Rf = 0.45 (100% EtOAc); 
FTIR (thin film) 3363, 2960, 2929, 2873, 1697, 1467, 1365, 1147, 812 cm-1; 
[𝜶]𝑫𝟐𝟎 = +32.2° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.45–7.39 (m, 2H), 7.06–6.99 (m, 2H), 5.12 (d, J = 14.9 Hz, 1H, 
NCHaHbPh), 4.87 (d, J = 14.9 Hz, 1H, NCHaHbPh), 3.93 [d, J = 6.8 Hz, 1H, HNCH(C=O)], 3.52–3.42 (m, 2H, 
O2SCH2CH2NH), 3.29 (dt, J = 14.2, 2.7 Hz, 1H, O2SCH2CHaHbNH), 2.89 (ddd, J = 14.2, 10.7, 5.7 Hz, 1H, 
O2SCH2CHaHbNH), 1.92 (ddqd, J = 9.4, 7.4, 6.6, 3.1 Hz, 1H, CH3CH2CHCH3), 1.66 (dqd, J = 13.4, 7.6, 3.2 Hz, 
1H, CH3CHaHbCHCH3), 1.16 (ddq, J = 13.0, 9.1, 7.3 Hz, 1H, CH3CHaHbCHCH3), 0.98 (d, J = 6.6 Hz, 3H, 
CH3CH2CHCH3), 0.93 (t, J = 7.4 Hz, 3H, CH3CH2CHCH3); 
13C NMR (126 MHz, CDCl3) δ ppm 172.7, 162.3 (1JC–F = 246.5 Hz), 132.6 (4JC–F = 3.25 Hz), 130.7 (3JC–F = 
8.12 Hz, 2), 115.5 (2JC–F = 21.42 Hz, 2), 64.6, 56.9, 47.5, 45.5, 35.9, 24.5, 16.4, 11.3; 
HRMS calculated for C15H21FN2O3SNa (M+Na)+ 351.1155; found 351.1154 (TOF MS ES+). 
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(S)-2-(4-fluorobenzyl)-4-isopropyl-1,2,5-thiadiazepan-3-one 1,1-dioxide (2.7.1c) 
 
According to the reaction protocol described in general procedure B, compound 2.7.1c (67%, 0.21 g) was 
isolated after chromatography as a light brown solid. 
M. P. 85–87 ºC; 
Rf = 0.39 (100% EtOAc); 
FTIR (thin film) 3357, 2954, 2929, 1697, 1693, 1540, 1457, 1365, 1209, 1141, 842 cm-1;  
[𝜶]𝑫𝟐𝟎 = +31.4° (c = 2.0, CHCl3);
 
1H NMR (500 MHz, CDCl3) δ ppm 7.45–7.40 (m, 2H), 7.05–7.00 (m, 2H), 5.13 (d, J = 14.9 Hz, 1H, 
NCHaHbPh), 4.88 (d, J = 15.0 Hz, 1H, NCHaHbPh), 3.85 [d, J = 6.5 Hz, 1H, HNCH(C=O)], 3.50–3.46 (m, 2H, 
O2SCH2CH2NH), 3.31 (ddd, J = 14.2, 2.6, 2.6 Hz, 1H, O2SCH2CHaHbNH), 2.90 (ddd, J = 14.3, 9.0, 7.4 Hz, 1H, 
O2SCH2CHaHbNH), 2.23–2.13 (dqq, J = 6.5, 6.5, 6.5 Hz, 1H, CH3CHCH3), 1.00 (d, J = 6.7 Hz, 6H, 
CH3CHCH3); 
13C NMR (126 MHz, CDCl3) δ ppm 172.8, 163.3 (1JC–F = 242.5 Hz), 132.5 (4JC–F = 3.28 Hz), 130.5  (3JC–F = 
8.11 Hz, 2), 115.5 (2J = 21.42 Hz, 2), 65.6, 57.0, 47.5, 45.6, 29.3, 20.3, 17.7;  
HRMS (ESI) m/z calculated for C14H19FN2O3SNa (M+Na)+ 337.0998, found 337.0998 (TOF MS ES+). 
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(S)-2-(4-chlorobenzyl)-4-methyl-1,2,5-thiadiazepan-3-one 1,1-dioxide (2.7.1d) 
 
According to the reaction protocol described in general procedure B, compound 2.7.1d (65%, 0.102 g) was 
isolated after chromatography as a light yellow solid. 
M. P. 98–100 ºC; 
Rf = 0.53 (100% EtOAc); 
FTIR (thin film) 3357, 2954, 2867, 1697, 1496, 1456, 1336, 1209, 1147, 862 cm-1; 
[𝜶]𝑫𝟐𝟎 = +22.2° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.38–7.32 (m, 2H), 7.31–7.24 (m, 2H), 5.09 (d, J = 15.0 Hz, 1H, 
NCHaHbPh), 4.84 (d, J = 15.0 Hz, 1H, NCHaHbPh), 4.21 [q, J = 6.8, Hz, 1H, HNCH(C=O)], 3.55 (ddd, J = 
15.2, 12.0, 3.2 Hz, 1H, O2SCHaHbCH2NH), 3.40–3.27 (m, 2H, O2SCHaHbCHaHbN), 3.04–2.93 (m, 1H, 
O2SCH2CHaHbN), 1.30 (d, J = 6.7 Hz, 3H, NHCHCH3); 
13C NMR (126 MHz, CDCl3) δ ppm 175.9, 136.1, 134.0, 129.4 (2), 128.9 (2), 56.3, 52.2, 46.5, 42.4, 19.0;  
HRMS (ESI) m/z calculated for C12H15ClN2O3SH (M+H)+ 303.0570, found 303.0566 (TOF MS ES+). 
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(R)-4-(mercaptomethyl)-2-octyl-1,2,5-thiadiazepan-3-one 1,1-dioxide (2.7.1e) 
 
According to the reaction protocol described in general procedure B, compound 2.7.1e (33%, 0.051 g) was 
isolated after chromatography as a light yellow solid. 
M. P. 124–126 ºC; 
Rf = 0.41 (100% EtOAc); 
FTIR (thin film) 2954, 2931, 1693, 1456, 1355, 1209, 1151 cm-1; 
[𝜶]𝑫𝟐𝟎 = +20.2° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 4.18–4.05 [m, 1H, HNCH(C=O)], 3.87–3.72 (m, 2H, O2SCH2CH2N), 
3.46–3.34 (m, 2H, NCH2CH2), 3.32–3.20 (m, 2H, O2SCH2CH2N), 3.16–3.10 (m, 1H, NHCHCHaHbSH), 2.68–
2.61 (m, 1H, NHCHCHaHbSH), 2.62–2.55 (m, 1H, among n-octyl), 1.93–1.83 (m, 1H, among n-octyl), 1.81–
1.71 (m, 2H, among n-octyl), 1.69–1.58 (m, 2H, among n-octyl), 1.36–1.25 (m, 6H, among n-octyl) 0.92 (t, J = 
6.8 Hz, 3H, among n-octyl); 
13C NMR (126 MHz, CDCl3) δ ppm 171.5, 64.3, 58.1, 55.7, 51.0, 46.4, 31.3, 29.4, 27.0, 26.1, 24.7, 22.8, 14.0; 
HRMS calculated for C13H26N2O3S2Na (M+Na)+ 345.1283, found 345.1284 (TOF MS ES+). 
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(S)-2-benzyl-4-(4-hydroxybenzyl)-1,2,5-thiadiazepan-3-one 1,1-dioxide (2.7.1f) 
 
According to the reaction protocol described in general procedure B, compound 2.7.1f (41%, 0.11 g) was 
isolated after chromatography as a white solid. 
M. P. 106–109 ºC; 
Rf = 0.31 (100% EtOAc); 
FTIR (thin film) 3601, 3200, 2946, 2933, 2870, 1693, 1612, 1454, 1305, 1149, 831, 703 cm-1; 
[𝜶]𝑫𝟐𝟎 = -28.2° (c = 2.0, CHCl3); 
1H NMR (500 MHz, Acetone) δ ppm 8.16 (s, 1H, Ar-OH), 7.39–7.34 (m, 2H), 7.34–7.29 (m, 2H), 7.28–7.23 
(m, 1H), 7.12 (d, J = 8.4 Hz, 2H), 6.75 (d, J = 8.5 Hz, 2H), 5.01 (d, J = 15.5 Hz, 1H, NCHaHbPh), 4.92 (d, J = 
15.3 Hz, 1H, NCHaHbPh), 4.33 [dd, J = 8.6, 5.6 Hz, 1H, HNCH(C=O)], 3.51–3.38 (m, 2H, O2SCH2CH2NH), 
3.32–3.22 (m, 2H, O2SCH2CH2NH), 3.12 (dd, J = 14.3, 5.6 Hz, 1H, HNCHCHaHbPhOH), 2.64 (dd, J = 14.3, 
8.6 Hz, 1H, HNCHCHaHbPhOH); 
13C NMR (126 MHz, Acetone) δ ppm 173.9, 156.9, 138.6, 131.3 (2), 130.2, 129.2 (2), 128.8 (2), 128.2, 116.0 
(2), 63.0, 57.1, 49.1, 46.6, 38.0; 
HRMS calculated for C18H20N2O4SH (M+H)+ 361.1222, found 361.1200 (TOF MS ES+). 
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(8R,9aS)-2-benzyl-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl cyclohexylcarbamate 
(2.8.1) 
 
According to the reaction protocol described in general procedure D, compound 2.8.1 (37%, 0.102 g) was 
isolated after chromatography as a white solid. 
M. P. 125–126 ºC; 
Rf = 0.32 (1:1 Hexane:EtOAc); 
FTIR (thin film) 3328, 2927, 1693, 1625, 1573, 1446, 1347, 1244, 1153, 1026, 742 cm-1; 
[𝜶]𝑫𝟐𝟎 = +17.5° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.40 (d, J = 7.2 Hz, 2H), 7.34 (dd, J = 8.1, 6.8 Hz, 2H), 7.30–7.26 (m, 1H), 
5.16 (d, J = 15.1 Hz, 1H, NCHaHbPh), 5.11–5.05 (m, 1H, NCH2CHCH2CH), 4.91 (d, J = 15.1 Hz, 1H, 
NCHaHbPh), 4.66 (bs, 1H, NH), 4.38 [t, J = 7.8 Hz, 1H, NCH2CHCH2CH(C=O)], 3.55 (dd, J = 11.4, 4.4 Hz, 
1H, NCHaHbCHCH2), 3.51–3.31 (m, 3H, O2SCHaHbCHaHbNCH2CHOCONHCH), 3.28–3.15 (m, 2H, 
O2SCHaHbCHaHbN), 2.78–2.68 (m, 2H, NCHaHbCHCHaHbCH), 2.14–2.06 (m, 1H, NCH2CHCHaHbCH), 1.98–
1.89 (m, 2H, among Cy), 1.76–1.67 (m, 2H, among Cy), 1.65–1.57 (m, 1H, among Cy), 1.42–1.29 (m, 2H, 
among Cy), 1.23–1.02 (m, 3H, among Cy); 
13C NMR (126 MHz, CDCl3) δ ppm 171.0, 154.8, 136.5, 128.6 (2), 128.3 (2), 127.7, 73.2, 64.4, 62.5, 56.5, 
52.9, 49.9, 48.5, 34.4, 33.4 (2), 25.4 (2), 24.8; 
HRMS calculated for C21H29N3O5SH (M+H)+ 436.1906, found 436.1910 (TOF MS ES+). 
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(8R,9aS)-8-hydroxy-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (2.8.4) 
 
According to the reaction protocol described in general procedure E, compound 2.8.4 (45%, 0.097 g) was 
isolated after chromatography as a white solid. 
M. P. 125–126 ºC; 
Rf = 0.27 (100% EtOAc); 
FTIR (neat) 3685, 3380, 3353, 2972, 1708, 1444, 1355, 1218, 1151, 881 cm-1; 
[𝜶]𝑫𝟐𝟎 = +17.5° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.45 (s, 1H, c-N=NNHC=C), 7.21–7.13 (m, 4H), 5.49 (d, J = 14.8 Hz, 1H, 
NCH2-triazole-CHaHb-Ar), 5.44 (d, J = 14.7 Hz, 1H, NCH2-triazole-CHaHb-Ar), 5.12 (d, J = 15.6 Hz, 1H, 
NCHaHb-triazole-CH2-Ar), 5.06 (d, J = 15.5 Hz, 1H, NCHaHb-triazole-CH2-Ar), 4.50–4.42 [m, 1H, 
NCH2CH(OH)CH2CH(C=O)], 4.34 [dddd, J = 5.2, 5.2, 5.1, 4.7 Hz, 1H, NCH2CH(OH)CH2], 3.77–3.67 (m, 1H, 
O2SCHaHbCH2N), 3.52–3.23 [m, 5H, O2SCHaHbCH2NCHaHbCH(OH)CH2], 2.78–2.62 [m, 2H, 
NCHaHbCH(OH)CHaHb], 2.36 (s, 3H, Ar-CH3), 1.99–1.92 [m, 1H, NCH2CH(OH)CHaHb]; 
13C NMR (126 MHz, CDCl3) δ ppm 171.0, 143.6, 138.6, 131.5, 129.8 (2), 128.0 (2), 122.6, 70.0, 64.0, 63.6, 
55.7, 53.7, 52.0, 40.1, 36.4, 21.1; 
HRMS calculated for C18H23N5O4SH (M+H)+ 406.1549, found 406.1558  (TOF MS ES+). 
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(8R,9aS)-3,3-dioxido-1-oxo-2-(prop-2-yn-1-yl)octahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl 4-
methylbenzoate (2.8.3) 
 
According to the reaction protocol described in general procedure F, compound 2.8.3 (42%, 0.096 g) was 
isolated after chromatography as a white solid. 
M. P. 117–119 ºC; 
Rf = 0.62 (1:1 Hexane:EtOAc); 
FTIR (thin film) 3365, 2975, 2929, 2254, 1735, 1708, 1444, 1355, 1220, 1153, 887 cm-1; 
[𝜶]𝑫𝟐𝟎 = +18.4° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.93 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 7.8 Hz, 2H), 5.42 [dd, J = 4.1, 4.0 Hz, 
1H, NCH2CH(OCOAr)CH2CH], 4.76 (dd, J = 17.5, 2.5 Hz, 1H, NCHaHbCCH), 4.53 (dd, J = 17.6, 2.5 Hz, 1H, 
NCHaHbCCH), 4.49 [t, J = 8.0 Hz, 1H, NCH2CHCH2CH(C=O)], 3.72 (dd, J = 11.3, 4.5 Hz, 1H, 
O2SCHaHbCH2N), 3.60–3.44 (m, 3H, O2SCHaHbCHaHbNCHaHb), 3.37–3.29 (m, 1H, O2SCH2CHaHbN), 2.95–
2.87 (m, 2H, NCHaHbCHCHaHbCH), 2.44 (s, 3H, Ar-CH3), 2.32 (t, J = 2.5 Hz, 1H, NCH2CCH), 2.31–2.28 (m, 
1H, NCH2CHCHaHbCH); 
13C NMR (126 MHz, CDCl3) δ ppm 170.0, 165.6, 144.1, 129.6 (2), 129.2 (2), 127.0, 77.8, 73.4, 72.1, 64.2, 
62.3, 56.6, 52.9, 34.4, 34.1, 21.7; 
HRMS calculated for C18H20N2O5SH (M+H)+ 377.1171, found 377.1171  (TOF MS ES+). 
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(8R,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 4-methylbenzoate (2.8.2) 
 
According to the reaction protocol described in general procedure G, compound 2.8.2 (35%, 0.091 g) was 
isolated after chromatography as a yellow solid. 
M. P. 127–129 ºC; 
Rf = 0.65 (100% EtOAc); 
FTIR (thin film) 3392, 2931, 2854, 1701, 1693, 1496, 1352, 1220, 1151, 1058, 891 cm-1; 
[𝜶]𝑫𝟐𝟎 = +18.8° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.92 (d, J = 8.2 Hz, 2H), 7.45 (s, 1H, c-N=NNHC=C), 7.31–7.24 (m, 2H), 
7.22–7.14 (m, 4H), 5.51 (d, J = 14.6 Hz, 1H, NCH2-triazole-CHaHb-Ar), 5.44 (d, J = 14.6 Hz, 1H, NCH2-
triazole-CHaHb-Ar), 5.34 [dddd, J = 4.5, 4.4, 4.4 and 4.3 Hz, 1H, NCH2CH(OCOAr)CH2], 5.13 (d, J = 15.3 Hz, 
1H, NCHaHb-triazole-CH2-Ar), 5.11 (d, J = 15.3 Hz, 1H, NCHaHb-triazole-CH2-Ar), 4.49 [t, J = 7.8 Hz, 1H, 
NCH2CHCH2CH(C=O)], 3.81–3.71 (m, 1H, O2SCHaHbCH2N), 3.60 (dd, J = 11.2, 4.5 Hz, 1H, 
NCHaHbCHCH2), 3.52–3.37 (m, 2H, O2SCHaHbCHaHbN), 3.26 (dt, J = 12.8, 3.7 Hz, 1H, O2SCH2CHaHbN), 
2.88–2.78 (m, 2H, NCHaHbCHCHaHb), 2.43 (s, 3H, Ar-CH3), 2.37 (s, 3H, Ar-CH3), 2.24 (dddd, J = 13.9, 8.2, 
4.2, 1.5 Hz, 1H, NCH2CHCHaHb); 
13C NMR (126 MHz, CDCl3) δ ppm 170.4, 166.0, 144.1, 143.4, 139.0, 131.5, 129.8 (2), 129.6 (2), 129.2 (2), 
128.1 (2), 127.0, 122.7, 73.3, 64.2, 62.1, 55.9, 54.0, 52.8, 40.3, 34.0, 21.8, 21.2; 
HRMS calculated for C26H29N5O5SH (M+H)+ 524.1968, found 524.1968  (TOF MS ES+). 
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5.2 Experimental for Chapter 3.1 
One-pot Click-Esterification and One-pot Click-Mitsnobu Protocols to a sp3-Rich Library 
of Bicyclic Acyl Sultams 
General procedures: All air and moisture sensitive reactions were carried out in flame- or oven-dried glassware 
under argon atmosphere using standard gas tight syringes, cannula, and septa. Stirring was achieved with oven-
dried, magnetic stir bars. CH2Cl2 was purified by passage through the Solv-Tek purification system employing 
activated Al2O3 (Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518-1520). Et3N was 
purified by passage over basic alumina and stored over KOH. Flash column chromatography was performed 
with SiO2 from Sorbent Technology (30930M-25, Silica Gel 60A, 40-63 um). Thin layer chromatography was 
performed on silica gel 60F254 plates (EM-5717, Merck). Deuterated solvents were purchased from Cambridge 
Isotope laboratories. 1H and 13C NMR spectra were recorded on a Bruker Avance operating at 500 MHz and 
126 MHz respectively. High-resolution mass spectrometry (HRMS) and FAB spectra were obtained in one of 
two manners: (i) on a VG Instrument ZAB double-focusing mass spectrometer and (ii) on a LCT Premier 
Spectrometer (Micromass UK Limited) operating on ESI (MeOH). All library syntheses were carried out in 1 
dram. Automated preparative reverse-phase HPLC purification was performed using an Waters Mass-Directed 
Fractionation system (Prep Pump 2525, Make-up pump 515, Sample Manager 2767, UV-DAD detection 2996, 
Micromass ZD quadrapole spectrometer) and a Waters X-Bridge C18 column (19 x 150mm, 5um, w/ 19 x 
10mm guard column). Samples were diluted in DMSO and purified utilized an elution of water (modified to pH 
9.8 through addition of NH4OH) and CH3CN, with a gradient increasing to 20% in CH3CN over 4 minutes at a 
flow rate of 20ml/min,. The preparative gradient, triggering thresholds, and UV wavelength were selected based 
on the HPLC analysis of each crude sample. Analytical analysis of each sample after purification employed an 
Waters Acquity system with UV and mass detection (Waters LCT Premier). The analytical method utilized a 
Waters Aquity BEH C18 column (2.1 x 50mm, 1.7um) eluting with a linear gradient of 5% water (modified to 
pH 9.8 through addition of NH4OH) to 100% CH3CN at 0.6 mL/min flow rate were purity was determined 
using UV peak area at 214 nm. 
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Note: All reactions involving the use and heating of azides were carried out behind a safety shield taking extra 
precaution due to the explosive nature of these materials. 
General procedure A for the synthesis of core via sulfonylation, aza-Michael and amide coupling.  To a 
round-bottom flask containing CH2Cl2 (344 mL, 0.5 M), propargyl amine  (9.46 g, 172 mmol, 1 equiv.) and 
Et3N (44.5 mL, 344 mmol, 2 equiv.) at 0ºC was added 2-chloro-sulfonyl chloride (18 mL, 172 mmol, 1 equiv.) 
drop-wise. The reaction was stirred overnight at room temperature. After the completion of the reaction, the 
solvent was evaporated to dryness. Methanol (172 mL, 1 M) and water (172 mL, 1 M) were added to the crude 
mixture followed by the addition of Et3N (67 mL, 516 mmol, 3 equiv.), then L-trans Hydroxyproline (23.84 g, 
186 mmol, 1.05 equiv.) was added to the reaction mixture. The reaction was stirred at 60ºC for 12 h. After the 
disappearance of the starting material the solvents were again evaporated to dryness. Next Dimethyl formamide 
(DMF) (860 mL, 0.2 M) was added followed by EDC (53.4 g, 344 mmol, 2 equiv.), HOBt (4.6 g, 34.4 mmol, 
0.2 equiv.) and Et3N (44.5 mL, 344 mmol, 2 equiv.). The reaction was stirred for 12 h at rt. After the completion 
of the reaction DMF was evaporated followed by addition of EtOAc and work up with water. 
General procedure B for the synthesis of library I via a one-pot click/Esterification protocol.  To a 1-
dram vial containing (8R,9aS)-8-hydroxy-2-(prop-2-yn-1-yl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-
one 3,3-dioxide 3.1.1 (50 mg, 0.29 mmol, 1 equiv.) was added OACC (64 mg, 0.25 mmol, 1 equiv.) DBU (6 
µL, 10 mol%), CH2Cl2 (1.2 mL, 0.5 M), DMAP (2.2 mg, 10 mol%),  azide (0.3 mmol, 1.2 equiv.), Carboxylic 
acid (0.3 mmol, 1.2 equiv.) and CuI (11 mg, 30 mol%). The reaction was heated at 60 ºC on a reaction block for 
for 12 hrs, after which time the reactions were cooled. The OACC polymer was precipitated with EtOAc and 
filtered through an SiO2 SPE into apre-weighed bar-coded vial, washed with eluent (2 mL, EtOAc) and 
concentrated under reduced pressure.  The crude reaction was concentrated and QC/purified by an automated 
preparative reverse phase HPLC (detected by mass spectroscopy). 
General procedure C for the synthesis of library I via a one-pot click/Mitsunobu protocol.  To a 1-dram 
vial containing (8R,9aS)-8-hydroxy-2-(prop-2-yn-1-yl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 
3,3-dioxide 3.1.1 (10 mg, 0.004 mmol, 1 equiv.),  was added carboxylic acid (0.0048 mmol, 1.2 equiv.) 
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followed by the dropwise addition of a stock solution Nb-PPh3 (0.008 mmol, 2 equiv.) and Nb-BEAD (0.008 
mmol, 2 equiv.) in THF. The reaction was run for 12 h. After the completion of the reaction was added CuI 
(0.152 mg, 0.0008 mmol, 0.2 equiv.) and DBU (2 µL, 0.0008 mmol, 0.2 equiv.). The reaction mixture was 
stirred for 12 h. After such time Grubbs-II catalyst (0.0008 mmol, 0.2 equiv.) was added and the reaction was 
run at 45ºC for 12 h. The reaction was cooled to rt, quenched by the addition of ethyl vinyl ether (EVE) and 
stirred for 30 minutes followed by addition of EtOAc and passing through a silica SPE. The SPE was washed 1x 
with EtOAc. The crude reaction was concentrated and QC/purified by an automated preparative reverse phase 
HPLC (detected by mass spectroscopy). 
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(8R,9aS)-2-((1-(2-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 4-fluorobenzoate 3.2.1(1){2} (NA-6-156B) 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(1){2} (77%, 118.5 mg) 
was isolated as brownish oil. 
FTIR (neat) 1712, 1602, 1433, 1311, 1174, 856, 769, 688, 513 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +21.2° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.07 – 8.00 (m, 2H), 7.35 (s, 1H), 7.32 – 7.27 (m, 1H), 7.25 – 7.20 (m, 2H), 
7.16 – 7.10 (m, 3H), 5.55 (d, J = 14.8 Hz, 1H), 5.50 (d, J = 14.8 Hz, 1H), 5.32 (dddd, J = 4.7, 4.7, 4.5, 4.5 Hz, 
1H), 5.12 (d, J = 15.6 Hz, 1H), 5.07 (d, J = 15.6 Hz, 1H), 4.47 (t, J = 7.7 Hz, 1H), 3.83–3.74 (m, 1H), 3.59 (dd, 
J = 11.1, 4.5 Hz 1H), 3.49 – 3.37 (m, 2H), 3.25 (ddd, J = 13.7, 4.3, 3.4 Hz, 1H), 2.92 – 2.78 (m, 2H), 2.26 (s, 
3H), 2.22 (dddd, J = 13.9, 8.2, 4.4, 1.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.3, 165.6 (1JC–F = 254.45 Hz), 164.9, 143.2, 136.9, 132.4, 132.1 (3JC–F 
= 9.41 Hz, 2), 131.0, 129.3, 129.1, 126.6, 125.9 (4JC–F = 3.28 Hz), 122.6, 115.7 (2J = 21.90 Hz, 2), 73.5, 64.0, 
62.0, 55.8, 52.6, 52.4, 40.2, 33.9, 18.9; 
HRMS calculated for C25H26FN5O5SH (M+H)+ 528.1717; found 528.1702 (TOF MS ES+). 
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(8R,9aS)-2-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 4-fluorobenzoate 3.2.1(1){3} (NA-6-156C) 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(1){3} (74%, 109.7 mg) 
was isolated as dark orange oil. 
FTIR (thin film) 2352, 2320, 1714, 1695, 1602, 1427, 1353, 1153, 1053, 555 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +22.6 ° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.06 –8.01 (m, 2H), 7.47 (s, 1H), 7.42 – 7.34 (m, 3H), 7.28 – 7.25 (m, 2H), 7.17 
– 7.10 (m, 2H), 5.55 (d, J = 14.9 Hz, 1H), 5.48 (d, J = 14.9 Hz, 1H), 5.33 (dddd,  J = 4.7, 4.7, 4.5, 4.5 Hz, 1H), 
5.14 (d, J = 15.5, Hz, 1H), 5.08 (d, J = 15.6 Hz, 1H), 4.48 (t, J = 7.8 Hz, 1H), 3.83–3.74 (m, 1H), 3.60 (dd, J = 
11.2, 4.6 Hz, 1H), 3.50 – 3.39 (m, 2H), 3.26 (ddd, J = 14.1, 4.3, 3.4 Hz, 1H), 2.89 – 2.79 (m, 2H), 2.23 (dddd, J 
= 13.8, 8.2, 4.2, 1.4 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.2, 165.92 (1JC–F = 254.60 Hz), 164.9, 143.4, 134.5, 132.1 (3JC–F = 
9.45 Hz, 2), 129.1 (2), 128.8, 128.0 (2), 125.9 (4JC–F = 3.04 Hz), 122.8, 115.7 (2J = 22.07 Hz, 2), 73.5, 64.0, 
62.0, 55.8, 54.2, 52.7, 40.3, 33.9; 
HRMS calculated for C24H24FN5O5SH (M+H)+ 514.1560; found 514.1574 (TOF MS ES+).  
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(8R,9aS)-2-((1-(2-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 4-fluorobenzoate 3.2.1(1){10} (NA-6-156-I) 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(1){10} (54%, 92.6 mg) 
was isolated as dark brown oil. 
FTIR (thin film) 1712, 1602, 1506, 1409, 1355, 1271, 1153, 1118, 854, 769, 553 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +25.5° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 8.07 – 8.01 (m, 2H), 7.53 – 7.49 (m, 2H), 7.47 (s, 1H), 7.17–7.10 (m, 4H), 
5.50 (d, J = 15.0 Hz, 1H), 5.44 (d, J = 15.0 Hz, 1H), 5.33 (dddd, J = 4.7, 4.7, 4.5, 4.5 Hz, 1H), 5.14 (d, J = 15.6 
Hz, 1H), 5.07 (d, J = 15.5 Hz, 1H), 4.47 (t, J = 7.7 Hz, 1H), 3.81–3.72 (m, 1H), 3.60 (dd, J = 11.1, 4.6 Hz, 1H), 
3.50 – 3.40 (m, 2H), 3.27 (ddd, J = 13.6, 4.2, 3.4 Hz, 1H), 2.89 – 2.80 (m, 2H), 2.23 (dddd, J = 13.9, 8.2, 4.3, 
1.4 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.4, 165.91, (1JC–F = 254.50 Hz), 164.9, 143.7, 133.5, 132.3, 132.2, 
132.1 (3JC–F = 9.30 Hz, 2), 129.6, 125.95, 125.9 (4JC–F = 3.10 Hz), 122.9, 122.8, 115.8 (2J = 22.47 Hz, 2), 73.5, 
64.1, 61.9, 55.8, 53.5, 52.6, 40.3, 33.9; 
HRMS calculated for C24H23BrFN5O5SH (M+H)+ 592.0666; found 592.0646 (TOF MS ES+).  
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(8R,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl isobutyrate 3.2.1(2){1} (NA-6-165-IA) 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(2){1} (61%, 83.5 mg) was 
isolated as dark orange oil. 
FTIR (thin film) 2974, 1731, 1703, 1434, 1353, 1151, 1053, 781, 555 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +26.4° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.42 (s, 1H), 7.19 – 7.13 (m, 4H), 5.49 (d, J = 14.8 Hz, 1H), 5.42 (d, J = 14.8 
Hz, 1H), 5.13–5.02 (m, 3H), 4.36 (t, J = 7.8 Hz, 1H), 3.78 – 3.68 (m, 1H), 3.47 (dd, J = 11.1, 4.5 Hz, 1H), 3.44 
– 3.35 (m, 2H), 3.23–3.16 (m, 1H), 2.77 – 2.63 (m, 2H), 2.59–2.46 (m, 1H), 2.35 (s, 3H), 2.06 (dddd, J = 13.7, 
8.1, 4.1, 1.5 Hz, 1H), 1.16 (d, J = 7.0 Hz, 6H); 
13C NMR (126 MHz, CDCl3) δ ppm 176.4, 170.4, 143.4, 138.6, 131.4, 129.7 (2), 128.0 (2), 122.6, 76.7, 72.6, 
64.0, 61.9, 55.8, 53.9, 52.6, 40.2, 33.9, 21.1, 18.9, 18.9; 
HRMS calculated for C22H29N5O5SH (M+H)+ 476.1968; found 476.2006 (TOF MS ES+).  
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(8R,9aS)-2-((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl isobutyrate 3.2.1(2){4} NA-6-165-I-D 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(2){4} (39%, 56.5 mg) was 
isolated as dark brown oil. 
FTIR (thin film) 2974, 1731, 1704, 1492, 1434, 1353, 1151, 904 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +29.9° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.46 (s, 1H), 7.37 – 7.33 (m, 2H), 7.22 – 7.17 (m, 2H), 5.51 (d, J = 15.0 
Hz, 1H), 5.44 (d, J = 15.0 Hz, 1H), 5.13 (d, J = 15.6 Hz, 1H), 5.10 – 5.02 (m, 2H), 4.37 (t, J = 7.8 Hz, 1H), 
3.77–3.67 (m, 1H), 3.48 (dd, J = 11.1, 4.6 Hz, 1H), 3.45 – 3.37 (m, 2H), 3.22 (ddd, J = 13.1, 3.6, 3.5 Hz, 1H), 
2.77 – 2.64 (m, 2H), 2.59 – 2.48 (m, 1H), 2.07 (dddd, J = 13.7, 8.1, 4.0, 1.5 Hz, 1H), 1.17 (d, J = 6.9 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 176.4, 170.5, 143.7, 134.8, 133.0, 129.3 (2), 129.3 (2), 122.8, 72.5, 64.0, 61.9, 
55.9, 53.4, 52.6, 40.2, 33.9, 33.8, 18.9, 18.9; 
HRMS calculated for C21H26ClN5O5SH (M+H)+ 496.1421; found 496.1421 (TOF MS ES+).  
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(8R,9aS)-3,3-dioxido-1-oxo-2-((1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)methyl) 
octahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl isobutyrate 3.2.1(2){6} NA-6-165-I-F 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(2){6}  (53%, 81.2 mg) 
was isolated as dark yellow solid. 
M.P. 124 – 129ºC 
FTIR (thin film) 2975, 1731, 1704, 1463, 1355, 1325, 1153, 1124, 825 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +26.8° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.64 (d, J = 7.8 Hz, 2H), 7.51 (s, 1H), 7.36 (d, J = 8.1 Hz, 2H), 5.61 (d, J = 
15.2 Hz, 1H), 5.54 (d, J = 15.3 Hz, 1H), 5.15 (d, J = 15.6 Hz, 1H), 5.11 – 5.03 (m, 2H), 4.38 (t, J = 7.8 Hz, 1H), 
3.77–3.69 (m, 1H), 3.49 (dd, J = 11.1, 4.5 Hz, 1H), 3.46–3.38 (m, 2H), 3.23 (ddd, J = 13.1, 3.6, 3.6 Hz, 1H), 
2.72 (ddd, J = 13.5, 7.5, 6 Hz, 1H), 2.67 (ddd, J = 11.1, 3.9, 1.4 Hz, 1H), 2.54 (hept, J = 7.0 Hz, 1H), 2.08 
(dddd, J = 13.8, 8.2, 4.3, 1.4 Hz, 1H), 1.17 (d, J = 7.0 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ ppm 176.5, 170.5, 143.9, 138.5, 131.1 (q, 2JC–F = 36.37 Hz), 128.2 (2), 126.1 
(q, 3JC–F = J = 3.81 Hz (2)), 124.0 (q, 1JC–F = 273.37 Hz), 123.0, 72.5, 64.1, 61.4, 55.9, 53.5, 52.6, 40.3, 33.9, 
33.8, 18.9, 18.9; 
HRMS calculated for C22H26F3N5O5SH (M+H)+ 530.1685; found 530.1682 (TOF MS ES+).  
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(8R,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 1-methyl-1H-pyrrole-2-carboxylate 3.2.1(3){1} NA-6-165-2A 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(3){1} (28%, 42.1 mg) was 
isolated as dark brown solid. 
M.P. 128 – 134ºC 
 
FTIR (thin film) 1699, 1681, 1411,1353, 1153, 1114, 821 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +27.7° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.44 (s, 1H), 7.20 – 7.13 (m, 4H), 6.94 (dd, J = 4.0, 1.8 Hz, 1H), 6.82 (dd, J = 
2.2, 2.2 Hz, 1H), 6.13 (dd, J = 4.0, 2.5 Hz, 1H), 5.50 (d, J = 14.8 Hz, 1H), 5.43 (d, J = 14.8 Hz, 1H), 5.25 (ddd, 
J = 8.7, 5.4, 4.0 Hz, 1H), 5.12 (d, J = 15.5 Hz, 1H), 5.06 (d, J = 15.5 Hz, 1H), 4.46 (t, J = 7.8 Hz, 1H), 3.93 (s, 
3H), 3.75 (J = ddd, 14.1, 12.1, 4.2 Hz, 1H), 3.55 (dd, J = 11.2, 4.4 Hz, 1H), 3.50 – 3.43 (m, 1H), 3.40 (ddd, J = 
14.1, 2.5, 2.5 1H), 3.24 (ddd, J = 13.2, 3.7, 3.5 Hz, 1H), 2.83 – 2.74 (m, 2H), 2.35 (s, 3H), 2.19 (dddd, J = 13.6, 
7.9, 3.9, 1.5 Hz, 1H). 
 13C NMR (126 MHz, CDCl3) δ ppm 170.3, 160.4, 143.4, 138.7, 131.5, 130.0, 129.7 (2), 128.0 (2), 122.7, 
121.9, 118.2, 108.0, 72.2, 64.2, 62.2, 55.8, 53.9, 52.8, 40.3, 36.8, 34.1, 21.2; 
HRMS calculated for C24H28N6O5SH (M+H)+ 513.1920; found 513.1926 (TOF MS ES+).  
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(8R,9aS)-3,3-dioxido-1-oxo-2-((1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-
yl)methyl)octahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl 1-methyl-1H-pyrrole-2-carboxylate 3.2.1(3){6} 
NA-6-165-2F 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(3){6} (26%, 43.3 mg) was 
isolated as dark orange oil. 
M.P. 137 – 144ºC 
FTIR (thin film) 2360, 1710, 1510, 1473, 1353, 1294, 1153, 1122, 827 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +29.7° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.65 (d, J = 8.0 Hz, 2H), 7.52 (s, 1H), 7.36 (d, J = 8.1 Hz, 2H), 6.94 (dd, J 
= 4.0, 1.8 Hz, 1H), 6.82 (dd, J = 2.2, 2.2 Hz, 1H), 6.13 (dd, J = 4.0, 2.5 Hz, 1H), 5.61 (d, J = 15.3 Hz, 1H), 5.55 
(d, J = 15.3 Hz, 1H), 5.26 (ddd, J = 8.9, 4.4, 4.4 Hz 1H), 5.17 (d, J = 15.6 Hz, 1H), 5.07 (d, J = 15.6 Hz, 1H), 
4.46 (t, J = 7.8 Hz, 1H), 3.93 (s, 3H), 3.80 – 3.70 (m, 1H), 3.56 (dd, J = 11.1, 4.5 Hz, 1H), 3.52 – 3.39 (m, 2H), 
3.30–3.23 (m, 1H), 2.84 – 2.75 (m, 2H), 2.20 (dddd, J = 13.9, 8.2, 4.3, 1.4 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ ppm 170.4, 160.4, 144.0, 138.5, 131.1, 130.1 (q, 2JC–F = 36.37 Hz), 130.0, 
128.1 (2), 126.2 (q, 3JC–F = 3.63 Hz (2)), 123.3 (1JC–F = 273.88 Hz), 121.9, 118.3, 108.0, 72.1, 64.2, 62.1, 55.8, 
53.4, 52.8, 40.3, 36.8, 34.0; 
HRMS calculated for C24H25F3N6O5SH (M+H)+ 567.1637; found 567.1629 (TOF MS ES+).  
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(8R,9aS)-2-((1-(2-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl furan-2-carboxylate 3.2.1(4){2} NA-6-165-3B 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(4){2} (54%, 78.6 mg) was 
isolated as a dark brownoil. 
FTIR (thin film) 2351, 1714, 1722, 1695, 1446, 1353, 1294, 1151, 1053, 1012, 775 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +33.1° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.61 (dd, J = 1.8, 0.8 Hz, 1H), 7.35 (s, 1H), 7.32 – 7.27 (m, 1H), 7.25 – 
7.20 (m, 2H), 7.20 (dd, J = 3.5, 0.8 Hz, 1H), 7.16 – 7.13 (dd, J = 7.9, 1.5 Hz, 1H), 6.53 (dd, J = 3.5, 1.7 Hz, 
1H), 5.55 (d, J = 14.9 Hz, 1H), 5.50 (d, J = 14.8 Hz, 1H), 5.30 (ddd, J = 9.3, 4.9, 4.8 Hz, 1H), 5.12 (d, J = 15.6 
Hz,  1H), 5.06 (d, J = 15.6 Hz, 1H), 4.47 (t, J = 7.7 Hz, 1H), 3.82 – 3.73 (m, 1H), 3.57 (dd, J = 11.1, 4.6 Hz, 
1H), 3.50 – 3.38 (m, 2H), 3.28–3.21 (m, 1H), 2.86 – 2.78 (m, 2H), 2.26 (s, 3H), 2.22 (dddd, J = 13.9, 8.3, 4.4, 
1.4 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.2, 157.9, 146.7, 144.2, 143.1, 136.9, 132.4, 131.0, 129.4, 129.2, 
126.6, 122.6, 118.5, 112.0, 73.2, 64.0, 62.0, 55.7, 52.5, 41.0, 40.2, 33.7, 18.9; 
HRMS calculated for C23H25N5O6SH (M+H)+ 500.1604; found 500.1612 (TOF MS ES+).  
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(8R,9aS)-2-((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl furan-2-carboxylate 3.2.1(4){5} NA-6-165-3E 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(4){5} (60%, 87.8 mg) was 
isolated as dark orange solid. 
FTIR (thin film) 2358, 1704, 1525, 1492, 1417, 1353, 1259, 1222, 1095, 1014 852 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +27.4° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.60 (dd, J = 1.7, 0.9 Hz, 1H), 7.46 (s, 1H), 7.28 – 7.23 (m, 2H), 7.20 (dd, 
J = 3.5, 0.9 Hz, 1H), 7.10 – 7.04 (m, 2H), 6.53 (dd, J = 3.5, 1.7 Hz, 1H), 5.52 (d, J = 14.9 Hz, 1H), 5.45 (d, J = 
14.9 Hz, 1H), 5.32 (ddd, J = 9.3, 4.5, 4.5 Hz, 1H), 5.13 (d, J = 15.6 Hz, 1H), 5.07 (d, J = 15.6 Hz, 1H), 4.46 (t, J 
= 7.7 Hz, 1H), 3.81–3.72 (m, 1H), 3.57 (dd, J = 11.1, 4.6 Hz, 1H), 3.50 – 3.39 (m, 2H), 3.26 (ddd, J = 14.4, 4.5, 
3.3 Hz, 1H), 2.87 – 2.79 (m, 2H), 2.22 (dddd, J = 13.9, 8.2, 4.3, 1.4 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ ppm 170.2, 165.9 (1JC–F = 254.60 Hz), 164.9, 143.4, 134.5, 132.1 (3JC–F = 9.45 
Hz, 2), 129.1, 128.8, 128.0, 125.9 (4JC–F = 3.04 Hz), 122.8, 115.7 (2J = 22.07 Hz, 2), 73.5, 64.0, 62.0, 55.8, 
54.2, 52.7, 40.3, 33.9; 
HRMS calculated for C22H22FN5O6SH (M+H)+ 504.1353; found 504.1354 (TOF MS ES+).  
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(8R,9aS)-3,3-dioxido-1-oxo-2-((1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-
yl)methyl)octahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl thiophene-2-carboxylate 3.2.1(5){6} NA-6-165-
4F 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(5){6} (39%, 65.0 mg) was 
isolated as a dark brown solid. 
M.P. 145 – 149ºC 
FTIR (thin film) 2351, 1697, 1556, 1446, 1355, 1325, 1263, 1153, 1122, 1018, 823 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +29.7° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.81 (dd, J = 3.8, 1.3 Hz, 1H), 7.64 (d, J = 8.2 Hz, 2H), 7.59 (dd, J = 4.9, 
1.3 Hz, 1H), 7.52 (s, 1H), 7.36 (d, J = 8.2 Hz, 2H), 7.13 (dd, J = 5.0, 3.7 Hz, 1H), 5.62 (d, J = 15.3 Hz, 1H), 
5.55 (d, J = 15.3 Hz, 1H), 5.32 (ddd, J = 8.8, 5.5, 4.2 Hz, 1H), 5.16 (d, J = 15.6 Hz, 1H), 5.08 (d, J = 15.6 Hz, 
1H), 4.46 (t, J = 7.8 Hz, 1H), 3.75 (ddd, J = 16.0, 12.2, 4.5 Hz, 1H), 3.57 (dd, J = 11.2, 4.4 Hz, 1H), 3.52 – 3.40 
(m, 2H), 3.27 (ddd, J = 13.0, 3.9, 3.2 Hz, 1H), 2.87 – 2.77 (m, 2H), 2.24 (dddd, J = 13.8, 8.1, 4.1, 1.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.5, 161.4, 143.9, 138.4, 133.8, 133.2, 133.0, 131.1 (q, 2JC–F = 32.26 
Hz), 128.1 (2), 128.0, 126.1 (q, 3JC–F = 3.63 Hz (2)), 123.1 (q, 1JC–F = 273.07 Hz), 123.0, 73.6, 64.1, 61.9, 55.9, 
53.4, 52.8, 40.3, 33.9; 
HRMS calculated for C23H22F3N5O5S2H (M+H)+ 570.1093; found 570.1103 (TOF MS ES+).  
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(8R,9aS)-2-((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl thiophene-2-carboxylate 3.2.1(5){4} NA-6-165-4D 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(5){4} (52%, 81.5 mg) was 
isolated as dark orange oil. 
FTIR (thin film) 1718, 1701, 1510, 1473, 1388, 1353, 1294,1180, 1153, 827 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +31.7° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.81 (dd, J = 3.8, 1.3 Hz, 1H), 7.59 (dd, J = 5.0, 1.3 Hz, 1H), 7.48 (s, 1H), 
7.37 – 7.33 (m, 2H), 7.22 – 7.18 (m, 2H), 7.13 (dd, J = 5.0, 3.7 Hz, 1H), 5.52 (d, J = 15.0 Hz, 1H), 5.45 (d, J = 
15.1 Hz, 1H), 5.32 (ddd, J = 8.8, 5.4, 3.9 Hz, 1H), 5.14 (d, J = 15.7 Hz, 1H), 5.07 (d, J = 15.4 Hz, 1H), 4.48 (t, J 
= 7.8 Hz, 1H), 3.76 (ddd, J = 14.2, 12.1, 4.2 Hz, 1H), 3.58 (dd, J = 11.3, 4.5 Hz, 1H), 3.53 – 3.40 (m, 2H), 3.27 
(ddd, J = 13.1, 3.6, 3.6 Hz, 1H), 2.89 – 2.77 (m, 2H), 2.24 (dddd, J = 13.7, 8.0, 4.0, 1.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.3, 161.4, 143.71, 134.8, 133.8, 133.2, 133.0, 132.9, 129.4 (2), 129.3 
(2), 128.0, 122.8, 73.6, 64.2, 61.9, 55.9, 53.4, 52.8, 40.3, 34.0; 
HRMS calculated for C22H22ClN5O5S2H (M+H)+ 536.0829; found 536.0826 (TOF MS ES+).  
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(8R,9aS)-2-((1-allyl-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 2-methoxyacetate 3.2.1(7){8} NA-6-165-6H 
 
According to the reaction protocol described in general procedure B, compound 3.2.1(7){8} (40%, 48.1 mg) was 
isolated as dark brown oil. 
FTIR (thin film) 2931, 2833, 1751, 1704, 1431, 1353, 1191, 1153, 1128, 1051 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +35.6° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.53 (s, 1H), 6.01 (dddd, J = 16.5, 10.2, 6.2, 6.2 Hz, 1H), 5.36 (ddd, J = 
10.2, 2.6, 1.1 Hz, 1H), 5.28 (ddd, J = 17.1, 2.4, 1.5 Hz, 1H), 5.19 (ddd, J = 9.6, 4.5, 4.5 Hz, 1H), 5.14 (d, J = 
15.5 Hz, 1H), 5.08 (d, J = 15.6 Hz, 1H), 5.01 – 4.91 (m, 2H), 4.46 – 4.33 (m, 1H), 4.04 – 4.02 (m, 1H), 3.81 – 
3.71 (m, 1H), 3.51 (dd, J = 10.9, 4.7 Hz, 1H), 3.46 – 3.44 (m, 2H), 3.45 (s, 3H), 3.23 (ddd, J = 13.3, 4.0, 3.8 Hz, 
1H), 2.83 – 2.75 (m, 1H), 2.73 – 2.67 (m, 1H), 2.40 – 2.23 (m, 1H), 2.10 (dddd, J = 14.0, 8.4, 4.6, 1.3 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ ppm 170.3, 169.7, 143.3, 131.0, 122.7, 120.2, 73.1, 69.7, 63.7, 61.5, 59.5, 55.8, 
52.7, 52.3, 40.3, 33.7; 
HRMS calculated for C16H23N5O6SH (M+H)+ 414.1447; found 414.1477 (TOF MS ES+).  
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(8R,9aS)-3,3-dioxido-1-oxo-2-((1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-
yl)methyl)octahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl 4-methoxybenzoate 3.2.1(8){6} NA-6-165-7F 
 
According to the reaction protocol described in general procedure C, compound 3.2.1(8){6} (35%, 60.7 mg) 
was isolated as dark brown solid. 
M.P. 138 – 142ºC 
FTIR (thin film) 2956, 2939, 1708, 1605, 1512, 1421, 1355, 1325, 1255, 1168, 1153, 1122 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +29.3° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.99 – 7.95 (m, 2H), 7.65 (d, J = 8.1 Hz, 2H), 7.52 (s, 1H), 7.36 (d, J = 8.1 
Hz, 2H), 6.96 – 6.91 (m, 2H), 5.62 (d, J = 15.3 Hz, 1H), 5.55 (d, J = 15.3 Hz, 1H), 5.32 (ddd, J = 9.0, 4.8, 4.8 
Hz, 1H), 5.16 (d, J = 15.6 Hz, 1H), 5.08 (d, J = 15.6 Hz, 1H), 4.46 (t, J = 7.8 Hz, 1H), 3.88 (s, 3H), 3.79 – 3.71 
(m, 1H), 3.58 (dd, J = 11.1, 4.5 Hz, 1H), 3.51 – 3.40 (m, 2H), 3.26 (ddd, J = 14.2, 4.4, 3.2 Hz, 1H), 2.86 – 2.78 
(m, 2H), 2.23 (dddd, J = 13.7, 8.1, 4.2, 1.4 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.6, 165.6, 163.6, 143.9, 138.5, 131.6 (2), 131.1 (q, 2JC–F = 32.98 Hz), 
130.9, 128.1 (2), 126.1 (q, 3JC–F = 3.65 Hz (2)), 123.7 (1JC–F = 273.07 Hz), 123.0, 122.1, 113.7 (2), 73.0, 64.2, 
62.1, 56.0, 55.8, 53.4, 52.8, 34.0; 
HRMS calculated for C26H26F3N5O6SH (M+H)+ 594.1634; found 594.1618 (TOF MS ES+).  
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(8R,9aS)-2-((1-allyl-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 4-methoxybenzoate 3.2.1(8){8} NA-6-165-7H 
 
According to the reaction protocol described in general procedure C, compound 3.2.1(8){8} (25%, 33.6 mg) 
was isolated as dark  brown oil. 
FTIR (thin film) 1701, 1604, 1512, 1421, 1355, 1257, 1168, 1153, 825 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +36.8° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.99 – 7.95 (m, 2H), 7.55 (s, 1H), 6.95 – 6.91 (m, 2H), 6.02 (dddd, J = 
17.1, 10.2, 6.1, 6.1 Hz, 1H), 5.36 (ddd, J = 10.2, 2.2, 1.2 Hz, 1H), 5.34 – 5.31 (m, 1H), 5.29 (ddd, J = 17.0, 2.4, 
1.5 Hz, 1H), 5.17 (d, J = 15.6 Hz, 1H), 5.10 (d, J = 15.5 Hz, 1H), 5.02 – 4.92 (m, 2H), 4.48 (t, J = 7.8 Hz, 1H), 
3.87 (s, 3H), 3.80 – 3.72 (m, 1H), 3.60 (dd, J = 11.2, 4.5 Hz, 1H), 3.51 – 3.40 (m, 2H), 3.26 (ddd, J = 14.1, 4.5, 
4.0 Hz, 1H), 2.87 – 2.79 (m, 2H), 2.24 (dddd, J = 13.8, 8.1, 4.1, 1.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.5, 165.6, 163.6, 143.4, 131.6 (2), 131.1, 122.8, 122.1, 120.2, 113.7 
(2), 73.1, 64.2, 62.1, 56.0, 55.5, 52.8, 52.7, 40.3, 34.0; 
HRMS calculated for C21H25N5O6SH (M+H)+ 476.1604; found 476.1591 (TOF MS ES+).  
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(8R,9aS)-2-((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 4-chlorobenzoate 3.2.1(9){5} NA-6-165-8E 
 
According to the reaction protocol described in general procedure C, compound 3.2.1(9){5} (45%, 72.4 mg) 
was isolated as golden oil. 
FTIR (thin film) 1718, 1701, 1512, 1431, 1355, 1271, 1153, 1120, 1014, 827 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +35.7° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.97 – 7.93 (m, 2H), 7.47 (s, 1H), 7.45 – 7.42 (m, 2H), 7.27 – 7.22 (m, 
2H), 7.11 – 7.04 (m, 2H), 5.52 (d, J = 15.0 Hz, 1H), 5.45 (d, J = 14.8 Hz, 1H), 5.33 (ddd, J = 9.3, 5.5, 4.8 Hz, 
1H), 5.14 (d, J = 15.6 Hz, 1H), 5.07 (d, J = 15.6 Hz, 1H), 4.47 (t, J = 7.7 Hz, 1H), 3.82 – 3.75 (m, 1H), 3.60 
(dd, J = 11.1, 4.6 Hz, 1H), 3.50 – 3.39 (m, 2H), 3.27 (ddd, J = 13.6, 4.2, 3.4 Hz, 1H), 2.90 – 2.80 (m, 2H), 2.23 
(dddd, J = 13.9, 8.1, 4.3, 1.4 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.3, 165.0, 163.6 (1JC–F = 249.11 Hz), 143.7, 139.8, 131.0 (2), 130.4 
(4JC–F = 2.76 Hz), 130.0 (3JC–F = 8.48 Hz, 2), 129.0 (2), 128.1, 122.7, 116.2 (2J = 22.38 Hz, 2), 73.5, 64.1, 61.9, 
55.8, 53.4, 52.6, 40.3, 33.9; 
HRMS calculated for C24H23ClFN5O5SH (M+H)+ 548.1171; found 548.1190 (TOF MS ES+).  
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(8R,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 2-chloronicotinate 3.2.1(10){1} NA-6-165-9A 
 
According to the reaction protocol described in general procedure C, compound 3.2.1(10){1} (37%, 58.1 mg) 
was isolated as yellow oil. 
FTIR (thin film) 1733, 1706, 1579, 1434, 1402, 1355, 1294, 1218, 1151, 1053, 825 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +33.4° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 8.55 (dd, J = 4.8, 2.0 Hz, 1H), 8.14 (dd, J = 7.8, 2.0 Hz, 1H), 7.43 (s, 1H), 
7.36 (dd, J = 7.7, 4.8 Hz, 1H), 7.20 – 7.12 (m, 4H), 5.50 (d, J = 14.8 Hz, 1H), 5.43 (d, J = 14.8 Hz, 1H), 5.37 
(ddd, J = 8.8, 5.4, 3.9 Hz, 1H), 5.11 (d, J = 15.6 Hz, 1H), 5.06 (d, J = 15.6 Hz, 1H), 4.49 (t, J = 7.8 Hz, 1H), 
(dddd, J = 14.2, 12.1, 3.9 Hz, 1H), 3.62 (dd, J = 11.4, 4.6 Hz, 1H), 3.50 (ddd, J = 13.1, 12.1, 2.2 Hz, 1H), 3.42 
(ddd, J = 14.2, 3.5, 2.1 Hz, 1H), 3.25 (ddd, J = 13.3, 3.7, 3.7 Hz, 1H), 2.91 – 2.83 (m, 2H), 2.35 (s, 3H), 2.25 
(dddd, J = 13.7, 7.9, 3.9, 1.4 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ ppm 170.2, 164.0, 152.1, 149.8, 143.3, 140.3, 138.7, 131.4, 129.7, 128.1 (2), 
126.6 (2), 122.6, 122.2, 74.7, 63.9, 61.6, 55.8, 53.9, 52.40 41.1, 34.0, 21.1; 
HRMS calculated for C24H25ClN6O5SH (M+H)+ 545.1374; found 545.1378 (TOF MS ES+).  
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(8R,9aS)-3,3-dioxido-1-oxo-2-((1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-
yl)methyl)octahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl 2-chloronicotinate 3.2.1(10){6} NA-6-165-9F 
 
According to the reaction protocol described in general procedure C, compound 3.2.1(10){6} (24%, 41.0 mg) 
was isolated as dark brown oil. 
FTIR (thin film) 1735, 1701, 1421, 1404, 1355, 1325, 1151, 1066, 825 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +28.6° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 8.55 (dd, J = 4.8, 2.0 Hz, 1H), 8.14 (dd, J = 7.7, 2.0 Hz, 1H), 7.64 (d, J = 
7.9 Hz, 2H), 7.51 (s, 1H), 7.38 – 7.34 (m, 3H), 5.62 (d, J = 15.3 Hz, 1H), 5.55 (d, J = 15.3 Hz, 1H), 5.38 (ddd, J 
= 14.2, 5.4, 4.4 Hz, 1H), 5.15 (d, J = 15.6 Hz, 1H), 5.07 (d, J = 15.5 Hz, 1H), 4.49 (t, J = 7.8 Hz, 1H), 3.77 
(ddd, J = 14.1, 12.1, 3.9 Hz, 1H), 3.62 (dd, J = 11.3, 4.6 Hz, 1H), 3.51 (ddd, J = 14.0, 12.2, 2.1 Hz, 1H), 3.44 
(ddd, J = 14.2, 3.4, 2.0 Hz, 1H), 3.27 (ddd, J = 13.2, 3.7, 3.6 Hz, 1H), 2.92 – 2.83 (m, 2H), 2.26 (dddd, J = 13.8, 
8.1, 4.2, 1.4 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ ppm 170.3, 164.0, 152.2, 149.9, 140.3, 138.4, 131.1 (q, 2JC–F = 32.74 Hz), 
130.89, 128.1 (2), 126.6, 126.1(q, 3JC–F = 4.05 Hz, 2), 123.5 (1JC–F = 272.04 Hz), 122.9, 122.2, 74.7, 64.0, 61.6, 
55.9, 53.4, 52.4, 41.0, 34.0; 
HRMS calculated for C24H22ClF3N6O5SH (M+H)+ 599.1091; found 599.1075 (TOF MS ES+).  
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(8R,9aS)-2-((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl cyclopropanecarboxylate 3.2.1(11){9} NA-6-165-10D 
 
According to the reaction protocol described in general procedure C, compound 3.2.1(11){9} (32%, 42.4 mg) 
was isolated as dark orange oil. 
FTIR (thin film) 2358, 2341, 1718, 1703, 1492, 1353, 1172, 1153, 1053, 821 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +29.7° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.45 (s, 1H), 7.36 – 7.33 (m, 2H), 7.21 – 7.17 (m, 2H), 5.51 (d, J = 15.0 
Hz, 1H), 5.44 (d, J = 15.0 Hz, 1H), 5.17 – 5.02 (m, 3H), 4.37 (t, J = 7.7 Hz, 1H), 3.71 (ddd, J = 14.0, 12.1, 4.1 
Hz, 1H), 3.49 – 3.38 (m, 3H), 3.22 (ddd, J = 13.7, 4.4, 3.3 Hz, 1H), 2.75 – 2.65 (m, 2H), 2.08 (dddd, J = 13.8, 
8.1, 4.2, 1.4 Hz, 1H), 1.59 (tt, J = 7.9, 4.6 Hz, 1H), 1.03 – 0.96 (m, 2H), 0.92 – 0.86 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ ppm 174.3, 170.5, 134.8, 133.0, 129.4 (2), 129.3 (2), 122.8, 72.7, 64.0, 61.8, 
55.9, 53.4, 52.5, 41.0, 40.2, 33.8, 13.0, 8.7 (2); 
HRMS calculated for C21H24ClN5O5SH (M+H)+ 494.1265; found 494.1292 (TOF MS ES+).  
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(8R,9aS)-2-((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl cyclopropanecarboxylate 3.2.1(11){5} NA-6-165-10E 
 
According to the reaction protocol described in general procedure C, compound 3.2.1(11){5} (27%, 36.5) was 
isolated as dark orange oil. 
FTIR (thin film) 1720, 1512, 1421, 1384, 1353, 1222, 1172, 1153, 1053, 825 cm-1; 
[𝜶]𝑫𝟐𝟎
 = +32.4° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 7.45 (s, 1H), 7.26 – 7.22 (m, 2H), 7.09 – 7.03 (m, 2H), 5.51 (d, J = 15.0 
Hz, 1H), 5.44 (d, J = 14.9 Hz, 1H), 5.15 – 5.01 (m, 3H), 4.37 (t, J = 7.7 Hz, 1H), 3.72 (ddd, J = 14.1, 12.1, 4.1 
Hz, 1H), 3.48 – 3.38 (m, 3H), 3.22 (ddd, J = 13.7, 4.2, 3.3 Hz, 1H), 2.77 – 2.66 (m, 2H), 2.08 (dddd, J = 13.8, 
8.1, 4.3, 1.4 Hz, 1H), 1.59 (tt, J = 7.9, 4.6 Hz, 1H), 1.02 – 0.97 (m, 2H), 0.92 – 0.86 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ ppm 174.3, 170.5, 162.8 (1JC–F = 250.55 Hz), 143.6, 130.3 (4JC–F = 3.42 Hz), 
129.9 (3JC–F = 8.41 Hz, 2), 122.7, 116.1 (2J = 21.76 Hz, 2), 72.7, 63.9, 61.8, 55.9, 53.4, 52.5, 41.0, 33.8, 12.9, 
8.7 (2); 
HRMS calculated for C21H24FN5O5SH (M+H)+ 478.1560; found 478.1559 (TOF MS ES+).  
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(8S,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 4-fluorobenzoate 3.3.1(1){1} (NA-7-42-IA) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(1){1} (48%, 10.2 mg) 
was isolated as brownish solid. 
M.P. 148 – 153ºC 
FTIR (neat) 2974, 1718, 1699, 1490, 1353, 1153, 1051 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +17.6° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.05 – 7.99 (m, 2H), 7.41 (s, 1H), 7.16 – 7.12 (m, 2H), 7.11 – 7.03 (m, 4H), 
5.39 – 5.36 (m, 1H), 5.33 (d, J = 14.7 Hz, 1H), 5.28 (d, J = 14.7 Hz, 1H), 5.17 (d, J = 15.7 Hz, 1H), 5.10 (d, J = 
15.7 Hz, 1H), 4.33 (dd, J = 10.4, 2.8 Hz, 1H), 3.57 (ddd, J = 14.2, 11.9, 4.4 Hz, 1H), 3.39 (dt, J = 14.2, 2.8 Hz, 
1H), 3.32 – 3.23 (m, 2H), 3.22 – 3.16 (m, 1H), 3.04 – 2.98 (m, 1H), 2.93 (dd, J = 10.5, 3.6 Hz, 1H), 2.39 – 2.34 
(m, 1H), 2.34 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.3, 165.8 (1JC–F = 253.53 Hz), 165.2, 143.8, 138.6, 132.4 (3JC–F = 
10.09 Hz, 2), 131.5, 129.7 (2), 127.9 (2), 126.4 (4JC–F = 2.95 Hz), 122.3, 115.5 (2J = 21.95 Hz, 2), 73.3, 63.6, 
61.9, 55.4, 53.8, 50.3, 40.5, 32.9, 21.1; 
HRMS calculated for C25H26FN5O5SH (M+H)+ 528.1717; found 528.1694 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 4-fluorobenzoate 3.3.1(1){2} (NA-7-42-IB) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(1){2} (70.5%, 14.9 mg) 
was isolated as brownish oil. 
FTIR (neat) 2918, 2848, 1693, 1641, 1483, 1352, 1178, 1053 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +13.2° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 8.04 – 7.98 (m, 2H), 7.34 (s, 1H), 7.31 – 7.24 (m, 2H), 7.22 – 7.11 (m, 
2H), 7.10 – 7.05 (m, 1H), 6.96 (d, J = 7.4 Hz, 1H), 5.41 (d, J = 15.7 Hz, 1H), 5.32 (d, J = 15.7 Hz, 1H), 5.18 (d, 
J = 15.8 Hz, 1H), 5.10 (d, J = 15.8 Hz, 1H), 4.32 (dd, J = 10.4, 2.8 Hz, 1H), 4.26 – 4.14 (m, 1H), 3.56 (ddd, J = 
14.2, 11.9, 4.4 Hz, 1H), 3.38 (dt, J = 14.2, 2.7 Hz, 1H), 3.31 (dd, J = 10.9, 2.3 Hz, 1H), 3.26 (dd, J = 12.0, 2.4 
Hz, 1H), 3.22 – 3.16 (m, 1H), 3.04 – 2.98 (m, 1H), 2.93 (dd, J = 10.4, 3.6 Hz, 1H), 2.42 – 2.28 (m, 1H), 2.21 (s, 
3H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.8, 165.8 (1JC–F = 253.93 Hz), 165.2, 143.8, 137.4, 137.2, 136.7, 132.5, 
132.4 (3JC–F = 9.03 Hz, 2), 129.0 (4JC–F = 2.72 Hz), 126.6, 125.8, 122.3, 115.5 (2J = 21.78 Hz, 2), 73.3, 63.7, 
61.9, 55.4, 52.2, 50.3, 40.5, 32.9, 18.9; 
HRMS calculated for C25H26FN5O5SH (M+H)+ 528.1717; found 528.1694 (TOF MS ES+). 
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(8S,9aS)-2-((1-(2-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 4-fluorobenzoate 3.3.1(1){10} (NA-7-42-IF) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(1){10} (51%, 12.0 mg) 
was isolated as brownish solid. 
M.P. 147 – 152ºC 
FTIR (neat) 2974, 1718, 1490, 1436, 1386, 1353, 1213, 1153, 1051, 896, 784 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +9.8° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ ppm 8.03 – 7.97 (m, 2H), 7.58 (dd, J = 7.9, 1.4 Hz, 1H), 7.56 (s, 1H), 7.25 (dd, 
J = 7.5, 1.4 Hz, 1H), 7.21 (td, J = 7.7, 1.8 Hz, 1H), 7.09 – 7.04 (m, 2H), 6.99 (dd, J = 7.6, 1.8 Hz, 1H), 5.51 (d, 
J = 15.3 Hz, 1H), 5.44 (d, J = 15.3 Hz, 1H), 5.38 (ddt, J = 5.4, 3.8, 0.9 Hz, 1H), 5.21 (d, J = 15.7 Hz, 1H), 5.14 
(d, J = 15.6 Hz, 1H), 4.35 (dd, J = 10.4, 2.8 Hz, 1H), 3.61 (ddd, J = 14.2, 11.4, 4.6 Hz, 1H), 3.41 (dt, J = 14.3, 
2.8 Hz, 1H), 3.36 – 3.28 (m, 2H), 3.28 – 3.21 (m, 1H), 3.05 – 3.00 (m, 1H), 2.95 (dd, J = 10.5, 3.6 Hz, 1H), 
2.37 (ddd, J = 14.8, 10.4, 5.4 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.3, 165.8 (1JC–F = 253.98 Hz), 165.7, 143.7, 134.0, 133.1, 132.4 (3JC–F 
= 9.58 Hz, 2), 129.0 (4JC–F = 2.72 Hz), 130.3, 130.0, 128.2, 123.2, 122.9, 115.5 (2J = 21.88 Hz, 2), 73.3, 63.7, 
62.0, 55.5, 53.7, 50.4, 40.5, 32.9; 
HRMS calculated for C24H23BrN5O5SH (M+H)+ 592.0666; found 592.0667 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 1-methyl-1H-pyrrole-2-carboxylate 3.3.1(3){1} (NA-7-42-IIIA) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(3){1} (34%, 6.9 mg) was 
isolated as brownish oil. 
FTIR (neat) 2956, 1710, 1679, 1433, 1353, 1224, 1153, 1051, 856, 769 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +12.2° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.45 (s, 1H), 7.14 (d, J = 7.7 Hz, 2H), 7.03 (d, J = 7.9 Hz, 1H), 6.89 (dd, J = 
4.0, 1.8 Hz, 1H), 6.77 (t, J = 2.2 Hz, 1H), 6.09 (dd, J = 4.0, 2.5 Hz, 1H), 5.37 – 5.10 (m, 6H), 4.28 (dd, J = 10.4, 
3.0 Hz, 1H), 3.85 (s, 3H), 3.49 (ddd, J = 14.2, 12.0, 4.3 Hz, 1H), 3.36 (dt, J = 14.2, 2.7 Hz, 1H), 3.27 – 3.19 (m, 
2H), 3.14 (ddd, J = 13.3, 4.4, 3.2 Hz, 1H), 3.01 – 2.95 (m, 1H), 2.88 (dd, J = 10.4, 3.7 Hz, 1H), 2.34 (s, 3H), 
2.33 – 2.28 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.3, 160.8, 143.7, 138.49, 131.7, 129.6 (3), 127.9 (2), 122.8, 122.5, 118.5, 
107.9, 72.2, 63.8, 62.2, 55.2, 54.0, 50.4, 41.0, 36.8, 32.9, 21.1; 
HRMS calculated for C24H28N6O5SH (M+H)+ 513.1920; found 513.1901 (TOF MS ES+). 
  
N
N
S
OO
O
O
N
N
N
O
Me
N
Me
 SI–197 
 
(8S,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 1-methyl-1H-pyrrole-2-carboxylate 3.3.1(1){2} (NA-7-42-IIIB) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(1){2} (40%, 8.2 mg) was 
isolated as brownish oil. 
FTIR (neat) 2839, 1710, 1683, 1456, 1419, 1379, 1259, 1168, 1043, 815, 757 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +13.6° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.39 (s, 1H), 7.25 (dd, J = 7.4, 1.4 Hz, 1H), 7.20 – 7.14 (m, 2H), 6.92 (d, J = 7.6 
Hz, 1H), 6.87 (dd, J = 4.0, 1.8 Hz, 1H), 6.77 (t, J = 2.1 Hz, 1H), 6.07 (dd, J = 4.0, 2.5 Hz, 1H), 5.41 (d, J = 14.9 
Hz, 1H), 5.32 – 5.25 (m, 2H), 5.14 (d, J = 1.37 Hz, 2H), 4.27 (dd, J = 10.4, 3.0 Hz, 1H), 3.85 (s, 3H), 3.49 (ddd, 
J = 14.2, 11.9, 4.3 Hz, 1H), 3.36 (dt, J = 14.2, 2.8 Hz, 1H), 3.29 – 3.19 (m, 2H), 3.14 (ddd, J = 13.4, 4.4, 3.2 Hz, 
1H), 2.97 (dddd, J = 14.7, 3.1, 2.1, 1.0 Hz, 1H), 2.88 (dd, J = 10.4, 3.8 Hz, 1H), 2.33 (ddd, J = 14.7, 10.5, 5.7 
Hz, 1H), 2.22 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.3, 160.7, 143.6, 136.6, 132.7, 130.8 (2), 129.6, 128.9, 126.5, 122.6, 122.4, 
118.5, 107.9, 72.1, 63.8, 62.3, 55.2, 52.1, 50.4, 41.0, 36.8, 32.9, 18.9; 
HRMS calculated for C24H28N6O5SH (M+H)+ 513.1920; found 513.1902 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 1-methyl-1H-pyrrole-2-carboxylate 3.3.1(3){4} (NA-7-42-IIIC) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(3){4} (40%, 8.5 mg) was 
isolated as brownish oil. 
FTIR (neat) 2966, 1710, 1604, 1514, 1438, 1353, 1257, 1153, 1066, 823 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +7.2° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.48 (s, 1H), 7.33 – 7.28 (m, 2H), 7.09 – 7.05 (m, 2H), 6.89 (dd, J = 4.0, 1.8 Hz, 
1H), 6.78 (t, J = 2.2 Hz, 1H), 6.08 (dd, J = 4.0, 2.5 Hz, 1H), 5.37 – 5.24 (m, 3H), 5.18 – 5.09 (m, 2H), 4.27 (dd, 
J = 10.4, 2.9 Hz, 1H), 3.86 (s, 3H), 3.49 (ddd, J = 14.2, 11.8, 4.4 Hz, 1H), 3.39 (dt, J = 14.2, 2.8 Hz, 1H), 3.31 – 
3.21 (m, 2H), 3.17 (ddd, J = 13.4, 4.5, 3.2 Hz, 1H), 3.04 – 2.94 (m, 1H), 2.89 (dd, J = 10.5, 3.7 Hz, 1H), 2.37 – 
2.29 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.3, 160.7, 144.0, 134.6, 133.2, 129.6, 129.2 (2), 129.1 (2), 122.9, 122.5, 
118.5, 107.9, 72.2, 63.8, 62.2, 55.3, 53.1, 50.4, 41.0, 36.8, 32.9; 
HRMS calculated for C23H25ClN6O5SH (M+H)+ 533.1374; found 533.1372 (TOF MS ES+). 
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(8S,9aS)-2-((1-(3-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 1-methyl-1H-pyrrole-2-carboxylate 3.3.1(3){12} (NA-7-42-IIID) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(3){12} (35%, 7.3 mg) 
was isolated as brownish oil. 
FTIR (neat) 2956, 1710, 1679, 1224, 1051, 769, 734 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +11.5° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.58 (s, 1H), 7.37 – 7.30 (m, 1H), 7.15 – 7.06 (m, 3H), 6.87 (dd, J = 4.0, 1.8 Hz, 
1H), 6.76 (t, J = 2.1 Hz, 1H), 6.08 (dd, J = 4.0, 2.5 Hz, 1H), 5.45 (dd, J = 15.0, 1.1 Hz, 1H), 5.35 (dd, J = 15.1, 
1.1 Hz, 1H), 5.30 – 5.27 (m, 1H), 5.15 (s, 2H), 4.29 (dd, J = 10.4, 2.9 Hz, 1H), 3.84 (s, 3H), 3.57 (ddd, J = 14.2, 
11.7, 4.6 Hz, 1H), 3.39 (dt, J = 14.3, 2.8 Hz, 1H), 3.34 – 3.22 (m, 2H), 3.20 (ddd, J = 13.3, 4.7, 3.2 Hz, 1H), 
3.02 – 2.96 (m, 1H), 2.90 (dd, J = 10.5, 3.7 Hz, 1H), 2.34 (ddd, J = 14.7, 10.4, 5.6 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.3, 161.3 (1JC–F = 248.99 Hz), 160.7, 143.8, 130.7 (3JC–F = 8.25 Hz), 130.2 
(5JC–F = 3.25 Hz), 129.6, 124.7 (4JC–F = 3.31 Hz), 123.0, 122.4, 122.0 (2JC–F = 14.56 Hz), 118.5, 115.7 (6JC–F = 
21.12 Hz), 107.8, 72.1, 63.8, 62.3, 55.3, 50.4, 47.5, 40.6, 36.8, 32.9; 
HRMS calculated for C23H25FN6O5SH (M+H)+ 517.1669; found 517.1664 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl furan-2-carboxylate 3.3.1(4){1} (NA-7-42-IVA) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(4){1} (59%, 11.7 mg) 
was isolated as brownish oil. 
FTIR (neat) 1964, 1712, 1604, 1514, 1463, 1353, 1325, 1280, 1153, 823 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +15.2° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.56 (dd, J = 1.7, 0.9 Hz, 1H), 7.46 (s, 1H), 7.14 (d, J = 8.4 Hz, 2H), 7.12 (dd, J 
= 3.4, 0.88 Hz, 1H), 7.08 – 7.04 (m, 2H), 6.48 (dd, J = 3.5, 1.7 Hz, 1H), 5.41 (d, J = 14.7 Hz, 1H), 5.36 (ddt, J = 
5.7, 3.9, 0.9 Hz, 1H), 5.31 – 5.27 (m, 1H), 5.15 (d, J = 15.7 Hz, 1H), 5.11 (d, J = 15.6 Hz, 1H), 4.28 (dd, J = 
10.3, 3.0 Hz, 1H), 3.48 – 3.40 (m, 1H), 3.36 (dt, J = 14.2, 2.8 Hz, 1H), 3.27 – 3.20 (m, 2H), 3.15 (ddd, J = 13.4, 
4.4, 3.2 Hz, 1H), 3.01 – 2.94 (m, 1H), 2.90 (dd, J = 10.6, 3.8 Hz, 1H), 2.38 – 2.34 (m, 1H), 2.34 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 158.2, 146.4, 144.5, 143.9, 138.6, 131.6, 129.7 (2), 127.9 (2), 122.7, 
118.5, 111.9, 73.2, 63.7, 61.8, 55.2, 53.8, 50.3, 41.0, 33.0, 21.1; 
HRMS calculated for C23H25N5O6SH (M+H)+ 500.1604; found 500.1570 (TOF MS ES+). 
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(8S,9aS)-2-((1-(2-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl furan-2-carboxylate 3.3.1(4){2} (NA-7-42-IVB) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(4){2} (43%, 8.6 mg) was 
isolated as brownish oil. 
FTIR (neat) 2968, 1712, 1604, 1514, 1421, 1353, 1257, 1224, 1153, 771 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +10.2° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.55 (dd, J = 1.8, 0.9 Hz, 1H), 7.39 (s, 1H), 7.30 – 7.24 (m, 1H), 7.20 – 7.16 (m, 
2H), 7.11 (dd, J = 3.5, 0.9 Hz, 1H), 6.99 (dd, J = 7.1, 1.8 Hz, 1H), 6.48 (dd, J = 3.5, 1.7 Hz, 1H), 5.47 (d, J = 
14.9 Hz, 1H), 5.37 (t, J = 5.3 Hz, 1H), 5.32 (d, J = 18.5 Hz, 1H), 5.16 (d, J = 15.7 Hz, 1H), 5.11 (d, J = 15.6 Hz, 
1H), 4.28 (dd, J = 10.3, 3.1 Hz, 1H), 3.45 (ddd, J = 14.2, 11.8, 4.4 Hz, 1H), 3.36 (dt, J = 14.3, 2.8 Hz, 1H), 3.29 
– 3.21 (m, 2H), 3.16 (ddd, J = 13.4, 4.4, 3.1 Hz, 1H), 3.00 – 2.94 (m, 1H), 2.90 (dd, J = 10.7, 3.8 Hz, 1H), 2.39 
– 2.31 (m, 1H), 2.22 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 158.3, 146.5, 144.6, 143.8, 136.7, 132.6, 130.9, 129.2, 129.1, 126.6, 
122.6, 111.9, 111.8, 73.2, 63.8, 61.9, 55.3, 52.3, 50.4, 41.0, 33.1, 18.9; 
HRMS calculated for C23H25N5O6SH (M+H)+ 500.1604; found 500.1580 (TOF MS ES+). 
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(8S,9aS)-2-((1-(3-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl furan-2-carboxylate 3.3.1(4){11} (NA-7-42-IVD) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(4){11} (43%, 8.7 mg) 
was isolated as brownish oil. 
FTIR (neat) 2962, 1712, 1591, 1492 1433, 1353, 1118, 1053, 759, 702 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +15.8° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.59 (s, 1H), 7.55 (dd, J = 1.8, 0.9 Hz, 1H), 7.34 (dddd, J = 8.1, 7.2, 5.4, 1.9 Hz, 
1H), 7.20 – 7.06 (m, 4H), 6.48 (dd, J = 3.5, 1.7 Hz, 1H), 5.50 (d, J = 15.0 Hz, 1H), 5.45 (d, J = 15.0 Hz, 1H), 
5.38 (ddt, J = 5.8, 3.9, 1.0 Hz, 1H), 5.16 (d, J = 15.7 Hz, 1H), 5.12 (d, J = 15.6 Hz, 1H), 4.30 (dd, J = 10.4, 3.0 
Hz, 1H), 3.52 (ddd, J = 14.2, 11.5, 4.7 Hz, 1H), 3.39 (dt, J = 14.2, 2.8 Hz, 1H), 3.33 – 3.19 (m, 3H), 3.02 – 2.96 
(m, 1H), 2.92 (dd, J = 10.6, 3.8 Hz, 1H), 2.36 (ddd, J = 14.8, 10.4, 5.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 159.7 (1JC–F = 246.77 Hz), 158.3, 146.4, 144.5, 143.9, 130.8 (3JC–F = 
7.99 Hz), 130.3 (5JC–F = 3.42 Hz), 124.8 (4JC–F = 3.79 Hz), 122.4, 122.0 (2JC–F = 14.73 Hz), 118.4, 115.8 (6JC–F 
= 21.80 Hz), 111.8, 72.2, 63.8, 62.3, 55.3, 50.4, 47.6, 41.0, 33.0; 
HRMS calculated for C22H22N5O6SH (M+H)+ 504.1353; found 504.1340 (TOF MS ES+). 
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(8S,9aS)-2-((1-(2-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl furan-2-carboxylate 3.3.1(4){10} (NA-7-42-IVF) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(4){10} (43%, 8.7 mg) 
was isolated as brownish oil. 
FTIR (neat) 2974, 1712, 1618, 1433, 1353, 1276, 1224, 1153, 1118, 761 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +19.2° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.60 (s, 1H), 7.54 (dd, J = 1.8, 0.9 Hz, 1H), 7.29 – 7.19 (m, 3H), 7.10 (dd, J = 
3.5, 0.9 Hz, 1H), 6.99 (dd, J = 7.6, 1.8 Hz, 1H), 6.47 (dd, J = 3.5, 1.7 Hz, 1H), 5.57 (d, J = 15.3 Hz, 1H), 5.49 
(d, J = 15.3 Hz, 1H), 5.37 (ddt, J = 5.7, 3.9, 1.0 Hz, 1H), 5.19 (d, J = 15.8 Hz, 1H), 5.16 (d, J = 15.5 Hz, 1H), 
4.30 (dd, J = 10.4, 3.0 Hz, 1H), 3.53 (ddd, J = 14.2, 11.5, 4.7 Hz, 1H), 3.40 (dt, J = 14.3, 2.8 Hz, 1H), 3.31 – 
3.19 (m, 3H), 3.02 – 2.96 (m, 1H), 2.92 (dd, J = 10.7, 3.8 Hz, 1H), 2.36 (ddd, J = 14.9, 10.4, 5.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 158.24 146.5, 144.52, 143.8, 134.1, 133.1, 130.3, 123.0, 128.2, 123.2, 
118.4, 111.9, 111.8, 73.2, 63.7, 61.9, 55.3, 53.7, 50.4, 41.0, 33.0; 
HRMS calculated for C22H22BrN5O6SH (M+H)+ 564.0552; found 564.0555 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl furan-2-carboxylate 3.3.1(4){13} (NA-7-42-IVH) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(4){13} (33%, 6.9 mg) 
was isolated as brownish oil. 
FTIR (neat) 2929, 2852, 1714, 1446, 1353, 1224, 1153, 1118, 823, 769, 686 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +9.8° (c = 2.0, CH2Cl2); 
M.P. 153 – 157ºC 
1H NMR (500 MHz, CDCl3) δ 7.57 (dd, J = 1.7, 0.9 Hz, 1H), 7.44 (s, 1H), 7.14 – 7.11 (m, 2H), 7.11 – 7.09 (m, 
1H), 6.88 – 6.84 (m, 2H), 6.49 (dd, J = 3.5, 1.7 Hz, 1H), 5.42 – 5.35 (m, 2H), 5.33 – 5.25 (m, 1H), 5.15 (d, J = 
15.6 Hz, 1H), 5.11 (d, J = 15.5 Hz, 1H), 4.28 (dd, J = 10.3, 3.0 Hz, 1H), 3.80 (s, 3H), 3.44 (ddd, J = 14.2, 11.7, 
4.4 Hz, 1H), 3.37 (dt, J = 14.2, 2.9 Hz, 1H), 3.28 – 3.21 (m, 2H), 3.16 (ddd, J = 13.4, 4.5, 3.2 Hz, 1H), 3.01 – 
2.95 (m, 1H), 2.90 (dd, J = 10.6, 3.7 Hz, 1H), 2.35 (ddd, J = 14.9, 10.4, 5.6 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 159.8, 158.2, 146.5, 144.6, 143.9, 129.4 (2), 126.6, 122.5, 118.5, 114.4, 
111.9 (2), 73.2, 63.7, 61.9, 55.3, 55.2, 53.6, 50.37, 41.0, 33.0; 
HRMS calculated for C23H25N5O7SH (M+H)+ 516.1553; found 516.1547 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 2-chloronicotinate 3.3.1(10){1} (NA-7-42-IXA) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(10){1} (60%, 13.0 mg) 
was isolated as brownish oil. 
FTIR (neat) 2950, 1745, 1708, 1514, 1433, 1353, 1249, 1153, 837, 732 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +12.4° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.47 (dd, J = 4.8, 2.0 Hz, 1H), 8.22 (dd, J = 7.7, 2.0 Hz, 1H), 7.42 (s, 1H), 7.29 
(dd, J = 7.7, 4.8 Hz, 1H), 7.18 – 7.10 (m, 4H), 5.45 – 5.40 (m, 2H), 5.38 (d, J = 15.7 Hz, 1H), 5.18 (d, J = 15.7 
Hz, 1H), 5.06 (d, J = 15.6 Hz, 1H), 4.33 (dd, J = 10.5, 2.6 Hz, 1H), 3.57 (ddd, J = 14.2, 11.6, 4.6 Hz, 1H), 3.40 
(dt, J = 14.3, 2.7 Hz, 1H), 3.35 – 3.20 (m, 3H), 3.05 (dt, J = 15.2, 2.0 Hz, 1H), 2.95 (dd, J = 10.5, 3.5 Hz, 1H), 
2.38 (ddd, J = 15.6, 10.3, 5.4 Hz, 1H), 2.35 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 163.9, 151.8, 150.0, 143.6, 141.2, 138.7, 131.4, 129.7 (2), 128.0 (2), 
126.6, 122.5, 122.4, 74.3, 63.4, 61.5, 55.5, 53.9, 50.2, 41.0, 32.1, 21.1; 
HRMS calculated for C24H25ClN6O5SH (M+H)+ 545.1374; found 545.1364 (TOF MS ES+). 
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(8S,9aS)-2-((1-(2-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 2-chloronicotinate 3.3.1(10){2} (NA-7-42-IXB) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(10){2} (48%, 10.4 mg) 
was isolated as brownish oil. 
FTIR (neat) 2956, 1712, 1602, 1421, 1353, 1325, 1280, 1153, 1120, 769 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +13.7° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.47 (dd, J = 4.8, 2.0 Hz, 1H), 8.22 (dd, J = 7.7, 2.0 Hz, 1H), 7.34 (s, 1H), 7.31 
– 7.25 (m, 2H), 7.22 – 7.17 (m, 2H), 7.07 (d, J = 7.4 Hz, 1H), 5.49 (d, J = 14.9 Hz, 1H), 5.45 – 5.41 (m, 2H), 
5.18 (d, J = 15.6 Hz, 1H), 5.06 (d, J = 15.6 Hz, 1H), 4.33 (dd, J = 10.4, 2.7 Hz, 1H), 3.55 (ddd, J = 14.2, 11.6, 
4.6 Hz, 1H), 3.39 (dt, J = 14.3, 2.7 Hz, 1H), 3.30 (ddd, J = 24.1, 11.1, 2.3 Hz, 2H), 3.27 – 3.20 (m, 1H), 3.06 
(dt, J = 15.2, 2.4 Hz, 1H), 2.95 (dd, J = 10.5, 3.5 Hz, 1H), 2.37 (ddd, J = 15.4, 10.3, 5.4 Hz, 1H), 2.24 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 163.9, 151.8, 150.0, 143.5, 141.2, 136.7, 132.5, 131.0, 130.1, 129.2, 
129.1, 126.6, 122.5, 122.4, 74.3, 63.4, 61.6, 55.5, 52.3, 50.2, 41.0, 32.9, 18.9; 
HRMS calculated for C24H25ClN6O5SH (M+H)+ 545.1374; found 545.1367 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 2-chloronicotinate 3.3.1(10){4} (NA-7-42-IXC) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(10){4} (46%, 10.4 mg) 
was isolated as brownish oil. 
FTIR (neat) 2966, 1710, 1604, 1512, 1442, 1353, 1280, 1257, 1222, 1153, 1056, 1027, 848, 815, 771 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +16.2° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.49 (dd, J = 4.8, 2.0 Hz, 1H), 8.23 (dd, J = 7.7, 2.0 Hz, 1H), 7.44 (s, 1H), 7.35 
– 7.29 (m, 3H), 7.19 – 7.15 (m, 2H), 5.47 – 5.41 (s, 3H), 5.15 (d, J = 15.6 Hz, 1H), 5.08 (d, J = 15.6 Hz, 1H), 
4.32 (dd, J = 10.5, 2.7 Hz, 1H), 3.57 (ddd, J = 14.2, 11.1, 5.1 Hz, 1H), 3.42 (dt, J = 14.3, 2.7 Hz, 1H), 3.34 (dd, 
J = 10.7, 2.3 Hz, 1H), 3.31 – 3.22 (m, 2H), 3.06 (dt, J = 17.3, 2.2 Hz, 1H), 2.96 (dd, J = 10.6, 3.6 Hz, 1H), 2.39 
(ddd, J = 15.4, 10.5, 5.4 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 164.0, 151.8, 150.0, 143.9, 141.1, 134.7, 133.0, 129.3 (2), 129.2 (2), 
126.69, 122.7, 122.4, 74.3, 63.5, 61.6, 55.6, 53.3, 50.2, 41.0, 32.9; 
HRMS calculated for C23H22Cl2N6O5SH (M+H)+ 565.0828; found 565.0816 (TOF MS ES+). 
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(8S,9aS)-2-((1-(2-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 2-chloronicotinate 3.3.1(10){12} (NA-7-42-IXE) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(10){12} (47%, 10.4 mg) 
was isolated as brownish oil. 
FTIR (neat) 2931, 2852, 1708, 1593, 1431, 1353, 1274, 1271, 1218, 1153, 1118, 781, 761 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +15.4° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.49 (dd, J = 4.8, 2.0 Hz, 1H), 8.24 (dd, J = 7.7, 2.0 Hz, 1H), 7.46 (s, 1H), 7.36 
– 7.30 (m, 2H), 7.09 – 6.98 (m, 2H), 6.88 (dt, J = 9.3, 2.1 Hz, 1H), 5.55 – 5.41 (m, 3H), 5.18 (d, J = 15.6 Hz, 
1H), 5.10 (d, J = 15.6 Hz, 1H), 4.34 (dd, J = 10.5, 2.7 Hz, 1H), 3.55 (ddd, J = 14.2, 11.2, 5.0 Hz, 1H), 3.42 (dt, 
J = 14.3, 2.8 Hz, 1H), 3.37 – 3.32 (m, 1H), 3.31 – 3.22 (m, 2H), 3.10 – 3.03 (m, 1H), 2.96 (dd, J = 10.6, 3.6 Hz, 
1H), 2.39 (ddd, J = 15.4, 10.5, 5.3 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 164.0, 162.9 (1JC–F = 247.86 Hz), 151.8, 150.0, 143.9, 141.1, 136.9 (3JC–
F = 7.33 Hz), 130.7 (5JC–F = 8.12 Hz), 126.7, 123.4 (4JC–F = 3.14 Hz), 122.9, 122.4, 115.7 (6JC–F = 21.01 Hz), 
114.8 (2JC–F = 22.07 Hz), 74.3, 63.5, 61.6, 55.6, 53.4, 50.2, 41.0, 32.9; 
HRMS calculated for C23H22ClFN6O5SH (M+H)+ 549.1123; found 549.1107 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 2-chloronicotinate 3.3.1(10){13} (NA-7-42-IXH) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(10){13} (75%, 15.5 mg) 
was isolated as brownish oil. 
FTIR (neat) 2968, 1703, 1531, 1413, 1353, 1245, 1224, 1155, 118, 1054, 823, 777 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +19.5° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 8.48 (dd, J = 4.8, 2.0 Hz, 1H), 8.22 (dd, J = 7.7, 2.0 Hz, 1H), 7.40 (s, 1H), 7.29 
(dd, J = 7.7, 4.8 Hz, 1H), 7.20 – 7.15 (m, 2H), 6.90 – 6.85 (m, 2H), 5.42 (dd, J = 3.3, 1.8 Hz, 1H), 5.40 (d, J = 
14.7 Hz, 1H), 5.35 (d, J = 14.7 Hz, 1H), 5.17 (d, J = 15.7 Hz, 1H), 5.05 (dd, J = 15.6, 0.6 Hz, 1H), 4.32 (dd, J = 
10.5, 2.6 Hz, 1H), 3.80 (s, 3H), 3.56 (ddd, J = 14.2, 11.5, 4.7 Hz, 1H), 3.40 (dt, J = 14.3, 2.7 Hz, 1H), 3.35 – 
3.20 (m, 3H), 3.08 – 3.01 (m, 1H), 2.94 (dd, J = 10.6, 3.5 Hz, 1H), 2.38 (ddd, J = 15.4, 10.5, 5.3 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 164.0, 159.8, 151.8, 150.0, 143.5, 141.2, 129.6 (2), 126.6, 126.4, 122.4, 
122.3, 114.4 (2), 74.3, 63.4, 61.5, 55.5, 55.3, 53.6, 50.2, 41.0, 32.9; 
HRMS calculated for C24H25ClN6O6SH (M+H)+ 561.1323; found 561.1316 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl thiophene-2-carboxylate 3.3.1(5){1} (NA-7-42-VA) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(5){1} (52%, 10.8 mg) 
was isolated as brownish oil. 
FTIR (neat) 2970, 1712, 1531, 1492, 1434, 1353, 1224, 1153, 1054, 823, 761 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +16.3° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.76 (dd, J = 3.8, 1.3 Hz, 1H), 7.54 (dd, J = 4.9, 1.3 Hz, 1H), 7.45 (s, 1H), 7.15 
– 7.11 (m, 2H), 7.08 (dd, J = 5.0, 3.7 Hz, 1H), 7.05 – 7.01 (m, 2H), 5.37 – 5.32 (m, 2H), 5.24 (d, J = 14.7 Hz, 
1H), 5.16 (d, J = 15.7 Hz, 1H), 5.12 (dd, J = 15.8, 0.65 Hz, 1H), 4.29 (dd, J = 10.4, 2.9 Hz, 1H), 3.44 (ddd, J = 
14.2, 11.8, 4.3 Hz, 1H), 3.36 (dt, J = 14.2, 2.8 Hz, 1H), 3.28 – 3.20 (m, 2H), 3.14 (ddd, J = 13.3, 4.3, 3.1 Hz, 
1H), 3.03 – 2.97 (m, 1H), 2.90 (dd, J = 10.6, 3.7 Hz, 1H), 2.38 – 2.35 (m, 1H), 2.34 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 161.8, 143.8, 138.5, 133.9, 133.8, 132.6, 131.6, 129.6 (2), 127.9 (2), 
127.8, 122.7, 73.5, 63.7, 61.9, 55.2, 53.8, 50.3, 41.0, 32.8, 21.1; 
HRMS calculated for C23H25N5O5S2H (M+H)+ 516.1375; found 516.1357 (TOF MS ES+). 
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(8S,9aS)-2-((1-(2-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl thiophene-2-carboxylate 3.3.1(5){2} (NA-7-42-VB) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(5){2} (40%, 8.3 mg) was 
isolated as brownish oil. 
FTIR (neat) 2970, 1714, 1473, 1415, 1353, 1325, 1153, 1120, 1066, 1018, 784, 763, 700 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +15.5° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.75 (dd, J = 3.7, 1.3 Hz, 1H), 7.53 (dd, J = 5.0, 1.3 Hz, 1H), 7.39 (s, 1H), 7.27 
– 7.24 (m, 1H), 7.20 – 7.15 (m, 2H), 7.07 (dd, J = 5.0, 3.7 Hz, 1H), 6.95 (d, J = 7.5 Hz, 1H), 5.42 (d, J = 14.9 
Hz, 1H), 5.35 (ddt, J = 5.8, 3.8, 1.0 Hz, 1H), 5.29 (d, J = 14.8 Hz, 1H), 5.17 (d, J = 15.8 Hz, 1H), 5.14 (dd, J = 
15.6, 0.65 Hz, 1H), 4.29 (dd, J = 10.4, 3.0 Hz, 1H), 3.45 (ddd, J = 14.2, 11.8, 4.3 Hz, 1H), 3.36 (dt, J = 14.2, 2.8 
Hz, 1H), 3.31 – 3.21 (m, 2H), 3.15 (ddd, J = 13.4, 4.4, 3.1 Hz, 1H), 3.03 – 2.97 (m, 1H), 2.90 (dd, J = 10.6, 3.7 
Hz, 1H), 2.35 (ddd, J = 14.8, 10.4, 5.6 Hz, 1H), 2.20 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.2, 161.8, 143.8, 136.6, 133.9, 133.7, 132.6, 132.5, 130.9, 129.0, 128.0, 
127.8, 126.6, 122.5, 73.4, 63.8, 61.9, 55.3, 52.2, 50.4, 41.0, 33.0, 18.9; 
HRMS calculated for C23H25N5O5S2H (M+H)+ 516.1375; found 516.1355 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl thiophene-2-carboxylate 3.3.1(5){4} (NA-7-42-VC) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(5){4} (47%, 10.1 mg) 
was isolated as brownish oil. 
FTIR (neat) 2797, 1716, 1492, 1434, 1353, 1215, 1153, 1051, 846 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +16.3° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 3.7, 1.3 Hz, 1H), 7.54 (dd, J = 5.0, 1.3 Hz, 1H), 7.47 (s, 1H), 7.33 
– 7.28 (m, 2H), 7.11 – 7.06 (m, 3H), 5.38 – 5.30 (m, 2H), 5.28 (d, J = 15.1 Hz, 1H), 5.16 (dd, J = 15.7, 0.66 Hz, 
1H), 5.12 (d, J = 15.7 Hz, 1H), 4.29 (dd, J = 10.4, 3.0 Hz, 1H), 3.47 (ddd, J = 14.2, 11.7, 4.4 Hz, 1H), 3.39 (dt, 
J = 14.3, 2.8 Hz, 1H), 3.32 – 3.22 (m, 2H), 3.18 (ddd, J = 13.4, 4.4, 3.1 Hz, 1H), 3.03 – 2.98 (m, 1H), 2.92 (dd, 
J = 10.6, 3.7 Hz, 1H), 2.35 (ddd, J = 14.7, 10.4, 5.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.3, 161.8, 144.2, 134.7, 133.9, 133.8, 133.1, 132.6, 129.2 (2), 129.1 (2), 
127.8, 122.8, 73.5, 63.8, 61.9, 55.3, 53.2, 50.4, 41.0, 33.0; 
HRMS calculated for C22H22ClN5O5S2H (M+H)+ 536.0829; found 536.814 (TOF MS ES+). 
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(8S,9aS)-2-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-8-yl 4-methoxybenzoate 3.3.1(8){13} (NA-7-42-VIIH) 
 
According to the reaction protocol described in general procedure C, compound 3.3.1(8){13} (40%, 8.8 mg) 
was isolated as brownish oil. 
FTIR (neat) 2954, 1693, 1413, 1352, 1317, 1247, 1153, 1112, 1053, 1027 cm-1; 
[𝜶]𝑫𝟐𝟎  =
 +17.2° (c = 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.90 – 7.87 (m, 2H), 7.30 (s, 1H), 6.97 – 6.94 (m, 2H), 6.84 – 6.80 (m, 2H), 
6.77 – 6.72 (m, 2H), 5.26 (ddt, J = 5.7, 3.8, 0.9 Hz, 1H), 5.15 (d, J = 14.6 Hz, 1H), 5.09 – 4.99 (m, 3H), 4.22 
(dd, J = 10.4, 2.8 Hz, 1H), 3.77 (s, 3H), 3.71 (s, 3H), 3.38 – 3.24 (m, 2H), 3.22 – 3.12 (m, 2H), 3.05 (ddd, J = 
13.2, 4.3, 3.1 Hz, 1H), 2.96 – 2.90 (m, 1H), 2.82 (dd, J = 10.5, 3.7 Hz, 1H), 2.26 (ddd, J = 14.8, 10.4, 5.5 Hz, 
1H); 
13C NMR (126 MHz, CDCl3) δ 170.5, 165.9, 163.5, 159.8, 143.9, 131.9 (2), 129.4 (2), 126.6, 122.5, 122.4, 
114.3 (2), 113.6 (2), 72.9, 63.8, 62.0, 55.5, 55.3, 55.2, 53.4, 50.3, 41.0, 32.8; 
HRMS calculated for C26H29N5O7SH (M+H)+ 556.1866; found 556.1877 (TOF MS ES+). 
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5.3 Experimental for Chapter 3.2 
Exploring Chemical Diversity via a Modular Reaction Pairing Strategy 
General Procedure A: one-pot, sequential 4-component (sulfonylation, Michael, amide coupling and 
Carbamoylation).  To a pressure tube containing a solution of amine (1.0 mmol, 1.05 equiv.) in dry CH2Cl2 
(0.5 M), was added Et3N (1.91 mmol, 2.0 equiv.).  The reaction mixture was stirred for 20 min and 2-
chloroethane sulfonyl chloride (0.96 mmol, 1.0 equiv.) was added in a drop-wise fashion.  The reaction was left 
to stir overnight and CH2Cl2 was removed in vacuo upon completion of the reaction.  MeOH/water (0.5 M, 5:1), 
Et3N (2.87 mmol, 3.0 equiv.) and amino acid (1.0 mmol, 1.05 equiv.) were added to the reaction mixture, which 
was stirred at 60 ºC for 12 h, after which solvents were evaporated to dryness.  DMF (0.08 M) EDC (1.91 
mmol, 2.0 equiv.), HOBt (0.48 mmol, 0.5 equiv.) and Et3N (1.91 mmol, 2.0 equiv.) were added to the crude 
mixture.  The reaction was stirred at rt for 12 h. Upon completion of the reaction it was divided into small vials 
of equal volume followed by evaporation of the DMF on a genevac and then addition of CH2Cl2. This was 
followed by the addition isocyanate (2.5 equiv.) and DMAP (0.5 equiv.). The reaction was again run for 12 
hours. Water was added to the crude mixture, which was extracted with EtOAc (3x).   Layers were separated 
and solvent was removed under reduced pressure to afford the crude product.  The crude product was 
QC/purified by an automated preparative reverse phase HPLC (detected by mass spectroscopy).   
General Procedure B: one-pot, sequential 4-component (sulfonylation, Michael, amide coupling and 
Click).  To a pressure tube containing a solution of amine (1.0 mmol, 1.05 equiv.) in dry CH2Cl2 (0.5 M), was 
added Et3N (1.91 mmol, 2.0 equiv.).  The reaction mixture was stirred for 20 min and 2 chloroethane sulfonyl 
chloride (0.96 mmol, 1.0 equiv.) was added in a drop-wise fashion.  The reaction was left to stir overnight and 
CH2Cl2 was removed in vacuo upon completion of the reaction.  MeOH/water (0.5 M, 5:1), Et3N (2.87 mmol, 
3.0 equiv.) and amino acid (1.0 mmol, 1.05 equiv.) were added to the reaction mixture, which was stirred at 60 
ºC for 12 h, after which solvents were evaporated to dryness.  DMF (0.08 M) EDC (1.91 mmol, 2.0 equiv.), 
HOBt (0.48 mmol, 0.5 equiv.) and Et3N (1.91 mmol, 2.0 equiv.) were added to the crude mixture.  The reaction 
was stirred at rt for 12 h. Upon completion of the reaction it was divided into small vials of equal volume 
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followed by evaporation of the DMF on a genevac. Dissolution of the crude reactions in (0.5 M, CH2Cl2, t-
BuOH, and water in a 1:1:1 ratio) was followed by the addition of CuSO4, L-sodium Ascorbate and the azide. 
The reaction was run at r.t. for 12 hours. Water was added to the crude mixture, which was extracted with 
EtOAc (3x).   Layers were separated and solvent was removed under reduced pressure to afford the crude 
product.  The crude product was QC/purified by an automated preparative reverse phase HPLC (detected by 
mass spectroscopy).   
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(8R,9aS)-2-allyl-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl isopropylcarbamate 
(NA-7-278-I-A) 3.4.1(1){1} 
 
According to general procedure C, 3.4.1(1){1} (58.2 mg, 24%) as yellow oil. 
[α]D20  = +49.1° (c = 0.239, CH2Cl2); 
FTIR (thin film) 1703, 1693, 1596, 1537, 1485, 1427, 1353, 1274, 1224, 1151, 1078, 1022 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 5.86 (dddd, J = 17.1, 10.3, 6.2, 5.4 Hz, 1H), 5.33 (dddd, J = 17.1, 1.5, 
1.4, 1.4 Hz, 1H), 5.22 (dddd, J = 10.2, 1.2, 1.2, 1.2 Hz, 1H), 5.08 (p, J = 3.7 Hz, 1H), 4.56 (d, J = 6.9 Hz, 1H), 
4.49 – 4.39 (m, 2H), 4.34 (t, J = 7.9 Hz, 1H), 3.86 – 3.72 (m, 1H), 3.56 (dd, J = 11.3, 4.3 Hz, 1H), 3.49 – 3.35 
(m, 3H), 3.31 – 3.21 (m, 1H), 2.80 – 2.65 (m, 2H), 2.15 – 2.06 (m, 1H), 1.17 (d, J = 3.0 Hz, 3H), 1.16 (d, J = 
3.0 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.6, 154.7, 131.9, 118.4, 73.2, 64.5, 62.6, 56.6, 53.0, 47.6, 43.1, 34.33, 22.98 
(2); 
HRMS calculated for C14H23N3O5SH (M + H)+ 346.1437; found 346.1435 (TOF MS ES+). 
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(8R,9aS)-2-allyl-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (2,3-
dichlorophenyl)carbamate (NA-7-278-I-B) 3.4.1(1){2} 
 
According to general procedure C, 3.4.1(1){2} (130.0 mg, 24%) as yellow oil. 
[α]D20  = +37.2° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2960, 2923, 1728, 1701, 1487, 1434, 1353, 1313, 1226, 1151, 1089, 1047, 952, 848, 734 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 8.10 (d, J = 7.8 Hz, 1H), 7.25 – 7.18 (m, 3H), 5.88 (dddd, J = 17.1, 10.2, 
6.3, 5.3 Hz, 1H), 5.35 (dddd, J = 17.1, 1.5, 1.4, 1.4 Hz, 1H), 5.26 – 5.19 (m, 2H), 4.52 – 4.40 (m, 3H), 3.64 (dd, 
J = 11.2, 4.6 Hz, 1H), 3.54 – 3.37 (m, 3H), 3.32 – 3.27 (m, 1H), 2.91 – 2.82 (m, 2H), 2.22 (dddd, J = 13.9, 8.2, 
4.1, 1.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.4, 152.2, 136.0, 132.9, 131.9, 127.8, 124.7, 120.8, 118.5, 117.8, 74.3, 64.2, 
62.1, 56.5, 52.6, 47.7, 33.9; 
HRMS calculated for C17H19Cl2N3O5SH (M + H)+ 448.0501; found 448.0499 (TOF MS ES+). 
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(8R,9aS)-2-allyl-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (3,5-
dimethylphenyl)carbamate (NA-7-278-I-C) 3.4.1(1){3} 
 
According to general procedure C, 3.4.1(1){3} (67.0 mg, 24%) as yellow oil. 
[α]D20  = +48.5° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3249, 3215, 1728, 1703, 1614, 1541, 1510, 1353, 1307, 1218, 1174, 1151, 1045, 1024, 835 
cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.02 (s, 2H), 6.73 (s, 1H), 6.65 (s, 1H), 5.87 (dddd, J = 17.1, 10.3, 6.2, 
5.3 Hz, 1H), 5.35 (dddd, J = 17.1, 1.4, 1.4, 1.4 Hz, 1H), 5.24 (dddd, J = 10.2, 1.1, 1.1, 1.1 Hz, 1H), 5.21 – 5.15 
(m, 1H), 4.48 – 4.43 (m, 1H), 4.41 (t, J = 7.9 Hz, 1H), 3.62 (dd, J = 11.6, 4.4 Hz, 1H), 3.52 – 3.44 (m, 1H), 3.44 
– 3.36 (m, 2H), 3.28 (ddd, J = 12.0, 3.2, 3.2 Hz, 1H), 2.84 (ddd, J = 11.5, 3.3, 1.7 Hz, 1H), 2.82 – 2.74 (m, 1H), 
2.30 (s, 6H) 2.22 – 2.15 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ 170.5, 152.6, 138.8 (2), 137.3, 131.9, 125.4 (2), 118.5, 116.4, 64.5, 62.5, 56.6, 
53.0, 47.6, 34.2, 30.9, 21.4 (2); 
HRMS calculated for C19H25N3O5SH (M + H)+ 408.1593; found 408.1594 (TOF MS ES+). 
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(8R,9aS)-2-allyl-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (3-
bromophenyl)carbamate (NA-7-278-I-E) 3.4.1(1){5} 
 
According to general procedure C, 3.4.1(1){5} (128.4 mg, 24%) as yellow oil. 
[α]D20  = +36.2° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3218, 3049, 1778, 1591, 1481, 1383, 1319, 1174, 1130, 1033, 952, 827 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.50 – 7.36 (m, 3H), 7.32 (d, J = 8.3 Hz, 2H), 5.86 (dddd, J = 17.1, 10.2, 
6.2, 5.3 Hz, 1H), 5.33 (dddd, J = 17.1, 1.4, 1.4, 1.4 Hz, 1H), 5.22 (dddd, J = 10.3, 1.2, 1.2, 1.2 Hz, 1H), 5.20 – 
5.16 (m, 1H), 4.49 – 4.37 (m, 3H), 3.61 (dd, J = 11.5, 4.3 Hz, 1H), 3.52 – 3.45 (m, 1H), 3.45 – 3.34 (m, 2H), 
3.27 (dt, J = 12.5, 3.4 Hz, 1H), 2.83 (ddd, J = 11.6, 3.2, 1.7 Hz, 1H), 2.80 – 2.73 (m, 1H), 2.20 – 2.13 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.5, 152.6, 137.0, 131.9, 131.8, 129.3, 128.3, 120.3, 118.5, 115.9, 64.4, 62.4, 
56.6, 53.0, 47.6, 34.2, 30.9; 
HRMS calculated for C17H20BrN3O5SH (M + H)+ 458.0385; found 458.0392 (TOF MS ES+). 
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(8R,9aS)-2-allyl-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (2,5-
dichlorophenyl)carbamate (NA-7-278-I-I) 3.4.1(1-{9}) 
 
According to general procedure C, 3.4.1(1-{9}) (220.2 mg, 24%) as yellow oil. 
[α]D20  = +28.9° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3240, 3174, 3053, 2960, 1728, 1703, 1596, 1539, 1515, 1427, 1353, 1224, 1151, 1047, 1024, 
950, 877, 779, 734, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 8.24 (s, 1H), 7.29 (d, J = 8.6 Hz, 1H), 7.15 (s, 1H), 7.01 (dd, J = 8.6, 2.4 
Hz, 1H), 5.88 (dddd, J = 17.1, 10.2, 6.2, 5.4 Hz, 1H), 5.35 (dddd, J = 17.2, 1.4, 1.4, 1.4 Hz, 1H), 5.26 – 5.19 (m, 
2H), 4.52 – 4.40 (m, 3H), 3.64 (dd, J = 11.2, 4.6 Hz, 1H), 3.54 – 3.37 (m, 3H), 3.29 (dt, J = 16.0, 3.5 Hz, 1H), 
2.90 – 2.82 (m, 2H), 2.22 (dddd, J = 13.9, 8.2, 4.1, 1.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.4, 152.0, 135.2, 133.6, 131.9, 129.8, 123.9, 120.1, 119.7, 118.6, 74.5, 64.2, 
62.1, 56.5, 52.7, 47.7, 33.9; 
HRMS calculated for C17H19Cl2N3O5SH (M + H)+ 448.0501; found 448.0477 (TOF MS ES+). 
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(8R,9aS)-2-(4-methylbenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl 
isopropylcarbamate (NA-7-278-II-A) 3.4.1(3-{1}) 
 
According to general procedure C, 3.4.1(1-{1}) (22.8 mg, 24%) as yellow oil. 
[α]D20  = +45.1° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2972, 1712, 1695, 1515, 1353, 1242, 1151, 1091, 1022, 885, 829, 732, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.29 (d, J = 7.9 Hz, 2H), 7.14 (d, J = 7.9 Hz, 2H), 5.13 (d, J = 15.0 Hz, 
1H), 5.11 – 5.05 (m, 1H), 4.86 (d, J = 15.0 Hz, 1H), 4.52 (d, J = 7.8 Hz, 1H), 4.38 (t, J = 7.9 Hz, 1H), 3.81 (h, J 
= 6.8, 6.2 Hz, 1H), 3.58 – 3.48 (m, 1H), 3.46 – 3.31 (m, 2H), 3.24 – 3.13 (m, 2H), 2.80 – 2.68 (m, 2H), 2.33 (s, 
3H), 2.15 – 2.04 (m, 1H), 1.18 (d, J = 3.6 Hz, 3H) 1.16 (d, J = 3.5 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.9, 154.7, 137.4, 133.4, 129.2 (2), 128.4 (2), 73.3, 64.4, 62.5, 56.6, 52.9, 
48.3, 43.1, 34.4, 23.0 (2), 21.1; 
HRMS calculated for C19H27N3O5SH (M + H)+ 410.1750; found 410.1720 (TOF MS ES+). 
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(8R,9aS)-2-(4-methylbenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (3-
chlorophenyl)carbamate (NA-7-278-II-F) 3.4.1(3-{6}) 
 
According to general procedure C, 3.4.1(3-{6}) (41.8 mg, 24%) as yellow oil. 
[α]D20  = +46.3° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3380, 3176, 1703, 1693, 1596, 1515, 1485, 1427, 1353, 1307, 1224, 1151, 1078, 1022, 952, 
896 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.54 (s, 1H), 7.31 – 7.27 (m, 2H), 7.24 – 7.19 (m, 2H), 7.14 (d, J = 7.0 
Hz, 2H), 7.08 – 7.03 (m, 1H), 6.96 (s, 1H), 5.20 (ddd, J = 8.2, 4.4, 3.8 Hz, 1H), 5.14 (d, J = 15.0 Hz, 1H), 4.86 
(d, J = 15.0 Hz, 1H), 4.43 (t, J = 7.9 Hz, 1H), 3.61 (dd, J = 11.5, 4.4 Hz, 1H), 3.50 – 3.41 (m, 1H), 3.40 – 3.32 
(m, 1H), 3.26 – 3.15 (m, 2H), 2.85 – 2.78 (m, 2H), 2.33 (s, 3H), 2.21 – 2.13 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.7, 152.4, 138.8, 137.5, 134.8, 133.3, 130.0, 129.2 (2), 128.4 (2), 123.6, 
118.6, 116.5, 74.2, 64.3, 62.3, 56.5, 52.8, 48.3, 34.2, 21.1; 
HRMS calculated for C22H24ClN3O5SH (M + H)+ 478.1203; found 478.1190 (TOF MS ES+). 
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(8R,9aS)-2-(4-methylbenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (3-
fluorophenyl)carbamate (NA-7-278-II-G) 3.4.1(3-{7}) 
 
According to general procedure C, 3.4.1(3-{7}) (33.5 mg, 24%) as yellow oil. 
[α]D20  = +29.6° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3281, 2959, 1778, 1512, 1445, 1383, 1325, 1143, 1086, 1059, 820 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.40 – 7.32 (m, 2H), 7.31 – 7.28 (m, 2H), 7.16 – 7.12 (m, 2H), 7.05 – 
6.99 (m, 2H), 6.83 (s, 1H), 5.20 (ddd, J = 8.2, 4.5, 3.7 Hz, 1H), 5.14 (d, J = 15.0 Hz, 1H), 4.86 (d, J = 15.0 Hz, 
1H), 4.43 (t, J = 7.9 Hz, 1H), 3.60 (dd, J = 11.5, 4.3 Hz, 1H), 3.52 – 3.40 (m, 1H), 3.39 – 3.33 (m, 1H), 3.25 – 
3.15 (m, 2H), 2.84 – 2.75 (m, 2H), 2.33 (s, 3H), 2.21 – 2.11 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.7, 159.0 (1JC–F = 247.23 Hz), 152.7, 137.5, 133.3 (2), 129.2 (2), 128.4 (2), 
120.3, 115.7 (2J = 22.61 Hz, (2)), 74.02, 64.3, 62.3, 56.5, 52.8, 48.3, 34.2, 30.9, 21.1; 
HRMS calculated for C22H24FN3O5SH (M + H)+ 462.1499; found 462.1497 (TOF MS ES+). 
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(8R,9aS)-2-(4-methylbenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (3-
methoxyphenyl)carbamate (NA-7-278-II-J) 3.4.1(3-{10}) 
 
According to general procedure C, 3.4.1(3-{10}) (28.0 mg, 24%) as yellow oil. 
[α]D20  = +39.1° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2997, 2968, 1699, 1604, 1593, 1539, 1510, 1409, 1379, 1352, 1305, 1220, 1182, 1151, 1089, 
1014, 833 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.31 – 7.28 (m, 2H), 7.21 (t, J = 8.1 Hz, 1H), 7.16 – 7.11 (m, 3H), 6.91 – 
6.86 (m, 1H), 6.78 (s, 1H), 6.64 (ddd, J = 8.3, 2.5, 0.9 Hz, 1H), 5.20 (ddd, J = 8.2, 4.5, 3.7 Hz, 1H), 5.14 (d, J = 
15.0 Hz, 1H), 4.86 (d, J = 15.0 Hz, 1H), 4.43 (t, J = 7.9 Hz, 1H), 3.81 (s, 3H), 3.61 (dd, J = 11.4, 4.3 Hz, 1H), 
3.51 – 3.40 (m, 1H), 3.39 – 3.32 (m, 1H), 3.25 – 3.14 (m, 2H), 2.86 – 2.75 (m, 2H), 2.33 (s, 3H), 2.21 – 2.13 
(m, 1H); 
13C NMR  (126 MHz, CDCl3) δ 170.76, 160.3, 152.5, 138.8, 137.5, 133.3, 129.8 (2), 129.2 (2), 128.4 (2), 109.4 
(2), 74.0, 64.3, 62.3, 56.5, 55.3, 52.9, 48.3, 34.2, 21.1; 
HRMS calculated for C23H27N3O6SH (M + H)+ 474.1699; found 474.1696 (TOF MS ES+). 
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(8R,9aS)-2-(4-methylbenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (4-
phenoxyphenyl)carbamate (NA-7-278-II-L) 3.4.1(3-{11}) 
 
According to general procedure C, 3.4.1(3-{11}) (42.5 mg, 24%) as yellow oil. 
[α]D20  = +42.2° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3053, 3039, 2956, 1710, 1589, 1546, 1504, 1488, 1431, 1413, 1353, 1307, 1222, 1151, 1047, 
1024, 950, 871, 842, 779, 736, 692, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.42 – 7.26 (m, 5H), 7.19 – 7.02 (m, 4H), 7.01 – 6.93 (m, 4H), 5.19 (ddd, 
J = 8.2, 4.4, 3.6 Hz, 1H), 5.13 (d, J = 15.0 Hz, 1H), 4.86 (d, J = 15.0 Hz, 1H), 4.43 (t, J = 7.9 Hz, 1H), 3.60 (dd, 
J = 11.4, 4.3 Hz, 1H), 3.49 – 3.40 (m, 2H), 3.39 – 3.31 (m, 1H), 3.25 – 3.15 (m, 2H), 2.85 – 2.75 (m, 2H), 2.32 
(s, 3H), 2.20 – 2.13 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.7, 158.0, 156.2, 148.8, 137.4, 133.3, 129.9 (2), 129.64 (2), 129.1 (2), 128.4 
(2), 124.0, 122.9, 119.8, 119.6, 118.8, 118.2, 73.9, 64.3, 62.4, 56.5, 52.9, 48.3, 34.2, 21.1; 
HRMS calculated for C28H29N3O6SH (M + H)+ 536.1855; found 536.1835 (TOF MS ES+). 
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(8R,9aS)-2-(4-methylbenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (3-
cyanophenyl)carbamate (NA-7-278-II-O) 3.4.1(3-{13}) 
 
According to general procedure C, 3.4.1(3-{13}) (27.0 mg, 24%) as yellow oil. 
[α]D20  = +26.9° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2950, 1770, 1731, 1699, 1591, 1558, 1506, 1434, 1352, 1226, 1149 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.84 (s, 1H), 7.59 (d, J = 8.6 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.36 (dt, J 
= 7.7, 1.3 Hz, 1H), 7.31 – 7.27 (m, 3H), 7.16 – 7.12 (m, 2H), 5.22 (ddd, J = 8.2, 4.4, 3.8 Hz, 1H), 5.14 (d, J = 
15.0 Hz, 1H), 4.87 (d, J = 15.0 Hz, 1H), 4.44 (t, J = 7.9 Hz, 1H), 3.62 (dd, J = 11.5, 4.3 Hz, 1H), 3.51 – 3.41 
(m, 1H), 3.40 – 3.34 (m, 1H), 3.26 – 3.16 (m, 2H), 2.86 – 2.79 (m, 2H), 2.33 (s, 3H), 2.21 – 2.14 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.7, 152.6, 138.7, 137.5, 133.3, 129.9 (2), 129.2 (2), 128.4, 127.0, 122.6, 
121.5, 118.5, 113.1, 74.4, 64.3, 62.2, 56.5, 52.8, 48.3, 34.2, 21.1; 
HRMS calculated for C23H24N4O5SH (M + H)+ 469.1546; found 469.1533 (TOF MS ES+). 
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(8R,9aS)-2-(4-methylbenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (3-
fluorophenyl)carbamate (NA-7-278-II-Q) 3.4.1(3-{7}) 
 
According to general procedure C, 3.4.1(3-{7}) (32.2 mg, 24%) as yellow oil. 
[α]D20  = +33.2° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3064,3026, 2975, 1726, 1703, 1608, 1546, 1533, 1494, 1446, 1353, 1226, 1151, 1056, 1043, 
1024, 972, 952, 883, 777, 734, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.37 – 7.31 (m, 1H), 7.31 – 7.21 (m, 3H), 7.14 (d, J = 7.9 Hz, 2H), 7.04 
(d, J = 8.2 Hz, 1H), 6.99 (s, 1H), 6.77 (tdd, J = 8.2, 2.5, 0.9 Hz, 1H), 5.21 (ddd, J = 8.2, 3.9, 3.9 Hz, 1H), 5.14 
(d, J = 14.9 Hz, 1H), 4.86 (d, J = 15.0 Hz, 1H), 4.43 (t, J = 7.9 Hz, 1H), 3.61 (dd, J = 11.5, 4.4 Hz, 1H), 3.51 – 
3.41 (m, 1H), 3.40 – 3.32 (m, 1H), 3.25 – 3.15 (m, 2H), 2.85 – 2.77 (m, 2H), 2.33 (s, 3H), 2.22 – 2.13 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.7, 164.1 (1JC–F = 245.53 Hz), 152.3, 139.2 (3JC–F = 11.10 Hz), 137.5, 133.3, 
130.1 (5JC–F = 9.37 Hz), 129.2 (2), 128.4 (2), 113.8, 110.3, (2JC–F = 21.45 Hz), 106.1 (6JC–F = 25.97 Hz), 74.1, 
64.3, 62.3, 56.5, 52.8, 48.3, 34.2, 21.1; 
HRMS calculated for C22H24FN3O5SH (M + H)+ 462.1499; found 462.1472 (TOF MS ES+). 
  
N
NS
OO
O
O
O
H
N
Me
F
 SI–228 
 
(8R,9aS)-2-(4-fluorobenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl 
isopropylcarbamate (NA-7-278-III-A) 3.4.1(2-{1}) 
 
According to general procedure C, 3.4.1(2-{1}) (77.8 mg, 24%) as yellow oil. 
M.P. 95 – 99ºC  
[α]D20  = +45.3° (c = 0.239, CH2Cl2);   
FTIR (thin film) 3388, 2972, 2931, 1701, 1510, 1353, 1244, 1222, 1151, 1093, 1076, 1058, 1024, 954, 902, 
885, 840, 779, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.41 – 7.36 (m, 2H), 7.03 – 6.98 (m, 2H), 5.11 – 5.05 (m, 2H), 4.87 (d, J 
= 15.0 Hz, 1H), 4.58 (d, J = 8.1 Hz, 1H), 4.35 (t, J = 7.9 Hz, 1H), 3.85 – 3.75 (m, 1H), 3.53 (dd, J = 11.4, 4.4 
Hz, 1H), 3.45 – 3.33 (m, 2H), 3.24 – 3.11 (m, 2H), 2.77 – 2.66 (m, 2H), 2.14 – 2.05 (m, 1H), 1.17 (d, J = 3.1 
Hz, 3H), 1.15 (d, J = 3.1 Hz, 3H); 
13C NMR (126 MHz, CDCl3) δ 170.9, 162.2 (1JC–F = 244.94 Hz), 154.7, 132.2 (4JC–F = 3.22 Hz), 130.4 (3JC–F = 
8.17 Hz) (2), 115.4(2JC–F = 21.36 Hz) (2), 73.1, 64.4, 62.5, 56.6, 52.9, 47.7, 43.1, 34.3, 23.0 (2); 
HRMS calculated for C18H24FN3O5SH (M + H)+ 414.1499; found 414.1476 (TOF MS ES+). 
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(8R,9aS)-2-(4-fluorobenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (2,3-
dichlorophenyl)carbamate (NA-7-278-III-B) 3.4.1(2-{2}) 
 
According to general procedure C, 3.4.1(2-{12}) (112.1 mg, 24%) as yellow oil. 
[α]D20  = +26.3° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2989, 2956, 1741, 1693, 1591, 1413, 1348, 1215, 1157, 1026, 964, 952, 877, 854, 775 551 
cm1; 
1H NMR (500 MHz, Chloroform-d) δ 8.08 (d, J = 7.5 Hz, 1H), 7.43 – 7.36 (m, 2H), 7.28 – 7.17 (m, 3H), 7.04 – 
6.98 (m, 2H), 5.21 (ddd, J = 8.5, 5.7, 4.2 Hz, 1H), 5.10 (d, J = 15.0 Hz, 1H), 4.88 (d, J = 15.0 Hz, 1H), 4.44 (t, J 
= 7.7 Hz, 1H), 3.60 (dd, J = 11.0, 4.5 Hz, 1H)), 3.51 – 3.36 (m, 2H), 3.28 – 3.13 (m, 2H), 2.90 – 2.80 (m, 2H), 
2.25 – 2.18 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.7, 162.1 (1JC–F = 245.86 Hz), 152.1, 136.0, 132.8, 132.2 (4JC–F = 3.22 Hz), 
130.4 (3JC–F = 8.27 Hz) (2), 127.8 (2), 124.7, 117.9, 115.4 (2JC–F = 21.56 Hz) (2), 74.2, 64.1, 61.9, 56.5, 52.5, 
47.8, 33.9; 
HRMS calculated for C21H20Cl2FN3O5SH (M + H)+ 516.0563; found 516.0554 (TOF MS ES+). 
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(8R,9aS)-2-(4-fluorobenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl 
phenylcarbamate (NA-7-278-III-D) 3.4.1(2-{4}) 
 
According to general procedure C, 3.4.1(2-{4}) (91.2 mg, 24%) as yellow oil. 
[α]D20  = +46.5° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3245, 3039, 3014, 1724, 1704, 1602, 1544, 1510, 1444, 1353, 1315, 1224, 1151, 1047, 1027, 
952, 889, 840, 759, 694, 607, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.42 – 7.37 (m, 4H), 7.33 – 7.28 (m, 2H), 7.07 (tt, J = 7.3, 1.2 Hz, 1H), 
7.04 – 6.98 (m, 3H), 5.20 (ddd, J = 8.1, 4.0, 3.5 Hz, 1H), 5.09 (d, J = 15.0 Hz, 1H), 4.88 (d, J = 15.0 Hz, 1H), 
4.41 (t, J = 7.9 Hz, 1H), 3.60 (dd, J = 11.2, 4.4 Hz, 1H), 3.50 – 3.43 (m, 1H), 3.41 – 3.35 (m, 1H), 3.26 – 3.12 
(m, 2H), 2.85 – 2.74 (m, 2H), 2.21 – 2.13 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.8, 162.2 (1JC–F = 246.60 Hz), 152.6, 137.6, 132.2 (4JC–F = 3.23 Hz), 130.4 
(3JC–F = 8.25 Hz) (2), 129.03 (3), 123.6, 118.5, 115.3 (2JC–F = 21.56 Hz) (2), 73.81, 64.3, 62.3, 56.6, 52.9, 47.8, 
34.2; 
HRMS calculated for C21H22FN3O5SH (M + H)+ 448.1342; found 448.1315 (TOF MS ES+). 
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(8R,9aS)-2-(4-fluorobenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (2,6-
difluorophenyl)carbamate (NA-7-278-III-H) 3.4.1(2-{8}) 
 
According to general procedure C, 3.4.1(2-{8}) (36.7 mg, 24%) as yellow oil. 
[α]D20  = +39.1° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3184, 2952, 1721, 1716, 1699, 1510, 1471, 1353, 1296, 1242, 1222, 1151, 1008, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.42 – 7.36 (m, 2H), 7.21 (dddd, J = 8.5, 8.4, 6.1, 6.1 Hz, 1H), 7.04 – 
6.94 (m, 4H), 6.29 (s, 1H), 5.23 – 5.19 (m, 1H), 5.09 (d, J = 15.0 Hz, 1H), 4.87 (d, J = 15.0 Hz, 1H), 4.37 (t, J = 
6.2 Hz, 1H), 3.59 (dd, J = 11.6, 4.2 Hz, 1H), 3.41 – 3.33 (m, 2H), 3.24 – 3.11 (m, 2H), 2.86 – 2.72 (m, 2H), 
2.22 – 2.15 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.8, 162.3 (d, 1JC–F = 244.40 Hz), 158.8 (dd, 2'JC–F = 250.69, 4.57 Hz) (2), 
153.0, 132.2 (d, 4JC–F = 3.48 Hz), 130.4 (d, 3JC–F = 8.12 Hz) (2), 127.6 (t, 4'JC–F = 9.58 Hz), 115.4 (d, 2JC–F = 
22.58 Hz) (2), 113.8 (t, 1'JC–F = 16.70 Hz), 111.87 (dd, 3'JC–F = 19.07, 4.51 Hz) (2), 74.9, 64.3, 62.2, 56.6, 52.8, 
47.8, 34.3; 
HRMS calculated for C21H20F3N3O5SH (M + H)+ 484.1154; found 484.1150 (TOF MS ES+). 
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(8R,9aS)-2-(4-fluorobenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (2,5-
dichlorophenyl)carbamate (NA-7-278-III-I) 3.4.1(2-{9}) 
 
 
According to general procedure C, 3.4.1(2-{9}) (134.5 mg, 24%) as yellow oil. 
[α]D20  = +25.3° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2954, 2923, 1701, 1602, 1529, 1348, 1224, 1151, 1043, 1024, 829, 636 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 8.24 (s, 1H), 7.44 – 7.38 (m, 2H), 7.29 (d, J = 8.6 Hz, 1H), 7.15 (s, 1H), 
7.07 – 6.99 (m, 3H), 5.25 – 5.19 (m, 1H), 5.11 (d, J = 15.0 Hz, 1H), 4.89 (d, J = 15.0 Hz, 1H), 4.44 (t, J = 7.7 
Hz, 1H), 3.62 (dd, J = 11.3, 4.6 Hz, 1H), 3.51 – 3.37 (m, 2H), 3.27 – 3.13 (m, 2H), 2.91 – 2.81 (m, 2H), 2.21 
(dddd, J = 12.4, 8.1, 4.2, 2.1 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.7, 163.3 (1JC–F = 246.72 Hz), 152.0, 135.2, 133.6, 132.2 (4JC–F = 3.36 Hz), 
130.4 (3JC–F = 8.28 Hz) (2), 129.8, 123.9, 120.1, 119.7, 115.4 (2JC–F = 21.44 Hz) (2), 74.4, 64.1, 62.0, 56.5, 
52.5, 47.8, 33.9; 
HRMS calculated for C21H20Cl2FN3O5SH (M + H)+ 516.0563; found 516.0543 (TOF MS ES+). 
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(8R,9aS)-2-(4-fluorobenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (3-
methoxyphenyl)carbamate (NA-7-278-III-J) 3.4.1(2-{10}) 
 
 
According to general procedure C, 3.4.1(2-{10}) (134.5 mg, 24%) as yellow oil. 
[α]D20  = +27.8° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3390, 3240, 3056, 2999, 2916, 1701, 1596, 1541, 1510, 1483, 1427, 1353, 1224, 1151, 1045, 
1026, 952, 877, 852, 781, 734, 696, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.42 – 7.36 (m, 2H), 7.19 (t, J = 8.1 Hz, 1H), 7.13 (s, 1H), 7.05 (s, 1H), 
7.03 – 6.96 (m, 2H), 6.89 (dd, J = 8.0, 2.5 Hz, 1H), 6.62 (ddd, J = 8.3, 2.5, 0.9 Hz, 1H), 5.19 (ddd, J = 7.6, 3.7, 
3.7 Hz, 1H), 5.09 (d, J = 15.0 Hz, 1H), 4.87 (d, J = 15.0 Hz, 1H), 4.41 (t, J = 7.9 Hz, 1H), 3.79 (s, 3H), 3.59 
(dd, J = 11.5, 4.3 Hz, 1H), 3.50 – 3.34 (m, 2H), 3.25 – 3.11 (m, 2H), 2.85 – 2.74 (m, 2H), 2.21 – 2.12 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.8, 163.2 (1JC–F = 244.30 Hz), 160.2, 152.5, 138.8, 132.2 (4JC–F = 3.28 Hz), 
130.4 (3JC–F = 8.02 Hz) (2), 129.7, 115.4 (2JC–F = 21.43 Hz) (2), 110.7, 109.3, 104.2, 73.8, 64.3, 62.3, 56.6, 
55.2, 52.9, 47.7, 34.2; 
HRMS calculated for C22H24FN3O6SH (M + H)+ 478.1448; found 478.1444 (TOF MS ES+). 
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(8R,9aS)-2-(4-fluorobenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl tert-
butylcarbamate (NA-7-278-III-W) 3.4.1(2-{16}) 
 
According to general procedure C, 3.4.1(2-{16}) (66.8 mg, 24%) as yellow oil. 
[α]D20  = +24.9° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2995, 2974, 1720, 1701, 1512, 1433, 1353, 1224, 1153, 1045, 1024, 952, 838, 821, 783, 734, 
555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.42 – 7.36 (m, 2H), 7.04 – 6.98 (m, 2H), 5.10 (d, J = 15.0 Hz, 1H), 5.05  
(bs, 1H), 4.87 (d, J = 15.0 Hz, 1H), 4.65 (s, 1H), 4.35 (t, J = 7.6 Hz, 1H), 3.53 (dd, J = 11.2, 3.9 Hz, 2H), 3.47 – 
3.33 (m, 2H), 3.24 – 3.12 (m, 2H), 2.77 – 2.67 (m, 2H), 2.13 – 2.05 (m, 1H), 1.32 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ 170.9, 163.3 (1JC–F = 246.99 Hz), 153.8, 132.2 (4JC–F = 3.41 Hz), 130.4 (3JC–F = 
8.32 Hz) (2), 115.4 (2JC–F = 21.44 Hz) (2), 72.7, 64.4, 62.5, 56.6, 52.9, 50.5, 47.7, 34.3, 28.8 (3); 
HRMS calculated for C19H27FN3O5SH (M + H)+ 428.1655; found 428.1638 (TOF MS ES+). 
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(8R,9aS)-2-(4-fluorobenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (4-
cyanophenyl)carbamate (NA-7-278-III-R) 3.4.1(2-{15}) 
 
According to general procedure C, 3.4.1(2-{15}) (104.6 mg, 24%) as yellow oil. 
[α]D20  = +34.5° (c = 0.239, CH2Cl2); 
FTIR (thin film) 238, 2341, 1730, 1701, 1598, 1529, 1510, 1413, 1353, 1222, 1151, 1047, 1024, 840, 732, 555 
cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.64 – 7.60 (m, 2H), 7.55 – 7.51 (m, 2H), 7.44 – 7.38 (m, 2H), 7.06 – 
6.99 (m, 3H), 5.27 – 5.19 (m, 1H), 5.11 (d, J = 15.0 Hz, 1H), 4.89 (d, J = 15.0 Hz, 1H), 4.43 (t, J = 7.9 Hz, 1H), 
3.62 (dd, J = 11.5, 4.4 Hz, 1H), 3.52 – 3.36 (m, 2H), 3.28 – 3.14 (m, 2H), 2.87 – 2.80 (m, 2H), 2.23 – 2.15 (m, 
1H); 
13C NMR (126 MHz, CDCl3) δ 170.6, 162.3 (1JC–F = 246.20 Hz), 151.9, 141.6, 133.4 (2), 132.1 (4JC–F = 3.30 
Hz), 130.5 (3JC–F = 8.16 Hz) (2), 118.8, 118.3 (2), 115.4 (2JC–F = 21.63 Hz) (2), 106.7, 74.5, 64.2, 62.1, 56.6, 
52.7, 47.8, 34.1; 
HRMS calculated for C22H21FN4O5SH (M + H)+ 473.1295; found 473.1271 (TOF MS ES+). 
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(8R,9aS)-2-(4-fluorobenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (2-chloro-5-
(trifluoromethyl)phenyl)carbamate 3.4.1(NA-7-278-III-N) (2-{12}) 
 
According to general procedure C, 3.4.1(2-{12}) (80.6 mg, 24%) as yellow oil. 
[α]D20  = +37.8° (c = 0.239, CH2Cl2); 
FTIR (thin film) 1730, 1701, 1604, 1591, 1529, 1210, 1433, 1355, 1332, 1220, 1170, 1153, 1128, 1083, 1045, 
896, 885, 823, 734, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 8.51 (s, 1H), 7.49 (dd, J = 8.4, 1.0 Hz, 1H), 7.43 – 7.37 (m, 2H), 7.30 – 
7.26 (m, 2H), 7.05 – 6.99 (m, 2H), 5.25 – 5.20 (m, 1H), 5.11 (d, J = 15.0 Hz, 1H), 4.88 (d, J = 15.0 Hz, 1H), 
4.44 (t, J = 7.7 Hz, 1H), 3.62 (dd, J = 11.3, 4.6 Hz, 1H), 3.50 – 3.36 (m, 2H), 3.27 – 3.14 (m, 2H), 2.93 – 2.81 
(m, 2H), 2.21 (dddd, J = 13.9, 8.2, 4.2, 1.4 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.6, 163.3 (1JC–F = 247.70 Hz), 152.1, 135.0, 132.1 (4JC–F = 3.27 Hz), 130.5 
(3JC–F = 8.14 Hz) (2), 130.0 (2'JC–F = 33.25 Hz), 129.6, 125.3, 123.4 (1'JC–F = 273.10 Hz), 120.4 (3'JC–F = 3.90 
Hz), 116.7, 115.5 (2JC–F = 21.55 Hz) (2), 74.5, 64.1, 61.9, 56.5, 52.5, 47.8, 33.9; 
HRMS calculated for C22H20ClF4N3O5SH (M + H)+ 550.0827; found 550.0805 (TOF MS ES+). 
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(8R,9aS)-2-(4-fluorobenzyl)-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5]thiadiazepin-8-yl (3-
cyanophenyl)carbamate (NA-7-278-III-O) 3.4.1(2-{13}) 
 
According to general procedure C, 3.4.1(2-{13}) (27.0 mg, 24%) as white solid. 
[α]D20  = +47.2° (c = 0.239, CH2Cl2); 
M.P. 106 – 110ºC 
FTIR (thin film) 3564, 2968, 2893, 1731, 1699, 1645, 1606, 1593, 1510, 1434, 1353, 1292, 1222, 1087, 1078, 
1024, 956, 883, 852, 790, 682 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.83 (s, 1H), 7.58 – 7.54 (m, 1H), 7.46 – 7.36 (m, 4H), 7.06 – 7.00 (m, 
2H), 6.77 (s, 1H), 5.25 – 5.20 (m, 1H), 5.11 (d, J = 15.0 Hz, 1H), 4.89 (d, J = 15.0 Hz, 1H), 4.43 (t, J = 7.9 Hz, 
1H), 3.62 (dd, J = 11.4, 4.3 Hz, 1H), 3.52 – 3.36 (m, 2H), 3.28 – 3.14 (m, 2H), 2.87 – 2.80 (m, 2H), 2.23 – 2.15 
(m, 1H); 
13C NMR (126 MHz, CDCl3) δ 170.62 162.3 (1JC–F = 246.86 Hz), 152.2, 138.4, 132.1 (4JC–F = 3.29 Hz), 130.5 
(3JC–F = 8.29 Hz) (2), 130.0, 127.2, 122.6, 121.5, 118.4, 115.4 (2JC–F = 21.44 Hz) (2), 113.3, 74.4, 64.2, 62.1, 
56.6, 52.7, 47.8, 34.1; 
HRMS calculated for C22H21FN4O5SH (M + H)+ 473.1295; found 473.1270 (TOF MS ES+). 
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(S)-2-((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-
one 3,3-dioxide (KC-1-153-III) 3.4.2(3)-[3] 
 
According to general procedure B, 3.4.2(3)-[3] (68.3 mg, 24%) as yellow oil. 
[α]D20  = +9.1° (c = 0.239, CH2Cl2); 
FTIR (thin film) 1704, 1512, 1352, 1222, 1153, 1053, 1020, 892, 844, 783 551 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.45 (s, 1H), 7.26 – 7.21 (m, 2H), 7.08 – 7.02 (m, 2H), 5.49 (d, J = 14.9 
Hz, 1H), 5.45 (d, J = 15.0 Hz, 1H), 5.13 (d, J = 15.6 Hz, 1H), 5.02 (d, J = 15.5 Hz, 1H), 4.10 (dd, J = 9.9, 2.5 
Hz, 1H), 3.64 (ddd, J = 14.1, 8.9, 7.5 Hz, 1H), 3.40 (dt, J = 14.2, 2.8 Hz, 1H), 3.24 (d, J = 2.8 Hz, 1H), 3.23 – 
3.20 (m, 1H), 3.03 (t, J = 7.3 Hz, 1H), 2.60 – 2.51 (m, 2H), 1.91 – 1.80 (m, 1H), 1.76 – 1.68 (m, 1H), 1.68 – 
1.56 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.4, 162.8 (1JC–F = 247.60 Hz), 144.0, 130.4 (4JC–F = 3.31 Hz), 129.8 
(3JC–F = 8.31 Hz, 2), 122.8, 116.1 (2J = 21.67 Hz, 2), 64.0, 57.7, 55.7, 53.3, 50.6, 41.0, 27.0, 24.5; 
HRMS calculated for C17H20FN5O3SH (M + H)+ 394.1349; found 394.1341 (TOF MS ES+). 
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(S)-2-((1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (KC-1-153-V) 3.4.2(3)-[5] 
 
According to general procedure B, 3.4.2(3)-[5] (80.2 mg, 24%) as yellow oil. 
[α]D20  = +8.6° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2972, 2947, 2829, 1704, 1444, 1382, 1353, 1325, 1121, 1178, 1153, 1116, 1066, 1051, 1020, 
892, 833, 775, 732, 595, 551 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.62 (d, J = 8.2 Hz, 2H), 7.50 (s, 1H), 7.34 (d, J = 8.1 Hz, 2H), 5.58 – 
5.55 (m, 2H), 5.15 (d, J = 15.5 Hz, 1H), 5.03 (d, J = 15.6 Hz, 1H), 4.09 (dd, J = 9.9, 2.4 Hz, 1H), 3.63 (ddd, J = 
14.2, 9.1, 7.3 Hz, 1H), 3.41 (dt, J = 14.2, 2.8 Hz, 1H), 3.24 (d, J = 2.8 Hz, 1H), 3.24 – 3.21 (m, 1H), 3.05 – 3.00 
(m, 1H), 2.60 – 2.51 (m, 2H), 1.91 – 1.80 (m, 1H), 1.76 – 1.68 (m, 1H), 1.67 –1.55 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 171.5, 144.2, 138.6, 131.5 (q, 2JC–F = 32.89 Hz), 128.1 (2), 126.03 (q, 3JC–F = 
3.79 Hz (2)), 123.6 (1JC–F = 271.73 Hz), 123.1, 64.0, 57.7, 55.8, 53.4, 50.6, 41.0, 27.0, 24.5; 
HRMS calculated for C18H20F3N5O3SH (M + H)+ 444.1317; found 444.1327 (TOF MS ES+). 
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(8R,9aS)-8-hydroxy-2-((1-(2-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (NA-6-219-A) 3.4.2(1)-[2] 
 
According to general procedure B, 3.4.2(1)-[2] (91.1 mg, 24%) as yellow oil. 
[α]D20  = +15.9° (c = 0.239, CH2Cl2); 
M.P. 201– 206ºC 
FTIR (thin film) 3334, 3315, 2927, 2835, 1701, 1629, 1431, 1377, 1352, 1326, 1218, 1172, 1151, 1101, 1053, 
1020, 898, 879, 850, 777, 734, 555 cm-1; 
1H NMR (500 MHz, Methanol-d4) δ 7.88 (s, 1H), 7.37 (td, J = 8.0, 5.9 Hz, 1H), 7.16 – 6.98 (m, 3H), 5.58 (s, 
1H), 5.04 (s, 2H), 4.31 (dd, J = 8.8, 5.7 Hz, 1H), 4.18 – 4.12 (m, 1H), 3.53 (ddd, J = 13.9, 3.3, 2.1 Hz, 1H), 3.45 
– 3.33 (m, 2H), 3.28 – 3.18 (m, 3H), 2.61 – 2.53 (m, 2H), 2.14 (s, 3H), 1.86 (dddd, J = 12.9, 8.9, 6.1, 1.0 Hz, 
1H); 
13C NMR (126 MHz, MeOD) δ 173.0, 145.6, 132.0, 125.6, 124.9, 116.5, 116.3, 116.0, 115.8, 70.6, 65.5, 65.1, 
57.2, 54.3, 54.2, 53.6, 41.1, 37.0; 
HRMS calculated for C18H23N5O4SH (M + H)+ 406.1549; found 406.1518 (TOF MS ES+). 
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(8R,9aS)-8-hydroxy-2-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (NA-6-219-B) 3.4.2(1)-[1] 
 
According to general procedure B, 3.4.2(1)-[1] (91.1 mg, 24%) as yellow oil. 
[α]D20  = +19.9° (c = 0.239, CH2Cl2); 
M.P. 206 – 209ºC 
FTIR (thin film) 3355, 3338, 3280, 2945, 2627, 2835, 1701, 1431, 1352, 1217, 1151, 1053, 1020, 898, 879, 
850, 825, 734, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.44 (s, 1H), 7.20 – 7.13 (m, 4H), 5.48 (d, J = 14.8 Hz, 1H), 5.43 (d, J = 
14.8 Hz, 1H), 5.11 (d, J = 15.6 Hz, 1H), 5.05 (d, J = 15.5 Hz, 1H), 4.44 (s, 1H), 4.32 (dddd, J = 5.3, 5.3, 5.2, 5.2 
Hz, 1H), 3.71 (s, 1H), 3.50 – 3.37 (m, 2H), 3.37 – 3.30 (m, 1H), 3.28 – 3.20 (m, 1H), 2.74 – 2.64 (m, 2H), 2.35 
(s, 3H), 1.94 (dt, J = 13.8, 7.4 Hz, 1H); 
13C NMR (126 MHz, Acetone) δ 175.6, 148.2, 142.3, 137.6, 133.8 (2), 132.1 (2), 127.3, 73.6, 68.5, 68.3, 60.0, 
57.4, 56.8, 44.9, 44.6, 24.6; 
HRMS calculated for C18H23N5O4SH (M + H)+ 406.1549; found 406.1549 (TOF MS ES+). 
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(8R,9aS)-2-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-8-hydroxyhexahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (NA-6-219-D) 3.4.2(1)-[4] 
 
According to general procedure B, 3.4.2(1)-[4] (24.8 mg, 24%) as yellow oil. 
[α]D20  = +13.8° (c = 0.239, CH2Cl2); 
M.P. 204 – 207ºC 
FTIR (thin film) 3143, 3074, 2945, 2837, 1704, 1631, 1433, 1352, 1220, 1151, 1053, 1020, 898, 879, 850, 734, 
555 cm-1; 
1H NMR (500 MHz, Methanol-d4) δ 7.82 (s, 1H), 7.40 – 7.26 (m, 5H), 5.56 (s, 2H), 5.03 (s, 2H), 4.30 (dd, J = 
8.8, 5.6 Hz, 1H), 4.14 (p, J = 5.7 Hz, 1H), 3.74 (dd, J = 12.2, 4.4 Hz, 1H), 3.69 – 3.58 (m, 1H), 3.56 – 3.41 (m, 
1H), 3.40 – 3.31 (m, 1H), 3.27 – 3.17 (m, 2H), 2.61 – 2.52 (m, 2H), 1.85 (dddd, J = 13.0, 8.9, 6.2, 1.0 Hz, 1H). 
 
13C NMR (126 MHz, MeOD) δ 173.0, 145.5, 137.0, 130.12 (2), 129.6 (2), 129.7, 125.3, 71.1, 65.5, 65.0, 57.1, 
55.1, 53.6, 41.15, 37.0; 
HRMS calculated for C17H21N5O4SH (M + H)+ 392.1392; found 392.1412 (TOF MS ES+). 
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(8R,9aS)-2-((1-(2-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-8-hydroxyhexahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (NA-6-219-FMe) 3.4.2(1)-[2] 
 
According to general procedure B, 3.4.2(1)-[2] (55.1 mg, 24%) as yellow oil. 
[α]D20  = +12.7° (c = 0.239, CH2Cl2); 
M.P. 215 – 219ºC 
FTIR (thin film) 3321, 3296, 3282, 2945, 2927, 1704, 1639, 1434, 1352, 1292, 1222, 1151, 1053, 1020, 900, 
879, 850, 734, 555 cm-1; 
1H NMR (500 MHz, Methanol-d4) δ 7.81 (s, 1H), 7.46 (dd, J = 7.9, 1.4 Hz, 1H), 7.39 – 7.25 (m, 3H), 7.21 (dd, 
J = 7.6, 1.7 Hz, 1H), 5.70 (s, 2H), 5.04 (s, 2H), 4.30 (dd, J = 8.9, 5.5 Hz, 1H), 4.17 – 4.09 (m, 1H), 3.59 – 3.48 
(m, 2H), 3.41 – 3.32 (m, 1H), 3.27 – 3.19 (m, 2H), 2.61 – 2.53 (m, 2H), 1.86 (dddd, J = 13.1, 9.0, 6.3, 0.9 Hz, 
1H); 
13C NMR (126 MHz, MeOD) δ 173.0, 145.2, 134.9, 134.3, 131.8, 131.6, 131.1, 128.9, 125.7, 70.6, 65.4, 65.0, 
57.1, 53.5, 52.7, 40.5, 37.0; 
HRMS calculated for C17H20ClN5O4SH (M + H)+ 426.1003; found 426.0995 (TOF MS ES+). 
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(8R,9aS)-2-((1-(2-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-8-hydroxyhexahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (NA-6-259) 3.4.2(1)-[13] 
 
According to general procedure B, 3.4.2(1)-[12] (85 mg, 24%) as yellow oil. 
[α]D20  = +19.1° (c = 0.239, CH2Cl2); 
FTIR (thin film) 3281, 2959, 1778, 1512, 1445, 1383, 1325, 1143, 1086, 1059, 820 cm-1; 
1H NMR (500 MHz, Methanol-d4) δ 7.88 (s, 1H), 7.37 (ddd, J = 8.2, 8.1, 5.9 Hz, 1H), 7.11 – 6.98 (m, 3H), 5.58 
(s, 2H), 5.04 (s, 2H), 4.31 (dd, J = 8.9, 5.7 Hz, 1H), 4.15 (p, J = 5.7 Hz, 1H), 3.53 (ddd, J = 13.9, 3.3, 2.1 Hz, 
1H), 3.44 – 3.34 (m, 2H), 3.27 – 3.18 (m, 3H), 2.61 – 2.53 (m, 2H) (dddd, J = 13.0, 8.9, 6.1, 1.0 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 173.0, 164.5 (1JC–F = 245.52 Hz), 145.6, 139.7 (3JC–F = 7.33 Hz), 132.0 (5JC–F = 
8.19 Hz), 125.6, 124.9 (4JC–F = 2.93 Hz), 116.4 (6JC–F = 21.21 Hz), 116.0 (2JC–F = 22.60 Hz), 70.6, 65.5, 65.1, 
57.2, 54.2, 53.6, 41.1, 37.0; 
HRMS calculated for C17H20ClN5O4SH (M + H)+ 410.1298; found 410.1443 (TOF MS ES+). 
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(R)-2-((1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (NA-6-274-VA) 3.4.2(2)-[5] 
 
According to general procedure B, 3.4.2(2)-[5] (110.7 mg, 24%) as yellow oil. 
[α]D20  = +29.6° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2970, 2945, 2827, 1704, 1444, 1382, 1352, 1211, 1180, 1153, 1051, 892, 775, 732, 551 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.62 (d, J = 7.7 Hz, 2H), 7.50 (s, 1H), 7.34 (d, J = 8.0 Hz, 2H), 5.56 (d, J 
= 2.1 Hz, 2H), 5.15 (d, J = 15.6 Hz, 1H), 5.03 (d, J = 15.5 Hz, 1H), 4.09 (dd, J = 9.9, 2.4 Hz, 1H), 3.63 (ddd, J 
= 14.1, 9.2, 7.3 Hz, 1H), 3.41 (dt, J = 14.2, 2.8 Hz, 1H), 3.24 (d, J = 2.8 Hz, 1H), 3.2 (t, J = 2.4 Hz, 1H), 3.03 – 
3.00 (m, 1H), 2.59 – 2.51 (m, 2H), 1.91 – 1.80 (m, 1H), 1.76 – 1.69 (m, 1H), 1.67 – 1.55 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 171.5, 144.2, 138.6, 131.5 (q, 2JC–F = 34.23 Hz), 128.1 (2), 126.1 (q, 3JC–F = 
3.82 Hz (2)), 123.6 (1JC–F = 271.73 Hz), 123.1, 64.0, 57.7, 55.8, 53.4, 50.6, 41.0, 27.0, 24.5; 
HRMS calculated for C18H20F3N5O3SH (M + H)+ 444.1317; found 444.1321 (TOF MS ES+). 
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(R)-2-((1-(3-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-
one 3,3-dioxide (NA-6-274-XIIIA) 3.4.2(2)-[12] 
 
According to general procedure B, 3.4.2(2)-[11] (68.8 mg, 24%) as yellow oil. 
[α]D20  = +25.3° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2972, 2948, 1704, 1589, 1494, 1352, 1232, 1215, 1151, 1051, 892, 846, 777, 732, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.55 (s, 1H), 7.38 – 7.32 (m, 1H), 7.22 (td, J = 7.6, 1.8 Hz, 1H), 7.16 – 
7.08 (m, 2H), 5.57 (s, 2H), 5.14 (d, J = 15.6 Hz, 1H), 5.07 (d, J = 15.5 Hz, 1H), 4.12 (dd, J = 9.9, 2.4 Hz, 1H), 
3.65 (ddd J = 14.2, 8.2, 8.2 Hz, 1H), 3.40 (dt, J = 14.1, 2.7 Hz, 1H), 3.26 – 3.21 (m, 2H), 3.07 – 3.02 (m, 1H), 
2.60 – 2.51 (m, 2H), 1.91 – 1.81 (m, 1H), 1.76 – 1.59 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ 171.4, 160.4 (1JC–F = 248.15 Hz), 143.8, 130.8 (3JC–F = 8.11 Hz), 130.4 (5JC–F = 
3.30 Hz), 124.8 (4JC–F = 3.76 Hz), 123.0, 121.9 (2JC–F = 8.11 Hz), 115.85 (6JC–F = 21.10 Hz), 63.9, 57.6, 55.7, 
50.6, 47.6 (CH2JC–F = 4.58 Hz), 41.0, 27.0, 24.5; 
HRMS calculated for C17H20FN5O3SH (M + H)+ 394.1349; found 394.1337 (TOF MS ES+). 
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(R)-2-((1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-
one 3,3-dioxide (NA-6-274-XVA) 3.4.2(2)-[14] 
 
According to general procedure B, 3.4.2(2)-[15] (122.4 mg, 24%) as yellow oil. 
[α]D20  = +24.8° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2974, 2945, 1701, 1637, 1523, 1477, 1427, 1350, 1217, 1178, 1153, 1114, 1051, 1018, 952, 
891, 732, 599, 551 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 8.24 – 8.20 (m, 2H), 7.55 (s, 1H), 7.40 – 7.34 (m, 2H), 5.64 (d, J = 15.7 
Hz, 1H), 5.59 (d, J = 15.8 Hz, 1H), 5.17 (d, J = 15.5 Hz, 1H), 5.02 (d, J = 15.6 Hz, 1H), 4.09 (dd, J = 9.9, 2.4 
Hz, 1H), 3.65 (ddd, J = 14.1, 10.5, 5.9 Hz, 1H), 3.42 (dt, J = 14.2, 2.8 Hz, 1H), 3.30 – 3.20 (m, 2H), 3.09 – 3.03 
(m, 1H), 2.60 – 2.52 (m, 2H), 1.92 – 1.81 (m, 1H), 1.78 – 1.70 (m, 1H), 1.69 – 1.57 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 171.5, 148.0, 144.5, 141.6, 128.4, 124.2 (2), 123.3 (2), 64.0, 57.7, 55.8, 53.0, 
50.6, 41.0, 27.0, 24.6; 
HRMS calculated for C17H20N6O5SH (M + H)+ 421.1294; found 421.1303 (TOF MS ES+). 
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(R)-2-((1-(2-bromo-5-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-
d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (NA-6-274-XVI A) 3.4.2(2)-[15] 
 
According to general procedure B, 3.4.2(2)-[13] (48.2 mg, 24%) as yellow oil. 
[α]D20  = +29.5° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2968, 2943, 2835, 1703, 1595, 1573, 1477, 1429, 1382, 1352, 1292, 1244, 1178, 1153, 1114, 
1153, 1114, 1051, 1020, 891, 732, 601, 549 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.57 (s, 1H), 7.47 (d, J = 8.8 Hz, 1H), 6.77 (dd, J = 8.8, 3.0 Hz, 1H), 6.62 
(d, J = 3.0 Hz, 1H), 5.58 (s, 2H), 5.14 (d, J = 15.5 Hz, 1H), 5.07 (d, J = 15.6 Hz, 1H), 4.11 (dd, J = 9.9, 2.4 Hz, 
1H), 3.73 (s, 3H), 3.67 – 3.56 (m, 1H), 3.39 (dt, J = 14.1, 2.8 Hz, 1H), 3.23 (d, J = 2.9 Hz, 1H), 3.23 – 3.20 (m, 
1H), 3.07 – 3.01 (m, 1H), 2.60 – 2.50 (m, 2H), 1.90 – 1.79 (m, 1H), 1.75 – 1.67 (m, 1H), 1.67 – 1.57 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 171.4, 159.4, 143.8, 134.9, 133.7, 123.2, 116.2, 115.6, 113.4, 63.9, 57.6, 55.8, 
55.5, 53.8, 50.6, 41.0, 27.0, 24.5; 
HRMS calculated for C18H22BrN5O4SH (M + H)+ 484.0654; found 484.0669 (TOF MS ES+). 
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(R)-2-((1-(2-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-
1(2H)-one 3,3-dioxide (NA-6-274-XII A) 3.4.2(2)-[11] 
 
According to general procedure B, 3.4.2(2)-[10] (50.0 mg, 24%) as yellow oil. 
[α]D20  = +25.2° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2968, 2945, 2825, 1750, 1703, 1494, 1352, 1303, 1290, 1211, 1180, 1153, 1114, 1095, 1051, 
1027, 891, 732, 549 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.61 (dd, J = 7.9, 1.3 Hz, 1H), 7.56 (s, 1H), 7.30 (td, J = 7.5, 1.3 Hz, 1H), 
7.23 (td, J = 7.7, 1.8 Hz, 1H), 7.10 (dd, J = 7.6, 1.7 Hz, 1H), 5.63 (s, 2H), 5.15 (d, J = 15.6 Hz, 1H), 5.08 (d, J = 
15.6 Hz, 1H), 4.11 (dd, J = 9.8, 2.4 Hz, 1H), 3.69 – 3.59 (m, 1H), 3.39 (dt, J = 14.1, 2.7 Hz, 1H), 3.25 – 3.23 
(m, 1H), 3.22 (d, J = 2.8 Hz, 1H), 3.06 – 3.01 (m, 1H), 2.61 – 2.51 (m, 2H), 1.91 – 1.80 (m, 1H), 1.76 – 1.69 
(m, 1H), 1.69 – 1.50 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 171.4, 143.7, 134.1, 133.1, 130.3, 130.2, 128.1, 123.4, 123.3, 63.9, 57.7, 55.8, 
53.8, 50.6, 40.3, 27.0, 24.6; 
HRMS calculated for C17H20BrN5O3SH (M + H)+ 454.0548; found 454.0555 (TOF MS ES+). 
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(R)-2-((1-(2-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-
1(2H)-one 3,3-dioxide (NA-6-274-VI A) 3.4.2(2)-[6] 
 
According to general procedure B, 3.4.2(2)-[6] (62.8 mg, 24%) as yellow oil. 
[α]D20  = +21.3° (c = 0.239, CH2Cl2); 
FTIR (thin film) 2975, 2921, 2860, 1685, 1425, 1365, 1348, 1288, 1163, 1149, 1120, 1018, 960, 885, 865, 821, 
790, 777,736, 622, 590 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.54 (s, 1H), 7.42 (dd, J = 7.9, 1.3 Hz, 1H), 7.31 (td, J = 7.7, 1.7 Hz, 1H), 
7.25 (td, J = 7.6, 1.4 Hz, 1H), 7.13 (dd, J = 7.6, 1.8 Hz, 1H), 5.63 (s, 2H), 5.14 (d, J = 15.6 Hz, 1H), 5.06 (d, J = 
15.5 Hz, 1H), 4.10 (dd, J = 9.9, 2.4 Hz, 1H), 3.67 – 3.57 (m, 1H), 3.38 (dt, J = 14.2, 2.8 Hz, 1H), 3.25 – 3.20 
(m, 2H), 3.06 – 2.98 (m, 1H), 2.60 – 2.50 (m, 2H), 1.91 – 1.79 (m, 1H), 1.76 – 1.68 (m, 1H), 1.68 – 1.56 (m, 
1H); 
13C NMR (126 MHz, CDCl3) δ 171.4, 143.7, 133.4, 132.4, 130.1 (2), 129.8, 127.5, 123.2, 63.9, 57.6, 55.7, 
51.4, 50.6, 40.3, 27.0, 24.5; 
HRMS calculated for C17H20ClN5O3SH (M + H)+ 410.1054; found 410.1060 (TOF MS ES+). 
 
 
 
 
 
  
N
NS
OO
O
N
N
N
Cl
 SI–251 
 
tert-butyl 2-((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1-oxohexahydro-1H-pyrazino[2,1-
d][1,2,5]thiadiazepine-9(2H)-carboxylate 3,3-dioxide (NA-6-274-VI B) 3.4.2(5)-[7] 
 
According to general procedure B, 3.4.2(5)-[7] (67.2 mg, 24%) as yellow oil. 
FTIR (thin film) 2975, 2925, 1689, 1425, 1365, 1348, 1288, 147, 1240, 1163, 1149, 1120, 1054, 1018, 962, 
885, 864, 821, 756, 736, 545 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.49 (s, 1H), 7.47 – 7.43 (m, 2H), 7.36 – 7.30 (m, 2H), 5.66 (s, 2H), 5.16 
(d, J = 15.6 Hz, 1H), 5.05 (d, J = 15.7 Hz, 1H), 4.36 (d, J = 12.3 Hz, 2H), 4.30 – 4.00 (m, 1H), 3.93 (t, J = 14.4 
Hz, 1H), 3.85 – 3.69 (m, 1H), 3.35 (dt, J = 15.6, 3.1 Hz, 1H), 3.21 (dt, J = 14.3, 2.6 Hz, 1H), 3.06 – 2.92 (m, 
2H), 2.89 – 2.78 (m, 1H), 2.47 – 2.30 (m, 1H), 1.50 (s, 9H); 
13C NMR δ (126 MHz, CDCl3) δ 170.9, 154.9, 143.5, 132.2, 130.3 (2), 130.0, 127.6 (2), 123.0, 79.6, 60.3, 51.9, 
51.5, 46.0, 45.1, 42.4, 39.7, 30.9, 28.5 (3); 
HRMS calculated for C22H29ClN6O5SH (M + H)+ 525.1687; found 525.1686 (TOF MS ES+). 
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tert-butyl 2-((1-allyl-1H-1,2,3-triazol-4-yl)methyl)-1-oxohexahydro-1H-pyrazino[2,1-
d][1,2,5]thiadiazepine-9(2H)-carboxylate 3,3-dioxide (NA-6-274-VIII B) 3.4.2(5)-[8] 
 
According to general procedure B, 3.4.2(5)-[7] (37.2 mg, 24%) as yellow oil. 
FTIR (thin film) 1691, 1504, 1425, 1365, 1348, 1288, 1240, 1163, 1149, 1120, 1054, 1018, 865, 732, 547 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.45 (s, 1H), 6.10 – 5.90 (m, 1H), 5.40 – 5.25 (m, 1H), 5.18 – 5.04 (m, 
2H), 4.97 (d, J = 6.1 Hz, 2H), 4.45 – 4.30 (m, 1H), 4.20 (s, 1H), 4.06 (ddd, J = 14.5, 12.7, 3.2 Hz, 1H), 3.90 (t, J 
= 13.9 Hz, 1H), 3.79 (d, J = 12.7 Hz, 1H), 3.34 (d, J = 16.0 Hz, 1H), 3.21 (dt, J = 14.4, 2.7 Hz, 1H), 2.97 (dd, J 
= 12.7, 3.6 Hz, 1H), 2.87 – 2.65 (m, 2H), 2.48 – 2.29 (m, 1H), 1.70 – 1.58 (m, 1H), 1.50 (s, 9H); 
13C NMR δ (126 MHz, CDCl3) δ 171.3, 154.8, 143.5, 131.0, 123.0, 120.5, 79.6, 60.6, 53.0, 52.0, 45.8, 45.3, 
42.3, 39.9, 31.0, 28.4 (3); 
HRMS calculated for C18H28N6O5SH (M + H)+ 441.1920; found 441.1911 (TOF MS ES+). 
 
  
N
NS
OO
O
N
N
N
N
Boc
 SI–253 
 
tert-butyl 2-((1-(2-methylallyl)-1H-1,2,3-triazol-4-yl)methyl)-1-oxohexahydro-1H-pyrazino[2,1-
d][1,2,5]thiadiazepine-9(2H)-carboxylate 3,3-dioxide (NA-6-274-IX B) 3.4.2(5)-[9] 
 
According to general procedure B, 3.4.2(5)-[8] (57.1 mg, 24%) as yellow oil. 
FTIR (thin film) 2975, 2927, 1693, 1683, 1454, 1427, 1365, 1348, 1288, 1247, 1240, 1163, 1149, 1056, 1018, 
962, 918, 885, 865, 736, 624, 547 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.44 (s, 1H), 5.27 – 4.98 (m, 3H), 4.94 – 4.82 (m, 3H), 4.36 (d, J = 13.6 
Hz, 1H), 4.21 (s, 1H), 4.11 – 4.03 (m, 1H), 3.90 (t, J = 13.8 Hz, 1H), 3.77 (d, J = 12.4 Hz, 1H), 3.34 (d, J = 15.3 
Hz, 1H), 3.21 (dt, J = 14.4, 2.6 Hz, 1H), 3.02 – 2.90 (m, 1H), 2.86 – 2.76 (m, 1H), 2.46 – 2.31 (m, 1H), 2.28 – 
2.19 (m, 1H), 1.68 (s, 3H), 1.47 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ 171.2, 154.8, 143.5, 139.1, 123.1, 115.6, 79.5, 60.4, 56.3, 51.9, 45.9, 45.2, 43.8, 
42.3, 39.9, 28.4 (3), 19.7; 
HRMS calculated for C19H30N6O5SH (M + H)+ 455.2077; found 455.2081 (TOF MS ES+). 
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tert-butyl 2-((1-(2-(methoxymethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-1-oxohexahydro-1H-
pyrazino[2,1-d][1,2,5]thiadiazepine-9(2H)-carboxylate 3,3-dioxide (NA-6-274-X B) 3.4.2(5)-[10] 
 
According to general procedure B, 3.4.2(5)-[9] (29.6 mg, 24%) as yellow oil. 
FTIR (thin film) 2975, 2935, 2875, 2835, 1730, 1701, 1492, 1353, 1193, 1151, 1089, 1053, 1016, 904, 852, 
823, 810, 781601, 555 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.58 (s, 1H), 5.30 – 5.12 (m, 1H), 5.10 – 4.96 (m, 1H), 4.65 – 4.50 (m, 
4H), 4.37 (d, J = 13.5 Hz, 1H), 4.21 (s, 1H), 4.07 (t, J = 13.6 Hz, 1H), 3.91 (tt, J = 11.3, 4.5 Hz, 2H), 3.80 (d, J 
= 12.7 Hz, 1H), 3.35 (d, J = 17.6 Hz, 1H), 3.28 (s, 3H), 3.20 (dt, J = 14.3, 2.6 Hz, 1H), 2.98 (dd, J = 12.8, 3.6 
Hz, 1H), 2.86 – 2.77 (m, 2H), 2.33 (dd, J = 34.1, 11.7 Hz, 2H), 1.48 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ 171.2, 154.8, 143.2, 123.9, 96.4, 79.6, 65.7, 60.5, 55.4, 52.0, 51.8, 50.4, 45.9, 
45.3, 42.3, 39.91, 28.4 (3); 
HRMS calculated for C19H32N6O7SH (M + H)+ 489.2131; found 489.2142 (TOF MS ES+). 
 
  
N
NS
OO
O
N
N
N
N
Boc
O
O
 SI–255 
 
2-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)octahydro-1H-pyrido[2,1-d][1,2,5]thiadiazepin-1-one 3,3-dioxide 
(NA-6-274-IV E) 3.4.2(4)-[4] 
 
According to general procedure B, 3.4.2(4)-[4] (209.1 mg, 24%) as yellow oil. 
FTIR (thin film) 2945, 2869, 1691, 1496, 1456, 1433, 1369, 1344, 1288, 1147, 1051, 883, 862, 725, 543 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.48 (s, 1H), 7.39 – 7.33 (m, 3H), 7.26 – 7.21 (m, 2H), 5.54 (d, J = 14.9 
Hz, 1H), 5.46 (d, J = 14.8 Hz, 1H), 5.15 (d, J = 15.5 Hz, 1H), 5.04 (d, J = 15.5 Hz, 1H), 4.30 – 4.27 (m, 1H), 
3.97 – 3.88 (m, 1H), 3.87 – 3.79 (m, 1H), 3.28 (dt, J = 15.2, 3.0 Hz, 1H), 3.20 – 3.13 (m, 1H), 2.45 – 2.37 (m, 
1H), 2.36 – 2.28 (m, 1H), 2.05 – 1.97 (m, 1H), 1.62 – 1.40 (m, 4H), 1.38 – 1.28 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 173.3, 144.0, 134.5, 129.1 (2), 128.8, 127.9 (2), 122.7, 60.6, 54.1, 52.3, 52.2, 
47.3, 39.8, 27.3, 25.8, 19.7; 
HRMS calculated for C18H23N5O3SH (M + H)+ 390.1600; found 390.1604 (TOF MS ES+). 
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2-((1-(2-methoxyethyl)-1H-1,2,3-triazol-4-yl)methyl)octahydro-1H-pyrido[2,1-d][1,2,5]thiadiazepin-1-one 
3,3-dioxide (NA-6-274-XVII E) 3.4.2(4)-[16] 
 
According to general procedure B, 3.4.2(4)-[9] (131.3 mg, 24%) as yellow oil. 
FTIR (thin film) 2943, 2871, 2852, 1689, 1496, 1456, 1433, 1369, 1344, 1207, 1147, 1118, 1051, 883, 862, 
796, 732, 636, 582, 543 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.67 (s, 1H), 5.21 (d, J = 15.6 Hz, 1H), 5.05 (d, J = 15.6 1H), 4.51 (ddd, 
J = 5.4, 4.2, 2.4 Hz, 2H), 4.34 – 4.30 (m, 1H), 3.99 – 3.90 (m, 1H), 3.90 – 3.81 (m, 1H), 3.73 (td, J = 5.2, 1.9 
Hz, 2H), 3.34 (s, 3H), 3.30 (dt, J = 15.2, 3.0 Hz, 1H), 3.21 – 3.13 (m, 1H), 2.49 – 2.40 (m, 2H), 2.10 – 2.01 (m, 
1H), 1.70 – 1.47 (m, 4H), 1.47 – 1.39 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 173.2, 143.5, 123.7, 70.7, 60.6, 59.0, 52.3, 52.2, 50.3, 50.2, 39.8, 27.4, 25.9, 
19.7; 
HRMS calculated for C14H23N5O4SH (M + H)+ 358.1549; found 358.1541 (TOF MS ES+). 
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2-((1-(2-methylallyl)-1H-1,2,3-triazol-4-yl)methyl)octahydro-1H-pyrido[2,1-d][1,2,5]thiadiazepin-1-one 
3,3-dioxide (NA-6-274-IX E) 3.4.2(4)-[9] 
 
According to general procedure B, 3.4.2(4)-[8] (184.8 mg, 24%) as yellow oil. 
FTIR (thin film) 2923, 2871, 2852, 1693, 1434, 1369, 1344, 1209, 1147, 1053, 1004, 883, 862, 796, 746, 732, 
638, 543 cm-1; 
1H NMR (500 MHz, Chloroform-d) δ 7.53 (s, 1H), 5.18 (d, J = 15.5 Hz, 1H), 5.06 (d, J = 15.6 Hz, 1H), 5.03 – 
5.01 (m, 1H), 4.93 – 4.81 (m, 3H), 4.34 – 4.28 (m, 1H), 3.99 – 3.90 (m, 1H), 3.89 – 3.80 (m, 1H), 3.30 (dt, J = 
15.3, 3.0 Hz, 1H), 3.22 – 3.13 (m, 1H), 2.49 – 2.36 (m, 2H), 2.10 – 1.97 (m, 1H), 1.66 (s, 3H), 1.65 – 1.44 (m, 
4H), 1.44 – 1.36 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 173.3, 143.9, 139.1, 122.8, 115.4, 60.6, 56.3, 52.3, 52.2, 47.4, 39.8, 27.4, 25.8, 
19.7, 19.6; 
HRMS calculated for C15H23N5O3SH (M + H)+ 354.1600; found 354.1594 (TOF MS ES+). 
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5.4 Experimental for Chapter 3.3 
 
Triazole-containing Isothiazolidine 1,1-dioxide Library Synthesis: One-Pot, Multi-
Component protocols for small molecular probe discovery 
2,3-Dihydroisothiazole 1,1-dioxide (3.5.1). 
 
Into a r.b flask was added allyl amine (6.57 mL, 87.6 mmol, 1.1 equiv.), dry DCM (160 mL, 0.5 M), and Et3N 
(36.6 mL, 262.2 mmol, 3 equiv.).  The stirring solution was cooled to 0 ºC to which was added dropwise 2-
chloroethanesulfonyl chloride (8.32 ml, 79.6 mmol, 1 equiv.).  After addition, the reaction was warmed to rt and 
stirrd for an additional 4 hrs.  Upon completion the reaction was quenched with 10% HCl aq. (60 ml), the 
organic layer extracted and washed with 10% HCl aq. (60 ml), H2O (60 ml) and Brine (60 ml).  The combined 
organic was dried over MgSO4, filtered and concentrated.   
To the crude material N-allylethenesulfonamide (11.5g, yellow oil) in a rb flask was added Ar degassed dry 
DCM (0.07M, 111 ml), and the reaction was heated at 45 ºC.  Over the required 3 hr reaction period at 45 ºC, 
Cat A [(IMesH2)(PCy3)(Cl)2Ru]CHPh] (2.5 mol%) was added in 5 equal portions every 30mins, essential for 
compelte converstion of the starting material to product.  After such time the reaction was concentrated and 
purified by flash chromatography (7:3 EtOAc:hexane, Rf 1 = 0.3, Rf N-allylethenesulfonamide = 0.7) to yield 
the desired product as a brown oil (8.35g, 70 mmol, 88% over 2 steps). 
FTIR (neat): 3552, 3274, 1386, 1274, 1151, 1103 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.89 (dt, J = 6.5, 2.3 Hz, 1H), 6.71 (dt, J = 6.5, 2.3 Hz, 1H), 5.23 (br s, 1H), 4.10 
(dt, J = 4.4, 2.3 Hz, 2H); 
13C NMR (126 MHz, CDCl3) δ 138.3, 127.2, 47.8; 
HRMS calculated for C3H6NO2S (M+H)+ 120.0119; found 120.0121 (TOF MS ES+). 
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2-(Prop-2-yn-1-yl)-2,3-dihydroisothiazole 1,1-dioxide (3.5.2). 
 
Into a 500 ml rb flask under Ar, was added 2,3-dihydroisothiazole 1,1-dioxide 3.5.1 (4.05g, 33.9 mmol, 1 
equiv), dry CH3CN (170 mL, 0.2 M) and K2CO3 (9.36g, 67.8 mmol, 2 equiv).  To the stirring slurry was added 
propargyl bromide ([80% in tol.], 7.58g, 50.9 mmol, 1.5 equiv), after which the reaction was heated at 60 ºC for 
5 hrs [TLC monitoring (7:3 EtOAc:hexane, Rf 2 = 0.5, Rf 1 = 0.3].  After such time the reaction was cooled to 
rt, filtered through a SiO2 SPE, washed with EtOAC (200 ml) and concentrated.  The resulting crude liquid was 
diluted in toluene (200 ml), concentrated and dried under vacuum to yield the desired product 2 (5.06g, 32.2 
mmol, 95%) as an yellow oil. 
FTIR (neat): 3274, 1386, 1274, 1141, 1103 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.91 (dt, J = 7.0, 2.4 Hz, 1H), 6.72 – 6.65 (m, 1H), 4.15 – 4.10 (m, 2H), 3.99 (d, 
J = 2.2 Hz, 2H), 2.35 (t, J = 2.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 135.6, 127.1, 74.1, 51.4, 33.8; 
HRMS calculated for C6H8NO2S (M+H)+ 158.0276; found 158.0279 (TOF MS ES+). 
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General procedure C for the synthesis of cores 3.5.3, 3.5.4 and 3.5.5 via aza-Michael. 
Into a rb flask was added a solution of 2-(prop-2-yn-1-yl)-2,3-dihydroisothiazole 1,1-dioxide 2 (1 equiv.) in dry 
MeOH (1M).  To the stirring solution was added DBU (10 mol %), the corresponding amino alcohol (1.5 
equiv.) and the reaction mixture was heated at 60 ºC for 12 hrs.  After such time the reaction was diluted in 
DCM:MeOH (9:1), filtered through a silica SPE and flushed with DCM:MeOH (9:1).  The resulting 
isothiazolidine 1,1-dioxide (16, 17 or 18) was concentrated and carried forward without the need for further 
purification. 
4-((2-Hydroxyethyl)(methyl)amino)-2-(prop-2-yn-1-yl)isothiazolidine 1,1-dioxide (3.5.3). 
 
According to general procedure C, 3.5.3 (0.89g, 3.85 mmol, 61%) was isolated as a yellow oil. 
FTIR (neat): 3271, 2952, 1305, 1234 1145, 1033 cm-1; 
1H NMR (500 MHz, CDCl3) δ 3.91 – 3.81 (m, 1H), 3.87 (t, J = 2.4 Hz, 2H), 3.63 (t, J = 4.8 Hz, 2H), 3.52 (dd, 
J = 10.1, 7.9 Hz, 1H), 3.34 – 3.25 (m, 2H), 3.15 (dd, J = 13.0, 7.5 Hz, 1H), 2.70 – 2.64 (m, 1H), 2.57 (dt, J = 
12.9, 4.8 Hz, 1H), 2.36 (dd, J = 5.7, 3.2 Hz, 1H), 2.33 (s, 3H), 2.29 (s, 1H); 
13C NMR (126 MHz, CDCl3) δ 74.2, 58.3, 57.0, 55.0, 49.1, 47.1, 37.8, 33.6; 
HRMS calculated for C9H17N2O3S (M+H)+ 233.0960; found 233.0962 (TOF MS ES+). 
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4-((3-Hydroxypropyl)(methyl)amino)-2-(prop-2-yn-1-yl)isothiazolidine 1,1-dioxide (3.5.4). 
 
According to general procedure C, 3.5.4 (0.70g, 2.85 mmol, 59%) was isolated as a yellow oil. 
FTIR (neat): 3274, 2948, 2358, 1305, 1234 1145, 1054 cm-1; 
1H NMR (500 MHz, CDCl3) δ 3.86 (dd, J = 5.7, 2.5 Hz, 2H), 3.85 – 3.80 (m, 1H), 3.76 (t, J = 5.5 Hz, 2H), 
3.52 (dd, J = 10.1, 7.9 Hz, 1H), 3.31 – 3.25 (m, 2H), 3.14 (dd, J = 13.0, 7.7 Hz, 1H), 2.68 (ddd, J = 12.7, 7.3, 
5.4 Hz, 1H), 2.63 – 2.57 (m, 1H), 2.36 (t, J = 2.5 Hz, 1H), 2.32 (s, 3H), 1.80 – 1.66 (m, 3H); 
13C NMR (126 MHz, CDCl3) δ 74.2, 63.2, 56.9, 53.3, 49.0, 46.6, 38.1, 33.7, 28.3; 
HRMS calculated for C10H19N2O3S (M+H)+ 247.1116; found 247.1117 (TOF MS ES+). 
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4-(4-(2-Hydroxyethyl)piperazin-1-yl)-2-(prop-2-yn-1-yl)isothiazolidine 1,1-dioxide (3.5.5). 
 
According to general procedure C, 3.5.5 (0.545g, 1.89 mmol, 60 %) was isolated as a yellow oil. 
FTIR (neat): 3267, 2945, 2823, 1649, 1458, 1305, 1143, 1051 cm-1; 
1H NMR (500 MHz, CDCl3) δ 3.87 (dd, J = 2.4, 1.2 Hz, 2H), 3.62 (dd, J = 9.5, 4.6 Hz, 3H), 3.51 (dd, J = 9.6, 
7.5 Hz, 1H), 3.36 – 3.26 (m, 2H), 3.17 (dd, J = 12.8, 8.0 Hz, 1H), 2.64 – 2.51 (m, 11H), 2.35 (t, J = 2.5 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 74.1, 59.1, 57.7, 57.1, 52.5, 49.8, 49.0, 48.3, 33.8; 
HRMS calculated for C12H22N3O3S (M+H)+ 288.1382; found 288.1379 (TOF MS ES+). 
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General procedure D for synthsis of Library C via one-pot Click/ OACC esterification protocol.  
To a 1-dram vial containing sultam 3.5.3, 3.5.4 or 3.5.5 (40 mg, 1 equiv.) was added CuI (30 mol%), DBU (10 
mol%), dry DCM (0.2 M), acid (1.2 equiv.) and azide (2 equiv.).  To the crude mixture was added a solution of 
OACC (1.5 eq.) in dry DCM (0.2M) and the resulting reaction mixture was heated at 50 ºC on a reaction block 
for for 12 hrs.  After which time the reactions were cooled, diluted in EtOAc (2 ml) and the correspondiong 
suspention filtered through SiO2 SPE into pre-weighed barcoded vials, washed with eluent (2 ml, EtOAc) and 
concentrated.  The crude reaction was concentrated and QC/purified by an automated preparative reverse phase 
HPLC (detected by mass spectroscopy). 
 
2-((2-((1-(2-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,1-dioxidoisothiazolidin-4-yl)(methyl)amino) 
ethyl benzofuran-2-carboxylate (3.5.6-A{2}). 
 
FTIR (neat): 2358, 1724, 1446, 1296, 1222, 1178, 1143 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.73 – 7.70 (m, 1H), 7.64 (s, 1H), 7.60 (dt, J = 6.0, 3.0 Hz, 1H), 7.50 (d, J = 0.9 
Hz, 1H), 7.48 – 7.44 (m, 1H), 7.41 (dd, J = 8.0, 1.2 Hz, 1H), 7.34 – 7.27 (m, 4H), 7.25 – 7.21 (m, 1H), 7.18 (dd, 
J = 7.6, 1.6 Hz, 1H), 5.63 (s, 2H), 4.44 – 4.38 (m, 1H), 4.37 (dd, J = 4.7, 2.5 Hz, 2H), 3.83 – 3.75 (m, 1H), 3.43 
(dt, J = 12.7, 6.3 Hz, 1H), 3.35 (dd, J = 13.0, 8.6 Hz, 1H), 3.14 (ddd, J = 17.2, 11.5, 7.3 Hz, 2H), 2.85 (ddd, J = 
13.9, 6.7, 4.9 Hz, 1H), 2.79 – 2.73 (m, 1H), 2.34 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 159.3, 155.8, 145.0, 142.5, 133.6, 132.2, 130.4, 130.4, 130.0, 127.8, 127.6, 
126.9, 123.9, 123.7, 123.0, 114.3, 112.4, 62.5, 56.8, 51.9, 51.2, 49.4, 47.6, 38.9, 38.8; 
HRMS calculated for C25H27ClN5O5SNa (M+H)+ 544.1421; found 544.1405 (TOF MS ES+). 
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2-((2-((1-(2-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,1-dioxidoisothiazolidin-4-yl)(methyl)amino) 
ethyl 5-methylisoxazole-3-carboxylate (3.5.6-A{3}). 
 
FTIR (neat): 2952, 1735, 1598, 1458, 1305, 1205, 1143, 1047 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.65 (s, 1H), 7.42 (dd, J = 7.9, 1.3 Hz, 1H), 7.31 (td, J = 7.7, 1.8 Hz, 1H), 7.28 
– 7.23 (m, 2H), 7.20 – 7.18 (m, 1H), 6.38 (d, J = 0.9 Hz, 1H), 5.65 (s, 2H), 4.42 – 4.31 (m, 2H), 4.34 (d, J = 1.5 
Hz, 2H), 3.74 (dt, J = 15.5, 7.6 Hz, 1H), 3.40 (dd, J = 10.1, 7.8 Hz, 1H), 3.30 (dd, J = 13.0, 8.7 Hz, 1H), 3.09 
(ddd, J = 15.0, 11.6, 7.2 Hz, 2H), 2.85 – 2.78 (m, 1H), 2.72 (dt, J = 14.0, 5.4 Hz, 1H), 2.50 (d, J = 0.8 Hz, 3H), 
2.31 (s, 3H); 
13C NMR (126 MHz, CDCl3) 171.6, 159.9, 156.0, 142.5, 133.5, 132.2, 130.4, 130.3, 130.0, 127.6, 127.6, 
123.7, 102.3, 62.9, 56.8, 51.8, 51.6, 49.3, 47.5, 38.8, 38.7, 12.4; 
HRMS calculated for C21H26ClN6O5SNa (M+Na)+ 509.1374; found 509.1379 (TOF MS ES+). 
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2-(Methyl(2-((1-(3-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,1-dioxidoisothiazolidin-4-yl)amino)ethyl 
pyrazine-2-carboxylate (3.5.6-D{1}). 
 
FTIR (neat): 1724, 1303, 1141, 1049, 1018, 775 cm-1; 
1H NMR (500 MHz, CDCl3) δ 9.29 (d, J = 1.3 Hz, 1H), 8.78 (d, J = 2.4 Hz, 1H), 8.74 (dd, J = 2.4, 1.5 Hz, 
1H), 7.53 (d, J = 4.0 Hz, 1H), 7.26 – 7.23 (m, 1H), 7.16 (d, J = 7.6 Hz, 1H), 7.09 – 7.03 (m, 2H), 5.51 – 5.43 
(m, 2H), 4.50 – 4.41 (m, 2H), 4.32 (d, J = 15.6 Hz, 2H), 3.80 – 3.72 (m, 1H), 3.42 (dd, J = 9.5, 8.3 Hz, 1H), 
3.35 (dd, J = 13.0, 8.6 Hz, 1H), 3.13 (ddd, J = 20.7, 12.6, 6.4 Hz, 2H), 2.91 – 2.84 (m, 1H), 2.79 (dt, J = 13.9, 
5.5 Hz, 1H), 2.35 (s, 3H), 2.33 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 163.8, 147.9, 146.3, 144.6, 143.2, 142.6, 139.0, 134.3, 129.6, 129.0, 128.8, 
125.1, 123.3, 63.1, 56.8, 54.3, 52.1, 49.4, 47.6, 38.8, 38.7, 21.3; 
HRMS calculated for C22H27N7O4S (M+H)+ 508.1743; found 508.1750 (TOF MS ES+). 
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2-(Methyl(2-((1-(3-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,1-dioxidoisothiazolidin-4-yl)amino)ethyl 
5-methylisoxazole-3-carboxylate (3.5.6-D{3}). 
 
FTIR (neat): 1733, 1458, 1305, 1205, 1143, 1049, 100 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 5.3 Hz, 1H), 7.28 – 7.25 (m, 1H), 7.16 (d, J = 7.6 Hz, 1H), 7.09 – 
7.04 (m, 2H), 6.39 (d, J = 0.9 Hz, 1H), 5.48 (s, 2H), 4.43 – 4.34 (m, 2H), 4.33 (d, J = 3.7 Hz, 2H), 3.77 – 3.68 
(m, 1H), 3.40 (dd, J = 10.1, 7.8 Hz, 1H), 3.29 (dd, J = 13.0, 8.7 Hz, 1H), 3.09 (ddd, J = 16.8, 11.6, 7.3 Hz, 2H), 
2.81 (ddd, J = 13.8, 6.5, 5.2 Hz, 1H), 2.73 (dt, J = 13.9, 5.5 Hz, 1H), 2.50 (d, J = 0.8 Hz, 3H), 2.34 (s, 3H), 2.30 
(s, 3H); 
13C NMR (126 MHz, CDCl3) δ 171.6, 159.9, 156.0, 142.5, 139.0, 134.3, 129.6, 129.0, 128.8, 125.2, 123.3, 
102.3, 62.9, 56.8, 54.3, 51.8, 49.3, 47.5, 38.8, 38.7, 21.3, 12.4; 
HRMS calculated for C22H29N6O5S (M+H)+ 489.1920; found 489.1921 (TOF MS ES+). 
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3-((2-((1-(2-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,1-dioxidoisothiazolidin-4-yl)(methyl)amino) 
propyl benzofuran-2-carboxylate (3.5.7-A{2}). 
 
FTIR (neat): 1724, 1564, 1446, 1296, 1178, 1143, 1047 cm-1; 
1H NMR (500 MHz, CDCl3) δ δ 7.73 – 7.69 (m, 1H), 7.63 – 7.58 (m, 2H), 7.54 (d, J = 0.9 Hz, 1H), 7.48 – 7.41 
(m, 2H), 7.34 – 7.29 (m, 2H), 7.29 – 7.24 (m, 3H), 7.19 (dd, J = 7.6, 1.7 Hz, 1H), 4.39 (dd, J = 10.2, 3.8 Hz, 
2H), 4.34 (d, J = 8.6 Hz, 2H), 3.71 – 3.64 (m, 1H), 3.41 (dd, J = 9.9, 7.7 Hz, 1H), 3.28 (dd, J = 12.9, 8.5 Hz, 
1H), 3.17 – 3.09 (m, 2H), 2.53 (t, J = 6.8 Hz, 2H), 2.22 (s, 3H), 1.91 (dq, J = 13.4, 6.7 Hz, 2H). 
13C NMR (126 MHz, CDCl3) δ 159.5, 155.7, 145.3, 142.5, 133.6, 132.2, 130.4, 130.4, 130.0, 127.7, 127.6, 
126.9, 123.8, 123.7, 122.9, 114.1, 112.4, 62.9, 56.9, 51.6, 50.3, 49.1, 47.6, 38.8, 37.6, 26.5; 
HRMS calculated for C26H29ClN5O5S (M+H)+ 558.1578; found 558.1582 (TOF MS ES+). 
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3-((2-((1-(2-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,1-dioxidoisothiazolidin-4-yl)(methyl)amino) 
propyl 5-methylisoxazole-3-carboxylate (3.5.7-C{3}). 
 
FTIR (neat): 2956, 2358, 1731, 1458, 1305, 1271, 1205, 1143, 1047 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H), 7.43 (dd, J = 7.9, 1.3 Hz, 1H), 7.32 (td, J = 7.7, 1.8 Hz, 1H), 7.29 
(d, J = 1.4 Hz, 1H), 7.19 (dd, J = 7.6, 1.7 Hz, 1H), 6.40 (d, J = 0.8 Hz, 1H), 5.66 (s, 2H), 4.39 – 4.32 (m, 3H), 
3.69 – 3.60 (m, 1H), 3.37 (dd, J = 9.9, 7.7 Hz, 1H), 3.24 (dd, J = 12.9, 8.5 Hz, 1H), 3.13 – 3.05 (m, 2H), 2.50 
(m, 2H), 2.50 (d, J = 0.8 Hz, 3H), 2.19 (s, 3H), 1.91 – 1.85 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ 171.5, 160.2, 156.3, 142.6, 133.5, 132.2, 130.4, 130.0, 127.6, 123.7, 102.3, 
63.5, 56.9, 51.6, 50.3, 49.2, 47.4, 38.8, 37.5, 26.2, 12.4; 
HRMS calculated for C22H28ClN6O5S (M+H)+ 523.1530; found 523.1520 (TOF MS ES+). 
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3-((2-((1-(2-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,1-dioxidoisothiazolidin-4-yl)(methyl)amino) 
propyl 3,5-dimethoxybenzoate (3.5.7-A{4}). 
 
FTIR (neat): 1706, 1514, 1292, 1271, 1222, 1141 cm-1; 
1H NMR (500 MHz, CDCl3) 7.64 (dd, J = 8.4, 2.0 Hz, 1H), 7.61 (s, 1H), 7.52 (d, J = 2.0 Hz, 1H), 7.44 – 7.40 
(m, 1H), 7.31 (tt, J = 7.3, 1.9 Hz, 1H), 7.28 – 7.24 (m, 1H), 7.18 (dd, J = 7.6, 1.6 Hz, 1H), 6.90 (t, J = 6.9 Hz, 
1H), 5.64 (s, 2H), 4.38 – 4.26 (m, 4H), 3.93 (t, J = 4.3 Hz, 5H), 3.69 – 3.61 (m, 1H), 3.39 (dd, J = 9.9, 7.7 Hz, 
1H), 3.28 – 3.22 (m, 1H), 3.14 – 3.06 (m, 2H), 2.53 – 2.48 (m, 2H), 2.21 (s, 3H), 1.91 – 1.84 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ 166.3, 153.1, 148.7, 142.5, 133.6, 132.2, 130.4, 130.0, 127.6, 123.7, 123.4, 
122.6, 111.9, 110.3, 62.4, 56.9, 56.0, 51.6, 50.5, 49.2, 47.6, 38.8, 37.7, 26.6; 
HRMS calculated for C26H33ClN5O6S (M+H)+ 578.1840; found 578.1832 (TOF MS ES+). 
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3-((2-((1-(2-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,1-dioxidoisothiazolidin-4-yl)(methyl)amino) 
propyl 3,5-dimethylbenzoate (3.5.7-A{5}). 
 
FTIR (neat): 1772, 1446, 1349, 1210, 1143, 1045 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.64 – 7.61 (m, 2H), 7.60 (s, 1H), 7.42 (dt, J = 7.9, 2.4 Hz, 1H), 7.33 – 7.28 (m, 
1H), 7.28 – 7.24 (m, 1H), 7.18 (dd, J = 7.4, 1.7 Hz, 2H), 5.64 (s, 2H), 4.38 – 4.26 (m, 4H), 3.69 – 3.62 (m, 1H), 
3.41 – 3.36 (m, 1H), 3.27 – 3.21 (m, 1H), 3.14 – 3.06 (m, 2H), 2.50 (ddd, J = 7.9, 6.4, 2.5 Hz, 2H), 2.35 (s, 6H), 
2.20 (s, 3H), 1.88 (tt, J = 13.5, 4.0 Hz, 2H); 
13C NMR (126 MHz, CDCl3) δ 166.8, 142.6, 138.1, 134.7, 133.5, 132.2, 130.4, 130.0, 127.6, 127.2, 123.7, 
62.5, 56.9, 51.6, 50.6, 49.2, 47.5, 38.8, 37.6, 26.6, 21.2; 
HRMS calculated for C26H33ClN5O4S (M+H)+ 546.1942; found 546.1943 (TOF MS ES+). 
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2-(4-(2-((1-(2-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,1-dioxidoisothiazolidin-4-yl)piperazin-1-
yl)ethyl benzofuran-2-carboxylate (3.3.8-A{2}). 
 
FTIR (neat): 1726, 1296, 1178, 1145, 1047 cm-1; 
1H NMR (500 MHz, CDCl3) 7.69 (d, J = 7.6 Hz, 1H), 7.63 (s, 1H), 7.60 – 7.56 (m, 2H), 7.46 (ddd, J = 10.6, 
5.9, 2.3 Hz, 1H), 7.43 (dd, J = 7.9, 1.3 Hz, 1H), 7.34 – 7.29 (m, 2H), 7.29 – 7.27 (m, 1H), 7.21 (dd, J = 7.6, 1.6 
Hz, 1H), 5.65 (s, 2H), 4.63 (s, 2H), 4.34 (s, 2H), 3.54 – 3.47 (m, 1H), 3.43 (dd, J = 9.7, 7.4 Hz, 1H), 3.33 – 3.26 
(m, 1H), 3.14 (ddd, J = 20.7, 11.3, 7.5 Hz, 2H), 2.95 (br m, 2H), 2.90 – 2.72 (br m, 4H), 2.65 (s, 4H); 
13C NMR (126 MHz, CDCl3) δ 155.8, 142.3, 133.6, 132.1, 130.5, 130.4, 130.0, 127.9, 127.6, 126.8, 123.9, 
123.8, 122.9, 112.4, 57.0, 56.1, 52.8, 51.7, 49.2, 48.6, 38.9; 
HRMS calculated for C28H32ClN6O5S (M+H)+ 599.1843; found 599.1837 (TOF MS ES+). 
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5.5 Experimental for Chapter 4.1 
 Facilitated Intermolecular Monomer-on-Monomer (MoM) Mitsunobu Reaction on 
Hydroxy-pyrrolo thiadiazepin-dioxide Scaffolds 
General procedures and reagents:  All air and moisture sensitive reactions were carried out in flame- or oven-
dried glassware under argon atmosphere using standard gas tight syringes, canullas and septa. CH2Cl2 and 
toluene were purified by passage through a Solv-Teki (www.solvtek.com) purification system employing 
activated Al2O3 and degassed with argon. Flash column chromatography was performed with SiO2 (Sorbent 
Technologies 30930M-25, Silica Gel 60 Å, 40-63 µm).  Thin layer chromatography was performed on silica gel 
60F 254 plates.  Visualization of TLC spots was effected using KMnO4 stain.  1H and 13C NMR spectra were 
recorded in CDCl3 (unless otherwise mentioned) on a Bruker DRX-400 spectrometer operating at 400 MHz, and 
100 MHz respectively as well as Bruker DRX-500 spectrometer operating at 500 MHz, and 125 MHz, 
respectively and calibrated to the solvent peak.  High-resolution mass spectrometry (HRMS) was recorded on a 
LCT Premier Spectrometer (Micromass UK Limited) operating on ESI (MeOH).  The nanoparticles were 
analyzed by scanning electron microscopy (Hitachi S-2700 equipped with a quartz PCI digital capture) and 
FTIR Perkin Elmer Spectrum 100 FT-IR spectrometer.  All other commercially available compounds were used 
as received. metathesis catalyst [(IMesH2)(PCy3)(Cl)2Ru=CHPh; cat-B] was provided by Materia Inc. and used 
without further purification.  Deuterated solvents were purchased from Cambridge Isotope laboratories.  
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General procedure A: Synthesis of Hydroxy-pyrrolo thiadiazepin-dioxide Scaffolds. 
To a round bottom flask/pressure tube containing a solution of amine (1.0 equiv.) in dry CH2Cl2 (0.5 M), 
was added Et3N (2.0 equiv.).   The reaction mixture was cooled to 0 ºC, stirred for 20 min followed by the drop-
wise addition of 2-chloroethane sulfonyl chloride (1.0 equiv.).  The reaction was warmed to rt and left to stir 
overnight.  After the completion of the reaction CH2Cl2 was removed by evaporation.  MeOH (0.5 M), water 
(0.5 M), Et3N (3.0 equiv.) and amino acid (1.0 equiv.) were added to the reaction mixture, which was stirred at 
60 ºC for 12 h, after which the solvents were evaporated to dryness.  This was followed by the addition of DMF 
(0.05 M) EDC (2.0 equiv.), HOBt (0.2 equiv.) and Et3N (2.0 equiv.) to the crude mixture.  The reaction was 
stirred at rt for 12 h, followed by evaporation of DMF.  Water was added to the crude mixture, which was 
extracted with EtOAc (2x).  The combined organic layers were dried (Na2SO4) and concentrated under reduced 
pressure to afford the crude product, which was purified by flash chromatography (100% EtOAc).  
General procedure B: Intermolecular monomer-on-monomer (MoM) Mitsunobu reaction utilizing 
metathesis catalyst B [Method A]. 
To a round-bottom under argon atmosphere was added hydroxy-pyrrolo thiadiazepin-dioxide (1 equiv) in dry 
THF (0.1 M).  The reaction was cooled to 0 ºC, stirred for 15 min, after which Nb-TPP (3 equiv) and Nb-BEAD 
(3 equiv) were added to the reaction mixture and stirred at room temperature for 2-12 hrs (TLC monitoring).  
The reaction was concentrated and resolvated in degassed CH2Cl2 (0.1 M), cat-B (0.05 
equiv)[[(IMesH2)(PCy3)(Cl)2Ru=CHPh] was added and reaction heated at 50 ºC for 30 mins to 1 hr (TLC 
monitoring).  Upon completion, the reaction was cooled to room temperature, quenched with ethyl vinyl ether 
(4 equiv) and stirred for an additional 30 mins. After such time was added Na2CO3 (10 equiv) followed by 
dropwise addition of tetrakis(hydroxymethyl) phosphonium chloride (THPC) 80% in water (10 equiv) while 
stirring and was refluxed for 4 h. The reaction mixture was cooled to room temperature, extracted with 
dichloromethane (2 x 20 mL), washed with water and brine.    The organic layer was dried over MgSO4, filtered 
through a celite plug and concentrated in vacuo. The resulting solution was filtered through a plug of silica, 
eluting with 2:1-Hexane/EtOAc.  The resulting eluent was then concentrated in vacuo to yield the desired 
products in good to excellent yields and purities. 
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General procedure C: Intermolecular monomer-on-monomer (MoM) Mitsunobu reaction utilizing Nb-
tagged Co/C magnetic nanoparticles [Method C]. 
To a round-bottom flask under argon atmosphere was added hydroxy-pyrrolo thiadiazepin-dioxide (1 equiv) 
solvated in dry THF (0.1 M).  The reaction was cooled to 0 °C, stirried for 20 mins, after which was added Nb-
TPP (3.0 equiv.) and Nb-BEAD (3.0 equiv.) and the reaction warmed to room temperature and stirred for 2–12 
h (TLC monitoring).  Upon completion of the reaction, the solvent was removed, the crude mixture was 
dissolved in degassed CH2Cl2 (0.1 M) and added to a pressure tube containing a mixture of Co/C-Nb (3 mol %) 
and Grubbs catalyst [3 mol %, (IMesH2)(PCy3)-(Cl)2Ru=CHPh, cat-II] in dry degassed CH2Cl2 (0.05 M), that 
had been sonicated at 60 °C for 30 min.  After additional sonication for 1–5 h at 60 ºC (TLC monitoring), a 
neodymium based magnet was attached to the side of the tube and the crude reaction mixture was decanted, 
filtered through a silica SPE and concentrated in vacuo, yielding the desired products in good purities. 
General procedure D: Intermolecular monomer-on-monomer (MoM) Mitsunobu reaction utilizing 
catalyst-armed Nb-tagged silica particles [Method D]. 
Into a 1-dram vial was added hydroxy-pyrrolo thiadiazepin-dioxide (1 equiv), dry THF (0.1 mL) and Nb-TPP 
(2.04 10-4 mol, 1.6 equiv) under an argon atmosphere.  After stirring for 5 mins, a solution of Nb-BEAD (2.04 
10-4 mol, 1.6 equiv) in dry THF (0.156 mL) was added dropwise and the reaction was stirred at room 
temperature for 2–12 h (TLC monitoring). After evaporation of the solvent, Nb-tagged silica (6.12 10-4 mol, 3 
mol %) was added followed by the addition of a solution of cat-II [3 mol %, (IMesH2)(PCy3)-(Cl)2Ru=CHPh] 
in dry Ar degassed CH2Cl2 (2 mL).  The reaction was heated at 50 ºC for 30 mins (TLC monitoring), after 
which the crude reaction was diluted with EtOAc, filtered through a silica SPE washing the SPE and residual 
Si-ROMP gel with EtOAc, concentrated, yielding the desired products in good purities. 
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(8S,9aS)-2-benzyl-8-hydroxyhexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide (4.5.1)  
 
Utilizing general procedure A, 4.5.1 compound (69%, 0.51 g) was isolated after chromatography as a light 
brown solid.  
M. P. 109–110 ºC;  
Rf = 0.52 (100% EtOAc); 
FTIR (neat) 3639, 3109, 2953, 2901, 1701, 1454, 1360, 1142, 1102, 712 cm-1; 
[𝜶]𝑫𝟐𝟎 = +25.2° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ ppm 7.42–7.37 (m, 2H), 7.36–7.32 (m, 2H), 7.31–7.28 (m, 1H), 5.13 (d, J = 
15.1 Hz, 1H), 4.90 (d, J = 15.1 Hz, 1H), 4.46 (dd, J = 10.6, 6.0 Hz, 1H), 4.42 (dddd, J = 5.2, 5.2, 5.2, 5.2 Hz, 
1H), 3.49–3.42 (m, 1H), 3.41–3.35 (m, 2H), 3.26–3.17 (m, 2H), 2.76 (dddd, J = 13.5, 5.9, 5.9, 1.0 Hz, 1H), 2.65 
(ddd, J = 9.9, 5.2, 1.2 Hz, 1H), 2.07 (bs, 1H, OH), 1.95 (dddd, J = 13.3, 8.5, 5.6, 1.0 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 170.6, 136.3, 128.6, 128.1(2), 127.7(2), 63.9, 61.6, 58.9, 55.4, 50.3, 49.0, 
32.3; 
HRMS calculated for C14H18N2O4SH (M+H)+ 311.1066; found 311.1061 (TOF MS ES+). 
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(8S,9aS)-8-hydroxy-2-(4-methylbenzyl)hexahydropyrrolo[2,1-d][1,2,5] thiadiazepin-1(2H)-one 3,3-dioxide 
(4.5.3) 
 
Utilizing general procedure A, 4.5.3 (34.7 mg, 0.107 mmol, 83%) was isolated as a white solid. 
[α]D20 =  +22.2 º (c = 0.25, CHCl3); 
FTIR (neat, cm-1): 2360, 1637, 1346, 1211, 1151. 
1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 7.9 Hz, 2H), 5.10 (d, J = 15.0 Hz, 1H), 
4.86 (d, J = 15.0 Hz, 1H), 4.42 (ddd, J = 15.8, 9.6, 5.7 Hz, 2H), 3.48 – 3.33 (m, 4H), 3.26 – 3.14 (m, 2H), 2.78 – 
2.70 (m, 1H), 2.65 (dd, J = 9.8, 5.2 Hz, 1H), 2.33 (s, 3H), 1.95 (ddd, J = 13.9, 8.6, 5.7 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 171.3, 137.4, 133.5, 129.2 (2), 128.4 (2), 77.2, 70.2, 64.1, 56.4, 52.4, 48.4, 36.6, 
21.1. 
HRMS calculated for C15H21N2O4S (M+H)+ 325.1222; found 325.1210 (TOF MS).  
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(8S,9aS)-2-(4-fluorobenzyl)-8-hydroxyhexahydropyrrolo[2,1-d] [1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide 
(4.5.2) 
 
Utilizing general procedure A, 4.5.2 (37 mg, 0.115 mmol, 86%) was isolated as a white solid. 
Melting Point 109-110ºC 
FTIR (neat) 3639, 3109, 3053, 2901, 1701, 1602, 1454, 1360, 1142 cm-1; 
[a]D20 = +23.9° (c = 2.0, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.42–7.37 (m, 2H), 7.04–6.99 (m, 2H), 5.07 (d, J = 15.1 Hz, 1H), 4.88 (d, J = 
15.1 Hz, 1H), 4.43 (dd, J = 8.7, 6.1 Hz, 1H), 4.39 (t, J = 5.2 Hz, 1H), 3.49 – 3.35 (m, 3H), 3.30–3.16 (m, 3H), 
2.72 (dddd, J = 13.0, 5.9, 5.9, 1.0 Hz, 1H), 2.66 (ddd, J = 9.9, 5.1, 1.1 Hz, 1H), 1.97 (dddd, J = 13.2, 8.6, 5.5, 
1.2 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 171.4, 162.3 (1JC–F = 248.8 Hz), 132.4 (4JC–F = 3.27 Hz), 130.4 (3JC–F = 8.17 
Hz, 2), 115.4 (2J = 21.42 Hz 2), 70.1, 64.1, 64.2, 56.5, 52.5, 48.0, 36.6; 
HRMS calculated for C14H17FN2O4SH (M+H)+ 329.0971; found 329.0971 (TOF MS ES+). 
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(8R,9aS)-2-benzyl-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5] thiadiazepin-8-yl 4-chlorobenzoate 
(4.5.7) 
 
Utilizing general procedure B, 4.5.7 (39 mg, 0.087 mmol, 73%) was isolated as a white solid. 
[α]D20 =  +67.6 º (c = 0.25, CHCl3). 
FTIR (neat, cm-1): 2920, 2360, 2333, 1712, 1593, 1353, 1276, 1218, 1153, 1118. 
1H NMR (500 MHz, CDCl3) δ 7.88 – 7.84 (m, 2H), 7.30–7.28 (m, 3H), 7.20 – 7.12 (m, 4H), 5.34 – 5.31 (m, 
1H), 5.18 (d, J = 15.3 Hz, 1H), 4.81 (d, J = 15.3 Hz, 1H), 4.29 (dd, J = 10.5, 2.6 Hz, 1H), 3.34 – 3.24 (m, 2H), 
3.24 – 3.07 (m, 3H), 3.00 (dt, J = 14.8, 2.1 Hz, 1H), 2.86 (dt, J = 14.8, 7.4 Hz, 1H), 2.34 – 2.25 (m, 1H). 
13C NMR (126 MHz, CDCl3): δ 170.8, 165.5, 139.5, 136.4, 131.2 (2), 128.7 (2), 128.6, 128.5 (2), 128.1 (2), 
127.7, 73.6, 63.8, 61.9, 55.9, 50.38, 48.3, 32.9. 
HRMS calculated for C21H21ClN2O5SH (M+H)+ 449.0938; found 449.0901 (TOF MS);  
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(8R,9aS)-2-benzyl-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5] thiadiazepin-8-yl 2-methylbenzoate 
(4.5.12) 
 
Utilizing general procedure B, 4.5.12 (45 mg, 0.105 mmol, 78%) was isolated as a white solid. 
[α]D20 =  +48.0 º (c = 0.30, CHCl3); 
FTIR (neat, cm-1): 2958, 2833, 1712, 1456, 1352, 1294, 1257, 1224, 1153, 1081; 
1H NMR (500 MHz, CDCl3) δ 7.83 (dd, J = 7.8, 1.2 Hz, 2H), 7.32 – 7.25 (m, 2H), 7.16 – 7.08 (m, 5H), 5.32 
(dd, J = 4.9, 4.2 Hz, 1H), 5.15 (d, J = 15.2 Hz, 1H), 4.79 (d, J = 15.2 Hz, 1H), 4.25 (dd, J = 10.5, 2.9 Hz, 1H), 
3.32 – 3.23 (m, 2H), 3.21 – 3.06 (m, 3H), 3.02 (dt, J = 14.9, 2.2 Hz, 1H), 2.85 (dd, J = 10.5, 3.7 Hz, 1H), 2.51 
(s, 3H), 2.35 – 2.26 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 170.7, 167.3, 140.4, 136.4, 132.1, 131.6, 131.0, 129.4, 128.5 (2), 128.3 (2), 
127.7, 125.8, 73.0, 64.0, 62.3, 55.9, 50.5, 48.4, 33.1, 21.8. 
HRMS calculated for C22H24N2O5SH (M+H)+ 429.1484; found 429.1443 (TOF MS);  
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(8R,9aS)-2-benzyl-3,3-dioxido-1-oxooctahydropyrrolo[2,1-d][1,2,5] thiadiazepin-8-yl 4-methoxybenzoate 
(4.5.13) 
 
Utilizing general procedure B, 4.5.13 (42 mg, 0.094 mmol, 74%) was isolated as a white solid. 
 [α]D20 = +44.2 º (c = 0.43, CHCl3); 
FTIR (neat, cm-1): 2360, 2331, 1731, 1520, 1286, 1255, 1205, 1151, 769. 
1H NMR (400 MHz, CDCl3) δ 8.03 – 7.98 (m, 2H), 7.44 – 7.38 (m, 2H), 7.26–7.24 (m, 3H), 6.92 – 6.87 (m, 
2H), 5.45 – 5.39 (m, 1H), 5.31 (d, J = 15.3 Hz, 1H), 4.92 (d, J = 15.3 Hz, 1H), 4.37 (dt, J = 11.7, 5.8 Hz, 1H), 
3.87 (s, 3H), 3.46 – 3.32 (m, 2H), 3.32 – 3.16 (m, 3H), 3.10 (d, J = 14.8 Hz, 1H), 2.96 (dt, J = 12.0, 6.0 Hz, 
1H), 2.40 (ddd, J = 15.7, 10.5, 5.4 Hz, 1H). 
13C NMR (126 MHz, CDCl3): δ 170.8, 166.1, 163.4, 136.5, 131.8 (2), 128.5 (2), 128.2 (2), 127.6, 122.6, 113.6 
(2), 73.0, 64.0, 62.2, 55.8, 55.4, 50.4, 48.3, 33.0. 
HRMS calculated for C22H24N2O6SH (M+H)+ 445.1433; found 445.1392 (TOF MS); 
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 (8R,9aS)-2-benzyl-8-(4-nitrophenoxy)hexahydropyrrolo[2,1-d][1,2,5] thiadiazepin-1(2H)-one 3,3-dioxide 
(4.5.4). 
 
Utilizing general procedure C, 4.5.4 (39 mg, 0.090 mmol, 77%) was isolated as a brown thick liquid. 
[α]D20 = +80.16 º (c = 0.62, CHCl3); 
FTIR (neat, cm-1): 2356, 2329, 1704, 1591, 1508, 1494, 1340, 1259, 1153, 1110; 
1H NMR (500 MHz, CDCl3): δ 8.15 – 8.09 (m, 2H), 7.33 – 7.28 (m, 2H), 7.26 – 7.17 (m, 3H), 6.85 – 6.80 (m, 
2H), 5.06 (d, J = 15.2 Hz, 1H), 4.84 (d, J = 15.2 Hz, 1H), 4.82 (t, J = 4.3 Hz, 1H), 4.25 (dd, J = 10.5, 3.0 Hz, 
1H), 3.38 (dd, J = 10.4, 2.3 Hz, 1H), 3.34 – 3.29 (m, 1H), 3.28 – 3.17 (m, 3H), 3.01 (dt, J = 14.7, 2.5 Hz, 1H), 
2.90 (dd, J = 10.4, 3.6 Hz, 1H), 2.34 – 2.25 (m, 1H). 
13C NMR (126 MHz, CDCl3): δ 170.4, 162.3, 141.7, 136.4, 128.6 (2), 128.2 (2), 127.7, 126.0 (2), 115.4 (2), 
76.0, 64.2, 62.0, 55.6, 50.5, 48.8, 32.7. 
HRMS calculated for C20H21N3O6SNH4 (M+NH4)+ 449.1495; found 449.0728 (TOF MS); 
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(8R,9aS)-8-(4-bromophenoxy)-2-(4-methylbenzyl)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 
3,3-dioxide (4.5.5) 
 
Utilizing general procedure C, 4.5.5 (49 mg, 0.102 mmol, 74%) was isolated as a colorless thick liquid. 
[α]D20 = +29.5 º (c = 0.22, CHCl3); 
FTIR (neat, cm-1): 2952, 1704, 1487, 1352, 1240, 1153, 1058, 849; 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.33 (m, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 7.9 Hz, 2H), 6.79 – 
6.75 (m, 2H), 5.11 (d, J = 15.1 Hz, 1H), 4.89 (d, J = 15.1 Hz, 1H), 4.75 (t, J = 4.4 Hz, 1H), 4.27 (dd, J = 10.5, 
3.3 Hz, 1H), 3.43 (dd, J = 10.3, 2.2 Hz, 1H), 3.37–3.32 (m, 2H), 3.29–3.24 (m, 2H), 3.07 (dt, J = 14.6, 2.5 Hz, 
1H), 2.90 (dd, J = 10.3, 3.8 Hz, 1H), 2.33 (s, 3H), 2.32 –2.26 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 170.5, 156.3, 137.4, 133.5, 132.4 (2), 129.2 (2), 128.3 (2), 117.7 (2), 113.5, 
75.6, 64.3, 62.4, 55.6, 50.7, 48.7, 32.9, 21.2. 
HRMS calculated for C21H23BrN2O4SH (M+H)+ 479.0640; found 479.0651 (TOF MS); 
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(8R,9aS)-2-(4-methylbenzyl)-8-(4-nitrophenoxy)hexahydropyrrolo[2,1-d] [1,2,5]thiadiazepin-1(2H)-one 
3,3-dioxide (4.5.6): 
 
Utilizing general procedure C, 4.5.6 (43 mg, 0.096 mmol, 79%) was isolated as a brown thick liquid. 
[α]D20 = +87.7 º (c = 1.06, CHCl3); 
FTIR (neat, cm-1): 2925, 2850, 1703, 1591, 1512, 1340, 1259, 1153, 1110; 
1H NMR (500 MHz, CDCl3): δ 8.15 – 8.08 (m, 2H), 7.22 – 7.15 (m, 2H), 7.04 (d, J = 7.9 Hz, 2H), 6.85 – 6.77 
(m, 2H), 5.03 (d, J = 15.1 Hz, 1H), 4.84 – 4.80 (m, 1H), 4.78 (d, J = 15.1 Hz, 1H), 4.24 (dd, J = 10.4, 3.1 Hz, 
1H), 3.37 (dd, J = 10.4, 2.2 Hz, 1H), 3.33 – 3.17 (m, 4H), 3.01 (dt, J = 14.7, 2.5 Hz, 1H), 2.90 (dd, J = 10.4, 3.6 
Hz, 1H), 2.33 – 2.26 (m, 1H), 2.24 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ 170.4, 162.3, 141.7, 137.5, 133.4, 129.2 (2), 128.3 (2), 126.0 (2), 115.4 (2), 
76.0, 64.2, 62.1, 55.6, 50.5, 48.6, 32.7, 21.2. 
HRMS calculated for C21H23N3O6SH (M+H)+ 446.1386; found 446.1378 (TOF MS); 
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(8R,9aS)-2-benzyl-8-(3-chlorophenoxy)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide 
(4.5.7): 
 
Utilizing general procedure D, 4.5.7 (38 mg, 0.090 mmol, 71%) was isolated as a olorless thick liquid. 
[α]D20 = +52.8 º (c = 0.21, CHCl3); 
FTIR (neat, cm-1): 2943, 1708, 1595, 1477, 1352, 1222, 1153, 1058, 1026; 
1H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 7.3 Hz, 2H), 7.35 – 7.31 (m, 2H), 7.30 – 7.25 (m, 1H), 7.20 (t, J = 
8.2 Hz, 1H), 6.95 (ddd, J = 7.9, 1.7, 0.6 Hz, 1H), 6.87 (t, J = 2.1 Hz, 1H), 6.77 (ddd, J = 8.2, 2.3, 0.5 Hz, 1H), 
5.18 – 5.13 (m, 1H), 4.96 – 4.91 (m, 1H), 4.80 – 4.76 (m, 1H), 4.29 (dt, J = 8.7, 4.3 Hz, 1H), 3.47 – 3.32 (m, 
3H), 3.31 – 3.23 (m, 2H), 3.09 (dt, J = 14.7, 2.5 Hz, 1H), 2.92 (dd, J = 10.3, 3.8 Hz, 1H), 2.39 – 2.31 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 170.5, 157.9, 136.5, 134.9, 130.3, 128.6 (2), 128.3(2), 127.7, 121.3, 116.1, 
114.3, 75.5, 64.4, 62.3, 55.6, 50.63, 48.9, 33.0; 
HRMS calculated for C20H21ClN2O4SH (M+H)+ 421.0989; found 421.0952 (TOF MS); 
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(8R,9aS)-2-benzyl-8-(4-bromophenoxy)hexahydropyrrolo[2,1-d][1,2,5]thiadiazepin-1(2H)-one 3,3-dioxide 
(4.5.8): 
 
Utilizing general procedure D, 4.5.8 (42 mg, 0.090 mmol, 71%) was isolated as a brown thick liquid. 
[α]D20 = +35.5 º (c = 0.245, CHCl3); 
FTIR (neat, cm-1): 2962, 1706, 1487, 1352, 1240, 1218, 1153, 1060; 
1H NMR (400 MHz, Chloroform-d) δ 7.43 – 7.35 (m, 4H), 7.35 – 7.28 (m, 3H), 6.81 – 6.72 (m, 2H), 5.31 – 
5.07 (m, 1H), 4.94 (d, J = 15.2 Hz, 1H), 4.81 – 4.71 (m, 1H), 4.29 (dd, J = 10.5, 3.3 Hz, 1H), 3.44 (dd, J = 10.3, 
2.3 Hz, 1H), 3.42 – 3.25 (m, 4H), 3.07 (dt, J = 14.7, 2.8 Hz, 1H), 2.92 (dd, J = 10.2, 3.8 Hz, 1H), 2.32 (ddd, J = 
14.7, 10.5, 5.4 Hz, 1H). 
13C NMR (126 MHz, CDCl3): δ 170.5, 156.3, 136.5, 132.4 (2), 128.5 (2), 128.3 (2), 127.7, 117.7 (2), 113.5, 
75.6, 64.4, 62.4, 55.6, 50.6, 48.9, 32.9. 
HRMS calculated for C20H21BrN2O4SH (M+H)+ 465.0484; found 465.0489 (TOF MS); 
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(8R,9aS)-8-(5-fluoro-2-nitrophenoxy)-2-(4-fluorobenzyl)hexahydropyrrolo [2,1-d][1,2,5]thiadiazepin-
1(2H)-one 3,3-dioxide (4.5.9) 
 
Utilizing general procedure D, 4.5.9 (37 mg, 0.078 mmol, 71%) was isolated as a brown thick liquid. 
[α]D20 = +109.6 º (c = 0.75, CHCl3); 
FTIR (neat, cm-1): 2966, 1722, 1436, 1330, 1220, 1176, 1118, 1058. 
1H NMR (500 MHz, CDCl3): δ 7.99 – 7.96 (m, 1H), 7.39 – 7.34 (m, 2H), 7.08 – 7.04 (m, 2H), 6.82 – 6.77 (m, 
2H), 5.18 (d, J = 15.1 Hz, 1H), 4.90 – 4.86 (m, 1H), 4.78 (d, J = 14.9 Hz, 1H), 4.34 (dt, J = 12.5, 6.2 Hz, 1H), 
4.22–4.13 (m, 1H), 3.50 – 3.37 (m, 1H), 3.36 – 3.25 (m, 3H), 3.09 (dt, J = 14.8, 2.5 Hz, 1H), 3.00 (dd, J = 10.4, 
3.6 Hz, 1H), 2.44 – 2.34 (m, 1H). 
13C NMR (126 MHz, CDCl3): δ 170.5, 165.3 (1JC–F = 254.92 Hz), 163.3 (1JC–F’ = 243.42 Hz), 161.0 (4JC–F’ = 
1.93 Hz), 152.9 (3JC–F’1 = 11.18 Hz), 132.1 (4JC–F = 3.14 Hz), 130.3 (3JC–F = 8.48 Hz, 2), 128.3 (3JC–F’2 = 11.53 
Hz), 115.4 (2JC–F = 21.35 Hz, 2), 107.9 (2JC–F’1 = 23.58 Hz), 103.4 (2JC–F’2 = 26.90 Hz), 77.8, 63.9, 61.8, 55.7, 
50.2, 48.2, 32.2. 
HRMS calculated for C20H19F2NO6SH (M+H)+ 468.1041; found 468.1050 (TOF MS). 
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(8R,9aS)-2-(4-fluorobenzyl)-8-(4-nitrophenoxy)hexahydropyrrolo[2,1-d] [1,2,5]thiadiazepin-1(2H)-one 
3,3-dioxide (4.5.10) 
 
Utilizing general procedure D, 4.5.10 (39 mg, 0.087 mmol, 72%) was isolated as a brown thick liquid. 
[α]D20 = +42.4 º (c = 0.75, CHCl3); 
FTIR (neat, cm-1): 2954, 2358, 2341, 1704, 1591, 1510, 1340, 1259, 1222, 1153, 1110; 
1H NMR (500 MHz, CDCl3): δ 8.25 – 8.19 (m, 2H), 7.43 – 7.34 (m, 2H), 7.05 – 6.97 (m, 2H), 6.94 – 6.89 (m, 
2H), 5.07 (d, J = 15.1 Hz, 1H), 4.94 – 4.85 (m, 2H), 4.32 (dt, J = 12.5, 6.2 Hz, 1H), 3.50 – 3.37 (m, 2H), 3.36 – 
3.25 (m, 3H), 3.09 (dt, J = 14.8, 2.5 Hz, 1H), 3.00 (dd, J = 10.4, 3.6 Hz, 1H), 2.39 (ddd, J = 15.1, 10.5, 5.2 Hz, 
1H). 
13C NMR (126 MHz, CDCl3): δ 170.4, 162.3 (1JC–F = 246.6 Hz), 162.2, 141.7, 132.2 (4JC–F = 3.45 Hz), 130.3 
(3JC–F = 8.13 Hz, 2), 126.0 (2), 115.4 (2JC–F = 21.16 Hz, 2), 115.3 (2), 76.0, 64.1, 62.1, 55.7, 50.5, 48.2, 32.7. 
HRMS calculated for C20H20FN3O6SH (M+H)+ 450.1135; found 450.1124 (TOF MS); 
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5.6 Experimental for Chapter 4.2  
Synthesis of epoxybenzo[d]isothiazole  1,1-dioxides via a reductive-Heck, metathesis-
sequestration protocol 
General procedure A for reductive Heck followed by in-situ ROMP 
To a 25 mL round-bottom flask, sultam 4.5.1 (50 mg, 0.174 mmol, 1.5 equiv.), aryl iodide (28.3 mg, 
0.12 mmol, 1.0 equiv.), Pd(OAc)2 (4 mg, 0.017 mmol, 15 mol%), PPh3 (9 mg, 0.036 mmol, 30 mol%), 4-
MeOPhOH (9.3 mg, 0.06 mmol, 0.5 equiv.), Zn (227 mg, 3.48 mmol, 10 equiv.) and HCO2H (0.00856 mL, 0.12 
mmol, 1.0 equiv.) were added under argon and followed by addition of dry DMF (6 mL). The resulting mixture 
was heated w/ stirring at 60 ºC for 14 hours until the iodide was consumed as indicated by TLC.  The reaction 
mixture was allowed to cool to room temperature and DMF was evaporated, followed by the addition of 4:1 
EtOAc/hexanes (30 mL).  The mixture was extracted with brine (4 x 5 mL), the organic layer was separated, 
dried over MgSO4 and filtered through a pad of Celite. The filtrate was concentrated in vacuo and the crude 
product was treated with cat-B [(IMesH2)(PCy3)(Cl)2Ru=CHPh] (2.43 mg, 2.9 umol mol) in deoxygenated 
CH2Cl2 (0.1 M) at 50 ºC overnight in a round-bottom flask under argon w/ water condenser.  The reaction 
mixture was allowed to cool to RT and 0.1 mL of ethyl vinyl ether (EVE) was added and stirred for 30 min.  
The reaction mixture was concentrated in vacuo until slight viscosity is observed and the resulting viscous 
liquid is then precipitated drop-wise into Et2O (40 mL).  Simple filtration through a medium glass frit afforded 
the dry (reclaimed) oligomer 4.5.3.  The filtrate was concentrated in vacuo and filtered through a SiO2 SPE with 
50% EtOAc/hexanes to afford reductive Heck products 4.5.2a-j.  
General procedure B for reductive Heck followed by in-situ ROMP utilizing catalyst-armed surface 
To a 25 mL round-bottom flask, sultam 4.5.1 (50 mg, 0.174 mmol, 1.5 equiv.), aryl iodide (28.3 mg, 0.12 
mmol, 1.0 equiv.), Pd(OAc)2 (4 mg, 0.017 mmol, 15 mol%), PPh3 (9 mg, 0.036 mmol, 30 mol%), 4-MeOPhOH 
(9.3 mg, 0.06 mmol, 0.5 equiv.), Zn (227 mg, 3.48 mmol, 10 equiv.) and HCO2H (0.00856 mL, 0.12 mmol, 1.0 
equiv.) were added under argon and followed by addition of dry DMF (6 mL). The resulting mixture was heated 
w/ stirring at 60 ºC for 14 hours until the iodide was consumed as indicated by TLC.  The reaction mixture was 
allowed to cool to room temperature and DMF was evaporated, followed by the addition of 4:1 EtOAc/hexanes 
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(30 mL).  This mixture was extracted 4 times with brine using 5 mL each. The organic layer was separated and 
dried over MgSO4 and filtered through a pad of Celite. The filtrate was concentrated in vacuo and the crude 
mixture was added to a second round-bottom flask containing Nb-Si (5 mol%), cat-B (3 mol%) 
[[(IMesH2)(PCy3)(Cl)2 Ru=CHPh;] in dry degassed CH2Cl2 (0.1M), that had been stirring at 50 ºC for 30 min.  
After stirring for an additional 30 min to 1 hr (TLC monitoring), the crude reaction mixture was filtered through 
a celite SPE with 50% EtOAc/hexanes to afford reductive Heck products 4.5.2a-j. 
 
General procedure C for oligomeric-bound Suzuki-coupling (reclaimed scaffold)  
 In a 15–20 mL round bottom flask w/ condenser under argon was added reclaimed oligomeric-bound 
sultam 4.8.3 (100 mg, 0.25 mmol, 20-mer), Cs2CO3 (155 mg, 1 mmol), Pd(dppf)Cl2 (37 mg, 50 µmol), boronic 
acid (155 mg, 1 mmol), and dry THF:DMF (5:1 v/v, 2.5 mL, 0.1 M).  The reaction was stirred at 70 ºC for 14-
16 hours and allowed to return to rt.  The reaction was quenched via addition of aqueous NaOH (5 mL, 2.5 M) 
and stirred for 30-45 min.  The reaction was washed w/ additional aqueous NaOH (3 x 5 ml, 2.5 M), dried 
(MgSO4), and rinsed through a pad of Celite w/ multiple portions of CH2Cl2.  The oligomeric-containing filtrate 
was concentrated in vacuo until slightly viscous and precipitated drop-wise into Et2O (200 mL).  The oligomeric 
precipitate was then filtered via glass frit, washed w/ excess anhydrous Et2O, and dried in vacuo to yield the 
light grey, powdered oligomer in excellent yield.  
General procedure D for reductive-ozonolysis of oligomer 
 The oligomeric-bound sultam (post coupling) was added to a 50 mL round bottom flask, dissolved in 
CH2Cl2, and cooled to -78 ºC.  This solution was then subjected to ozonolysis via bubbling ozone gently 
through the solution in the open flask.  After 1 hour the solution was allowed to warm to -30 ºC while being 
purged with an argon-filled balloon and 4 in. needle.  Excess solid LiBH4 was added to the flask at -30 ºC while 
stirring and the flask was sealed over argon.  The cool bath was removed and the resulting solution was slowly 
warmed to RT and stirred overnight.  The reaction was quenched with water over 1 hour, extracted w/ 
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chloroform (3 x 5 mL), and concentrated in vacuo to yield the pure sultam diol.  No further purification was 
carried out.  
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(±) tert-Butyl3,6,7,7a-tetrahydro-2H-3a,6-epoxybenzo[d] isothiazole-2-carboxylate 1,1-dioxide  (4.5.1)  
 
FTIR (neat) 1720, 1330, 1170, 1135, 983 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 6.55 (dd, J = 5.8, 1.7 Hz, 1H), 6.27 (d, J = 6.0 Hz, 1H), 5.20 (dd, J = 4.7, 
1.6 Hz, 1H), 4.20 (q, J = 12.3 Hz, 2H), 3.30 (dd, J = 7.6, 3.2 Hz, 1H), 2.66 (ddd, J = 12.5, 4.6, 3.2 Hz, 1H), 1.81 
(dd, J = 12.5, 7.7 Hz, 1H), 1.48 (s, 9H);  
13C NMR (126 MHz, CDCl3) δ ppm 149.7, 140.5, 132.7, 88.1, 84.4, 79.5, 62.2, 47.1, 30.1, 28.0;  
HRMS calculated for C12H17NO5SNa (M+Na)+ = 310.0725; found 310.0698 (TOF MS ES+). 
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(±) tert-Butyl-5-(4-acetylphenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-carboxylate 1,1-dioxide 
(4.5.2a) 
  
FTIR (neat) 1720, 1679, 1332, 1309, 1135 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.93 (d, J = 8.2 Hz, 2H); 7.40 (d, J = 8.2 Hz, 2H), 4.76 (d, J = 5.4 Hz, 1H), 
4.35 (d, J = 12.3 Hz, 1H), 3.98 (d, J = 12.3 Hz, 1H), 3.70 (dd, J = 8.5, 4.1 Hz, 1H), 3.17 (dd, J = 8.7, 5.2 Hz, 
1H), 2.78 (dt, J = 13.3, 4.7 Hz, 1H), 2.62 (s, 3H), 2.45 (dd, J = 12.6, 8.8 Hz, 1H), 2.31 (dd, J = 13.4, 8.3 Hz, 
1H), 1.91 (dd, J = 12.8, 5.2 Hz, 1H), 1.58 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ ppm 197.5, 149.6, 149.3, 135.9, 128.9, 127.2, 85.7, 84.5, 83.4, 65.2, 48.2, 46.6, 
41.9, 35.3, 28.0, 26.6;  
HRMS calculated for C20H25NO6SNa (M+Na)+ = 430.1300; found 430.1296 (TOF MS ES+). 
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(±) tert-Butyl-5-(4-acetylphenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-carboxylate 1,1-dioxide 
(4.5.2b)  
 
FTIR (neat) 2983, 1720, 1330, 1309, 1157, 1132 cm-1; 
1H NMR (500 MHz, CDCl3) δ ppm 7.16 (dd, J = 8.7, 5.2 Hz, 2H), 6.92 (dd, J = 8.5, 4.4 Hz, 2H), 4.62 (d, J = 
5.0 Hz, 1H), 3.87 (d, J = 12.3 Hz, 1H), 3.58 (dd, J = 8.5, 4.1 Hz, 1H), 2.99 (dd, J = 8.8, 5.4 Hz, 1H), 2.65 (ddd, 
J = 13.2, 4.9, 4.6 Hz, 1H), 2.33 (dd, J = 12.8, 8.7 Hz, 1H), 2.18 (dd, J = 13.4, 8.4 Hz, 1H), 1.77 (dd, J = 12.8, 
5.2 Hz, 1H), 1.49 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ ppm 161.8 (d, 1JCF = 246 Hz), 160.8, 149.7, 139.9 (d, 4JCF = 3.8 Hz), 128.5 (d, 
3JCF = 7.6 Hz), 115.6 (d, 2JCF = 20.2 Hz), 85.6, 84.5, 83.8, 47.5, 46.6, 42.2, 35.3, 28.0;  
HRMS calculated for C18H22FNO5SNa (M+Na)+ = 406.1100; found 406.0997 (TOF MS ES+). 
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(±) tert-Butyl 5-(4-(methoxycarbonyl)phenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-carboxylate 
1,1-dioxide (4.5.2c)  
 
FTIR (neat) 1720, 1332, 1280, 1166, 985 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 8.00 (d, J = 8.5 Hz, 2H), 7.34 − 7.40 (m, 2H), 4.76 (d, J = 5.0 Hz, 1H), 4.35 
(d, J = 12.0 Hz, 1H), 3.94 − 4.01 (m, 1H), 3.93 (s, 3H), 3.70 (dd, J = 8.5, 4.1 Hz, 1H), 3.16 (dd, J = 8.8, 5.4 Hz, 
1H), 2.77 (d, J = 13.2 Hz, 1H), 2.45 (dd, J = 12.9, 8.8 Hz, 1H), 2.30 (dd, J = 13.4, 8.4 Hz, 1H), 1.91 (dd, J = 
12.9, 5.4 Hz, 1H), 1.58 (s, 9H);  
13C NMR (126 MHz, CDCl3) δ ppm 166.7, 149.6, 149.1, 130.1, 128.9, 127.0, 85.7, 84.5, 83.4, 65.2, 52.1, 48.2, 
46.6, 41.9, 35.3, 28.0;  
HRMS calculated for C20H25NO7SNa (M+Na)+ = 446.1249; found 446.1235 (TOF MS ES+). 
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(±)-tert-Butyl-5-(4-hydroxyphenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-carboxylate 1,1-
dioxide (4.5.2d) 
 
FTIR (neat) 2979, 1722, 1515, 1371, 1290, 1238 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.06 (d, J = 8.5 Hz, 2H), 6.70 (d, J = 8.5 Hz, 2H), 4.60 (s, 1H), 4.23 (d, J = 
12.3 Hz, 1H), 3.86 (d, J = 12.3 Hz, 1H), 3.57 (dd, J = 8.4, 3.9 Hz, 1H), 2.94 (dd, J = 8.7, 5.2 Hz, 1H), 2.63 (dt, J 
= 13.3, 4.7 Hz, 1H), 2.29 (dd, J = 12.6, 8.8 Hz, 1H), 2.16 (dd, J = 13.2, 8.5 Hz, 1H), 1.77 (dd, J = 12.9, 5.0 Hz, 
1H), 1.48 (s, 9H);  
13C NMR (126 MHz, CDCl3) δ ppm 154.4, 149.7, 136.5, 128.2, 115.5, 85.6, 84.5, 83.9, 65.4, 47.5, 46.7, 42.2, 
35.3, 28.0;  
HRMS calculated for C18H23NO6SNa (M+Na)+ = 404.1144; found 404.1120 (TOF MS ES+). 
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(±) tert-Butyl-5-(3-fluorophenyl) hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-carboxylate 1,1-dioxide 
(4.5.2e) 
 
FTIR (thin film) 2978, 1720, 1371, 1329,1310, 1242, 1138, 984, 735 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.29 – 7.25 (m, 3H), 7.02 (ddd, J = 10.1, 8.8, 4.7 Hz, 3H), 6.94 (td, J = 8.4, 
2.2 Hz, 1H), 4.73 (d, J = 5.2 Hz, 1H), 4.32 (d, J = 12.1 Hz, 1H), 3.94 (t, J = 9.9 Hz, 1H), 3.66 (dd, J = 8.4, 4.0 
Hz, 1H), 3.08 (dd, J = 8.7, 5.2 Hz, 1H), 2.77 – 2.69 (m, 1H), 2.41 (dd, J = 12.8, 8.8 Hz, 1H), 2.26 (dd, J = 13.4, 
8.4 Hz, 2H), 1.88 (dd, J = 12.8, 5.2 Hz, 1H), 1.56 (d, J = 7.3 Hz, 12H), 1.50 (s, 1H);  
13C NMR (126 MHz, CDCl3) δ ppm 163.2 (d, 1JCF = 247 Hz), 149.9, 146.7 (d, 2JCF = 7.2 Hz), 130.5 (d, 2JCF = 
8.3 Hz), 122.9 (d, 4JCF = 2.7 Hz), 114.2 (d, 3JCF = 6.2 Hz), 114.1 (d, 3JCF = 5.4 Hz), 85.8, 84.7, 83.7, 48.1, 46.8, 
42.2, 35.3, 28.2;  
HRMS calculated for C18H22FNO5SNa (M+Na)+ 406.1100; found 406.1101 (TOF MS ES+). 
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(±) tert-Butyl 5-(3,5-dimethylphenyl) hexahydro-2H-3a,6 epoxybenzo [d]iso thiazole-2-carboxylate 1,1-
dioxide (4.5.2f) 
 
FTIR (thin film) 2980, 1724, 1345, 1310, 1259, 1138, 845, 735 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.22 – 7.07 (m, 4H), 4.70 (d, J = 5.2 Hz, 1H), 4.31 (d, J = 12.1 Hz, 1H), 
3.94 (d, J = 12.1 Hz, 1H), 3.66 (dd, J = 8.4, 4.1 Hz, 1H), 3.04 (dd, J = 8.7, 5.3 Hz, 1H), 2.78 – 2.63 (m, 1H), 
2.38 (dd, J = 12.7, 8.8 Hz, 1H), 2.33 (s, 3H), 2.29 – 2.21 (m, 1H), 1.88 (dd, J = 12.8, 5.2 Hz, 1H), 1.56 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ ppm 149.7, 144.0, 138.3, 128.5, 124.7, 85.6, 84.4, 83.7, 65.4, 48.1, 46.7, 41.9, 
35.4, 28.0, 28.0, 21.3;  
HRMS calculated for C20H27NO5SNa (M+Na)+ = 416.1508; found 416.1510 (TOF MS ES+). 
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(±) tert-Butyl-5-(p-tolyl) hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-carboxylate 1,1-dioxide (4.5.2g) 
FTIR (thin film) 2982, 1722, 1333, 1167, 1136, 735 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.20 – 7.09 (m, 4H), 4.70 (d, J = 5.2 Hz, 1H), 4.31 (d, J = 12.1 Hz, 1H), 
3.94 (d, J = 12.1 Hz, 1H), 3.65 (dt, J = 17.6, 8.8 Hz, 1H), 3.04 (dd, J = 8.7, 5.3 Hz, 1H), 2.77 – 2.66 (m, 1H), 
2.38 (dd, J = 12.7, 8.8 Hz, 1H), 2.33 (s, 3H), 2.25 (dd, J = 13.3, 8.4 Hz, 1H), 1.88 (dd, J = 12.8, 5.2 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 149.8, 141.1, 136.6, 129.4, 126.8, 85.6, 84.4, 83.9, 65.4, 47.8, 46.7, 42.1, 
35.4, 28.0, 21.0;  
HRMS calculated for C19H25NO5SNa (M+Na)+ = 402.1351; found 402.1357 (TOF MS ES+). 
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(±) tert-Butyl-5-(4-(thiophen-3-yl)phenyl) hexahydro-2H-3a,6-epoxybenzo[d]isothia-zole-2-carboxylate 
1,1-dioxide (4.5.2h) 
 
FTIR (thin film) 2980, 1722, 1333, 1136, 735 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.29 (dd, J = 5.0, 3.0 Hz, 1H), 7.06 – 7.00 (m, 2H), 4.71 (d, J = 5.2 Hz, 
1H), 4.28 (d, J = 12.1 Hz, 1H), 3.95 – 3.90 (m, 1H), 3.67 – 3.60 (m, 1H), 3.24 (dd, J = 8.6, 5.0 Hz, 1H), 2.75 – 
2.69 (m, 1H), 2.38 – 2.32 (m, 1H), 2.23 (dt, J = 20.7, 10.4 Hz, 1H), 1.89 – 1.82 (m, 1H), 1.56 (d, J = 4.8 Hz, 
9H);  
13C NMR (126 MHz, CDCl3) δ ppm 144.6, 126.5, 126.4, 120.2, 85.7, 84.4, 83.3, 65.3, 46.7, 43.5, 41.3, 35.5, 
34.9, 30.6, 29.3, 28.0, 27.9;  
HRMS calculated for C16H21NO5S2Na (M+Na)+ = 394.0759; found 394.0750 (TOF MS ES+). 
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(±) tert-Butyl-5-(4-(trifluoromethoxy)phenyl) hexahydro-2H-3a,6-epoxybenzo[d]iso thiazole -2-
carboxylate 1,1-dioxide (4.5.2i) 
1H NMR (500 MHz, CDCl3) δ ppm 7.32 – 7.29 (m, 2H), 7.16 (d, J = 8.0 Hz, 2H), 4.72 (d, J = 5.2 Hz, 1H), 4.31 
(d, J = 12.1 Hz, 1H), 3.95 (d, J = 12.2 Hz, 1H), 3.66 (dt, J = 8.5, 4.3 Hz, 1H), 3.10 (dd, J = 8.7, 5.2 Hz, 1H), 
2.77 – 2.71 (m, 1H), 2.42 (dd, J = 12.8, 8.8 Hz, 1H), 2.27 (dd, J = 13.4, 8.4 Hz, 1H), 1.88 – 1.83 (m, 1H), 1.56 
(s, 9H);  
13C NMR (126 MHz, CDCl3) δ ppm 149.1 (d, 1JCF = 200 Hz), 143.1, 128.6, 121.5, 85.9, 84.8, 83.8, 65.5, 47.8, 
42.4, 35.5, 28.3 cm-1;  
HRMS calculated for C19H22F3NO6SNa (M+Na)+ = 472.1018; found 472.1023 (TOF MS ES+). 
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(±) tert-Butyl-5-(4-cyanophenyl) hexahydro-2H-3a,6-epoxybenzo[d]isothiazole-2-carboxylate 1,1-dioxide 
(4.5.2j) 
 
FTIR (thin film) 2928, 2359, 1722, 1606, 1332, 1138, 835 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.62 (d, J = 8.2 Hz, 2H), 7.40 (d, J = 8.3 Hz, 2H), 4.73 (d, J = 5.2 Hz, 1H), 
4.32 (d, J = 12.2 Hz, 1H), 3.96 (d, J = 12.2 Hz, 1H), 3.69 – 3.65 (m, 1H), 3.14 (dd, J = 8.6, 5.2 Hz, 1H), 2.79 – 
2.73 (m, 1H), 2.45 (dd, J = 12.9, 8.8 Hz, 1H), 2.29 (dt, J = 13.5, 6.1 Hz, 1H), 1.87 (dd, J = 12.9, 5.1 Hz, 1H), 
1.57 (s, 9H);  
13C NMR (126 MHz, CDCl3) δ ppm 149.5, 132.9, 129.1, 128.1, 118.9, 111.3, 86.0, 84.9, 83.5, 65.4, 48.5, 46.7, 
42.2, 35.5, 29.9, 28.3, 28.2;  
HRMS; calculated for C19H22N2O5SNa (M+Na)+ = 413.1147; found 413.1147 (TOF MS ES+). 
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(±) Benzyl-6,7,7a-tetrahydro-2H-3a,6-epoxybenzo[d] isothiazole-2-carboxylate 1,1-dioxide  (4.7.1)  
1H NMR (500 MHz, CDCl3) δ ppm 7.29 – 7.25 (m, 3H), 7.02 (ddd, J = 10.1, 8.8, 4.7 Hz, 3H), 6.94 (td, J = 8.4, 
2.2 Hz, 1H), 4.73 (d, J = 5.2 Hz, 1H), 4.32 (d, J = 12.1 Hz, 1H), 3.94 (t, J = 9.9 Hz, 1H), 3.66 (dd, J = 8.4, 4.0 
Hz, 1H), 3.08 (dd, J = 8.7, 5.2 Hz, 1H), 2.77 – 2.69 (m, 1H), 2.41 (dd, J = 12.8, 8.8 Hz, 1H), 2.26 (dd, J = 13.4, 
8.4 Hz, 2H), 1.88 (dd, J = 12.8, 5.2 Hz, 1H), 1.56 (d, J = 7.3 Hz, 12H), 1.50 (s, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 139.4, 134.1, 128.8, 128.6, 128.0, 90.4, 79.7, 77.4, 77.1, 76.8, 60.4, 48.8, 
48.4, 29.1 
HRMS calculated for C14H16NO3S (M+H)+ = 278.0851; found 278.0846 (TOF MS ES+). 
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(3aS,5R,6R,7aS)-2-benzyl-5-(3-fluorophenyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole 1,1-dioxide 
(4.7.5a) 
1H NMR (500 MHz, CDCl3) δ ppm 7.41 – 7.34 (m, 4H), 7.32 (d, J = 6.8 Hz, 1H), 7.22 (dd, J = 14.0, 8.0 Hz, 
1H), 6.97 (dd, J = 15.5, 8.9 Hz, 2H), 6.89 (t, J = 8.0 Hz, 1H), 4.67 (d, J = 5.0 Hz, 1H), 4.32 (dd, J = 41.2, 14.5 
Hz, 2H), 3.55 (d, J = 11.2 Hz, 1H), 3.50 (dd, J = 8.6, 4.8 Hz, 1H), 3.39 (d, J = 11.2 Hz, 1H), 3.03 (dd, J = 8.6, 
5.5 Hz, 1H), 2.64 – 2.54 (m, 1H), 2.36 (dd, J = 12.6, 8.7 Hz, 1H), 2.23 (dd, J = 13.1, 8.6 Hz, 1H), 1.72 (dd, J = 
12.6, 5.5 Hz, 1H);  
13C NMR (126 MHz, CDCl3) δ ppm 164.0, 162.0, 146.9, 135.2, 130.2, 130.1, 128.8, 128.6, 122.7, 113.8, 113.6 
88.1, 83.7, 63.3, 48.6, 35.3, 29.7;  
HRMS calculated for C20H20FNO5SNa (M+Na)+ = 396.1046; found 396.1039 (TOF MS ES+). 
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(3aS,5R,6R,7aS)-2-benzyl-5-(p-tolyl)hexahydro-2H-3a,6-epoxybenzo[d]isothiazole 1,1-dioxide (4.7.5b) 
1H NMR (500 MHz, CDCl3) δ ppm 7.36 – 7.27 (m, 4H), 7.28 – 7.22 (m, 1H), 7.07 – 6.99 (m, 4H), 4.58 (d, J = 
5.0 Hz, 1H), 4.33 – 4.17 (m, 2H), 3.48 (d, J = 11.1 Hz, 1H), 3.44 (dd, J = 8.5, 4.8 Hz, 1H), 3.32 (d, J = 11.1 Hz, 
1H), 2.93 (dd, J = 8.6, 5.6 Hz, 1H), 2.52 (dt, J = 13.1, 4.9 Hz, 1H), 2.27 (dd, J = 12.5, 8.7 Hz, 1H), 2.23 (s, 3H), 
2.21 – 2.13 (m, 1H), 1.66 (dd, J = 12.5, 5.6 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ ppm 141.5, 135.2, 129.4, 128.8, 128.6, 128.0, 126.9, 88.1, 84.1, 63.4, 48.7, 
48.7, 47.8, 43.0, 35.4, 21.0;  
HRMS calculated for C21H23NO3SNa (M+Na)+ = 392.1296; found 392.1289 (TOF MS ES+). 
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(±) Hexahydro-2H-3a,7-epoxyoxepino[3,4-d]isothiazole 1,1-dioxide (4.8.2) 
FTIR (neat) 1771, 1615, 1460, 1371, 1312 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 4.63 (br s, 1H); 4.47 (d, J = 6.3 Hz, 1H), 3.80 (dd, J = 9.3, 4.6 Hz, 1H), 
3.75 (d, J = 11.7 Hz, 1H), 3.66 (t, J = 11.0 Hz, 1H), 3.61 (t, J = 11.2 Hz, 1H), 3.51 (d, J = 11.7 Hz, 1H), 3.23 
(dd, J = 13.7, 5.8 Hz, 1H), 3.09 (t, J = 11.3 Hz, 1H), 2.63 (dt, J = 12.6, 6.3 Hz, 1H), 2.44 (dd, J = 13.4, 9.6 Hz, 1 
H);  
13C NMR (126 MHz, CDCl3) δ ppm 93.3, 78.4, 70.1, 69.9, 64.3, 44.8, 33.2;  
HRMS calculated for C7H11NO4SNa (M+Na)+ = 228.0306; found 228.0291 (TOF MS ES+). 
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(±) 2-((4'-(tert-Butyl)-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl) hexahydro- furo[2,3-
d]isothiazole 1,1-dioxide (4.8.4a) 
 
FTIR (neat) 3377, 2960, 2924, 2866, 1772, 1612, 1499, 1460, 1439, 1364, 1310, 1150, 1057, 951, cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.65 – 7.43 (m, 6H), 7.36 (d, 7.4 Hz, 2H), 4.46 (s, 1H), 4.38 (d, J = 13.8 
Hz, 1H), 4.07 (d, J = 13.7 Hz, 1H), 3.93 (d, J = 9.6 Hz, 1H), 3.83 (d, 6.9 Hz, 1Hz), 3.78 − 3.45 (m, 3H), 3.10 (d, 
J = 10.0 Hz, 1H), 2.92 (d, J = 10.2 Hz, 1H), 2.63 − 2.48 (m, 2H), 1.37 (s, 9H);  
13C NMR (125 MHz, CDCl3) 150.6, 141.0, 137.5, 133.3, 128.9, 127.4, 126.7, 125.8, 87.7, 81.2, 66.2, 63.6, 
62.4, 53.4, 47.0, 34.6, 30.4, 29.7;  
HRMS calculated for C24H31NO5SNa (M+Na)+ = 468.1821; found 468.1801 (TOF MS ES+). 
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(±) 2-((3'-(1-Hydroxyethyl)-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl) hexa- hydrofuro[2,3-
d]isothiazole 1,1-dioxide (4.8.4b) – mixture of diastereomers  
 
FTIR (neat) 3381, 2966, 2924, 2854, 1439, 1306, 1150, 1076, 797, 752, 706 cm-1;  
1H NMR (500 MHz, CDCl3) δ ppm 7.60 − 7.53 (m, 3H), 7.47 (d, J = 7.4 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.33 
(d, J = 6.8 Hz, 3H) 4.94 (q, J = 6.2 Hz, 1H), 4.40 − 4.25 (m, 1H), 4.32 (d, J = 14.0 Hz, 1H), 4.00 (d, J = 14.0 
Hz, 1H), 3.95 (s, 1H), 3.85 (d, J = 12.0 Hz, 1H), 3.73 (d, J = 9.2 Hz, 1H), 3.65 (d, J = 11.7 Hz, 1H), 3.56 (d, J = 
12.1 Hz, 1H), 3.51 (d, J = 12.1 Hz, 1 H), 3.36 (s, 1H), 3.01 (d, J = 10.7 Hz, 1H), 2.87 (d, J = 10.8 Hz, 1H), 2.68 
(s, 1H), 2.5 (dd, J = 13.6, 5.5 Hz, 1H), 2.40 − 2.31 (m, 1H), 1.52 (d, J = 6.4 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ ppm 146.4, 141.0, 140.9, 140.6, 133.8, 130.7, 129.1, 129.0, 127.6, 126.2, 124.7, 
87.6, 81.2, 70.4, 65.9, 63.4, 62.2, 61.3, 53.3, 46.9, 30.3, 25.3;  
HRMS calculated for C22H28NO6S (M+H)+ = 434.1639; found 434.1621 (TOF MS ES+). 
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(±) 2-((4'-Fluoro-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl)hexahydrofuro[2,3-d]isothiazole 
1,1-dioxide (4.8.4c) 
 
FTIR (neat) 3381, 2953, 2918, 2849, 1603, 1499, 1308, 1232, 1150, 1059, 947, 822, 756 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.55 − 7.48 (m, 4 H), 7.35 (d, J = 8.0 Hz, 2H), 7.11 (t, J = 8.6 Hz, 2H), 4.47 
− 4.38 (m, 1H), 4.35 (d, J = 13.9 Hz, 1H), 4.15 (d, J = 13.9 Hz, 1H), 3.91 (d, J = 11.1 Hz, 1H), 3.79 (d, J = 8.5 
Hz, 1H), 3.78 − 3.48 (m, 3H), 3.06 (d, J = 10.7 Hz, 1H), 2.91 (d, J = 10.7 Hz, 1H), 2.54 (dd, J = 13.1, 5.3 Hz, 
1H), 2.50 − 2.38 (m, 1H);  
13C NMR (125 MHz, CDCl3) δ ppm 162.6 (d, 1J = 247 Hz), 140.1, 136.6 (d, 4J = 3.4 Hz), 133.7, 129.0, 128.6 
(d, 3J = 8.1 Hz), 127.4, 115.7 (d, 2J = 21.6 Hz);  
HRMS calculated for C20H22FNO5SNa (M+Na)+ = 430.1100; found 430.1104 (TOF MS ES+). 
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(±) 2-((3'-Chloro-[1,1'-biphenyl]-4-yl)methyl)-3a,5-bis(hydroxymethyl)hexahydrofuro[2,3-d]isothiazole 
1,1-dioxide (4.8.4d) 
 
FTIR (neat) 3354, 2924, 1664, 1595, 1440, 1396, 1308, 1150, 1037, 787 cm-1;  
1H NMR (400 MHz, CDCl3) δ ppm 7.55 (dd, J = 8.92, 2.0 Hz, 3H), 7.46 (dt, J = 7.4, 1.5 Hz, 1H), 7.42 − 7.32 
(m, 4H), 4.49 − 4.42 (m, 1H), 4.38 (d, J = 14.0 Hz, 1H), 4.06 (d, J = 14.0 Hz, 1H), 3.95 (d, J = 11.9 Hz, 1H), 
3.82 (d, J = 8.9 Hz, 1H), 3.73 (d, J = 11.7 Hz, 1H), 3.68 − 3.57 (m, 2H), 3.07 (d, J = 10.7 Hz, 1H), 2.93 (d, J = 
10.7 Hz, 1H), 2.58 (dd, J = 13.0, 6.0 Hz, 1H), 2.47 (dt, J = 13.8, 9.6 Hz, 1H);  
13C NMR (125 MHz, CDCl3) 142.2, 139.7, 134.7, 134.3, 130.1, 129.1, 127.2, 125.18, 87.6, 81.2, 66.1, 63.5, 
62.3, 53.3, 46.9, 30.4;  
HRMS calculated for C20H22ClNO5SNa (M+Na)+ = 446.0805; found 446.0812 (TOF MS ES+). 
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